11th Human Amyloid Imaging

January 11-13, 2017 Miami, Florida



Co-Organizers: Keith A. Johnson, MD • William J. Jagust, MD • William E. Klunk, MD, PhD • Chester A. Mathis, PhD

Conference Program and Abstracts

www.worldeventsforum.com/hai

Table of Contents

PRESENTER INDEX	11
POSTER INDEX	13
HAI 2017 PROGRAM	19
HAI 2017 ABSTRACTS	22
WEDNESDAY	22
Wednesday, January 11, 2017 - 12:40 pm - 01:40 pm	22

SESSION 1: Quantifying Tau and Amyloid PET Signal 22

	, ,	•	0
Evaluating differen use as biomarkers	t in vivo measure	es of tau pathol	ogy for
Anne Maass ^{1,2} , S	Susan Landau ^{1,3} , s	Andy Horng ¹ , S	Samuel
N. Lockhart ¹ , Re	enaud La Joie ³ , S	uzanne L. Bake	er ⁴ , Gil
D. Rabinovici ^{1,3,}	⁴ , William J. Jagu	ust ^{1,3,4}	23
Tau Load: a novel r	nethod for quant	ifying subject-s	specific
neuropathologic tau	signal from Flor	rtaucipir PET	25
Michael Navitsk	y, Michael Devo	us, Abhinay Jo	shi, Ian
Kennedy, Sudee	pti Southekal, M	ichael Pontecor	rvo,
Ming Lu, Mark l	Mintun		25

Recovering signal from AV1451 in frontotemporal lobar degeneration with partial volume correction 27

Adam Martersteck^{1,2}, Jaiashre Sridhar², Allison Rainford², M.-Marsel Mesulam^{2,3}, Emily Rogalski².. 27

Unbiased clustering using entorhinal and neocortical tau-PET uptake on [18F]AV-1451 maps onto age and clinical

Jennifer Whitwell ¹ , Jonathan Graff-radford ¹ , Nirubol
Tosakulwong ¹ , Stephen Weigand ¹ , Matthew Senjem ¹ ,
Anthony Spychalla ¹ , David Jones ¹ , Daniel Drubach ¹ ,
Ronald Petersen ¹ , Val Lowe ¹ , Clifford Jack ¹ , Keith
Josephs ¹
*

Nonlinear alignment of multimodal empirical distributions for level-2 Centiloid transformations 29

Michael Properzi¹, Cristina Lois Gomez², Federico d'Oleire Uquillas¹, Reisa Sperling^{1,3,4}, Keith Johnson^{2,3,4}, Aaron Schultz^{1,3}......29

Wednesday, January 11, 2017 - 02:25 pm - 03:10 pm 31

Wednesday, January 11, 2017 - 03:10 pm - 04:40 pm.... 32

Kinetics of [18F]GTP1 (Genentech tau probe 1) in the basal ganglia of Alzheimer's patients and healthy controls

Sandra Sanabria Bohorquez¹, Thomas Bentsson², Olivier Barret³, Gilles Tamagnan³, David Alagille³, Alex de Crespigny¹, Gai Ayalon⁴, Michael Ward⁵,

Geoffrey Kerchner ⁵ , Danna Jennings ³ , John Seibyl ³ , Ken Marek ³ , Robby Weimer ⁶ , Jan Marik ⁶ 32
Development of novel tau PET tracers, [18F]AM-PBB3 and [18F]PM-PBB3
Maiko Ono ^{1,2} , Soichiro Kitamura ¹ , Hitoshi Shimada ¹ , Naruhiko Sahara ¹ , Hiroyuki Takuwa ¹ , Yasumasa Yoshiyama ³ , John Trojanowski ⁴ , Virginia Lee ⁴ , Tetsuya Suhara ¹ , Ming-Rong Zhang ¹ , Ming-Kuei Jang ⁵ , Gilles Tamagnan ⁶ , Kenneth Marek ⁶ , Makoto Higuchi ¹ 34
Optimization of early phase [18F]flutemetamol scanning window as a proxy for relative tracer delivery35
Kerstin Heurling ^{1,2} , Koen Van Laere ³ , Rik Vandenberghe ³ , Christopher Buckley ⁴ , Gill Farrar ⁴ , Mark Lubberink ^{2,5}
Algorithm for reference region delineation for amyloid imaging using pattern recognition scheme and kinetics of administered A β probe — considering the number of clusters
Takahiro Yamada ¹ , Yuichi Kimura ¹ , Takashi Nagaoka ¹ , Chisa Hosokawa ² , Takamichi Murakami ² , Kazunari Ishii ²
Rigid registration contributes significant imprecision to amyloid PET SUVR measurements
Christopher Schwarz ¹ , David Jones ¹ , Jeffrey Gunter ¹ , Val Lowe ¹ , Prashanthi Vemuri ¹ , Matthew Senjem ¹ , Ronald Petersen ¹ , David Knopman ¹ , Clifford Jack ¹ 38
18F-Flortaucipir SUV normalization using a Parametric Estimate of Reference Signal Intensity (PERSI)40
Sudeepti Southekal ¹ , Michael D. Devous Sr. ¹ , Ian Kennedy ¹ , Michael Navitsky ¹ , Ming Lu ¹ , Abhinay D. Joshi ¹ , Michael J. Pontecorvo ¹ , Mark A. Mintun ¹ 40
Validation of the semi-quantitative static SUVR method by pharmacokinetic modeling on dynamic cross-sectional [18F]-AV45 data
Julie Ottoy ¹ , Jeroen Verhaeghe ¹ , Ellis Niemantsverdriet ² , Leonie wyffels ³ , Charisse Somers ² , Ellen De Roeck ^{2,4} , Hanne Struyfs ² , Femke Soetewey ² , Steven Deleye ¹ , Tobi Van den Bossche ^{5,6,7} , Sara Van Mossevelde ^{5,6,7} , Sarah Ceyssens ³ , Jan Versijpt ⁸ , Sigrid Stroobants ³ , Sebastiaan Engelborghs ^{2,7} , Steven Staelens ¹
A simulation study on the quantification of the blood flow-dependent component in [18F]-AV45 SUVR differences between the MCI and AD stage46
Julie Ottoy ¹ , Jeroen Verhaeghe ¹ , Sigrid Stroobants ³ , Sebastiaan Engelborghs ² , Steven Staelens ¹ 46
18F-PM-PBB3 a novel imaging tracer for visualization and quatification of TAU pathologies with Positron Emission Tomography49
Paul Tempest ¹ , Ming-Kuei Jang ¹ , Gilles Tamagnan ² , Ken Marek ² , John Seibyl ² , David Alagille ² , Olivier Barret ² , Makoto Higuchi ³ , Hitoshi Shimada ³ , Maiko

Ono³, Tetsuya Suhara³, Ming-Rong Zhang³.....49

Quantitative analysis and correlation with clinical endpoints of [18F]MK6240 targeting neurofibrillary tangles (NFTs) in healthy volunteers and subjects with Alzheimer's disease
Cristian Salinas ¹ , Ping Chiao ¹ , Ajay Purohit ¹ , Karl Schmidt ¹ , John Beaver ¹ , Cyrille Sur ² , Arie Struyk ³ , Idriss Bennacef ² , Talakad Lohith ² , Jeffrey Evelhoch ² , Rick Hiatt ⁴ , Gilles Tamagnan ⁵ , Danna Jennings ⁵ , Ken Marek ⁵ , Richard Hargreaves ¹
Implementation of the Centiloid transformation for 18F- florbetaben
Christopher C Rowe ^{1,2} , Gareth Jones ¹ , Vincent Doré ^{1,3} , David Baxendale ¹ , Rachel S Mulligan ¹ , Andrew Stephens ⁴ , Susan De Santi ⁴ , Colin L Masters ⁵ , Ludger Dinkelborg ⁴ , Victor L Villemagne ^{1,2,5}
Selection of reference region for 18F-THK-5351 PET imaging analysis
Po-Yen Chen ¹ , Ing-Tsung Hsiao ^{1,2} , Kun-Ku Lin ^{1,2} , Chin-Chang Huang ³
Noise reduction algorithm for amyloid imaging without loss of image resolution
Yuichi Kimura ¹ , Kohsuke Fujii ¹ , Takahiro Yamada ¹ , Chisa Hosokawa ² , Muneyuki Sakata ³ , Takamichi Murakami ² , Kazunari Ishii ² 54
Cerebral brain perfusion in cognitively normal elderly: measured with arterial spin labelling and [18F]Flutemetamol PET
Stephen Carter ¹ , Laura Parkes ² , Rainer Hinz ¹ , Neil Pendleton ² , Karl Herholz ¹ 55
[18F]flutemetamol – quantification on the centiloid scale
Christopher Buckley ¹ , Mark Battle ¹ , Adrian Smith ¹ , Koen Van Laere ² , Rik Vandenberghe ² , Val Lowe ³ 56
Blood-brain barrier disruption in Alzheimer disease measured by PiB PET: a preliminary study
Yi Su, Andrei Vlassenko, Marcus Raichle, John Morris, Tammie Benzinger57
Binding of a tau positron emission tomography ligand, PBB3, to α-synuclein pathology as assessed by fluorescence and autoradiographic labeling
Shunsuke Koga ¹ , Maiko Ono ^{2,3} , Naruhiko Sahara ² , Makoto Higuchi ² , Dennis Dickson ¹ 58
A computationally efficient method for making PET measurements: the T1-GTM approach
Aaron Schultz, Reisa Sperling, Keith Johnson 60
Simplified reference tissue methods in [18F]AV1451 PET61
Tessa Timmers ^{1,2} , Sandeep Golla ¹ , Rik Ossenkoppele ^{1,2} , Colin Groot ^{1,2} , Sander Verfaillie ¹ , Philip Scheltens ¹ , Wiesje van der Flier ^{1,3} , Lothar Schwarte ⁴ , Mark Mintun ⁵ , Michael Devous ⁵ , Robert Schuit ¹ , Albert Windhorst ¹ , Adriaan Lammertsma ¹ ,

Ronald Boellaard ^{1,6} , Maqsood Yaqub ¹ , Bart van Berckel ¹ 61
In vitro binding of [3H]RO6958948, [3H]AV-1451, [3H]THK5351 and [3H]T808 to tau aggregates in non-AD tauopathies62
Michael Honer ¹ , Luca Gobbi ¹ , Dieter Muri ¹ , Edilio Borroni ¹ 62
Evaluation of Caspase-3 activation in Alzheimer's disease using [18F]ICMT-11 PET/CT63
Valeria Calsolaro, Grazia Daniela Femminella, Zhen Fan, Melanie Dani, Kasia Kozlowski, Eric Aboagye, Paul Edison63
Considerations for defining a striatal region of interest in amyloid PET studies within the Down syndrome population
Patrick Lao ¹ , Tobey Betthauser ¹ , Julie Price ² , William Klunk ² , Peter Bulova ² , Sigan Hartley ¹ , Regina Hardison ² , Rameshwari Tumuluru ² , Dhanabalan Murali ¹ , Chester Mathis ² , Annie Cohen ² , Todd Barnhart ¹ , Dana Tudorascu ³ , Darlynne Devenny ² , Charles Laymon ¹ , Sterling Johnson ² , Ben Handen ¹ , Bradley Christian
Head-to-head comparison of tau-specific tracers in Alzheimer's disease: [11C]THK5351 vs [11C]PBB3 PET imaging
Konstantinos Chiotis ¹ , Per Stenkrona ² , Ove Almkvist ^{1,3} , Ryosuke Arakawa ² , Akihiro Takano ² , Vladimir Stepanov ² , Andrea Varrone ² , Makoto Higuchi ⁴ , Christer Halldin ² , Agneta Nordberg ^{1,5} 66
Flow changes affect SUVr but not binding potential in an AD clinical trial67
Colin Groot ^{1,2} , Tessa Timmers ^{1,2} , Rik Ossenkoppele ^{1,2} , Maqsood Yaqub ¹ , Niels D Prins ^{2,3} , Adriaan A Lammertsma ¹ , Philip Scheltens ² , Bart NM van Berckel ¹ 67
Developing a tracer agnostic pipeline for amyloid and tau PET data
Zachary Hobel ¹ , Suzanne Baker ² , Matthew Ellis ¹ , Judy Pa68
Kinetic modeling of the tau PET tracer [18F](S)THK- 5351 in healthy controls and Alzheimer's disease subjects
Olivier Barret ¹ , Cristian Constantinescu ¹ , Christopher Buckley ³ , Grethe Dalsgaard ³ , Alex Gibson ³ , Ajay Purohit ² , John Beaver ² , John Seibyl ¹ , Gilles Tamagnan ¹ , Ken Marek ¹ , Danna Jennings ¹ , Cristian Salinas-Valenzuela ² 69
Longitudinal changes in [18]F-RO6958948 Tau PET signal in four Alzheimer's subjects70
Dean Wong ^{1,2,3} , Hiroto Kuwabara ¹ , Robert Comley ⁵ , Gregory Klein ⁴ , Christina Vozzi ⁴ , Michael Honer ⁴ , Joshua Roberts ¹ , Kelly Kitzmiller ¹ , Lorena Gapasin ¹ , Edilio Borroni ⁴

Longitudinal Centiloid change in ADNI [18F]Florbetapir PET data: implications for clinical trials
Donald McLaren ¹ , Felix Carbonell ¹ , Vincent Auclair ¹ , Alex Zijdenbos ¹ , Abhinay Joshi ² , Micheal Navitsky ² , Mark Mintun ² , Ping Chiao ³ , Barry Bedell ^{1,4}
FreeSurfer approach to the Centiloid standardization method: Evaluation of alternative cortical target regions and partial volume correction
Davneet Minhas ¹ , Brian Lopresti ¹ , Howard Aizenstein ^{2,3} , Charles Laymon ^{1,3} , Elizabeth Campbell ¹ , Zheming Yu ¹ , Dana Tudorascu ⁴ , Chester Mathis ¹ , William Klunk ^{2,5}
The quantitative impact of emission-transmission scan misalignment and region selection upon amyloid measurement accuracy
Randolph Andrews ¹ , Dawn Matthews ¹ , Anne Smith ² 73
High quantitative accuracy amyloid PET imaging with precision estimation
Pawel Markiewicz ^{1,2} , Kjell Erlandsson ² , Jonathan Schott ³ , Catherine Scott ¹ , David Cash ³ , Frederik Barkhof ¹ , Nick Fox ³ , Sebastien Ourselin ^{1,3}
Comparison of region of interest segmentation methods for extraction of 11C-PiB SUVR in the Down syndrome population
Tobey Betthauser ¹ , Patrick Lao ¹ , Dana Tudorascu ² , Julie Price ² , Peter Bulova ² , Sigan Hartley ¹ , Regina Hardison ² , Rameshwari Tumuluru ² , Davneet Minhas ³ , Charles Laymon ² , Dhanabalan Murali ¹ , Chester Mathis ² , Annie Cohen ² , Todd Barnhart ¹ , Darlynne Devenny ³ , William Klunk ² , Sterling Johnson ¹ , Ben Handen ² , Bradley Christian ¹
Comparison of tau distribution according to tau tracers in various neurodegenerative diseases: Using [18F]AV1451 and [18F]THK-5351
Young Koung Jang ¹ , Gil Rabinovich ² , Heejin Kim ¹ , Jin San Lee ¹ , Ko Woon Kim ¹ , Sang Won Seo
A comparison of DVR and SUVR methods for THK5317 and THK5351
Tobey Betthauser ¹ , Patrick Lao ¹ , Dhanabalan Murali ¹ , Todd Barnhart ¹ , Shozo Furumoto ² , Nobuyuki Okamura ² , Charles Stone ¹ , Sterling Johnson ¹ , Bradley Christian ¹
A cortical cluster-based measure of change in longitudinal 18F-T807 FTP PET
J. Alex Becker ¹ , Danielle Cosio ^{1,3} , Chris Lee ¹ , Nick Andrea ¹ , Reisa Sperling ² , Keith Johnson ^{1,2}
Selegiline reduces brain [18F]THK5351 binding
Kok Pin Ng ^{1,3} , Gassan Massarweh ² , Jean-Paul Soucy ² , Paul Gravel ² , Tharick A. Pascoal ¹ , Sulantha Mathotaarachchi ¹ , Min Su Kang ¹ , Monica Shin ¹ , Joseph Therriault ¹ , Sophie Levasseurr ¹ , Kayla Horowitz ¹ , Serge Gauthier ¹ , Pedro Rosa-Neto ¹
Wednesday, January 11, 2017 - 04:40 pm - 05:25 pm 86

Effects of [18F]AV-1451 binding in cerebellar gray and extra-cortical areas
Suzanne Baker ¹ , Anne Maass ^{2,3} , Susan Landau ² , Samuel Lockhart ² , William Jagust ^{1,2} 87
[18F]MK-6240, a novel neurofibrillary tangles PET tracer: evaluation in healthy subjects and Alzheimer's disease patients
Cyrille Sur ¹ , Arie Struyk ² , Idriss Bennacef ¹ , Talakad Lohith ¹ , Cristian A Salinas ⁵ , Florestina Telan-Choing ² , Ruben Declercq ⁴ , Tom Reynders ⁴ , Sofie Celen ⁸ , Kim Serdons ⁸ , Guy Bormans ⁸ , Mathieu Vandenbulcke ^{8,10} , Rik Vandenberghe ^{9,10} , Jan de Hoon ⁸ , Corinne Vandermeulen ⁸ , Michel Koole ⁸ , Koen Van Laere ^{8,10} , Gilles Tamagnan ⁷ , Danna Jennings ⁷ , Ken Marek ⁷ , Olivier Barret ⁷ , John Seibyl ⁷ , Ping Chiao ⁵ , Zhizhen Zeng ¹ , Abbas Walji ³ , Eric Hostetler ¹ , Richard J Hargreaves ⁵ , Rick Hiatt ⁶ , Mark Forman ² , Jeffrey Evelhoch ¹
Current efforts to overcome drawbacks of [11C]PBB3 by developing new PBB3 derivatives: first-in-human PET study with [18F]AM-PBB390
Hitoshi Shimada ¹ , Soichiro Kitamura ¹ , Yasuyuki Kimura ^{1,2} , Masanori Ichise ¹ , Maiko Ono ¹ , Hitoshi Shinotoh ^{1,3} , Manabu Kubota ¹ , Keisuke Takahata ¹ , Sho Moriguchi ¹ , Tetsuya Ishii ¹ , Chie Seki ¹ , Ming-Rong Zhang ⁴ , Tetsuya Suhara ¹ , Makoto Higuchi ¹ 90
Evaluation of baseline and longitudinal tau burden in Alzheimer's disease using [18F]GTP1 (Genentech Tau Probe 1) PET imaging91
Robby Weimer ^{1,2} , Olivier Barret ³ , Gilles Tamagnan ³ , David Alagille ³ , Jan Marik ¹ , Gai Ayalon ² , Thomas Bengtsson ⁴ , Mike Ward ⁵ , Geoffrey Kerchner ⁵ , Danna Jennings ⁵ , John P. Seibyl ³ , Ken Marek ³ , Sandra Sanabria ⁶ 91
Wednesday, January 11, 2017 - 05:40 pm - 06:00 pm92
Invited Lecture:
Molecular Imaging Analysis for Tracer Validation and Clinical Trials92
Roger N Gunn92
THURSDAY
Thursday, January 12, 2017 - 08:00 am - 08:45 am93
SESSION 3: Neuropathology I: Tau PET Ligand Selectivity and Comparative Studies
Evaluation of the selectivity of Tau PET radioligand THK5351 in AD brain in vitro and nonhuman primate brain in vivo94
Qi Guo ¹ , Bernd Otterstätter ² , Simone Benninghoff ² , David Reuter ¹ , Jiquan Wang ¹ , Marc Skaddan ¹ , Ann Tovcimak ¹ , Cecelia Schroeder ¹ , Gokul Krishnan ¹ , Kyle Wilcox ¹ , Robert Comley ¹ , Paul Makidon ¹ , Martin Voorbach ¹ , Andreas Haupt ² , Manolo Mugnaini ² , Laurent Martarello ¹

SESSION 2: Novel Tau Tracers86

Characterizing the "off-target" binding of 18F-THK5351 in Alzheimer's disease: correlation between ante-mortem and post-mortem findings	
Ryuichi Harada ^{1,2} , Aiko Ishiki ³ , Shozo Furumoto ⁴ , Katsutoshi Furukawa ^{4,5} , Manabu Tashiro ⁴ , Hiroyuki Arai ³ , Kazuhiko Yanai ^{1,4} , Yukitsuka Kudo ² , Nobuyuki Okamura ^{4,5}	
In vitro binding properties comparison of the tau PET tracers THK5117, THK5351, PBB3 and T807 in autopsy brain from Alzheimer's diseases cases	
Laetitia Lemoine ¹ , Per-göran Gillberg ¹ , Marie Svedberg ² , Vladimir Stepanov ² , He Tian ³ , Makoto Higuchi ³ , Christer Halldin ² , Agneta Nordberg ^{1,4} 97	
An autoradiographic evaluation of THK-5351 compared to AV-145198	
Val Lowe ¹ , Melissa Murray ² , Vidur Sarma ¹ , Geoffry Curran ¹ , Ping Fang ¹ , Mukesh Pandey ¹ , Tyler Bruinsma ¹ , David Jones ¹ , Casey Cook ² , Keith Josephs ¹ , Joseph Parisi ¹ , David Knopman ¹ , Bradley Boeve ¹ , Kejal Kantarci ¹ , Leonard Petrucelli ² , Clifford Jack ¹ , Dennis Dickson ² , Ronald Petersen ¹	
Thursday, January 12, 2017 - 09:30 am - 10:15 am 100	
Poster Session 2A 100	
Hippocampal activation is associated with longitudinal amyloid accumulation and cognitive decline	
Stephanie Leal ¹ , Susan Landau ¹ , Rachel Bell ¹ , William Jagust ¹ 100	
Tau-PET imaging with [18F]AV-1451 in progressive apraxia of speech with and without aphasia	
Rene Utianski ¹ , Jennifer Whitwell ¹ , Christopher Schwarz ¹ , Matthew Senjem ¹ , Nirubol Tosakulwong ¹ , Joseph Duffy ¹ , Heather Clark ¹ , Mary Machulda ¹ , Clifford Jack ¹ , Val Lowe ¹ , Keith Josephs ¹	
Lower white matter integrity is associated with higher amyloid deposition in older adults without dementia in two independent samples	
Hwamee Oh ¹ , Atul Narkhede ¹ , Qolamreza R. Razlighi ¹ , Yaakov Stern ¹ , Richard P. Mayeux ¹ , Adam M. Brickman ¹ 102	
Uncovering the local-to-distributed relationship between β-amyloid and glucose metabolism	
Felix Carbonell ¹ , Donald G. Mclaren ¹ , Alex P. Zijdenbos ¹ , Barry J. Bedell ^{1,2}	
[F-18]-AV-1451 binding correlates with neurofibrillary tangle Braak staging in postmortem brain tissue samples	
Marta Marquié-Sayagués ^{1,2} , Alejandro Antón- Fernández ^{1,2} , Michael Siao Tick Chong ^{1,2} , Avery C. Meltzer ^{1,2} , Nil Sáez-Calveras ^{1,2} , Eline Verwer ³ , Prianca Ramanan ^{1,2} , Marc D. Normandin ³ , Matthew P. Frosch ⁴ , Teresa Gómez-Isla ^{1,2}	

Measurement of pathological amyloid in routine clinical assessment: comparison of visual [18F]Flutemetamol PET and CSF107
Nenad Bogdanovic ¹ , Enrico Fantoni ² , Gill Farrar ² 107
Metabolic syndrome and amyloid accumulation in the aging brain108
Gabriela Gomez ¹ , Lori Beason-Held ¹ , Murat Bilgel ¹ , Yang An ¹ , Stephanie Studenski ¹ , Susan Resnick ¹ 108
Left frontal global connectivity is a substrate of cognitive reserve in mild cognitively impaired patients with a high amyloid burden
Nicolai Franzmeier ¹ , Marco Duering ¹ , Michael Weiner ² , Martin Dichgans ^{1,3,4} , Michael Ewers ¹ 109
Detection of radiologic and laboratory features of cerebral amyloid angiopathy in patients with Alzheimer's disease
Panagiotis Fotiadis ¹ , John Becker ² , Kristin Schwab ¹ , Jonathan Rosand ¹ , Anand Viswanathan ¹ , Reisa Sperling ² , Keith Johnson ² , Steven Greenberg ¹ , Edip Gurol ¹ , Alzheimer's Disease Neuroimaging Initiative ³
Elevated 18F-AV-1451 PET tracer uptake detected in incidental imaging findings112
Samuel Lockhart ¹ , Nagehan Ayakta ² , Joseph Winer ³ , Renaud La Joie ² , Gil Rabinovici ² , William Jagust ¹ 112
18F-AV-1451 PET demonstrates Braak stage-specific associations with limbic white matter integrity in normal aging
Samuel Lockhart ¹ , Anne Maass ¹ , Shawn Marks ¹ , Suzanne Baker ² , William Jagust ¹ 114
Microglial activation correlates in vivo with tau aggregation and amyloid deposition in mild cognitive impairment and Alzheimer's disease
Melanie Dani ¹ , Melanie Wood ¹ , Ruth Mizoguchi ¹ , Zhen Fan ¹ , Richard Morgan ² , Zuzana Walker ^{3,4} , Valeria Calsolaro ¹ , Grazia Femminella ¹ , Rainer Hinz ⁵ , David Brooks ⁶ , Paul Edison ¹ 116
Correlation of regional amyloid load in cognitively healthy monozygotic twin pairs, measured using [18F]Flutemetamol117
Mara ten Kate ¹ , Elles Konijnenberg ¹ , Anouk den Braber ^{1,2} , Sofie Adriaanse ³ , Maqsood Yaqub ³ , Dorret Boomsma ² , Philip Scheltens ¹ , Bart van Berckel ³ , Pieter Jelle Visser ^{1,4}
In vivo tau imaging in Parkinson's disease using 18F-AV- 1451 PET118
Allan Hansen ¹ , Malene Damholdt ² , Peter Parbo ¹ , David Brooks ^{1,3} , Per Borghammer ¹
Tau PET imaging and atrophy in neurodegenerative dementias
Brad Dickerson ¹ , Scott McGinnis ¹ , Stephen Gomperts ¹ , Sara Makaretz ¹ , David Wolk ² , Aaron Schultz ¹ , Neil Vasdev ¹ , Keith Johnson ¹ 119

Insulin resistance in midlife increases the risk for brain amyloid accumulation 15 years later
Laura Ekblad ¹ , Jarkko Johansson ¹ , Hanna Laine ^{2,3} , Matti Viitanen ^{2,4} , Antti Jula ⁵ , Juha Rinne ^{1,6}
Imaging tau deposition in the Lewy body diseases 121
Stephen Gomperts ¹ , Joseph Locascio ¹ , Sara Makaretz ¹ , Aaron Schultz ² , Christina Caso ⁴ , Vasdev Neil ² , Reisa Sperling ^{1,3} , John Growdon ¹ , Brad Dickerson ¹ , Keith Johnson ^{1,2}
Nonfluent variant of primary progressive aphasia: Tau deposition in the language network
Belen Pascual ¹ , Paolo Zanotti-Fregonara ¹ , Quentin Funk ¹ , Elijah Rockers ¹ , Neha Pal ¹ , Meixiang Yu ² , Bryan Spann ¹ , Paul Schulz ³ , Joseph C Masdeu ¹ 122
Longitudinal decrease of white matter PiB uptake in aging and Alzheimer's disease
Yi Su ¹ , Kewei Chen ² , Eric Reiman ² , John Morris ¹ , Tammie Benzinger ¹
18F-AV-1451 and 11C-PIB PET do not explain impairment in Parkinson's disease
Joseph Winer ¹ , Peter Pressman ² , Jordan Stiver ² , Anne Maass ³ , Daniel Schonhaut ² , Joel Kramer ² , Gil Rabinovici ² , William Jagust ³
Longitudinal tau-PET imaging using [18F]AV-1451 in progressive supranuclear palsy 126
Jennifer Whitwell ¹ , Val Lowe ¹ , Bradley Boeve ¹ , Kejal Kantarci ¹ , Matthew Senjem ¹ , Nirubol Tosakulwong ¹ , Christopher Schwarz ¹ , Anthony Spychalla ¹ , Ronald Petersen ¹ , Clifford Jack ¹ , Keith Josephs ¹
Pittsburgh compound-B PET and MRI biomarkers of cognition in aging multiple sclerosis patients
Burcu Zeydan ^{1,2} , Val J. Lowe ¹ , Scott A. Przybelski ³ , Christopher G. Schwarz ¹ , Nirubol Tosakulwong ³ , Samantha M. Zuk ¹ , Matthew L. Senjem ⁴ , Jeffrey L. Gunter ⁴ , Rosebud O. Roberts ² , Michelle M. Mielke ² , Eduardo E. Benarroch ² , Moses Rodriguez ² , Mary M. Machulda ⁵ , Timothy G. Lesnick ³ , David S. Knopman ² , Ronald C. Petersen ² , Clifford R. Jack Jr ¹ , Kejal Kantarci ¹ , Orhun H. Kantarci ²
Improved estimation of gray matter volume in presence of white matter hyperintensities in Alzheimer's and Down syndrome studies with amyloid burden
Dana Tudorascu ¹ , Helmet Karim ¹ , Lea Alhilali ² , Patrick Lao ³ , Tobey Betthauser ³ , Erica Tamburo ¹ , Rebecca Maccloud ¹ , Jeffrey James ¹ , Davneet Minhas ¹ , Annie Cohen ¹ , Beth Snitz ¹ , Julie Price ⁴ , Brian Lopresti ¹ , Chet Mathis ¹ , Oscar Lopez ¹ , Sterling Johnson ³ , Ciprian Crainiceanu ⁵ , Ben Handen ¹ , Brad Christian ³ , Howard Aizenstein ¹ , William Klunk ¹ 128
Global white matter diffusion characteristics predict longitudinal cognitive change independently from amyloid accumulation in older adults

Jennifer S. Rabin ¹ , Rodrigo Perea ⁴ , Rachel Rachel Buckley ^{3,5,6} , Keith A. Johnson ^{3,4} , Reisa A. Sperling ^{3,4,5} , Trey Hedden ^{2,4}
[18F]AV1451 tau PET distinguishes PSP from controls and Parkinson's disease131
Daniel Schonhaut ¹ , Corey McMillan ² , Brad Dickerson ³ , Andrew Siderowf ⁴ , Michael Devous ⁴ , Richard Tsai ¹ , Joe Winer ⁵ , David Russell ⁶ , Irene Litvan ⁷ , Erik Roberson ⁸ , Joel Kramer ¹ , Peter Pressman ¹ , Ilya Nasrallah ² , Suzanne Baker ⁹ , Stephen Gomperts ³ , Keith Johnson ³ , Murray Grossman ² , William Jagust ⁹ , Adam Boxer ¹ , Gil Rabinovici ¹ 131
Antemortem-postmortem correlation of florbetapir (18F) PET amyloid imaging with quantitative biochemical measures of Aβ40 and Aβ42133
Thomas Beach, Chera Maarouf, Anthony Intorcia, Lucia Sue, Geidy Serrano, Alex Roher133
Proteomics signatures of Alzheimer's disease: gender differences and relationship to pathological markers134
Shantanu Srivatsa ¹ , Joseph Lucas ¹ , Murali Doraiswamy ¹ 134
Tau PET in subjects at risk for chronic traumatic encephalopathy
Nicolas Andrea ¹ , Jonathan Alverio ¹ , Christopher Lee ¹ , Christopher Nowinski ² , Heidi Jacobs ¹ , Ann McKee ² , Keith Johnson ¹ , David Jin ¹
PET staging of brain amyloidosis using striatum136
Bernard Hanseeuw ¹ , Rebecca Betensky ² , Beth Mormino ¹ , Aaron Schultz ¹ , Kate Papp ^{1,3} , Rachel Buckley ¹ , Jasmeer Chhatwal ¹ , Gad Marshall ^{1,3} , Dorene Rentz ^{1,3} , Reisa Sperling ^{1,3} , Keith Johnson ^{1,3}
Tau PET imaging tracks both pathology and brain perfusion in non-AD tauopathies: a multimodal study138
Elena Rodriguez-Vieitez ¹ , Antoine Leuzy ¹ , Konstantinos Chiotis ¹ , Laure Saint-Aubert ¹ , Ove Almkvist ¹ , Anders Wall ² , Agneta Nordberg ^{1,3} 138
Hippocampal cingulum integrity predicts change in tau accumulation in a downstream-connected region in amyloid-positive normal older individuals
Heidi Jacobs ^{1,3} , Aaron Schultz ³ , Rebecca Amariglio ⁴ , Trey Hedden ³ , Kathryn Papp ⁴ , Rodrigo Perea ³ , Dorene Rentz ⁴ , Jorge Sepulcre ³ , Reisa Sperling ^{2,3,4} , Keith Johnson ^{1,2,3}
Greater regional cortical thickness is associated with selective vulnerability to atrophy in Alzheimer's disease, independent of regional amyloid load141
Chunfei Li ¹ , Ranjan Duara ^{2,4} , David A. Loewenstein ^{3,4,5} , Mercedes Cabrerizo ¹ , Warren Barker ^{2,4} , Malek Adjouadi ^{1,4} 141
Distinctive clinical significance of hemorrhagic and amyloid imaging markers in patients with clinical- radiological cerebral amyloid angiopathy in memory clinic patients
Chine puttents

Young Kyoung Jang ¹ , Jin San Lee ¹ , Ko Woon Kim ¹ , Sang Won Seo ^{1,2} 144	Milos Ikonomovic, Eric Abrahamson, Julia Kofler, William Paljug, Manik Debnath, Julie Price, Carl
Is tau accumulation detectable before neuronal injury markers? – Analysis from tau PET imaging with [C- 11]PPB3 in clinical variants of Alzhaimer's disease 145	Becker, Chester Mathis, Oscar Lopez, William Klunk
Masamichi Imai ^{1,2} , Kenii Ishij ¹ , Mika Tanaka ¹ , Kenii	in an autopsy confirmed Parkinson's disease case
Ishibashi ¹ , Kei Wagatsuma ¹ , Muneyuki Sakata ¹ , Tetsuro Tago ¹ , Jun Toyohara ¹ , Shigeo Murayama ³ , Hirotaka Maruno ^{2,4} , Hitoshi Shimada ⁵ , Makoto Higuchi ⁵ , Tetsuya Suhara ⁵	Marta Marquie-Sayagues ^{1,2} , Avery C. Meltzer ^{1,2} , Eline Verwer ³ , Marc D. Normandin ³ , Michael A. Schwarzschild ^{1,2} , Stephen N. Gomperts ^{1,2} , Keith A. Johnson ² , Matthew P. Frosch ⁴ , Teresa Gomez-Isla ^{1,2}
Investigation of gait speed and β-amyloid in older adults from the Harvard Aging Brain Study 147	Multimodal evaluation of 18E-AV-1451 PET in an
Dylan R. Kirn ¹ , Rachel F. Buckley ^{1,3,4,5} , Bernard J. Hanseeuw ¹ Rebecca F. Amariglio ^{1,2,3} Reisa A	autopsy-confirmed corticobasal degeneration patient 159
Sperling ^{1,2,3} , Keith A. Johnson ^{1,2,3}	Jeffrey Phillips ¹ , Meredith Spinler ¹ , Katya
Greater [F-18]THK-5351 binding in medial and ventral temporal lobe is associated with altered microstructure and reduced myelin	Kascovsky', Kylie Ternes', Charles Jester', David Wolk ¹ , Linda Kwong ³ , Virginia Lee ³ , Andrew Siderowf ⁴ , Edward Lee ³ , John Trojanowski ³ , Murray Grossman ¹
Andrew Merluzzi ¹ , Nagesh Adluru ¹ , Andrew Schoen ¹ , Douglas Dean ¹ Vikas Singh ¹ Bradley Christian ¹	Thursday, January 12, 2017 - 11:30 am - 12:15 pm162
Tobey Betthauser ¹ , Patrick Lao ¹ , Todd Barnhart ¹ ,	Keynote Lecture: Thomas Beach162
Murali Dhanabalan ¹ , Sanjay Asthana ¹ , Andrew Alexander ¹ , Sterling Johnson ¹ , Barbara Bendlin ¹ 148	Tau PET for Alzheimer's Disease: Possible Promise and Pitfalls162
Contribution of neuritic and diffuse plaques to signal derived from CN-Flutemetamol: a preliminary study in	Thomas Beach162
AD autopsy brains	Thursday, January 12, 2017 - 01:45 pm - 02:45 pm163
Milos Ikonomovic ¹ , Eric Abrahamson ¹ , Christopher Bucklau ² Chaster Mathic ¹ William Klunk ¹ Gill	SESSION 5: Tau PET: Non-AD Targets163
Farrar ²	18F Flortaucipir binding in choroid plexus: association with race and hippocampus binding164
determines the clinical status in predementia stages of Alzheimer's disease	Christopher Lee ¹ , Marta Marquie ¹ , Nicolas Andrea ¹ , Molly LaPoint ^{1,2} , David Jin ¹ , Heidi Jacobs ¹ , Aaron Schultz ¹ , Matthew Frosch ¹ , Teresa Gomez-Isla ¹ , Reisa
Tharick Pascoal, Sulantha Mathotaarachchi, Min Su Kang, Kon Pin Ng, Jean-Paul Soucy, Serge Gauthier,	Sperling ^{1,2} , Keith Johnson ^{1,2} 164
Pedro Rosa-Neto	[18F]Flortaucipir, aka [18F]AV-1451, autoradiography matches immunofluorescent staining from AT8 tau
Staging of amyloid- β , tau, regional atrophy rates and cognitive change in a non-demented cohort	antibody in Chronic Traumatic Encephalopathy (CTE) post-mortem brain tissue sections165
Evan Fletcher Fletcher ^{1,2} , Alice Renaud ³ , Abhninandan Nandi ¹ , Charles DeCarli ^{1,2} 152	Yin-Guo Lin ¹ , Qianwa Liang ¹ , Felipe Gomez ¹ , Ann Mckee ² , Mark A. Mintun ¹ , Giorgio Attardo ¹ 165
Increased level of CSF neurofilament light chain is associated with amyloidosis in transgenic rat model of Alzheimer's disease	Microscopic neuropathological evaluation of the binding profile of tau selective PET ligands in Alzheimer's disease and primary tauopathies
Min Su Kang ^{1,2,6} , Eduardo R. Zimmer ^{1,5} , Monica Shin ^{1,2,6} , Sulantha Mathotaarachchi ^{1,2} , Tharick	Melissa Wren ^{1,2} , Kerstin Sander ¹ , Tammaryn Lashley ² , Nick Fox ³ , Erik Arstad ¹ 166
Pascoal ^{1,2} , Kok Pin Ng ^{1,2} , Henrik Zetterberg ⁷ , Jean- Paul Soucy ³ , Judes Poirier ⁶ , Serge Gauthier ^{1,2,6} , A.	AV-1451 tau-PET uptake in MAPT mutation carriers varies by tau isoforms167
	David Jones ¹ , Val Lowe ¹ , Jonathan Graff-Radford ¹ ,
Thursday, January 12, 2017 - 10:15 am - 10:45 am 156	Jeremy Syrjanene ¹ , Matthew Senjem ¹ , Christina Dheel ¹ , Zbigniew Wszolek ² , Rosa Rademakers ² . David
SESSION 4: Nauropathology II: PET to Autopsy Correlations 156	Knopman ¹ , Ronald Petersen ¹ , Clifford Jack ¹ , Bradley Boeve ¹
Neuropathology and biochemical correlations of [F- 18]AV-1451 and [C-11]PiB PET imaging in a subject with Alzbeimer's disease	18F-AV-1451 binding in familial frontotemporal lobar degeneration with tau pathology169
with rizhemer 5 disease	

William Kreisl, Jill Goldman, Edward Huey 169
Thursday, January 12, 2017 - 03:30 pm - 04:15 pm 170
Poster Session 2B 170
Thursday, January 12, 2017 - 04:15 pm - 04:30 pm 170
SESSION 6: Thresholds and Centiloids 170
Defining cut-points for imaging biomarkers used in brain aging and Alzheimer's disease research
Clifford Jack ¹ , Heather Wiste ¹ , Stephen Weigand ¹ , Terry Therneau ¹ , Val Lowe ¹ , David Knopman ¹ , Jeffrey Gunter ¹ , Matthew Senjem ¹ , David Jones ¹ , Kejal Kantarci ¹ , Mary Machulda ¹ , Michelle Mielke ¹ , Rosebud Roberts ¹ , Prashanthi Vemuri ¹ , Denise Reyes ¹ , Ronald Petersen ¹
Thursday, January 12, 2017 - 04:30 pm - 04:30 pm 174
Further Adventures in the World of Centiloids 174
Robert A. Koeppe ¹ , Julie C. Price ² , Centiloid Working Group174
FRIDAY
Friday, January 13, 2017 - 08:00 am - 08:45 am 175
SESSION 7: Amyloid and Tau PET in Clinical Trials 175
The A4 Study: Preliminary Analyses of Baseline Tau PET Imaging
Reisa Sperling ^{1,2} , Aaron Schultz ² , Dorene Rentz ¹ , Elizabeth Mormino ² , Eric Siemers ³ , Roy Yaari ³ , Sergey Schcherbinin ³ , Adam Schwarz ³ , Michael Devous ⁴ , Mark Mintun ⁴ , Michael Donohue ⁵ , Paul Aisen ⁵ , Keith Johnson ²
Conversion of aMCI subjects to AD in relation to [18F]flutemetamol Amyloid status, and hippocampal volume in a phase III longitudinal study
Wolk David ¹ , Andrea Cherubini ² , Chris Buckley ³ , Michelle Zanette ⁴ , Paul Sherwin ⁴ 177
Baseline 18F Flortaucipir SUVR, but not amyloid or cognition, predicts cognitive decline over 18 months in Phase 2 trial subjects
Michael D. Devous, Sr. ¹ , Navitsky Michael ¹ , Andrew Siderowf ¹ , Ian Kennedy ¹ , Abhinay D. Joshi ¹ , Sudeepti Southekal ¹ , Ming Lu ¹ , Michael J. Pontecorvo ¹ , Mark A. Mintun ¹
PET amyloid and tau imaging in a Phase 3 study of solanezumab181
Mark A Mintun ¹ , Michael D Devous, Sr. ¹ , Ming Lu ¹ , Michael J Pontecorvo ¹ , Abhinay D Joshi ¹ , Sudeepti Southekal ¹ , Andrew Siderowf ¹ , Mark J Lowrey ¹ , Marybeth Devine ¹ , Tyler E Benedum ¹ , Caitlin Pearson ¹ , Nathaniel C Lim ¹ , Adam S Fleisher ² , Karen L Sundell ² , Eric R Siemers ²
Poster Session 3A

Concordance improves between amyloid-PET and CSF amyloid- β for diagnosing Alzheimer's disease in a clinical setting by applying A β 1-42/A β 1-40 ratio183
Ellis Niemantsverdriet ¹ , Julie Ottoy ² , Jeroen Verhaeghe ² , Charisse Somers ¹ , Ellen De Roeck ¹ , Hanne Struyfs ¹ , Femke Soetewey ¹ , Maria Bjerke ¹ , Tobi Van den Bossche ^{3,4} , Sara Van Mossevelde ^{3,4} , Johan Goeman ⁴ , Peter Paul De Deyn ⁴ , Peter Mariën ^{4,5} , Jan Versijpt ⁶ , Paul Parizel ⁷ , Kristel Sleegers ³ , Christine Van Broeckhoven ³ , Leonie wyffels ^{2,8} , Adrien Albert ⁸ , Sarah Ceyssens ⁸ , Sigrid Stroobants ^{2,8} , Steven Staelens ² , Sebastiaan Engelborghs ^{1,4}
Regional visual read inspection of [18F]Flutemetamol brain images from end-of-life and amnestic MCI Subjects
Gill Farrar ¹ , Michelle Zanette ² 184
Tau mediates temporal lobe structure-function relationships and disrupts memory encoding in normal aging
Shawn Marks ¹ , Samuel Lockhart ¹ , Taylor Mellinger ¹ , Kaitlin Swinnerton ¹ , Andy Horng ¹ , Suzanne Baker ² , William Jagust ^{1,2}
AMYPAD: A European public-private partnership to investigate the value of β -amyloid brain scans as a diagnostic and therapeutic marker for Alzheimer's disease
Frederik Barkhof ^{1,2} , Gill Farrar ³ 186
Amyloid positivity is associated with steeper declines in prospective verbal episodic memory independent of neurodegeneration in cognitively normal older adults187
Murat Bilgel ¹ , Yang An ¹ , Gabriela Gomez ¹ , Jessica Helphrey ¹ , Wendy Elkins ¹ , Dean Wong ² , Susan Resnick ¹
Tau burden localized in functional brain networks is associated with cognitive performance in beta amyloid positive subjects across the Alzheimer's spectrum189
Arnaud Charil ¹ , Sergey Shcherbinin ¹ , Sudeepti Southekal ² , Abhinay D Joshi ² , Michael D Devous ² , Bradley B Miller ¹ , Adam J Schwarz ¹ 189
Gait variability, an indicator of subclinical amyloid burden
Qu Tian ¹ , Woei-Nan Bair ¹ , Murat Bilgel ¹ , Dean Wong ² , Susan Resnick ¹ , Stephanie Studenski ¹ 191
Does the tau signal increase over time differ across brain regions and stage of impairment in Alzheimer's disease?
Sergey Shcherbinin ¹ , Mark Mintun ² , Claire Brittain ³ , Ming Lu ² , Abhinay Joshi ² , Sudeepti Southekal ² , Michael Devous ² , Adam Schwarz ¹ 192
MRI-based amyloid imaging in Alzheimer's disease on clinical scanner
Dmitriy Yablonskiy, Yue Zhao, Tammie Benzinger,

Andrei Vlassenko, Serguei Astafiev, Marcus Raichle, John Morris
Years to parental symptom onset predicts amyloid burden, neurodegeneration and resting state connectivity changes in healthy elderly with a parental history of Alzheimer's disease
Sylvia Villeneuve ^{1,3,4} , Jacob W. Vogel ^{3,4} , Julie Gonneaud ^{1,4} , Judes Poirier ^{1,4} , Pedro Rosa-Neto ⁵ , Anne M. Fagan ^{1,2,4} , Randall Bateman ⁵ , John Morris ⁷ , Alexa Pichet Binnette ^{1,3,4} , Etienne Vachon-Presseau ¹⁰ , Tammie L. Benzinger ^{6,7} , Sterling Johnson ^{9,10} , John C. Breitner ^{1,3} , for the PREVENT-AD Research Group . ³
Clinical significance of visually equivocal amyloid PET on ADNI cohort
Minyoung Oh ¹ , Minjung Seo ² , Sun Young Oh ³ , Jungsu S. Oh ¹ , Jee Hoon Roh ⁴ , Jae-Hong Lee ⁴ , Jae Seung Kim ¹
Severity of lifetime trauma is related to hippocampal tau deposition in Vietnam war veterans with PTSD
Susan Landau ¹ , Andy Horng ¹ , Thomas Neylan ² , William Jagust ¹ , Jacqueline Hayes ² , Paul Aisen ⁴ , Ronald Petersen ⁵ , Dallas Veitch ² , Clifford Jack ⁵ , Charles DiCarli ⁸ , Andrew Saykin ⁶ , Jordan Grafman ⁷ , Duygu Tosun ² , Michael Weiner ²
Relationships between tau and glucose metabolism differ by amyloid status in aging
Jenna Adams ¹ , Samuel Lockhart ¹ , William Jagust ^{1,2} 199
Relationships between NREM-sleep fragmentation and changes in brain structure, metabolism, amyloid burden and cognitive performance in healthy older adults 200
Géraldine Rauchs ¹ , Claire Andre ¹ , Cléménce Tomadesso ¹ , Florence Mezenge ¹ , Pierre Branger ² , Morgane Fossey ¹ , Robin de Flores ¹ , Alice Laniepce ¹ , Francis Eustache ¹ , Gaël Chetelat
Is microglial activation protective in mild cognitive impairment?
Grazia Daniela Femminella ¹ , Melanie Dani ¹ , Melanie Wood ¹ , Zhen Fan ¹ , Valeria Calsolaro ¹ , Ruth Mizoguchi ¹ , Rebecca Atkinson ¹ , Trudi Edginton ² , Adam Waldman ¹ , Rainer Hinz ³ , David Brooks ^{1,4} , Paul Edison ¹
β-Amyloid PET imaging of neurodegenerative disorders in a Chinese specialty hospital
HW Qiao ¹ , John Seibyl ² , Y Han ¹ , W Mao ¹ , EH Xu ¹ , J Lu ¹ , Kenneth Marek ² , Gilles Tamagnan ² , Piu Chan ¹ 202
Potential for Braak staging based on quantitative analysis of THK 5351 PET images 203
Christopher Buckley ¹ , Elisabeth Lysvic ² , Grethe Dalsgaard ¹ , Nobuyuki Okamura ³
Both odor identification and amyloid status predict memory decline in older adults

William Kreisl ¹ , Peng Jin ¹ , Seonjoo Lee ¹ , Ezra Dayan ¹ , Shankar Vallabhajosula ² , Gregory Pelton ¹ , Leslie Shaw ³ , D. P. Devanand ¹ 205
Relationship between neuroticism and biomarkers of AD pathology in familial Alzheimer's disease206
Yakeel Quiroz ^{1,2} , Ana Baena ² , Daniel Norton ¹ , Danielle Cosio ¹ , Aaron Schultz ¹ , Jennifer Gatchel ¹ , Reisa Sperling ¹ , Keith Johnson ¹ , Francisco Lopera ² 206
Functional network integrity predicts cognitive decline in preclinical Alzheimer's disease
Rachel Buckley ^{1,2,3,4} , Aaron Schultz ^{3,5,6} , Trey Hedden ^{4,5} , Kathryn Papp ^{3,4,9} , Bernard Hanseeuw ^{3,4,5} , Gad Marshall ^{3,4,9} , Jorge Sepulcre ^{5,7} , Emily Smith ⁸ , Dorene Rentz ^{3,4,9} , Keith Johnson ^{3,4,5,9,10} , Reisa Sperling ^{3,4,9} , Jasmeer Chhatwal ^{3,4,9} 207
Subjective cognitive concerns exhibit region-specific relationships with tauopathy in the Harvard Aging Brain Study
Rachel Buckley ^{1,2,3,4} , Bernard Hanseeuw ^{2,4,5} , Patrizia Vannini ^{3,4,5} , Elizabeth Mormino ^{3,4} , Dorene Rentz ^{3,4,7} , Reisa Sperling ^{3,4,7} , Keith Johnson ^{3,4,5,7,8} , Rebecca Amariglio ^{3,4,7}
Longitudinal Measures of Cognition and Clinical Status are Associated with Tau Deposition in Early Symptomatic Stages of AD211
Shannon Risacher ^{1,2} , Kacie Deters ^{1,2} , Adam Schwarz ^{3,4} , Andrew Saykin ^{1,2} 211
Determining smallest detectable difference from longitudinal data – Application to hippocampal volume data from ADNI
Aniket Joshi ¹ , Dai Feng ² , Richard Baumgartner ² 212
Additive effects of subjective cognitive decline and amyloid-β burden predict cognitive decline in healthy elderly individuals
Jacob Vogel ¹ , Monika Varga Dolezalova ¹ , Renaud La Joie ² , Shawn Marks ¹ , Henry Schwimmer ¹ , Susan Landau ¹ , William Jagust ¹ 214
Amyloid- β associated cortical thinning of the lateral temporo-parietal cortex predicts symptom severity over time in amnestic MCI patients
Federico d'Oleire Uquillas ¹ , Heidi I.L. Jacobs ² , Michael Properzi ¹ , Aaron P. Schultz ^{1,3} , Molly R. LaPoint ¹ , Bernard Hanseeuw ^{2,4} , Keith A. Johnson ^{2,3,4} , Reisa A. Sperling ^{1,3,4} , Patrizia Vannini ^{2,3,4} 216
Does high baseline amyloid predict declines in activity participation and need for cognition over four years? Results from the Dallas Lifespan Brain Study218
Allison Parker ¹ , Sara Festini ¹ , Michelle Farrell ¹ , Denise Park ¹ 218
Amyloid- β related memory decline is modified by years of school education in cognitively normal subjects: A study of PiB PET and cognitive reserve

Takashi Kato ^{1,2} , Iwata Kaori ² , Izumi Kuratsubo ² , Yoshitaka Inui ¹ , Naohiko Fukaya ¹ , Kengo Ito ¹ , Akinori Nakamura ² , Study Group MULNIAD ²
Memory encoding and recalling assessed by functional Near-Infrared Spectroscopy
Sahar Jahani ¹ , David Harper ² , Jim Ellison ² , Antoniu Fantana ¹ , David Boas ¹ , Meryem Yucel ¹
Associations between regional amyloid load, cortical thickness, APOE genotype and cognition in ADNIGO/ADNI2 participants
Chunfei Li ¹ , Ranjan Duara ^{2,4} , David A. Loewenstein ^{3,4,5} , Mercedes Cabrerizo ¹ , Warren Barker ^{2,4} , Malek Adjouadi ^{1,4}
Regional uptake of FDDNP and exposure to professional fighting
Sarah Banks ¹ , Vladimir Kepe ² , Frank DiFilippo ² , Bern Lee ¹ , Jorge Barrio ² , Charles Bernick ¹
Tau imaging in professional fighters
Sarah Banks, Karthik Sreenivisan, Charles Bernick 226
Clinical utility of amyloid PET in amnestic mild cognitive impairment
Ko Woon Kim ¹ , Jin San Lee ¹ , Young Kyoung Jang ¹ , Sang Won Seo ^{1,2}
Relationships between [11C]PIB, [18F]AV1451 PET, and gray matter volumes within functional networks in Alzheimer's disease
Jungho Cha ¹ , Alexandre Bejanin ¹ , Renaud La Joie ¹ , Nagehan Ayakta ¹ , Suzanne L. Baker ³ , Mustafa Janabi ³ , James P. O'Neil ³ , Bruce L. Miller ¹ , William J. Jagust ^{2,3} , Gil D. Rabinovici ^{1,2}
Prevalence of amyloid PET positivity according to APOE genotype in subcortical vascular cognitive impairment 230
Jin San Lee ¹ , Seonwoo Kim ² , Heejin Yoo ² , Seongbeom Park ¹ , Yeongsim Choe ¹ , Young Kyoung Jang ¹ , Rik Ossenkoppele ³ , Ko Woon Kim ¹ , Yeshin Kim ¹ , Hyemin Jang ¹ , Hee Jin Kim ¹ , Key-Chung Park ⁴ , Duk L. Na ¹ , Sang Won Seo ¹
Genetic drivers of resilience in asymptomatic Alzheimer's disease
Timothy Hohman, Logan Dumitrescu
Heterogeneity of amyloid-related cognitive decline in clinically normal older adults
Kate Papp ¹ , Dorene Rentz ^{1,2} , Rebecca Amariglio ² , Aaron Schultz ² , Keith Johnson ^{1,2} , Reisa Sperling ^{1,2} , Elizabeth Mormino ²
Predicting the rate of amyloid accumulation using multimodal data
Yan Jin ¹ , Shuai Huang ¹ , the ADNI ²
PET based network analysis reveals temporal lobe as a hub for tau propagation in MCI
Sulantha Mathotaarachchi ^{1,2} , Tharick Pascoal ^{1,2} , Monica Shin ^{1,2} , Min Su Kang ^{1,2} , Vladimir Fonov ^{1,2} ,

Andrea Benedet ^{1,2} , Serge Gauthier ¹ , Pedro Rosa- Neto ^{1,2} 236
Regional tau correlates of instrumental activities of daily living and apathy in mild cognitive impairment and Alzheimer's disease dementia238
Gad Marshall ^{1,2} , Jennifer Gatchel ⁴ , Nancy Donovan ^{4,5} , Aaron Schultz ³ , J. Alex Becker ³ , Jasmeer Chhatwal ² , Bernard Hanseeuw ² , Kathryn Papp ^{1,2} , Rebecca Amariglio ^{1,2} , Dorene Rentz ^{1,2} , Reisa Sperling ^{1,2} , Keith Johnson ^{1,3}
Friday, January 13, 2017 - 10:15 am - 11:15 am239
SESSION 8: Preclinical AD239
Implementing and testing the new A/T/N classification in AIBL participants combining fluid (CSF) and different $A\beta\Box$ and tau imaging radiotracers240
Samantha C Burnham ^{1,2} , Christopher C Rowe ³ , Pierrick Bourgeat ⁴ , Vincent Doré ^{3,4} , Greg Savage ⁵ , Simon Laws ² , Qiao-Xin Li ⁶ , Steven Collins ⁶ , Ralph Martins ² , Olivier Salvado ⁴ , Colin L Masters ⁶ , Victor L Villemagne ^{3,6}
The relationship of elevated medial temporal lobe and diffuse brain Tau-PET signal in clinically normal participants241
Val Lowe ¹ , Emily Lundt ¹ , Heather Wiste ¹ , Ping Fang ¹ , Matthew Senjem ¹ , Bradley Boeve ¹ , Keith Josephs ¹ , Mukesh Pandey ¹ , Melissa Murray ² , Kejal Kantarci ¹ , David Jones ¹ , Christopher Schwarz ¹ , David Knopman ¹ , Ronald Petersen ¹ , Clifford Jack ¹ 241
Prevalence and incidence of amyloid positivity in cognitively normal elderly individuals243
Neelesh Nadkarni ^{1,5} , Dana Tudorascu ^{2,4} , Beth Snitz ^{3,5} , Edythe Halligan ³ , Annie Cohen ^{4,5} , Howard Aizenstein ^{3,4} , Oscar Lopez ^{3,4,5} , William Klunk ^{4,5} 243
Longitudinal tau accumulation is associated with cognitive decline in normal elderly244
Bernard Hanseeuw, Alex Becker, Aaron Schultz, Jorge Sepulcre, Beth Mormino, Kate Papp, Heidi Jacobs, Danielle Cosio, Jasmeer Chhatwal, Trey Hedden, Reisa Sperling, Keith Johnson244
Baseline amyloid burden predicts cognitive decline four years later in healthy adults: the value of a dose-response analysis
Michelle E. Farrell ¹ , Kristen M. Kennedy ¹ , Karen M. Rodrigue ¹ , Gagan S. Wig ¹ , Gérard N. Bischof ² , Xi Chen ¹ , Sara B. Festini ¹ , Denise C. Park ¹ 246
Friday, January 13, 2017 - 12:00 pm - 12:45 pm248
Keynote Lecture
Alzheimer's disease clinical trials: 2017 update—Staying the course? Correcting the course? Shifting the paradigms used in trials?
Howard Feldman
Friday, January 13, 2017 - 02:15 pm - 03:15 pm249

SESSION 9: Amyloid, Tau, and Neurodegeneration ... 249

Neocortical Tau and hippocampus volume reflect distinct processes in preclinical Alzheimer's disease	
Elizabeth Mormino ¹ , Aaron Schultz ¹ , Kathryn Papp ¹ , Molly LaPoint ¹ , Bernard Hanseeuw ¹ , Trey Hedden ¹ , Dorene Rentz ¹ , Reisa Sperling ¹ , Keith Johnson ¹ 250	
Do neurodegeneration or amyloid pathology contribute to the relationship between AV-1451 and cognitive symptoms in Alzheimer's disease?	
Alexandre Bejanin ¹ , Daniel R. Schonhaut ¹ , Renaud La Joie ¹ , Joel H. Kramer ¹ , Suzanne L. Baker ² , James P. O'Neil ² , Bruce L. Miller ¹ , William J. Jagust ^{2,3} , Gil D. Rabinovici ^{1,3}	
Comparing the contributions of tau and neurodegenerative biomarkers to cognitive decline	
Susan Landau, Andy Horng, William Jagust 255	
Differential genotypic variance in PET and CSF measures of amyloid burden: findings from the DIAN Study 256	
Jasmeer Chhatwal ¹ , Eric McDade ² , Peter Wang ² , Tammie Benzinger ² , Anne Fagan ² , Aaron Schultz ¹ , Bernard Hanseeuw ¹ , Colin Masters ³ , Adrian Danek ⁵ , Peter Schofield ⁴ , Martin Farlow ⁷ , John Morris ² , Randall Bateman ¹ , Keith Johnson ¹ , Reisa Sperling. 256	
Relationships between AV1451-PET and CSF biomarkers in a heterogeneous clinical sample	
Renaud La Joie ¹ , Alexandre Bejanin ^{2,3,4} , Anne Fagan ¹ , Nagehan Ayakta ⁵ , Suzanne Baker ¹ , Viktoriya Bourakova ¹ , Anna Karydas ⁵ , James O'Neil ¹ , Julie Pham ¹ , Adrienne Visani ¹ , Howard Rosen ¹ , Adam Boxer ¹ , Bruce Miller ¹ , William Jagust ^{5,6} , Gil Rabinovici ^{1,6}	
Friday, January 13, 2017 - 04:00 pm - 04:45 pm 261	
Poster Session 3B	
Friday, January 13, 2017 - 04:50 pm - 05:35 pm 261	
SESSION 10: Amyloid and Tau PET in Distinct Populations	
Association of regional FDG hypometabolism with age, amyloid, tau, and cardiac and metabolic conditions along	

the AD continuum

Prashanthi Vemuri, Val Lowe, David Knopman, Jonathan Graff-Radford, David Jones, Matthew Senjem, Heather Wiste, Mary Machulda, Ronald Petersen, Clifford Jack Jr262
18F-AV1451 PET in patients with subcortical vascular cognitive impairment
Hee Jin Kim ¹ , Hanna Cho ² , Seongbeom Park ¹ , Young Kyoung Jang ¹ , Jin San Lee ¹ , Hyemin Jang ¹ , Yeshin Kim ¹ , Ko Woon Kim ¹ , Young Hoon Ryu ³ , Jae Yong Choi ³ , Duk L. Na ¹ , Chul Hyoung Lyoo ² , Sang Won Seo ¹
White matter hyperintensities and brain amyloid deposition: The ARIC-PET Study264
Rebecca Gottesman ¹ , Zeyi Wang ¹ , Yun Zhou ¹ , Brian Caffo ¹ , Edward Green ² , Naresh Gupta ³ , Timothy Hughes ⁴ , Cliff Jack ⁵ , David Knopman ⁵ , Akiva Mintz ⁴ , Arman Rahmim ¹ , A. Richey Sharrett ¹ , Lynne Wagenknecht ⁴ , Dean Wong ¹ , Thomas Mosley ² 264
Association of amyloid-β plaque accumulation and glucose hypometabolism in Down syndrome demonstrates pattern associated with Alzheimer's disease266
Patrick Lao ¹ , Tobey Betthauser ¹ , Julie Price ² , William Klunk ² , Peter Bulova ² , Sigan Hartley ¹ , Regina Hardison ² , Rameshwari Tumuluru ² , Dhanbalan Murali ¹ , Chester Mathis ² , Annie Cohen ² , Todd Barnhart ¹ , Dana Tudorascu ² , Darlynne Devenny ³ , Charles Laymon ² , Sterling Johnson ¹ , Ben Handen ² , Bradley Christian ¹

PRESENTER INDEX

Last Name, First Name – Abstract ID	Page #
Adams, Jenna - 83	199
Andrea, Nicolas - 138	
Baker, Suzanne - 137	
Banks, Sarah - 153	
Banks, Sarah - 154	
Barkkof, Frederik - 45	
Barret, Olivier - 125	69
Beach, Thomas - 131	
Beason-Held, Lori - 54	108
Becker, J. Alex - 183	
Bejanin, Alexandre - 84	
Betthauser, Tobey - 157	
Betthauser, Tobey - 172	
Bilgel, Murat - 46	
Bogdanovic, Nenad - 43	107
Buckley, Christopher - 100	203
Buckley, Christopher - 87	
Buckley, Rachel - 115	
Buckley, Rachel - 120	
Calsolaro, Valeria - 101	63
Carbonell, Felix - 29	
Carter, Stephen - 76	55
Cha, Jungho - 163	
Charil, Arnaud - 47	189
Chen, Po-Yen - 70	
Chhatwal, Jasmeer - 182	
Chiotis, Konstantinos - 104	66
d'Oleire Uquillas, Federico - 136	
Dani, Melanie - 73	116
David, Wolk - 90	
DeCarli, Charles - 185	
Devous, Sr., Michael D 31	179
Diamond, Marc	
Dickerson, Brad - 86	119
Duara, Ranjan - 147	
Ekblad, Laura - 89	120
Fantana, Antoniu - 149	220
Farrar, Gill - 42	
Farrar, Gill - 45	186
Farrell, Michelle E 155	

Feldman, Howard249
Femminella, Grazia Daniela - 88201
Franzmeier, Nicolai - 57109
Gomperts, Stephen - 91121
Gottesman, Rebecca - 114264
Groot, Colin - 10767
Guo, Qi - 12794
Gunn, Roger93
Gurol, Edip - 63111
Hanseeuw, Bernard - 140244
Hanseeuw, Bernard - 142136
Hansen, Allan - 79118
Harada, Ryuichi - 8296
Heurling, Kerstin - 1435
Hohman, Timothy - 165232
Honer, Michael - 9962
Ikonomovic, Milos - 179150
Ikonomovic, Milos - 64157
Imai, Masamichi - 166145
Jack, Clifford - 41171
Jacobs, Heidi - 146139
Jang, Young Kyoung - 161144
Jin, Yan - 169234
Jones, David - 150167
Joshi, Aniket - 126212
Kang, Min Su - 186154
Kato, Takashi - 143219
Kim, Ko Woon - 160227
Kimura, Yuichi - 7254
Kirn, Dylan - 171147
Koeppe, Robert171
Koga, Shunsuke - 9458
Kreisl, William - 10169
Kreisl, William - 106205
La Joie, Renaud - 170258
Landau, Susan - 181255
Landau, Susan - 81197
Lao, Patrick - 10264
Lao, Patrick - 110266
Leal, Stephanie - 1100
Lee, Christopher - 158164

Lee, Jin San - 164	
Lemoine, Laetitia - 122	
Li, Chunfei - 152	
Lin, Yin-Guo Lin - 58	
Lockhart, Samuel - 68	
Lockhart, Samuel - 69	
Lowe, Val - 109	
Lowe, Val - 162	
Maass, Anne - 7	
Markiewicz, Pawel - 151	75
Marks, Shawn - 44	
Marquie-Sayagues, Marta - 34	106
Marquie-Sayagues, Marta - 39	
Marshall, Gad - 180	
Martersteck, Adam - 176	
Mathotaarachchi, Sulantha - 178	
Matthews, Dawn - 141	
McLaren, Donald - 132	71
McMillan, Corey - 75	159
Merluzzi, Andrew - 173	
Minhas, Davneet - 133	
Mintun, Mark - 60	
Mormino, Elizabeth - 177	
Nadkarni, Neelesh - 67	
Navitsky, Michael - 32	
Ng, Kok Pin - 187	
Niemantsverdriet, Ellis - 40	
Oh, Hwamee - 19	
Oh, Minyoung - 77	
Ono, Maiko - 8	
Ottoy, Julie - 24	
Ottoy, Julie - 28	46
Pa, Judy - 117	
Papp, Kate - 167	
Parker, Allison - 139	
Pascoal, Tharick - 184	
Pascual, Belen - 97	
Properzi, Michael - 105	
Quiroz, Yakeel - 108	
Rabin, Jennifer S 123	
Rabinovici, Gil - 130	
Rauchs, Géraldine - 85	
Risacher, Shannon - 124	

Rodriguez-Vieitez, Elena - 144	138
Rowe, Christopher C - 65	51
Salinas, Cristian - 59	50
Sanabria, Sandra - 3	32
Schultz, Aaron - 95	60
Schwarz, Christopher - 21	38
Seibyl, John - 92	202
Seo, Sang Won - 156	
Seo, Sang Won - 159	80
Shcherbinin, Sergey - 55	192
Shimada, Hitoshi - 74	90
Southekal, Sudeepti - 22	40
Sperling, Reisa - 128	176
Srivatsa, Shantanu - 135	134
Su, Yi - 93	57
Su, Yi - 98	123
Sur, Cyrille - 16	89
Tamagnan, Gilles - 50	49
ten Kate, Mara - 78	117
Tian, Qu - 52	191
Timmers, Tessa - 96	61
Tudorascu, Dana - 119	128
Utianski, Rene - 5	101
Vemuri, Prashanthi - 121	262
Villemagne, Victor L - 48	240
Villeneuve, Sylvia - 62	194
Vogel, Jacob - 134	214
Weimer, Robby - 80	91
Whitwell, Jennifer - 112	126
Whitwell, Jennifer - 113	28
Winer, Joseph - 111	124
Wong, Dean - 129	70
Wren, Melissa - 66	166
Yablonskiy, Dmitriy - 61	193
Yamada, Takahiro - 15	36
Zeydan, Burcu - 116	127

POSTER INDEX (www.worldeventsforum.com/hai/posters) WEDNESDAY

Abs. ID	Board #	Poster Title	Authors	Presenter
125	1	Kinetic modeling of the tau PET tracer [18F](S)THK-5351 in healthy controls and Alzheimer's disease subjects	Barret Constantinescu Buckley Dalsgaard Gibson Purohit Beaver Seibyl Tamagnan Marek Jennings Salinas-Valenzuela	Barret
183	2	A cortical cluster-based measure of change in longitudinal 18F-T807 FTP PET	Becker Cosio Lee Andrea Sperling Johnson	Becker
157	3	Comparison of region of interest segmentation methods for extraction of 11C-PiB SUVR in the Down syndrome population	Betthauser Lao Tudorascu Price Bulova Hartley Hardison Tumuluru Minhas Laymon Murali Mathis Cohen Barnhart Devenny Klunk Johnson Handen Christian	Betthauser
172	4	A comparison of DVR and SUVR methods for THK5317 and THK5351	Betthauser Lao Murali Barnhart Furumoto Okamura Stone Johnson Christian	Betthauser
87	5	[18F]flutemetamol – quantification on the centiloid scale	Buckley Battle Smith Van Laere Vandenberghe Lowe	Buckley
101	6	Evaluation of Caspase-3 Activation in AD using [18F]ICMT-11 PET/CT	Calsolaro Femminella Fan Dani Kozlowski Aboagye Edison	Calsolaro
76	7	Cerebral Brain Perfusion in Cognitively Normal Elderly: Measured with Arterial Spin Labelling and [18F]Flutemetamol PET	Carter Parkes Hinz Pendleton Herholz	Carter
70	8	Selection of reference region for 18F-THK- 5351 PET imaging analysis	Chen Hsiao Lin Huang	Chen
104	9	Head-to-head comparison of tau-specific tracers in Alzheimer's disease: [11C]THK5351 vs [11C]PBB3 PET imaging	Chiotis Stenkrona Almkvist Arakawa Takano Stepanov Varrone Higuchi Halldin Nordberg	Chiotis
107	10	Flow changes affect SUVr but not binding potential in an AD clinical trial	Groot Timmers Ossenkoppele Yaqub Prins Lammertsma Scheltens van Berckel	Groot
14	11	Optimization of early phase [18F]flutemetamol scanning window as a proxy for relative tracer delivery	Heurling Van Laere Vandenberghe Buckley Farrar Lubberink	Heurling
99	12	In vitro binding of [3H]RO6958948, [3H]AV- 1451, [3H]THK5351 and [3H]T808 to tau aggregates in non-AD tauopathies	Honer Gobbi Muri Borroni	Honer
174	13	Measuring amyloid change using florbetapir over a 4 year interval in SUVR and Centiloid units	Joshi Navitsky Kennedy Pontecorvo Mintun Devous Sr., ADNI	Joshi
72	14	Noise reduction algorithm for amyloid imaging without loss of image resolution	Kimura Fujii Yamada Hosokawa Sakata Murakami Ishii	Kimura
94	15	Binding of a tau positron emission tomography ligand, PBB3, to alpha synuclein pathology as assessed by fluorescence and autoradiographic labeling	Koga Ono Sahara Higuchi Dickson	Koga
102	16	Considerations for defining a striatal region of interest in amyloid PET studies within the Down syndrome population	Lao Betthauser Price Klunk Bulova Hartley Hardison Tumuluru Murali Mathis Cohen Barnhart Tudorascu Devenny Laymon Johnson Handen Christian	Lao
151	17	High quantitative accuracy amyloid PET imaging with precision estimation	Markiewicz Erlandsson Schott Scott Cash Barkhof Fox Ourselin	Markiewicz
141	18	The quantitative impact of emission- transmission scan misalignment and region selection upon amyloid measurement accuracy	Matthews Matthews Smith	Matthews
132	19	Longitudinal Centiloid Change in ADNI [18F]Florbetapir PET Data: Implications for Clinical Trials	McLaren Carbonell Auclair Zijdenbos Joshi Navitsky Mintun Chiao Bedell	McLaren
133	20	FreeSurfer approach to the Centiloid standardization method: evaluation of	Minhas Lopresti Aizenstein Laymon Campbell Yu Tudorascu Mathis Klunk	Minhas

Abs. ID	Board #	Poster Title	Authors	Presenter
		alternative cortical target regions and partial volume correction		
187	21	Selegiline reduces brain [18F]THK5351 binding	Ng Massarweh Soucy Gravel Pascoal Mathotaarachchi Kang Shin Therriault Levasseurr Horowitz Gauthier Rosa-Neto	Ng
8	22	Development of novel tau PET tracers, [18F]AM-PBB3 and [18F]PM-PBB3	Ono Kitamura Shimada Sahara Takuwa Yoshiyama Trojanowski Lee Suhara Zhang Jang Tamagnan Marek Higuchi	Ono
24	23	Validation of the semi-quantitative static SUVR method by pharmacokinetic modeling on dynamic cross-sectional [18F]-AV45 data	Ottoy Verhaeghe Niemantsverdriet Wyffels Somers De Roeck Struyfs Soetewey Deleye Van den Bossche Van Mossevelde Ceyssens Versijpt Stroobants Engelborghs Staelens	Ottoy
28	24	A simulation study on the quantification of the blood flow-dependent component in [18F]- AV45 SUVR differences between the MCI and AD stage	Ottoy Verhaeghe Stroobants Engelborghs Staelens	Ottoy
117	25	Developing a tracer agnostic pipeline for amyloid and tau PET data	Hobel Baker Ellis Pa	Ра
65	26	Implementation of the Centiloid transformation for 18F-florbetaben	Rowe Jones Dore Baxendale Mulligan Stephens De Santi Masters Dinkelborg Villemagne	Rowe
59	27	Quantitative analysis and correlation with clinical endpoints of [18F]MK6240 targeting neurofibrillary tangles (NFTs) in healthy volunteers and subjects with AD	Salinas Chiao Purohit Schmidt Beaver Sur Struyk Bennacef Lohith Evelhoch Hiatt Tamagnan Jennings Marek Hargreaves	Salinas
3	28	Kinetics of [18F]GTP1 (Genentech tau probe 1) in the basal ganglia of Alzheimer's patients and healthy controls	Sanabria Bohorquez Bentsson Barret Tamagnan Alagille de Crespigny Ayalon Ward Kerchner Jennings Seibyl Marek Weimer Marik	Sanabria
95	29	A computationally efficient method for making PET measurements: the T1-GTM approach.	Schultz Sperling Johnson	Schultz
21	30	Rigid registration contributes significant imprecision to amyloid PET SUVR measurements	Schwarz Jones Gunter Lowe Vemuri Senjem Petersen Knopman Jack	Schwarz
159	31	Comparison of tau distribution according to tau tracers in various neurodegenerative diseases: Using [18F]AV1451 and [18F]THK-5351	Jang Rabinovich Kim Lee Kim Seo	Seo
22	32	18F-Flortaucipir SUV normalization using a Parametric Estimate of Reference Signal Intensity (PERSI)	Southekal Devous Sr. Kennedy Navitsky Lu Joshi Pontecorvo Mintun	Southekal
93	33	Blood-brain barrier disruption in AD measured by PiB PET: a preliminary study	Su Vlassenko Raichle Morris Benzinger	Su
50	34	18F-PM-PBB3 a novel imaging tracer for visualization and quatification of TAU pathologies with Positron Emission Tomography	Tempest Jang Tamagnan Marek Seibyl Alagille Barret Higuchi Shimada Ono Suhara Zhang	Tamagnan
96	35	Simplified reference tissue methods in [18F]AV1451 PET	Timmers Golla Ossenkoppele Groot Verfaillie Scheltens van der Flier Schwarte Mintun Devous Schuit Windhorst Lammertsma Boellaard Yaqub van Berckel	Timmers
129	36	Longitudinal changes in [18]F-RO6958948 Tau PET signal in four Alzheimer's subjects	Wong Kuwabara Comley Klein Vozzi Honer Roberts Kitzmiller Gapasin Borroni	Wong
15	37	Algorithm for reference region delineation for amyloid imaging using pattern recognition scheme and kinetics of administered Aβ probe — considering the number of clusters	Yamada Kimura Nagaoka Hosokawa Murakami Ishii	Yamada

THURSDAY

Abs. ID	Board #	Poster Title	Authors	Presenter
138	1	Tau PET in subjects at risk for chronic traumatic encephalopathy	Andrea Alverio Lee Nowinski Jacobs McKee Johnson Jin	Andrea
131	2	Antemortem-postmortem correlation of florbeta-pir (18F) PET amyloid imaging with quantitative biochemical measures of Aβ40 and Aβ42	Beach Maarouf Intorcia Sue Serrano Roher	Beach
54	3	Metabolic Syndrome and Amyloid Accumulation in the Aging Brain	Gomez Beason-Held Bilgel An Studenski Resnick	Beason- Held
43	4	Measurement of pathological amyloid in routine clinical assessment: comparison of visual [18F]Flutemetamol PET and CSF	Bogdanovic Fantoni Farrar	Bogdanovic
29	5	Uncovering the local-to-distributed relationship between \hat{I}^2 -amyloid and glucose metabolism	Carbonell Mclaren Zijdenbos Bedell	Carbonell
73	6	Microglial activation correlates in vivo with tau aggregation and amyloid deposition in mild cognitive impairment and Alzheimer's disease	Dani Wood Mizoguchi Fan Morgan Walker Calsolaro Femminella Hinz Brooks Edison	Dani
86	7	Tau PET imaging and atrophy in neurodegenerative dementias	Dickerson McGinnis Gomperts Makaretz Wolk Schultz Vasdev Johnson	Dickerson
147	8	Greater regional cortical thickness is associated with selective vulnerability to atrophy in AD, independent of regional amyloid load	Li Duara Loewenstein Cabrerizo Barker Adjouadi	Duara
89	9	Insulin resistance in midlife increases the risk for brain amyloid accumulation 15 years later	Ekblad Johansson Laine Viitanen Jula	Ekblad
185	10	Staging of amyloid-beta, tau, regional atrophy rates and cognitive change in a non-demented cohort	Fletcher Renaud Nandi DeCarli	DeCarli
63	11	Detection of radiologic and laboratory features of cerebral amyloid angiopathy in patients with AD	Fotiadis Becker Schwab Rosand Viswanathan Sperling Johnson Greenberg Gurol Neuroimaging Initiative	Gurol
57	12	Left frontal global connectivity is a substrate of cognitive reserve in mild cognitively impaired patients with a high amyloid burden	Franzmeier Duering Weiner Dichgans Ewers	Franzmeier
91	13	Imaging tau deposition in the Lewy body diseases	Gomperts Locascio Makaretz Schultz Caso Neil Sperling Growdon Dickerson Johnson	Gomperts
142	14	PET staging of brain amyloidosis using striatum	Hanseeuw Betensky Mormino Schultz Papp Buckley Chhatwal Marshall Rentz Sperling Johnson	Hanseeuw
79	15	In vivo tau imaging in Parkinson's disease using 18F-AV-1451 PET	Hansen Damholdt Parbo Brooks Borghammer	Hansen
179	16	Contribution of neuritic and diffuse plaques to signal derived from CN-Flutemetamol: a preliminary study in AD autopsy brains	Ikonomovic Abrahamson Buckley Mathis Klunk Farrar	Ikonomovic
166	17	Is tau accumulation detectable before neuronal injury markers? – Analysis from tau PET imaging with [C-11]PBB3 in clinical variants of Alzheimer's disease	Imai Ishii Tanaka Ishibashi Wagatsuma Sakata Tago Toyohara Murayama Maruno Shimada Higuchi Suhara	Imai
146	18	Hippocampal cingulum integrity predicts change in tau accumulation in a downstream-connected region in amyloid-positive normal older individuals	Jacobs Schultz Amariglio Hedden Papp Perea Rentz Sepulcre Sperling Johnson	Jacobs
161	19	Distinctive clinical significance of hemorrhagic and amyloid imaging markers in patients with clinical- radiological cerebral amyloid angiopathy in memory clinic patients	Jang Lee Kim Seo	Jang
186	20	Increased level of CSF neurofilament light chain is associated with amyloidosis in transgenic rat model of AD	Kang Zimmer Shin Mathotaarachchi Pascoal Ng Zetterberg Soucy Poirier Gauthier Cuello Rosa-Neto Blennow	Kang
171	21	Investigation of gait speed and β -amyloid in older adults from the Harvard Aging Brain Study	Kirn Buckley Hanseeuw Amariglio Sperling Johnson	Kirn

Abs. ID	Board #	Poster Title	Authors	Presenter
1	22	Hippocampal activation is associated with longitudinal amyloid accumulation and cognitive decline	Leal Landau Bell Jagust	Leal
69	23	18F-AV-1451 PET demonstrates Braak stage- specific associations with limbic white matter integrity in normal aging	Lockhart Maass Marks Baker Jagust	Lockhart
68	24	Elevated 18F-AV-1451 PET tracer uptake detected in incidental imaging findings	Lockhart Ayakta Winer La Joie Rabinovici Jagust	Lockhart
34	25	[F-18]-AV-1451 binding correlates with neurofibrillary tangle Braak staging in postmortem brain tissue samples	Marquie-Sayagues Anton-Fernandez Siao Tick Chong Meltzer Saez-Calveras Verwer Ramanan Normandin Frosch Gomez-Isla	Marquie- Sayagues
173	26	Greater [F-18]THK-5351 binding in medial and ventral temporal lobe is associated with altered microstructure and reduced myelin	Merluzzi Adluru Schoen Dean Singh Christian Betthauser Lao Barnhart Dhanabalan Asthana Alexander Johnson Bendlin	Merluzzi
19	27	Lower white matter integrity is associated with higher amyloid deposition in older adults without dementia in two independent samples	Oh Narkhede Razlighi Stern Mayeux Brickman	Oh
184	28	PET tau and amyloid synergy in default mode network determines the clinical status in predementia stages of Alzheimer's disease	A. Pascoal Mathotaarachchi Kang Ng Soucy Gauthier Rosa-Neto	Pascoal
97	29	Nonfluent variant of primary progressive aphasia: Tau deposition in the language network	Pascual Zanotti-Fregonara Funk Rockers Pal Yu Spann Schulz Masdeu	Pascual
123	30	Global white matter diffusion characteristics predict longitudinal cognitive change independent- ly from amyloid accumulation in older adults	Rabin Perea Rachel Buckley Johnson Sperling Hedden	Rabin
130	31	[18F]AV1451 tau PET distinguishes PSP from controls and Parkinson's disease	Schonhaut McMillan Dickerson Siderowf Devous Tsai Winer Russell Litvan Roberson Kramer Pressman Nasrallah Baker Gomperts Johnson Grossman Jagust Boxer Rabinovici	Rabinovici
144	32	Tau PET imaging tracks both pathology and brain perfusion in non-AD tauopathies: a multimodal study	Rodriguez-Vieitez Leuzy Chiotis Saint-Aubert Almkvist Wall Nordberg	Rodriguez- Vieitez
135	33	Proteomics Signatures of AD: gender differences and relationship to pathological markers	Srivatsa Lucas Doraiswamy	Srivatsa
98	34	Longitudinal decrease of white matter PiB uptake in aging and AD	Su Chen Reiman Morris Benzinger	Su
78	35	Correlation of regional amyloid load in cognitively healthy monozygotic twin pairs, measured using [18F]Flutemetamol	ten Kate Konijnenberg den Braber Adriaanse Yaqub Boomsma Scheltens van Berckel Visser	ten Kate
119	36	Improved estimation of gray matter volume in presence of white matter hyperintensities in AD and Down syndrome studies with amyloid burden	Tudorascu Karim Alhilali Lao Betthauser Tamburo Maccloud James Minhas Cohen Snitz Price Lopresti Mathis Lopez Johnson Crainiceanu Handen Christian Aizenstein Klunk	Tudorascu
5	37	Tau-PET imaging with [18F]AV-1451 in progressive apraxia of speech with and w/aphasia	Utianski Whitwell Schwarz Senjem Tosakulwong Duffy Clark Machulda Jack Lowe Josephs	Utianski
112	38	Longitudinal tau-PET imaging using [18F]AV- 1451 in progressive supranuclear palsy	Whitwell Lowe Boeve Kantarci Senjem Tosakulwong Schwarz Spychalla Petersen Jack Josephs	Whitwell
111	39	18F-AV-1451 and 11C-PIB PET do not explain impairment in Parkinson's disease	Winer Pressman Stiver Maass Schonhaut Kramer Rabinovici Jagust	Winer
116	40	Pittsburgh compound-B PET and MRI biomarkers of cognition in aging multiple sclerosis patients	Zeydan Lowe Przybelski Schwarz Tosakulwong Zuk Senjem Gunter Roberts Mielke Benarroch Rodriguez Machulda Lesnick Knopman Petersen Jack Jr Kantarci Kantarci	Zeydan

FRIDAY

Abs.	Board	Poster Title	Authors	Presenter
ID	#			
83	1	Relationships between tau and glucose metabolism differ by amyloid status in aging	Adams Lockhart Jagust	Adams
153	2	Regional Uptake of FDDNP and Exposure to Professional Fighting	Banks Kepe DiFilippo Lee Barrio Bernick	Banks
154	3	Tau Imaging in Professional Fighters	Banks Sreenivisan Bernick	Banks
46	4	Amyloid positivity is associated with steeper	Bilgel An Gomez Helphrey Elkins Wong	Rilgel
40	-	declines in prospective verbal episodic memory independent of neurodegeneration in cognitively normal older adults	Resnick	bliger
115	5	Functional network integrity predicts cognitive decline in preclinical Alzheimer's disease	Buckley Schultz Hedden Papp Hanseeuw Marshall Sepulcre Smith Rentz Johnson Sperling Chhatwal	Buckley
100	6	Potential for Braak staging based on quantitative analysis of THK 5351 PET images'	Buckley Lysvic Dalsgaard Okamura	Buckley
120	7	Subjective cognitive concerns exhibit region-specific relationships with tauopathy in the Harvard Aging Brain Study	Buckley Hanseeuw Vannini Mormino Rentz Sperling Johnson Amariglio	Buckley
163	8	Relationships between [11C]PIB, [18F]AV1451 PET, and gray matter volumes within functional networks in Alzheimer's Disease	Cha Benjanin La Joie Ayakta L. Baker Janabi O'Neil Miller J. Jagust D. Rabinovici	Cha
47	9	Tau burden localized in functional brain networks is associated with cognitive performance in beta amyloid positive subjects across the AD spectrum	Charil Shcherbinin Southekal Joshi Devous Miller Schwarz	Charil
136	10	Amyloid-beta associated cortical thinning of the lateral temporo-parietal cortex predicts symptom severity over time in amnestic MCI patients	d'Oleire Uquillas Jacobs Properzi Schultz LaPoint Hanseeuw Johnson Sperling Vannini	d'Oleire Uquillas
149	11	Memory Encoding and Recalling assessed by functional Near-Infrared Spectroscopy	Jahani Harper Ellison Fantana Boas Yucel	Fantana
42	12	Regional Visual Read Inspection of [18F]Flutemetamol Brain Images from End-of-Life and amnestic MCI Subjects	Farrar Zanette	Farrar
45	13	AMYPAD: A European public-private partnership to investigate the value of beta-amyloid brain scans as a diagnostic and therapeutic marker for AD	Barkhof Farrar	Farrar
88	14	Is microglial activation protective in mild cognitive impairment?	Femminella Dani Wood Fan Calsolaro Mizoguchi Atkinson Edginton Waldman Hinz Brooks Edison	Femminella
165	15	Genetic Drivers of Resilience in Asymptomatic AD	Hohman Dumitrescu	Hohman
169	16	Predicting the Rate of Amyloid Accumulation Using Multimodal Data	Jin Huang ADNI	Jin
126	17	Determining smallest detectable difference from longitudinal data – Application to hippocampal volume data from ADNI	Joshi Feng Baumgartner	Joshi
143	18	Amyloid-beta related memory decline is modified by years of school education in cognitively normal subjects: A study of PiB PET and cognitive reserve	Kato Kaori Kuratsubo Inui Fukaya Ito Nakamura MULNIAD	Kato
160	19	Clinical Utility of Amyloid PET in amnestic mild cognitive impairment.	Kim Lee Jang Seo	Kim
106	20	Both odor identification and amyloid status predict memory decline†in older adults	Kreisl Jin Lee Dayan Vallabhajosula Pelton Shaw Devanand	Kreisl
81	21	Severity of lifetime trauma is related to hippocampal tau deposition in Vietnam war veterans with PTSD	Landau Horng Neylan Jagust Hayes Aisen Petersen Veitch Jack DiCarli Saykin Grafman Tosun Weiner	Landau
164	22	Prevalence of amyloid PET positivity according to APOE genotype in subcortical vascular cognitive impairment	Lee Kim Yoo Park Choe Jang Ossenkoppele Kim Kim Jang Kim Park Na Seo	Lee

Abs.	Board	Poster Title	Authors	Presenter
ID	#			
152	23	Associations between regional amyloid load, cortical thickness, APOE genotype and cognition in ADNIGO/ADNI2 Participants	Li Duara Loewenstein Cabrerizo Barker Adjouadi	Li
44	24	Tau mediates temporal lobe structure-function relationships and disrupts memory encoding in normal aging	Marks Lockhart Mellinger Swinnerton Horng Baker Jagust	Marks
180	25	Regional tau correlates of instrumental activities of daily living and apathy in mild cognitive impairment and Alzheimer's disease dementia	Marshall Gatchel Donovan Schultz Becker Chhatwal Hanseeuw Papp Amariglio Rentz Sperling Johnson	Marshall
178	26	PET based network analysis reveals temporal lobe as a hub for tau propagation in MCI	Mathotaarachchi Pascoal Shin Kang Fonov Benedet Gauthier Rosa-Neto	Mathota- arachchi
40	27	Concordance improves between amyloid-PET and CSF amyloid- β for diagnosing Alzheimer's disease in a clinical setting by applying A β 1-42/A β 1-40 ratio	Niemantsverdriet Ottoy Verhaeghe Somers De Roeck Struyfs Soetewey Bjerke Van den Bossche Van Mossevelde Goeman De Deyn Marien Versijpt Parizel Sleegers Van Broeckhoven Wyffels Albert Ceyssens Stroobants Staelens Engelborghs	Niemants- verdriet
77	28	Clinical significance of visually equivocal amyloid PET on ADNI cohort	Oh Seo Oh Oh Roh Lee Kim	Oh
167	29	Heterogeneity of amyloid-related cognitive decline in clinically normal older adults	Papp Rentz Amariglio Schultz Johnson Sperling Mormino	Рарр
139	30	Does high baseline amyloid predict declines in activity participation and need for cognition over 4 years? Results from the Dallas Lifespan Brain Study	Parker Festini Farrell Park	Parker
108	31	Relationship between neuroticism and biomarkers of AD pathology in familial Alzheimer's disease	Quiroz Baena Norton Cosio Schultz Gatchel Sperling Johnson Lopera	Quiroz
85	32	Relationships between NREM-sleep fragmentation and changes in brain structure, metabolism, amyloid burden and cognitive performance in healthy OA	Rauchs Andre Tomadesso Mezenge Branger Fossey De Flores Laniepce Eustache Chetelat	Rauchs
124	33	Longitudinal Measures of Cognition and Clinical Status are Associated with Tau Deposition in Early Symptomatic Stages of AD	Risacher Deters Schwarz Saykin	Risacher
92	34	Beta-Amyloid PET imaging of neurodegenerative disorders in a Chinese specialty hospital	Qiao Seibyl Han Mao Xu Lu Marek Tamagnan Chan	Seibyl
55	35	Does the tau signal increase over time differ across brain regions and stage of impairment in Alzheimer's disease?	Shcherbinin Mintun Brittain Lu Joshi Southekal Devous Schwarz	Shcherbinin
52	36	Gait variability, an indicator of subclinical amyloid burden	Tian Bair Bilgel Wong Resnick Studenski	Tian
62	37	Years to parental symptom onset predicts amyloid burden, neurodegeneration and resting state connectivity changes in healthy elderly with a parental history of Alzheimer's disease	Villeneuve Vogel Gonneaud Poirier Rosa- Neto Fagan Bateman Morris Pichet Binnette Vachon-Presseau Benzinger Johnson Breitner .	Villeneuve
134	38	Additive effects of subjective cognitive decline and Amyloid-beta burden predict cognitive decline in healthy elderly individuals	Vogel Varga Dolezalova La Joie Marks Schwimmer Landau Jagust	Vogel
61	39	MRI-based amyloid imaging in Alzheimer's disease on clinical scanner	Yablonskiy Zhao Benzinger Fagan Hassenstab Cairns Wen Vlassenko Astafiev Raichle Morris	Yablonskiy

HAI 2017 PROGRAM

Wednesday, January 11, 2017			
11:30am	Check-in		
12:30pm	Welcome Notes	Keith Johnson, <i>Massachusetts General</i> <i>Hospital</i>	
12:40	SESSION 1 Quantifying Tau and Amyloid PET Signal	CHAIRS: Chester Mathis, University of Pittsburgh, and Bradley Christian, University of Wisconsin	
12:40	Evaluating different in vivo measures of tau pathology for use as biomarkers	Anne Maas , University of California, Berkeley	
12:55	Tau Load: a novel method for quantifying subject-specific neuropathologic tau signal from Flortaucipir PET	Michael Navitsky , Avid Radiopharmaceuticals	
1:10	Recovering signal from AV1451 in frontotemporal lobar degeneration with partial volume correction	Adam Martersteck, Northwestern University Feinberg School of Medicine	
1:25	Unbiased clustering using entorhinal and neocortical tau-PET uptake on [18F]AV-1451 maps onto age and clinical presentation in Alzheimer's disease	Jennifer Whitwell, Mayo Clinic	
1:40	Nonlinear alignment of multimodal empirical distributions for Level-2 Centiloid transformations	Michael Properzi , Massachusetts General Hospital, Harvard Medical School	
1:55	Discussion		
2:25	Keynote Lecture: Tau Prion Strains: Implications for Imaging	Marc Diamond, University of Texas Southwestern	
2:55	Keynote Discussion		
3:10	POSTER SESSION 1 and Coffee Break		
4:40	SESSION 2 Novel Tau Tracers	CHAIRS: Julie Price, Massachusetts General Hospital and Robert Koeppe, University of Michigan	
4:40	Effects of [18F]AV-1451 binding in cerebellar gray and extra- cortical areas	Suzanne Baker , Lawrence Berkeley National Laboratory	
4:55	[18F]MK-6240, a novel neurofibrillary tangles PET tracer: Evaluation in healthy subjects and Alzheimer's Disease patients	Cyrille Sur, Merck & Co., Inc.	
5:10	Current efforts to overcome drawbacks of [11C]PBB3 by developing new PBB3 derivatives: first-in-human PET study with [18F]AM- PBB3	Hitoshi Shimada , National Institute of Radiological Sciences	
5:25	Evaluation of baseline and longitudinal tau burden in Alzheimer's disease using [18F]GTP1 (Genentech tau probe 1) PET imaging	Robby Weimer, Genentech Inc.	
5:40	Invited Lecture: Molecular Imaging Analysis for Tracer Validation and Clinical Trials	Roger Gunn, Imanova Ltd	
6:00	Discussion		
6:30-8:30	Welcome Reception		

	Thursday, January 12,	2017
7:00am	Check-in and Breakfast	
8:00	SESSION 3 Neuropathology I: Tau PET Ligand Selectivity and Comparative Studies	CHAIRS: William Klunk, University of Pittsburgh and Milos Ikonomovic, University of Pittsburgh
8:00	Evaluation of the selectivity of Tau PET radioligand THK5351 in AD brain in vitro and nonhuman primate brain in vivo	Qi Guo, AbbVie Inc.
8:15	Characterizing the "off-target" binding of 18F-THK5351 in Alzheimer's disease: correlation between ante-mortem and post- mortem findings	Ryuichi Harada , Tohoku University Graduate School of Medicine
8:30	In vitro binding properties comparison of the tau PET tracers THK5117, THK5351, PBB3 and T807 in autopsy brain from Alzheimer diseases cases	Laetitia Lemoine, Karolinska Institute
8:45	An autoradiographic evaluation of THK-5351 compared to AV-1451	Melissa Murray, Mayo Clinic
9:00	Discussion	
9:30	POSTER SESSION 2A and Coffee Break	
10:15	SESSION 4 Nauropathology II: PET to Autopsy Correlations	CHAIRS: Melissa Murray, Mayo Clinic Teresa Gomez-Isla, Massachusetts General Hospital
10:15	Neuropathology and biochemical correlations of [F-18]AV-1451 and [C-11]PiB PET imaging in a subject with Alzheimer's disease	Milos Ikonomovic, University of Pittsburgh
10:30	Neuroimaging-pathologic correlation of [F-18]-AV-1451 in an autopsy confirmed Parkinson's disease case	Marta Marquie-Sayagues, MassGeneral Institute for Neurodegenerative Disease
10:45	Multimodal evaluation of 18F-AV-1451 PET in an autopsy- confirmed corticobasal degeneration patient	Corey McMillan , Perelman School of Medicine at the University of Pennsylvania
11:00	Discussion	
11:25	Announcement: Alpha–synuclein Imaging Prize	Jamie Eberling, The Michael J. Fox Foundation for Parkinson's Research
11:30	Keynote Lecture	Thomas Beach, Banner Sunhealth Research Institute
12:00pm	Keynote Discussion	
12:15	Lunch	
1:45	SESSION 5 Tau PET: Non-AD Targets	CHAIRS: Gil Rabinovici , University of California, San Francisco and Brad Dickerson , Massachusetts General Hospital
1:45	18F Flortaucipir binding in choroid plexus: association with race and hippocampus binding	Christopher Lee , Massachusetts General Hospital, Harvard Medical School
2:00	[18F]Flortaucipir, aka [18F]AV-1451, autoradiography matches immunofluorescent staining from AT8 tau antibody in Chronic Traumatic Encephalopathy (CTE) post-mortem brain tissue sections	Yin-Guo Lin , <i>Avid Radiopharmaceuticals, Inc.</i>
2:15	Microscopic neuropathological evaluation of the binding profile of tau selective PET ligands in AD and primary tauopathies	Melissa Wren, University College London
2:30	AV-1451 tau-PET uptake in MAPT mutation carriers varies by tau isoforms	David Jones, Mayo Clinic
2:45	18F-AV-1451 binding in familial frontotemporal lobar degeneration with tau pathology	William Kreisl, Columbia University
3:00	Discussion	
3:30	POSTER SESSION 2B and Coffee Break	
4:15	SESSION 6 Thresholds and Centiloids	CHAIRS: Keith Johnson, Massachusetts General Hospital and Sylvia Villeneuve, McGill University
4:15	Defining cut-points for imaging biomarkers used in brain aging and Alzheimer's disease research	Clifford Jack, Mayo Clinic
4:30	Centiloids	Robert Koeppe, University of Michigan
5:00	Discussion	
5:30- 7:30	Networking Reception	

	Friday, January 13, 2	017
7:00am	Check-in and Breakfast	
8:00	SESSION 7 AMYLOID AND TAU PET IN CLINICAL TRIALS	CHAIRS: Bill Jagust, University of California, Berkeley and Susan Resnick, National Institutes of Health
8:00	The A4 Study: preliminary analyses of baseline tau PET imaging	Reisa Sperling, Harvard Medical School
8.15	Conversion of aMCI subjects to AD in relation to [18F]flutemetamol	David Wolk, Perelman School of Medicine at
0.15	amyloid status, and hippocampal volume in a phase III longit. study	the University of Pennsylvania
8:30	Baseline 18F Flortaucipir SUVR, but not amyloid or cognition, predicts cognitive decline over 18 months in Phase 2 trial subjects	Michael Devous, Sr., Avid Radiopharmaceuticals
8:45	PET amyloid and tau imaging in a Phase 3 study of solanezumab	Mark Mintun, Avid Radiopharmaceuticals
9:00	Discussion	
9:30	POSTER SESSION 3A and Coffee Break	
10:15	SESSION 8 PRECLINICAL AD	CHAIRS: Reisa Sperling and Beth Mormino , <i>Harvard Medical School</i>
10:15	Implementing and testing the new A/T/N classification in AIBL participants combining fluid (CSF) and different A β and tau imaging radiotracers	Victor Villemagne, University of Melbourne
10:30	The relationship of elevated medial temporal lobe and diffuse brain tau-PET signal in clinically normal participants	Val Lowe, Mayo Clinic
10:45	Prevalence and incidence of amyloid positivity in cognitively normal elderly individuals	Neelesh Nadkarni, University of Pittsburgh
11:00	Longitudinal tau accumulation is associated with cognitive decline in normal elderly	Bernard Hanseeuw, Harvard Medical School
11:15	Baseline amyloid burden predicts cognitive decline four years later in healthy adults: the value of a dose-response analysis	Michelle Farrell , University of Texas at Dallas
11:30	Discussion	
12:00pm	Keynote Lecture	Howard Feldman, Univ. of California, SD
12:30	Keynote Discussion	
12:45	Lunch	CITADE: Clifford Look Mana Clinic and
2:15	SESSION 9 AMYLOID, TAU, AND NEURODEGENERATION	Tammie Benzinger , Washington University at St Louis
2:15	Neocortical Tau and hippocampus volume reflect distinct processes	Elizabeth Mormino, Massachusetts General
	in preclinical Alzheimer's disease	Hospital
2:30	Do neurodegeneration or amyloid pathology contribute to the relationship between AV-1451 and cognitive symptoms in AD?	Alexandre Bejanin, University of California, San Francisco
2:45	Comparing the contributions of tau and neurodegenerative biomarkers to cognitive decline	Susan Landau , University of California, Berkeley
3:00	Differential genotypic variance in PET and CSF measures of amyloid burden: Findings from the DIAN Study	Jasmeer Chhatwal, Massachusetts General Hospital
3:15	Relationships between AV1451-PET and CSF biomarkers in a heterogeneous clinical sample	Renaud La Joie , University of California, San Francisco
3:30	Discussion	
4:00	POSTER SESSION 3B and Coffee Break	
4:45	Awards Ceremony	
4:50	SESSION 10 AMYLOID AND TAU PET IN DISTINCT POPULATIONS	CHAIRS: Trey Hedden , Massachusetts General Hospital and Charles de Carli , University of California, Davis
4:50	Association of regional FDG hypometabolism with age, amyloid, tau, and cardiac and metabolic conditions along the AD continuum	Prashanthi Vemuri, Mayo Clinic
5:05	18F-AV1451 PET in patients with subcortical vascular cognitive impairment	Sang Won Seo, Sungkyunkwan University School of Medicine
5:20	White matter hyperintensities and brain amyloid deposition: the ARIC-PET Study	Rebecca Gottesman , Johns Hopkins University
5.25	Association of amyloid-beta plaque accumulation and glucose hypo-	Detaich Leo University CUV
5:35	metabolism in Down syndrome demonstrates pattern assoc. w/AD	rautick Lao, University of Wisconsin
5:50	Discussion	
6:20	Closing Notes	Keith Johnson, Massachusetts Gen. Hospital

HAI 2017 ABSTRACTS

WEDNESDAY

Wednesday, January 11, 2017 - 12:40 pm - 01:40 pm

SESSION 1: Quantifying Tau and Amyloid PET Signal

SESSION 1 Quantifying Tau and Amyloid PET Signal	CHAIRS: Chester Mathis University of Pittsburgh Bradley Christian University of Wisconsin
Evaluating different in vivo measures of tau pathology for use as biomarkers	Anne Maas University of California, Berkeley
Tau Load: a novel method for quantifying subject- specific neuropathologic tau signal from Flortaucipir PET	Michael Navitsky Avid Radiopharmaceuticals
Recovering signal from AV1451 in frontotemporal lobar degeneration with partial volume correction	Adam Martersteck Northwestern University Feinberg School of Medicine
Unbiased clustering using entorhinal and neocortical tau- PET uptake on [18F]AV-1451 maps onto age and clinical presentation in Alzheimer's disease	Jennifer Whitwell Mayo Clinic
Nonlinear alignment of multimodal empirical distributions for Level-2 Centiloid transformations	Michael Properzi Massachusetts General Hospital, Harvard Medical School
Discussion	

Evaluating different in vivo measures of tau pathology for use as biomarkers

<u>Anne Maass</u>^{1,2}, Susan Landau^{1,3}, Andy Horng¹, Samuel N. Lockhart¹, Renaud La Joie³, Suzanne L. Baker⁴, Gil D. Rabinovici^{1,3,4}, William J. Jagust^{1,3,4}

¹University of California, Berkeley, Berkeley, CA, USA ²German Center for Neurodegenerative Diseases, Magdeburg, Germany ³Memory and Aging Center, University of California San Francisco, San Francisco, CA, USA ⁴Lawrence Berkeley National Lab, Berkeley, CA, USA

Objectives: To evaluate multiple whole-brain and region-specific approaches to quantify Alzheimer's Disease (AD)-related tau accumulation by AV-1451 tau PET, derive tau positivity cut-offs, and relate these measures to cognition, beta-amyloid (A β) and atrophy.

Methods: Two independent cohorts received AV-1451 PET, structural MRI, and A β PET (sample 1: PiB; sample 2: Florbetapir). Sample 1 comprised 11 young/middle-aged (YC/MAC: 39±17yrs), 66 older cognitively normal controls (OC: 78±6yrs) and 48 PiB⁺ MCI/AD-dementia patients from UC Berkeley/UCSF. Sample 2 included 37 OC (73±6yrs) and 21 FBP⁺ MCI/AD patients (80±6yrs) from ADNI. Tau PET measures were derived from native-space SUVR (80-100min post-injection, cerebellar gray reference) images after partial volume correction using Freesurfer-defined regions; for voxel-wise measures images were warped to MNI space. Several methods were used: (i) participants were categorized into Braak stages (Fig.1); (ii) SUVRs within the Braak ROIs were measured; (iii) tracer uptake was quantified by different whole-brain measures (e.g. number of supra-threshold voxels; Fig.2); (iv) AD-vulnerable voxels were identified to quantify tau (Fig.3); (v) a factor analysis defined key regions; and (vi) SUVR was derived from a previously-reported meta-ROI (Jack, et al., 2016). Receiver operating curves characterized accuracy in distinguishing A β ⁻ OC from AD/MCI patients. Each measure was regressed against clinical and other imaging variables.

Results: Braak staging, global and region-specific measures yielded similar diagnostic accuracy, which was higher in cohort 1 than cohort 2. All measures were strongly related to amyloid and global cognition (MMSE), but verbal memory and hippocampal/entorhinal volume/thickness were associated with tracer retention in more specific ROIs. Key regions contributing to high tau measures included medial temporal, inferior/middle temporal, retrosplenial, and inferior parietal cortex.





Conclusions: While whole-brain tau PET measures might be adequate biomarkers for capturing AD-related tau pathology, measures that assess AD-vulnerable regions may increase sensitivity to early tau accumulation and cognitive differences.

Keywords: tau, AV-1451, Braak staging, biomarker, cut points

Tau Load: a novel method for quantifying subject-specific neuropathologic tau signal from Flortaucipir PET

<u>Michael Navitsky</u>, Michael Devous, Abhinay Joshi, Ian Kennedy, Sudeepti Southekal, Michael Pontecorvo, Ming Lu, Mark Mintun

Avid Radiopharmaceuticals, Philadelphia, PA, USA

Background: Flortaucipir images generally demonstrate patterns of tau pathology predicted by the neuropathology literature. However, substantial heterogeneity in the image patterns has been observed that seems to relate to the character of cognitive impairment. Quantitating such heterogeneity poses challenges to the use of typical fixed anatomical VOIs. Herein we present a technique which incorporates both the density and distribution of the tau signal.

Methods: Flortaucipir scans from 52 amyloid negative (A β -) cognitively normal subjects (67.6±10.2 yr, MMSE 29.5±0.5) were used to create mean and standard deviation (SD) SUVr images (normalized to a parametrically derived white-matter reference region) in MNI space. Z-score images from control, MCI and AD subjects were then masked to include only voxels with Z \geq 3 (i.e., the pathologic volume PV) within subject-specific tissue segmentations obtained from co-registered T1 MRI scans (i.e., total tissue volume TV). Tau load was calculated as the average SUVr within the PV normalized by TV to account for differences in brain size (Fig. 1). Tau load was evaluated in test-retest, cross-sectional and longitudinal data in comparison to a weighted neocortical VOI (MUBADA).

Results: Tau load achieved high test-retest reproducibility (n=21, R²=0.99), and distinguished groups based on A β status and diagnosis (Fig. 2). Both tau load and MUBADA demonstrated low uptake in young controls presumed to have no cortical tau. Similarly, among A β + subjects, both measures detected longitudinal change and showed good correlation between baseline and Δ tau (R² >0.5) at 18 months of follow up.

Conclusions: Tau load demonstrated equivalent performance on typical metrics to MUBADA while capturing characteristics of both the density and distribution of the tau signal. The subject-specific information captured by tau load by not being fixed to a given neuroanatomic brain region may be important in assessing natural disease progression or potential therapeutic response.



Figure 1. A) Flortaucipir SUVr image (normalized to a parametrically derived white-matter reference region). B) Tissue volume derived from subject-specific T1 MRI tissue segmentations. C) Pathologic volume defined as voxels with $Z \ge 3$ relative to a normal control data base. D) Tau load equation, where SUVr is the mean SUVr value from the masked pathologic tissue volume.



Figure 2. Cross-sectional (n=215) measures across groups defined by both clinical diagnosis and amyloid status for A) tau load and B) MUBADA SUVr. Both a tau load of 0 and SUVr of 1 are representative of no tau signal.

Keywords: Alzheimer's Disease, tau imaging, Flortaucipir, PET, quantification

Recovering signal from AV1451 in frontotemporal lobar degeneration with partial volume correction

<u>Adam Martersteck</u>^{1,2}, Jaiashre Sridhar², Allison Rainford², M.-Marsel Mesulam^{2,3}, Emily Rogalski²

¹Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA ²Cognitive Neurology and Alzheimer's Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

³Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Background: Primary progressive aphasia (PPA) is a clinical dementia syndrome often characterized by asymmetric atrophy and proteinopathy of the language-dominant (usually left) hemisphere. Common neuropathologies reported for PPA include Alzheimer's disease (AD), frontotemporal lobar degeneration with tauopathy (FTLD-tau) or TDP43 (FTLD-TDP). PET imaging with ¹⁸F-AV1451 has shown high binding to lesions of paired helical filament tau found in AD and there have been reports of clinically relevant signal found in FTLD-tau cases that match the expected straight filament tau deposition.

Objective: Determine if 1) the AV1451 binding found in PPA cases with suspected FTLD-tau pathology showed a clinically concordant distribution and 2) if using partial volume correction could improve our ability to detect a pattern of tau deposition above the grey cerebellar reference.

Methods: Eight participants with PPA underwent T₁-weighted MRI, florbetapir amyloid PET, and AV1451 tau PET imaging. Freesurfer (FS) was used to reconstruct the T₁-weighted MRI scans (v5.1.0), generate atrophy maps (v5.1.0) and to complete partial volume correction (PVC; v6.0.0-beta). Partial volume correction was applied using the modified Müller-Gärtner (mMG) method, solving for white matter, ventricular CSF, and extracerebral segmentations by a symmetric geometric transfer matrix. Partial volume corrected and non-corrected AV1451 PET signal from the middle of the cortical ribbon were resampled to the FS pial surface and compared.

Results: Two agrammatic PPA participants showed a florbetapir mean cerebral-to-cerebellar SUVR < 1.10

(Aβ-negative) and were classified as "suspected FTLDtau". In both PPA cases, there was no AV1451 tau signal above the 1.0 grey matter cerebellar SUVR before PVC (see figure). After applying mMG PVC, the regional distribution of AV1451 more closely aligned with patterns of neurodegeneration observed in PPA.

Conclusions: Using partial volume correction to recover signal in AV1451 PET may improve the detection of straight filament tau found in FTLD tauopathies.

Keywords: partial volume correction, frontotemporal



lobar degeneration, primary progressive aphasia, freesurfer

Unbiased clustering using entorhinal and neocortical tau-PET uptake on [18F]AV-1451 maps onto age and clinical presentation in Alzheimer's disease

<u>Jennifer Whitwell</u>¹, Jonathan Graff-radford¹, Nirubol Tosakulwong¹, Stephen Weigand¹, Matthew Senjem¹, Anthony Spychalla¹, David Jones¹, Daniel Drubach¹, Ronald Petersen¹, Val Lowe¹, Clifford Jack¹, Keith Josephs¹

¹Mayo Clinic, Rochester, MN, USA

Background: Alzheimer's disease (AD) is a heterogeneous disorder that often results in atypical clinical presentations, particularly in patients under the age of 65. We aimed to perform an unbiased assessment of tau uptake on AV-1451 tau-PET in AD and determine whether patterns of entorhinal cortex (allocortex) and neocortical tau uptake can help explain the emergence of atypical clinical presentations.

Methods: Seventeen patients with an atypical presentation of AD underwent AV-1451 PET. We also identified 47 typical dementia of the Alzheimer's type patients with tau-PET (20 under age 65 and 27 older than age 65). All patients showed amyloid deposition on Pittsburgh Compound B (PiB) PET. AV-1451 uptake was calculated in entorhinal cortex (ERC) and a neocortical region-of-interest (including temporal, parietal, frontal and occipital cortices). Values were normalized to the cerebellum to create SUVRs. Tau-PET SUVRs were log transformed and clustered unbiased to clinical diagnosis into three groups using K-mean cluster analysis.

Results: The cluster analysis identified a cluster with low cortical SUVRs (cortical sparing), one with high cortical SUVRs but relatively low ERC SUVRs (low ERC) and one with high cortical and ERC SUVRs (high ERC) (Figure). Clinical groups differed across clusters (p<0.001), with atypical AD associated with low ERC, young AD associated with high ERC and old AD associated with cortical sparing (Figure). Age differed across clusters, with older age observed in the cortical sparing cluster (p<0.001). Gender ratio, APOE genotype, global PiB ratio and mini-mental state examination score did not differ across clusters.

Conclusions: An unbiased clustering of tau-PET based on the ERC and neocortex maps well onto age and clinical presentation in AD. Atypical presentations tend to be associated with a pattern of high cortical tau similar to young-onset AD, but with relatively less involvement of the entorhinal cortex.





Keywords: tau, PET, AV-1451, Alzheimer's disease, atypical

Nonlinear alignment of multimodal empirical distributions for level-2 Centiloid transformations

<u>Michael Properzi</u>¹, Cristina Lois Gomez², Federico d'Oleire Uquillas¹, Reisa Sperling^{1,3,4}, Keith Johnson^{2,3,4}, Aaron Schultz^{1,3}

¹Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ²Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ³Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ⁴Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Department of Neurology, Dirgham and Homen's Hospital, Harvara Mealear School, Doston, Mil, OSH

Introduction: The Centiloid project is intended to set a standard scale for reporting amyloid-PET measures. The current level-2 implementation relies on a strong linear assumption. We find alterations in processing methodology, target region, reference region, and partial volume correction (PVC) can all contribute to nonlinearities. We present a transformation that enables nonlinear mapping of a wider range of scale distributions onto the standard Centiloid scale (SCS).

Methods: The GAAIN Centiloid dataset was combined with baseline data from the Harvard Aging Brain Study (HABS) (278 Clinically normal older adults,74yrs SD=6.1). The combined PIB-PET dataset was processed with both the SCS and study specific HABS pipelines. The translation algorithm involved mapping between kernel-density smoothed empirical cumulative distribution functions from each pipeline. Centiloid values from the alternate pipelines were translated onto the SCS. Our method allows for mapping equivalent values between any two distributions where approximate rank-ordered matching can be assumed to hold. **Results:** Figure 1 shows A) linearity between two SCS measures and B) greater variance between the SCS and Harvard/MGH pipelines for a cortical aggregate region (FLR), C) strong non-linearity within a focal region, and D) non-linearity with PVC. Discrepancies between linear and non-linear mapping to the SCS ranged as high as 19 Centiloids, with the location of strongest discrepancies dependent on the measure being mapped. For the regional measure shown in B), the max discrepancy occurs around 10 Centiloids, whereas PVC correction produced the strongest discrepancy at values exceeding 120.

Discussion: Our novel method has the advantage of accounting for realistic variation in measurement distributions, allowing for reporting of equivalent level-2 values that are more consistent with the SCS. Our approach offers an alternative for translating between any two empirical distributions, which has natural extension to combining data from multiple tracers. Future work will assess goodness-of-fit and distributions of errors.



PIB, PET, Centiloid

Keynote Lecture

Tau Prion Strains: Implications for Imaging

Marc Diamond

University of Texas Southwestern Medical Center, Dallas, TX, USA

Tauopathies are neurodegenerative disorders that affect distinct brain regions, progress at different rates, and exhibit specific patterns of tau accumulation. PET ligands cannot yet reliably identify and discriminate these conditions. Our lab has long studied the role transcellular propagation of protein aggregation in the pathogenesis and diversity of tauopathies. We have determined that tau shares essential biological properties with the prion protein. We have tested the idea that discrete tau aggregate conformers, or "strains" underlie unique patterns of progression and neuropathology. We previously characterized two tau prion strains that stably maintain unique conformations in vitro and in vivo, but did not determine the relationship of each strain to parameters that discriminate among tauopathies such as regional vulnerability or rate of spread. We have now isolated and characterized 18 tau strains in cells based on detailed biochemical and biological criteria.

Inoculation of transgenic tau P301S (PS19) mice with these strains causes strain-specific intracellular pathology in distinct cell types and brain regions, and induces different rates of network propagation. In this system, strains alone are sufficient to account for diverse neuropathological presentations, similar to those that define human tauopathies. Distinct conformations of tau aggregates could explain the failure of PET ligands to reliably distinguish the tauopathies. Detailed knowledge of strains could provide a rational approach both to understand the biological basis of tauopathies, and to design more effective imaging agents.

POSTER SESSION 1

Sanabria, Sandra - 3

Kinetics of [18F]GTP1 (Genentech tau probe 1) in the basal ganglia of Alzheimer's patients and healthy controls

<u>Sandra Sanabria Bohorquez</u>¹, Thomas Bentsson², Olivier Barret³, Gilles Tamagnan³, David Alagille³, Alex de Crespigny¹, Gai Ayalon⁴, Michael Ward⁵, Geoffrey Kerchner⁵, Danna Jennings³, John Seibyl³, Ken Marek³, Robby Weimer⁶, Jan Marik⁶

¹Clinical Imaging Group, Genentech, Inc., South San Francisco, CA, USA
 ²Biostats, Genentech, Inc., South San Francisco, CA, USA
 ³Molecular NeuroImaging LLC, New Haven, CT, USA
 ⁴Department of Neuroscience, Genentech, Inc, South San Francisco, CA, USA
 ⁵Early Clinical Development, Genentech, Inc, South San Francisco, CA, USA
 ⁶Department of Biomedical Imaging, Genentech, Inc, South San Francisco, CA, USA

Background: SUVR images from various tau ligands have shown increased retention in basal ganglia (BG). Here, we characterize the GTP1 kinetics and quantify the specific binding (C_S) and non-displaceable (C_{ND}) component in these regions.

Methods: GTP1 imaging with arterial input function (AIF) was performed in 5 healthy volunteers (HV) and 5 AD subjects. ROIs were defined in the cerebellum gray (CBL), cortex and BG. The AIF-2-tissue model (2TM) was applied to estimate $V_{ND} = K_1/k_2$ and $BP_{ND} = k_3/k_4$. CBL was used as reference to estimate SRTM BP_{ND} and the CBL k_2 ' as well as SUVR-CBL.

Results: V_{ND} values were larger in BG than in CBL and cortex whereas similar K₁ values were observed across regions (figure 1). The SRTM-CBL k₂' value obtained when fitting BG regions was higher than in cortex (figure 1) suggesting differences in V_{ND} across regions. These results show that while CBL is a good reference for estimating cortical V_{ND} , it is not an appropriate reference for BG resulting in specific binding overestimation: estimated $BP_{ND}(BG) = P_{ND}$ *actual $BP_{ND}(BG)$, $P_{ND} = V_{ND}(BG)/V_{ND}(CBL)^1$. SUVR-CBL measurements will have a similar bias.

Figure 2 shows time activity curves in CBL, cortex and BG as well as SUVR-CBL in an AD patient (top); and the 2TM C_{ND} and C_{S} (bottom). Although the BG SUVR-CBL values can be similar to cortical SUVR-CBL, the specific binding is lower because of the larger C_{ND} . SUVR-CBL in cortex and BG do not reflect the same level of specific binding.

Conclusions: In cortex, GTP1 SUVR-CBL is a good surrogate of tau specific binding. In contrast, BG SUVR-CBL is strongly biased and may reflect age- and/or disease-related changes not directly related to tau accumulation. Although some specific binding may be present, BG SUVR-CBL values should be interpreted with caution.

1.Salinas et al.doi:10.1038/jcbfm.2014.202



Keywords: Tau imaging, GTP1, basal ganglia, modeling, kinetics

Development of novel tau PET tracers, [18F]AM-PBB3 and [18F]PM-PBB3

<u>Maiko Ono^{1,2}</u>, Soichiro Kitamura¹, Hitoshi Shimada¹, Naruhiko Sahara¹, Hiroyuki Takuwa¹, Yasumasa Yoshiyama³, John Trojanowski⁴, Virginia Lee⁴, Tetsuya Suhara¹, Ming-Rong Zhang¹, Ming-Kuei Jang⁵, Gilles Tamagnan⁶, Kenneth Marek⁶, Makoto Higuchi¹

 ¹National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
 ²Tohoku University, Sendai, Japan
 ³Chiba-East National Hospital, Chiba, Japan
 ⁴University of Pennsylvania, Philadelphia, PA, USA
 ⁵Aprinoia Therapeutics, Taipei, Taiwan
 ⁶MNI, New Haven, CT, USA

PBB3 is a PET imaging agent for fibrillary tau lesions, and was shown to bind to tau inclusions in diverse neurodegenerative disorders, including Alzheimer's disease (AD) and 3-repeat and 4-repeat tauopathies, and in different tau transgenic mouse models. For the purpose of widely available and high-contrast tau PET scans, we have developed novel PET radioligands for tau aggregates, AM-PBB3 and PM-PBB3, which are ¹⁸F-labeled analogs of PBB3, and characterized these compounds by in-vitro, ex-vivo and in-vivo assays. Invitro fluorescence and autoraiographic labeling of brain sections demonstrated binding of AM-PBB3 and PM-PBB3 to various tau pathologies in AD, progressive supranuclear palsy (PSP), corticobasal degeneration, Pick's disease and tau transgenics (PS19 and rTg4510). High affinity binding of AM-PBB3 and PM-PBB3 to tau aggregates with Kd values < 10 nM was also observed in AD and PSP brain homogenates. In-vivo PET and ex-vivo autoradiography of rTg4510 tau transgenic mice supported the ability of AM-PBB3 and PM-PBB3 to capture tau deposits in living brains with a higher contrast than PBB3, primarily owing to their higher uptake into the brain. PM-PBB3 underwent faster clearance from the brain following peak uptake than AM-PBB3, and accordingly yielded the highest contrast of tau lesions among these three radioligands. Correspondingly, in-vivo two-photon fluorescence microscopy showed the most intense signals in individual tau inclusions of rTg4510 mice yielded by PM-PBB3. We also observed less radiometabolites of AM-PBB3 and PM-PBB3 in mouse plasma and brain than those of PBB3 along the course after intravenous injection. Our non-clinical findings support the utility of AM-PBB3 and PM-PBB3 as tau PET radioligands, and have finally been compared to results of pilot clinical PET with these compounds.

Keywords: Tau PET ligand, PBB3 derivative, Tau transgenic mouse, Alzheimer's disease, Progressive supranuclear palsy

Optimization of early phase [18F] flutemetamol scanning window as a proxy for relative tracer delivery

<u>Kerstin Heurling</u>^{1,2}, Koen Van Laere³, Rik Vandenberghe³, Christopher Buckley⁴, Gill Farrar⁴, Mark Lubberink^{2,5}

¹Göteborgs Universitet, Göteborg, Sweden
²Uppsala Universitet, Uppsala, Sweden
³UZ Leuven, Leuven, Belgium
⁴GE Healthcare, Amersham, United Kingdom
⁵Uppsala Academic Hospital, Uppsala, Sweden

Background: The "dual-phase" PET imaging concept, combining late-phase specific tracer binding with the early-phase influx aspect of tracer kinetics, has gained increasing attention for amyloid imaging due to its potential to replace a dedicated perfusion or metabolism scan. Our objective was to identify the optimal time window for capturing perfusion information from early-phase flutemetamol perfusion SUVR (p-SUVR) as compared to the delivery in target relative to reference region (R_1) estimated using kinetic modeling.

Methods: Six subjects (four amyloid-positive and two amyloid-negative) underwent dynamic flutemetamol PET scanning for 90 min post injection (p.i.). Parametric R_1 images were estimated using a basis function implementation of the simplified reference tissue model, and grey matter masked template regional values were extracted. p-SUVR was estimated over a range of scanning windows with start times 0-7 min and end times 1-11 min. Pearson's correlation coefficient and percentage bias were estimated for each time window.

Results: p-SUVR correlated best with R_1 for the time window 0.5-3 min p.i. (r=0.98) (Figure 1A). Correlations were, however, strong (r >0.95) over all combinations of scanning windows with start times between 0.5-2 min and end times up to 8 min. The lowest bias of p-SUVR compared to R_1 was found for the time window 1-2 min, (-0.7%) but bias was <2% for all time windows with start 0.5-2 min p.i. and end 1.5 to 6 min (Figure 1B). Average R_1 and p-SUVR_{0.5-3 min} images are shown in Figure 2, alongside a publicly available dementia-specific FDG template illustrating current practice.

Conclusion: Based on our findings, flutemetamol p-SUVR shows low sensitivity to the exact choice of start and end time within range 0-3 min. Future studies validating the use of early-phase flutemetamol imaging against perfusion imaging should collect data during a time window excluding the first 30 sec p.i., with a duration no longer than 6 min.



Keywords: [18F]flutemetamol, early-phase SUVR, perfusion, scanning window optimization
Algorithm for reference region delineation for amyloid imaging using pattern recognition scheme and kinetics of administered Aβ probe — considering the number of clusters

<u>Takahiro Yamada</u>¹, Yuichi Kimura¹, Takashi Nagaoka¹, Chisa Hosokawa², Takamichi Murakami², Kazunari Ishii²

¹Graduate School of Biology-Oriented Science and Technology, Kindai University, Wakayama, Japan., Kinnokawa-shi, Japan ²Department of Diagnostic Radiology, Faculty of Medicine, Kindai University, Osaka, Japan., Osakasayamashi, Japan

Introduction: For quantitative measurement of amyloid beta (A β) deposit, a kinetic analysis is applied to acquire binding potential () (Hosokawa, JNM, 56, 2015), and a reference region is placed on the cerebellar gray matter. Because it has a thin and complicated shape, an automated algorithm is required. The aim of this study is to propose a new automated algorithm (AutoRef) to delineate the reference region. AutoRef clusters voxels around the cerebellum into some clusters based on the shape of a tissue time activity curve (tTAC). The basic idea has been presented at SNM2016, and the number of the clusters is investigated.

Methods: tTACs have different shapes among different tissue groups. AutoRef detects the shape difference using a statistical clustering algorithm of Gaussian mixture model (GMM). The number of clusters should be given to GMM. The large number may capture the difference in tTACs, but it makes the estimation process astable. An appropriate number of clusters is thus investigated. AutoRef is evaluated using clinical 86 cases: 43 positive, 33 negative, and 10 equivocal cases.

Results: The typical result is demonstrated in Fig. 1 when 8-clusters clustering was conducted. If the case of 3-cluster clustering, the estimated reference region was located some voxels out from the manually defined reference region. All GMM were converged appropriately for 8-cluster clustering. No significant difference in was observed (p<0.05) between AutoRef and the manually defined reference region, and the difference was smaller than 0.46.

Conclusion: The difference is almost the same between the threshold of $A\beta$ positive and negative, and we conclude that AutoRef is applicable.



Fig. 1 (a) The result of 8-clusters clustering where a reference region is in yellow-green. (b) Manually defined reference region is superimposed.



Keywords: PET, kinetic analysis, reference region

Rigid registration contributes significant imprecision to amyloid PET SUVR measurements

<u>Christopher Schwarz</u>¹, David Jones¹, Jeffrey Gunter¹, Val Lowe¹, Prashanthi Vemuri¹, Matthew Senjem¹, Ronald Petersen¹, David Knopman¹, Clifford Jack¹

¹Mayo Clinic, Rochester, MN, USA

Background: Quantitative measurements of amyloid PET scans typically use rigid registration to corresponding MRI scans for localizing atlas regions and applying partial volume correction (PVC). Although quality control (QC) is often performed to prevent gross failures, subtle variations within QC-acceptable registrations have not been studied as a source of imprecision in SUVR measurements.

Methods: We performed simulations using 598 Mayo PiB scans and 598 ADNI florbetapir scans, each matched by age, sex, and clinical status. For each PET scan, we applied 50 small random perturbations of starting location and orientation, then performed rigid registration between each perturbed PET scan and its corresponding MRI using *spm_coreg* in SPM12. SUVR measurements were calculated for each perturbed PET scan by using these registrations to localize MRI-based atlas regions. We examined effects of these perturbations upon registration parameters and their resulting SUVR measurements.

Conclusions: Registration parameters and SUVR values were significantly affected by registration starting position; they did not exhibit the ideal behavior of consistently reaching the same endpoint. Across perturbations, standard deviations of rotation parameters were ≈ 0.05 degrees about each axis, and those for translation were ≈ 0.025 mm in each direction. Although this subtle variation was visible to human inspection, all registrations appeared equally valid. Imprecision in PET-MRI rigid registration: 1) contributes significant imprecision to SUVR measurements, on the order of $\approx 50\%$ of the expected reference values for annual change in subjects with AD dementia; 2) increases with amyloid load, and thus indirectly with clinical

severity; 3) differs with choice of reference region; 4) has a larger effect when using PVC. These findings were consistent across both datasets i.e. tracers. and also replicated using FreeSurfer's mri_coreg. Although PET-MRI registration imprecision does not account for all test-retest variability in amyloid PET SUVR values, processing pipelines that emphasize consistent registrations for serial scans could significantly reduce imprecision in changeover-time measures.







18F-Flortaucipir SUV normalization using a Parametric Estimate of Reference Signal Intensity (PERSI)

<u>Sudeepti Southekal</u>¹, Michael D. Devous Sr.¹, Ian Kennedy¹, Michael Navitsky¹, Ming Lu¹, Abhinay D. Joshi¹, Michael J. Pontecorvo¹, Mark A. Mintun¹

¹Avid Radiopharmaceuticals, Inc, Philadelphia, PA, USA

Background: White matter reference regions have shown reduced variability in longitudinal SUVr measurements for amyloid imaging agents (Landau et al. 2015). However, such regions are susceptible to partial volume contamination from the cortex. We present a new strategy (PERSI) to extract the white matter reference signal for ¹⁸F-Flortaucipir SUV normalization.

Methods: Test-retest (n=21; 5-34 days between scans) and Phase 2 cross-sectional (n=215) and longitudinal (n=140/215; 18±2 months between scans) data comprising 3 clinical cohorts (AD, MCI, CN) were analyzed. Subjects underwent T1 MRI and Florbetapir imaging at screening, and Flortaucipir imaging at single or multiple time points. Baseline amyloid (A β) status was determined as described in Clark et al. 2012. Flortaucipir images acquired as 4x5 min frames, 80 min after a 370 MBq injection were motion corrected, averaged and transformed to MNI space. For each scan, the voxel intensity histogram within an atlas-based white matter mask was fit to a bimodal Gaussian distribution (Fig. 1). The center and width of the first peak were used to determine reference region voxels. A cerebellar gray matter reference region was also evaluated for comparison. SUVr values were calculated for a neocortical volume-of-interest. Test-retest reproducibility (SD of % difference between scans) and effect sizes for cross-sectional and longitudinal group differences (Cohen's d; A β + impaired vs. A β - normal) were assessed.

Results: PERSI yielded >2-fold improvement in test-retest reproducibility (1.84% vs. 4.18%) and superior group separation (cross-sectional Cohen's d 9.54 vs 4.57; longitudinal Cohen's d 2.28 vs. 1.54) (Fig 2, Table 1) relative to cerebellar gray. Baseline variability in A β - CNs with no specific uptake was minimal (SUVr 1.0±0.04, Δ SUVr 0.0±0.02; Table 1).

Conclusions: PERSI reference regions reduced variability while enhancing discrimination between diagnostic cohorts. These improvements could lead to more accurate disease staging and robust measurements of changes in tau burden over time for evaluation of therapeutic response.



Figure 1. Graphical description of PERSI. The original PET image in A is masked by the atlas-based WM mask in B resulting in C (PET counts within the WM). These counts are then plotted as an intensity histogram (D) and fit to a bimodal Gaussian distribution. The parameters of the first Gaussian peak (mean \pm FWHM) are used to identify the range of values selected as the reference region (E).

Measure	Reference Region	Aβ+ Impaired (MCI and AD)			Aβ- Cognitively Normal			Effect Size
		n	Mean	SD	n	Mean	SD	Cohen's d
SUVr	cerebellar gray	77	1.58	0.45	68	1.12	0.10	4.57
	PERSI	77	1.35	0.37	68	1.01	0.04	9.54
ΔSUVr	cerebellar gray	46	0.07	0.12	46	0.01	0.04	1.54
18-month	PERSI	46	0.05	0.05	46	0.00	0.02	2.28

Table 1. Comparison of cross-sectional (SUVr) and longitudinal (Δ SUVr) values using PERSI and cerebellar gray matter, for impaired ($A\beta$ +) and normal ($A\beta$ -) subjects.

Cross-sectional SUVr (n=215)





Keywords: reference region, flortaucipir, AV1451, quantification

Validation of the semi-quantitative static SUVR method by pharmacokinetic modeling on dynamic cross-sectional [18F]-AV45 data

<u>Julie Ottoy</u>¹, Jeroen Verhaeghe¹, Ellis Niemantsverdriet², Leonie wyffels³, Charisse Somers², Ellen De Roeck^{2,4}, Hanne Struyfs², Femke Soetewey², Steven Deleye¹, Tobi Van den Bossche^{5,6,7}, Sara Van Mossevelde^{5,6,7}, Sarah Ceyssens³, Jan Versijpt⁸, Sigrid Stroobants³, Sebastiaan Engelborghs^{2,7}, Steven Staelens¹

¹Molecular Imaging Center Antwerp (MICA), University of Antwerp, Antwerp, Belgium
²Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium
³Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium
⁴Developmental and Lifespan Psychology, Vrije Universiteit Brussel, Brussels, Belgium
⁵Department of Molecular Genetics, VIB, University of Antwerp, Antwerp, Belgium
⁶Department of Neurology, Antwerp University Hospital, Edegem, Belgium
⁷Dept of Neurology and Memory Clinic, Hospital Network (ZNA) Antwerp Middelheim and Hoge Beuken, Antwerp, Belgium
⁸Department of Neurology, University Hospital Brussels, Brussels, Belgium

Background Increased brain uptake of -AV45 (Florbetapir) visualized by PET is a key biomarker in Alzheimer's disease. The standardized uptake value ratio (SUVR) is widely used for quantification, but is subject to variability based on choice of reference region and changes in cerebral blood flow. Here we validated the SUVR method against the gold standard volume of distribution (V_T).

Methods Dynamic 60-min -AV45 (291 \pm 67 MBq) and 1-min -H₂O (370 MBq) scans were obtained in 10 probable AD dementia (AD), 15 amnestic MCI (aMCI) and 10 cognitively healthy control (HC) subjects. - AV45 V_T was determined from two-tissue compartment modeling using a metabolite-corrected plasma input function. Static SUVR was calculated from the 50-60 min p.i. data, using either cerebellar gray matter (CB) or whole subcortical white matter (WM) as the reference region. Blood flow was quantified by -H₂O SUV and the -AV45 delivery rate K1.

Results Compared to V_T, differences in A β -load between the aMCI and AD group were overestimated by SUVR_{WM} (+4±2%) and underestimated by SUVR_{CB} (-10±2%)



FIGURE 1. Regional [¹⁸F]-AV45 V_T (top), SUVR_{CB} (middle) and SUVR_{WM} (bottom) (mean ± SEM) values for the three groups. Stars denote significant differences with the HC group (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001). Abbreviations: V_T = volume of distribution; SUVR_{CB} and SUVR_{WM} = standardized uptake value ratio with resp. reference cerebellar gray matter and subcortical white matter.



FIGURE 2. Average spatially normalized [¹⁸F]-AV45 V_T (A), SUVR_{CB} (B) and SUVR_{WM} (C) images for the three groups. Abbreviations: V_T = volume of distribution; SUVR_{CB} and SUVR_{WM} = standardized uptake value ratio with resp. reference cerebellar gray matter and subcortical white matter.

(Figure 1 Figure 2). V_T correlated better with SUVR_{WM} (Pearson r: 0.63 for posterior cingulate to 0.89 for precuneus, p<0.0001) than with SUVR_{CB} (r: 0.51 for temporal lobe (p=0.0023) to 0.82 for precuneus (p<0.0001)). -AV45 K1 was decreased in AD compared to aMCI in cortical regions (-6±1%) and in the reference regions (CB: $-10\pm6\%$, WM: $-4\pm7\%$)



FIGURE 3. (A) Regional [¹⁵O]-water SUV (mean \pm SEM) values for the three groups. (B) Average spatially normalized [¹⁵O]-water SUV images. White arrows indicate regions with reduced flow compared to controls (parieto-temporal cortex, posterior cingulate cortex, cerebellum). (C) [¹⁸F]-AV45 delivery rate K1 (mean \pm SEM). Stars denote significant differences with the HC group (*p < 0.05, ** p < 0.01, **** p < 0.0001). Abbreviations: SUV = standardized uptake value.

(Figure 3), and correlated well with -H₂O SUV to measure flow (Pearson's r: 0.50 for WM, temporal and frontal cortex (p<0.01) to 0.68 for posterior cingulate (p<0.0001).

Conclusion -AV45 assessed by the simplified static SUVR protocol does not truly reflect A β -load. However, SUVR_{WM} is better correlated with V_T and more closely reflects V_T differences between the aMCI and AD group than SUVR_{CB}. This might be partly due to differential flow effects in the respective reference regions. *Keywords: Alzheimer's disease, [18F]-AV45, SUVR, reference region, validation*

A simulation study on the quantification of the blood flow-dependent component in [18F]-AV45 SUVR differences between the MCI and AD stage

Julie Ottoy¹, Jeroen Verhaeghe¹, Sigrid Stroobants³, Sebastiaan Engelborghs², Steven Staelens¹

¹Molecular Imaging Center Antwerp (MICA), University of Antwerp, Antwerp, Belgium ²Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium ³Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium ⁴Dept of Neurology/Memory Clinic, Hospital Network Antwerp (ZNA) Hoge Beuken en Middelheim, Antwerp, Belgium

Background: The standardized uptake value ratio (SUVR) with respect to a reference region quantifies - AV45 brain uptake in Alzheimer's disease (AD) patients, but is subject to variability. Here we evaluate how SUVR in a cortical target region is affected by flow changes in both the target and reference.

Methods: Regional time-activity curves were simulated based on 2-tissue compartment modeling with a plasma input function, impulse response function (H(time;K1,k2,k3,k4)) and a contribution from whole blood. A change in flow was simulated as a change in K1 (and k2) in either the target region (precuneus) or reference region (cerebellar gray matter (CB) or subcortical white matter (WM)) to derive the corresponding change in SUVR_{50-60min}. Realistic parameters and input function were obtained from a aMCI and AD cohort. K1 was varied within the aMCI-AD range whereas other parameters were fixed at average aMCI values.

Results: Flow reduction in the target precuneus resulted in an increased SUVR (Figure 1, Figure 2).



FIGURE 1. A) Changes in time-activity curves of the (from top to bottom) precuneus due to $K1_{prec}$ change, CB due to $K1_{CB}$ change, WM due to $K1_{WM}$ change. B) Percent change in (from top to bottom) precuneus SUVR due to $K1_{prec}$ change, SUVR_{CB} due to $K1_{CB}$ change and SUVR_{WM} due to $K1_{WM}$ change. Baseline was set as mean aMCI K1. Abbreviations: TAC= tissue time-activity curve; K1= tracer delivery rate; SUVR= standardized uptake value ratio; prec= precuneus; CB= cerebellar gray matter; WM= subcortical white matter.



FIGURE 2. Changes in K1_{prec} (circles) or K1_{CB} (squares) versus changes in SUVR_{CB} in the precuneus; changes in K1_{prec} (circles) or K1_{WM} (triangles) versus changes in SUVR_{WM} in the precuneus Percent K1 changes are relative to mean K1 of the aMCI group. A second order polynomial function was fitted to the curves. Abbreviations: K1= tracer delivery rate; SUVR= standardized uptake value ratio; prec= precuneus; CB= cerebellar gray matter; WM= subcortical white matter.

Flow alterations in the two reference regions, WM and CB, exerted opposite effects on the respective SUVRs of the target: a flow reduction in WM caused an increase in $SUVR_{WM}$, whereas flow reduction in CB caused a decrease in $SUVR_{CB}$ (Figure 1, Figure 2).

On the individual level (Figure 3), the most extreme variations in $SUVR_{CB}$ and $SUVR_{WM}$ reached -4.4 and +9.3%. This was due to a combined flow decrease of -14 and -36% in the precuneus and CB, and -19 and -25% in the precuneus and WM, respectively.



FIGURE 3. Flow-induced changes in SUVR_{WM} (left) and SUVR_{CB} (right) for all aMCI and AD subjects, compared to baseline mean aMCI values. Abbreviations: SUVR= standardized uptake value ratio; aMCI = amnestic mild cognitive impairment; AD= Alzheimer's disease.

Conclusion: Flow reductions in AD introduce a small bias in SUVR on group level (Figure 3), but have larger impact on the individual level. This is clinically relevant for reliable assessment of A β -modifying treatment in AD. Flow changes in the references CB and WM alter SUVR in opposing directions. *Keywords: Alzheimer's disease, [18F]-AV45, SUVR, blood flow, reference region*

18F-PM-PBB3 a novel imaging tracer for visualization and quatification of TAU pathologies with Positron Emission Tomography

Paul Tempest¹, Ming-Kuei Jang¹, <u>Gilles Tamagnan²</u>, Ken Marek², John Seibyl², David Alagille², Olivier Barret², Makoto Higuchi³, Hitoshi Shimada³, Maiko Ono³, Tetsuya Suhara³, Ming-Rong Zhang³

¹Aprinoia Therapeutics, Tapei, Taiwan ²MNI, New Haven, CT, USA ³National Institute for Quantum and Radiological Science and Technology, Chiba, Japan

Non-invasive imaging diagnostics are critical in profiling and developing treatments for CNS diseases, including tracking disease progression, stratifying patients and monitoring efficacy for therapeutic interventions. A positron emission tomography (PET) tau tracer is desired for visualizing and quantifying neuronal and glial tau inclusions, a key pathological marker of tauopathies, including Alzheimer's Disease (AD) and progressive supranuclear palsy (PSP). 18F-PM-PBB3 is a novel PET imaging tau tracer under development for both preclinical and clinical utilities.

Here, we present data of in-vitro characterization and in-vivo imaging studies in animal models and humans. In PET imaging of normal mice and macaque monkeys, 18F-PM-PBB3 presented high brain uptake followed by rapid clearance from the brain. High-contrast 18F-PM-PBB3-PET signals corresponding to fibrillar tau deposition were also observed in the forebrain of a murine tauopathy model, rTg4510. Furthermore, kinetic and binding properties of 18F-PM-PBB3 have been clinically analyzed in normal controls and tauopathy patients.

Keywords: TAU, PET, imaging, PBB3, tauopathy

Quantitative analysis and correlation with clinical endpoints of [18F]MK6240 targeting neurofibrillary tangles (NFTs) in healthy volunteers and subjects with Alzheimer's disease

<u>Cristian Salinas</u>¹, Ping Chiao¹, Ajay Purohit¹, Karl Schmidt¹, John Beaver¹, Cyrille Sur², Arie Struyk³, Idriss Bennacef², Talakad Lohith², Jeffrey Evelhoch², Rick Hiatt⁴, Gilles Tamagnan⁵, Danna Jennings⁵, Ken Marek⁵, Richard Hargreaves¹

¹Biogen, Boston, MA, USA ²Translational Biomarkers, Merck & Co., West Point, PA, USA ³Translational Pharmacology, Merck & Co., West Point, PA, USA ⁴Enigma Biomedical Group Inc., Toronto, ON, Canada ⁵Invicro, New Haven, CT, USA

Introduction: MK6240 is a sub-nanomolar affinity, highly selective NFT PET radiotracer and is not liable for off-target bindings as other tau radiotracers. It was developed as a biomarker for Alzheimer's (AD) pathology to support the development of novel therapies targeting NFTs. Herein the quantitative analysis of a Ph0 study in 3 healthy volunteers (HV) and 3 subjects with AD is presented.

Methods: Three HVs (amyloid negative, MMSE 30-28) and three AD subjects (amyloid positive, MMSE 26-18) were administered with ~10mCi_MK6240 and dynamically scanned for up to 180 minutes. Biding potential (BP_{ND}) and SUVR were calculated in relevant brain regions using cerebellar grey matter as reference.

Results: In HVs MK6240 readily entered the brain and washed out fast and uniformly supporting the hypothesis of minimal in vivo off-target binding. In AD the tracer was selectively retained in regions prone to NFT deposition. A linear relationship was found between BP_{ND} and SUVR. Analytical analysis showed that SUVR measurements were robust against blood flow changes, an essenatial property supporting their usage to measure longitudinal changes in interventional studies. SUVR and BPnd measurements were highly correlated (R2>0.9) with MMSE in brain regions that are known to be affected in AD (hippocampus and enthorinal ctx).

Conclusion: MK6240 shows suitable kinetic properties and correlation between uptake and clinical endpoints. Although the results are encouraging, more data is needed to fully determine its utility as a AD biomarker.

Keywords: Tau, PET, MK6240, Alzheimer's

Implementation of the Centiloid transformation for 18F-florbetaben

<u>Christopher C Rowe</u>^{1,2}, Gareth Jones¹, Vincent Doré^{1,3}, David Baxendale¹, Rachel S Mulligan¹, Andrew Stephens⁴, Susan De Santi⁴, Colin L Masters⁵, Ludger Dinkelborg⁴, Victor L Villemagne^{1,2,5}

¹Dept of Molecular Imaging & Therapy, Centre for PET, Austin Health, Melbourne, Australia ²Dept of Medicine, University of Melbourne, Melbourne, Australia ³eHealth, CSIRO Health and Biosecurity, Brisbane, Australia ⁴Piramal Imaging GmBH, Berlin, Germany ⁵The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia

Background: A common quantitative output value for A β imaging across tracers and methods will improve clinical and research use. A method has recently been developed for this purpose that produces a unit of measurement called the Centiloid (CL) (*Klunk et al, Alzheimers Dement, 2015*). This approach was implemented on A β imaging studies performed with ¹⁸F-florbetaben (FBB) and ¹¹C-PiB (PiB).

Methods: All participants underwent PET imaging with both PiB and FBB, including 10 healthy young controls (32±9 yo) that were used to establish the "relative variance" (^{FBB}CL_{Std}/^{PiB}CL_{Std}) of FBB. Spatially normalized images were analyzed using the standard Centiloid regions (cortex and whole cerebellum reference region) downloaded from the Global Alzheimer's Association Investigators Network website (GAAIN; http://www.gaain.org). The non-standard reference regions, cerebellar cortex, pons, and whole cerebellum + pons were also investigated.

Results: FBB SUVR_{WCb} had a smaller dynamic range in neocortex compared to PiB SUVR_{WCb}. Both tracers were highly correlated ($R^2>0.93$), irrespective of the reference region used for the scaling. The average A β burden for the young controls was -2.50±6.49 CL for FBB and -1.09±3.53 CL for PiB, yielding a FBB "relative variance" of 1.84.

Conclusions: ¹⁸F-florbetaben results can soon be expressed in the common language of Centiloids by centers across the world using data that will be available through the GAAIN website. This is an important step towards better use of the clinical and research potential of A β imaging. *Keywords: Centiloid, florbetaben, PiB, A\beta imaging*

Selection of reference region for 18F-THK-5351 PET imaging analysis

Po-Yen Chen¹, Ing-Tsung Hsiao^{1,2}, Kun-Ku Lin^{1,2}, Chin-Chang Huang³

¹Department of Medical Imaging and Radiological Sciences, Chang Gung University, Taoyuan, Taiwan ²Department of Nuclear Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan ³Department of Neurology, Chang Gung Memorial Hospital, Taoyuan, Taiwan

Introduction: The novel PET radiotracer ¹⁸F-THK-5351 allows in vivo quantification of regional tau accumulation and monitoring the distribution of tau pathology. For semiquantitation using SUVR (standard uptake value ratios) in PET, the selection of reference region is important. The aim of this study is to explore the use of a proper reference region in ¹⁸F-THK-5351 imaging based on group difference between Alzheimer's disease (AD) patients and normal controls (NC).

Methods: A total of 20 subjects included in this study were divided into two groups: one group with 10 NC, and another one with 10 AD. Each subject underwent MRI and PET scans. PET images were spatially normalized into MNI template aided from individual MRI. Total 19 VOIs merged from the AAL VOIs were applied for computing regional SUVR and effect size between AD and NC. Optimal reference regions were chosen based on larger effect size derived from SUVR normalized by the selected reference regions.



Fig.1 The heat map of effect size between

AD and NC.

Results: The result indicates that both SUVR difference and effect size between AD and NC with intensity normalization from pons achieves stable and higher differentiation power than others (Fig.1). Moreover, larger effect size was observed when using the pons or the combination of pons and other regions as compared to those without pons. As compared to cerebellum cortex reference region, group SUVRs based on pons reference region are with less variation (Fig.2) but with smaller SUVRs.



Fig.2 The group SUVRs differences between cerebellem cortex reference region and pons reference region in Braak stage 1/2.

Conclusions: Our results indicate that the regional ¹⁸F-THK-5351 SUVR based on the selected pons reference region shows larger differentiation power than others, and thus is potentially useful for ¹⁸F-THK-5351 imaging quantitation.

Keywords: 18F-THK-5351, PET, reference region

Noise reduction algorithm for amyloid imaging without loss of image resolution

<u>Yuichi Kimura</u>¹, Kohsuke Fujii¹, Takahiro Yamada¹, Chisa Hosokawa², Muneyuki Sakata³, Takamichi Murakami², Kazunari Ishii²

¹Graduate School of Biology-Oriented Science and Technology, Kindai University, Kinokawa, Japan ²Department of Diagnostic Radiology, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan ³Research Team of Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Itabashi, Japan

Introduction: This study aims at proposing a noise reduction algorithm for amyloid imaging without a loss of image resolution. In a reading of amyloid imaging, positiveness and negativeness to $A\beta$ deposit is determined using an appearance of the white matter, and it has a thin and complicated structure. Such noise reduction algorithm is therefore expected that has small loss of spatial resolution. An ordinary noise reduction algorithm uses a spatial information of voxels; an averaging neighboring voxels, but another type of algorithm was proposed that utilize a kinetics of administered PET radiopharmaceutical, CAKS. CAKS was originally proposed for 1-tissue-2-compartment model, *e.g.* ¹⁵O–H₂O, and its availability is investigated for ¹¹C–PiB whose kinetics is describes with 2-tissue-3-compartment model denoting a specific binding to $A\beta$ in tissues.

Method: The ratio of is the function of a clearance rate from tissues to venous where is a tissue time activity curve (tTAC), T_E denotes the time of the last frame, and λ is a decay constant. *R* is computed for every voxels using tTAC. Voxels are then clustered based on *R*, and the tTACs are averaged to reduce the noise level. The performance is evaluated using a simulated PiB dynamic data, and CAKS is applied to a clinical data. **Results and Discussion:** Estimated *BP*_{ND} were identical with the truth in a noise free simulation, and they were within 5% from the truth when a clinical level of noise was added. Fig. 1 demonstrates the results of CAKS. The white matter is well visualized. We can conclude that CAKS is applicable to an amyloid imaging. **Reference:**

Yuichi Kimura, Hongbing Hsu, Hinako Toyama, and Nathaniel M. Alpert, "Improved Signal-To-Noise Ratio in Parametric Images by Cluster Analysis", *NeuroImage*, **9**, 554–561, 1999.

Keywords: PET, kinetic analysis, noise reduction, algorithm



Fig. 1: BP_{ND} images of a typical A β negative case. The upper raw is the case of no noise reduction, and the lower raw is the results of CAKS.

Cerebral brain perfusion in cognitively normal elderly: measured with arterial spin labelling and [18F]Flutemetamol PET

Stephen Carter¹, Laura Parkes², Rainer Hinz¹, Neil Pendleton², Karl Herholz¹

¹University of Manchester, Wolfson Molecular Imaging Centre, Faculty of Biology Medicine and Health, Manchester, United Kingdom ²University of Manchester, Faculty of Biology Medicine and Health, Manchester, United Kingdom

Background: Amyloid PET and Arterial Spin Labelling (ASL) were acquired from elderly individuals to measure fibrillar amyloid-beta ($A\beta$) pathology and to compare perfusion measures from each modality.

Methods: 33 cognitively normal elderly (85.2 ± 4.3 years; range 79-93; MMSE 28.9 ± 1.3 ; delayed CERAD words 8.5 ± 1.2 ; M/F = 8/25) were investigated. Participants underwent MRI at 3T (Philips Achieva), including T1 and ASL, and high-resolution PET (HRRT, Siemens); injected Flutemetamol dose = 187 ± 3.2 MBq. ASL and PET data were coregistered to T1 MR and unique anatomical brain atlases for each participant, derived from T1 images, were used to extract grey matter (GM) perfusion data. Cerebral perfusion (ml/min/100ml) was calculated with ASL; summing PET data acquired 4-8 mins post-injection created a pseudo-perfusion image (SUVR with cerebellar GM reference).

Results: SUVR values were extracted from a global neocortical region of Flutemetamol images (90-110mins) revealing 20/33 (61%) A β positive individuals (A β + = SUVR>1.5); 6 carried the ApoE4 gene. There was only a fair agreement between SUVR and visual assessment of PET images (k = .38, p <.05). Mean global perfusion in the GM with ASL was 21.8±5.4 ml/min/100ml. There was no correlation between perfusion measured with ASL and PET either globally or in composite frontal and posterior GM regions. Sub-dividing the population into A β + and A β negative (A β -) groups revealed no significant difference in MMSE score or delayed CERAD words; the A β + group was significantly younger (83.9 vs 87.2 years). Within the neocortex there was a significant difference in pseudo-perfusion between the A β + and A β - groups; the A β + participants displayed relative hyperperfusion (MannWhitney U = 173, p <.05).

Conclusions: The data revealed that 61% of cognitively normal elderly individuals (79-93 years) possessed pathological levels of brain A β . Perfusion (ASL) and pseudoperfusion (PET) were decoupled, suggesting global GM and anterior/posterior GM values of perfusion may not reliably compare between modalities. *Keywords: Preclinical AD, Amyloid PET, Arterial Spin Labelling*

[18F]flutemetamol – quantification on the centiloid scale

<u>Christopher Buckley</u>¹, Mark Battle¹, Adrian Smith¹, Koen Van Laere², Rik Vandenberghe², Val Lowe³

¹GE Healthcare, Amersham, United Kingdom ²KU Leuven, Leuven, Belgium ³Mayo Clinic, Rochester, MN, USA

Objectives

- To determine the flutemetamol centiloids equation.
- To compare the centiloid SPM8 & PMOD processing Pipelines
- To obtain the centiloid value for the CERAD² style division between sparse and moderate plaque assessments from autopsy data.

Methods: PiB data from HVs and ADs were processed by both by SPM8 and PMOD-PNEURO PET/MRI Centiloid VOI pipelines using whole cerebellum(wc), as a reference. The correlation metrics¹ were met for both processing pipelines. 23 HV and 17 AD subject flutemetamol PET & MRI images were both then processed by these two pipelines and the centiloids conversion equations obtained.

An autopsy determined sparse/moderate² boundary equivalent centiloid value was obtained. MRI data was not available in the majority of the end-of-life subjects in our autopsy studies. Therefore, we utilised the AD and HC subjects to obtain a linear relationship between SUVR obtained via a white-matter masked AAL atlas PET-only processing pipeline (Via Cortex IDTM) and using the SPM8 Centiloids pipeline. This relationship was used to convert the PET-only SUVRs from the AAL analysis of the end of life subject to centiloid values. The autopsy pathology measures were then used in a ROC analysis to estimate the centiloid value corresponding to the boundary between none and sparse in the CERAD-style plaque scoring.

Results: The equation relating flutemetamol SUVR via the centiloid VOI atlas on the standard **SPM8 and PMOD** PET/MR pipeline to centiloid values were:

Centiloid _{flutemetamol_SPM8}	$= 117.14 \text{ x SUVR}_{\text{flutemetamol}} - 116.57$	(1)
Centiloid _{flutemetamol_PMOD}	= 113.15 x SUVR _{flutemetamol} - 105.90.57	(2)

The boundary between sparse and moderate neuritic plaque density by CERAD scoring - i.e. the pathology boundary beyond which the majorityflutemetamol images are visually read as positive³ was estimated via a PET-only analysis to be a value of 30 centiloids.

References

Klunk et. al. Alzheimer's & Dementia 2015 Jan;11(1):1-15.
Mirra et. al. Neurology. 1991 Apr;41(4):479-86.
Curtis et. al. JAMA Neurol. 2015 Mar;72(3):287-94

Keywords: Centioloid, [18F]flutemetamol, CERAD, autopsy, SUVR

Blood-brain barrier disruption in Alzheimer disease measured by PiB PET: a preliminary study

Yi Su, Andrei Vlassenko, Marcus Raichle, John Morris, Tammie Benzinger

¹Washington University in St. Louis School of Medicine, Saint Louis, MO, USA

Background: Alzheimer disease (AD) is a disorder with complex etiology and multiple pathogenesis pathways. Recently, there is an increased interest in understanding the role of vascular factors in AD pathogenesis and progression. As a key component of the neurovascular system, the function of the bloodbrain barrier (BBB) in aging and AD is an important area of research, and it is hypothesized that BBB disruption can contribute to subsequent neurodegeneration which in turn lead to AD and dementia. In this preliminary study, we used a recently developed imaging technique to quantify BBB permeability and examine its relationship to cognitive impairment

Methods: A total of 50 participants (43 asymptomatic, 6 CDR 0.5, and 1 CDR 1) from local memory and aging studies who had both dynamic PiB PET scans and ¹⁵O-water scans were included in this study. A recently developed image-derived arterial input function (IDAIF) technique was adopted to quantify regional tracer influx rate (K1) and cerebral blood flow (CBF). The ratio of this two parameters (E=K1/CBF) is the single pass extraction fraction of the tracer and directly reflects the permeability of BBB.

Results: A significant positive correlation (p=0.001, r=0.32) was found between hippocampi single pass extraction fraction (*E*) of PiB tracer and the CDR rating of the participants. (Fig. 1). This finding suggests BBB permeability is increased in participants with cognitive impairment.

Conclusion: Disruption of BBB is observed in cognitively impaired participants using a novel imaging technique measuring BBB permeability based on PiB PET. The finding confirms recent report of BBB breakdown in AD using contrast enhanced MR. Further investigation is ongoing to examine BBB function in aging and AD.



Figure 1. Positive correlation (p=0.001) between hippocampi single pass extraction fraction (E) and CDR score.

Keywords: blood-brain barrier, PiB, PET, Alzheimer disease,

Binding of a tau positron emission tomography ligand, PBB3, to α -synuclein pathology as assessed by fluorescence and autoradiographic labeling

Shunsuke Koga¹, Maiko Ono^{2,3}, Naruhiko Sahara², Makoto Higuchi², Dennis Dickson¹

¹Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA ²National Institutes for Quantum and Radiological Science and Technology, National Institute of Radiological Sciences, Chiba, Japan ³Tohoku University Graduate School of Medicine, Department of Molecular Neuroimaging, Sendai, Japan

Background: Tau positron emission tomography (PET) ligand, PBB3, binds to a wide range of tau pathology; however, binding property of PBB3 to non-tau inclusions remains unknown. Given that α -synucleinopathy is often clinically misdiagnosed as tauopathy, it is important to clarify whether PBB3 binds to α -synuclein pathology. To address this issue, reactivity of PBB3 was assessed by in vitro fluorescence and autoradiographic labeling of brain sections from patients with Lewy body disease (LBD) without Alzheimer-type pathology (pure form LBD, pLBD) and multiple system atrophy (MSA).

Method: Of 10 pLBD and 120 MSA in the Mayo Clinic brain bank, we selected 3 pLBD and 4 MSA cases with different severity of α -synuclein pathology, based on the quantitative analysis of α -synuclein burden performed in the amygdala of pLBD and in the striatopallidal fibers of MSA (Figure 1). PBB3 fluorescence labeling, double or single immunostaining for α -synuclein and phospho-tau, and in vitro autoradiography with PBB3 were performed for these selected samples.

Results: PBB3 fluorescence labeled various α-synuclein lesions including Lewy bodies, Lewy neurites, spheroids, glial cytoplasmic inclusions (GCIs) and neuronal cytoplasmic inclusions. Meanwhile, autoradiographic labeling with PBB3 at a 5,000-fold lower concentration (~10 nM) than fluorescence staining demonstrated no significant binding in pLBD cases. In contrast, significant autoradiographic binding of PBB3 to the striatopallidal fibers was found in two MSA cases (MSA-3 and MSA-4). This was in consistent with high density of GCIs in these cases (Figure 2). Furthermore, the absence of tau deposition in both cases was proven by immunohistochemistry.

Conclusions: Given that the maximum concentration of PBB3 in human PET scans is approximately 10 nM, the present data imply that α -synuclein pathology in pDLB is undetectable by PBB3-PET, while α -synuclein lesions in a considerable subset of MSA cases with high density of GCIs could be captured by this radioligand.



Figure 1. Cases with pLBD or MSA are selected based on the quantitative analysis of a-synuclein burden. LBD cases with minimum, median, and maximum burden are designated as pLBD-1, pLBD-2, and pLBD-3. MSA cases with minimum, 25th percentile, 75th percentile, and maximum burden are defined as MSA-1, MSA-2, MSA-3, and MSA-4.



Figure 2. Representative images of Autoradiography. Even the most severe pLBD case (pLBD-3) shows no binding of [11]PBB3 to the amygdala, which have abundant Lewy bodies and Lewy neuites. In contrast, weak binding in MSA-3 and strong binding in MSA-4 to the striatopallidal fibers indicate the significant binding of [11]PBB3 to the glial cytoplasmic inclusions in this region. Less-intense signal is seen in the anterior commissure (ac) and optic tract (opt) due to nonspecific binding in all cases.

Keywords: Lewy body disease, multiple system atrophy, PBB3, autoradiography

A computationally efficient method for making PET measurements: the T1-GTM approach

Aaron Schultz, Reisa Sperling, Keith Johnson

Brigham and Women Hospital/Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA

Background: It is often advantageous practices to use T1-MRI imaging to drive the regional measures in PET. Anatomical labeling to define grey matter regions of interest yield higher quality measures. The current standard is FreeSurfer(FS), however full FS recons are time and computation intensive. We present an alternative that utilizes a probabilistic version of the GTM atlas (FS-6; 100 ROIs covering the entire head), combined with automated tissue segmentation in SPM12 to create ROI that have 1) good overlap with the FS defined ROI, 2) high shared variance with the FS pipeline, and 3) greatly reduced processing time and effort.

Methods: 275 HABS subjects where processed with FS and SPM12-Segment. Normalizations computed by SPM12 were used to map the FS-gtmseg atlas to template space, where a winner-take-all approach was used to assign every voxel to one of the 100 ROI in the gtmseg atlas. This probabilistic template-space atlas is then reverse normalized to native T1 space where ROI are crossed with the applicable tissue classes, followed by iterative tissue-class based assignment of uncategorized voxels to existing labels. ROI measures are made in 100 ROI using co-registered PET data, including PVC with GTM method.

Results: Utilizing 353 AV1451-PET scans, comparison of FS-GTM ROI and T1-GTM ROI reveal good overlap with an average dice coefficient of 0.70 ± 0.13 , and an average correlation between suvr measurements of 0.97 ± 0.06 . In small ROI of interest such as entorhinal we observe a correlation of 0.99, and when excluding values greater than 1.2 the correlation is still 0.86. When examining GTM-PVC measures the average correlation across ROI is 0.94 ± 0.10 .

Conclusion: This approach allows for rapid processing of PET data (~45min.) that maintains high fidelity to a more fully optimized FS-based pipeline (14-30hrs), though without the benefit of detailed structural measures or the ability to create native surface maps. *Keywords: PET, PVC, GTM, T1, AV1451*

Simplified reference tissue methods in [18F]AV1451 PET

<u>Tessa Timmers</u>^{1,2}, Sandeep Golla¹, Rik Ossenkoppele^{1,2}, Colin Groot^{1,2}, Sander Verfaillie¹, Philip Scheltens¹, Wiesje van der Flier^{1,3}, Lothar Schwarte⁴, Mark Mintun⁵, Michael Devous⁵, Robert Schuit¹, Albert Windhorst¹, Adriaan Lammertsma¹, Ronald Boellaard^{1,6}, Maqsood Yaqub¹, Bart van Berckel¹

¹Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands ²Alzheimer Center, Department of Neurology, VU University Medical Center, Amsterdam, Netherlands ³Department of Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands ⁴Department of Anaesthesiology, VU University Medical Center, Amsterdam, Netherlands ⁵Avid Radiopharmaceuticals, Philadelphia, PA, USA ⁶Department of Radiology & Molecular Imaging, University of Groningen, Groningen, Netherlands

Background: Previous studies with AV1451 PET quantified tau load using the standardized uptake value ratio (SUVr) derived from a static scan. SUVr may, however, be flow dependent and should be validated against a fully quantitative approach. The objective of this study was to compare simplified reference tissue models to plasma input tracer kinetic models for AV1451.

Methods: Following intravenous injection of 225±16 MBq AV1451, 130 min dynamic PET scans were performed in 5 biomarker confirmed AD patients and 5 controls. Arterial blood sampling was performed to obtain a metabolite corrected plasma input function. Next, regional time-activity curves were generated using PVElab software. The optimal kinetic model for describing *in vivo* kinetics of AV1451 was selected based on the Akaike criteria. The simplified reference tissue model (SRTM) was performed with grey matter cerebellum as reference region. SRTM derived binding potential (BP_{ND}) was compared to distribution volume ratio (DVR) derived from the optimal plasma input tracer kinetic model. In addition, SUVr values were calculated using the time interval 80-100 minutes post injection.

Results: The reversible two tissue compartment model with blood volume parameter $(2T4k_V_B)$ best described the kinetics of AV1451 in AD and controls. The SRTM derived BP_{ND} showed good correlation (AD: $r^2 = 0.87$, slope = 1.06; controls: $r^2 = 0.87$, slope = 0.86) with indirect plasma input binding (DVR-1). SUVr (80-100 min) correlated well with DVR ($r^2 = 0.93$, slope = 1.07) and SRTM derived BP_{ND} ($r^2 = 0.84$, slope = 0.95).

Conclusion: SRTM derived BP_{ND} correlated well with DVR-1. High correlations obtained for SUVr (80-100 min) suggest that it might be an alternative for DVR and BP_{ND} (SRTM). However, since the present results are based on a small cohort and as SUVr values may be flow dependent, these results should be interpreted with caution, especially when used longitudinally.

Keywords: AV1451, tau, PET, kinetic modelling, simplified reference tissue models

In vitro binding of [3H]RO6958948, [3H]AV-1451, [3H]THK5351 and [3H]T808 to tau aggregates in non-AD tauopathies

Michael Honer¹, Luca Gobbi¹, Dieter Muri¹, Edilio Borroni¹

¹Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

Objectives: Aggregation of tau is a hallmark of many neurodegenerative diseases, and tau imaging with PET tracers would allow early diagnosis and efficacy monitoring of a therapeutic intervention. Recently, AV-1451, THK5351 and RO6958948 have been described as promising PET tracers to visualize and quantify aggregated tau in AD patients. This study presents a detailed comparison of in vitro binding of RO6958948, AV-1451, THK5351 and T808 to tau aggregates in non-AD tauopathies such as PSP, FTLD-tau, CBD and Pick's disease.

Methods: Binding of tritiated tracers to fresh frozen tissue sections from patients with different, histopathologically confirmed tauopathies was analyzed under physiological conditions without tissue fixation or stringent washing conditions to reflect the in vivo situation of a PET scan. Tracer binding was visualized by high-resolution phosphor screen autoradiography, followed by co-localization studies with tau mAb immunohistochemistry on the same tissue section. Binding specificity was also analyzed by tracer displacement studies using co-incubation with cold variants of the different tracers.

Results: All tracers showed a similar binding profile to tau aggregates in AD and non-AD tauopathy tissue. Radioligand binding to tau aggregates in AD brain sections was confirmed by macroscopic and microscopic co-localization of radioligand binding and tau mAb staining. In vitro displacement studies suggested that all four tracers bind to an overlapping binding site on the AD-type of tau aggregates. None of the tracers displayed a significant binding to tau pathology in PSP, CBD and Pick's disease. Only in brain tissue samples from certain FTLD-tau MAPT mutation carriers some tau tracer binding to tau aggregates could be identified.

Conclusions: The results highlight the importance of characterizing the in vitro binding of tau PET tracer candidates to different species of tau aggregates to guide the clinical application of these tracers for the detection and quantification of tau aggregates in non-AD tauopathies. *Keywords: tau, autoradiography, RO6958948, PSP, AV-1451*

Evaluation of Caspase-3 activation in Alzheimer's disease using [18F]ICMT-11 PET/CT

Valeria Calsolaro, Grazia Daniela Femminella, Zhen Fan, Melanie Dani, Kasia Kozlowski, Eric Aboagye, Paul Edison

¹Faculty of Medicine, Imperial College London, London, United Kingdom

Introduction. Caspase 3 belongs to the family of cysteine aspartate-specific proteases involved in apoptosis, but it also exerts different functions in the central nervous system. Caspase 3 is involved in several neurodegenerative diseases, like Alzheimer's disease (AD), and increased Caspase 3 immunoreactivity in has been shown in AD patient's hippocampus. Moreover, activated Caspase 3 seems to co-localize with neurofibrillary tangles (NFT) and amyloid plaques in AD brains. ICMT-11 has been characterized as a caspase-3/7 specific positron emission tomography (PET) imaging radiotracer for the assessment of apoptosis. In this study we examine for the first time the brain uptake and kinetics of ICMT-11 in healthy volunteers and in patients diagnosed with AD.

Methods. Seven subjects (four AD and three HC) underwent ICMT-11 PET with arterial input and structural MRI. Arterial input data was analysed using two tissue compartmental model, and region of interest (ROI) analysis was performed. Object map was created in PET space, and distribution volumes (V_T) were calculated for each brain region.

Results. We detected statistically significant increase in the uptake of ICMT-11 in medial temporal lobe (MTL) (p=0.036) and fusiform gyrus (p=0.002) in the Alzheimer's group compared to controls, with at least two fold increase. The AD group also showed a significant smaller hippocampal volume compared to HC (p=0.047).

Conclusions. This pilot study evaluated ICMT-11 in an AD population, and demonstrated that there is increased ICMT-11 uptake in a cohort of Alzheimer's disease subjects. This is in line with ex vivo demonstration of Caspase 3 activity in different aspects of Alzheimer's disease. While larger studies necessary to validate the finding, these preliminary data suggest that ICMT-11 has the potential to detect apoptosis in Alzheimer's disease.

Keywords: Alzheimer's disease, Caspase 3, positron emission tomography, [18F]ICMT-11

Considerations for defining a striatal region of interest in amyloid PET studies within the Down syndrome population

Patrick Lao¹, Tobey Betthauser¹, Julie Price², William Klunk², Peter Bulova², Sigan Hartley¹, Regina Hardison², Rameshwari Tumuluru², Dhanabalan Murali¹, Chester Mathis², Annie Cohen², Todd Barnhart¹, Dana Tudorascu³, Darlynne Devenny², Charles Laymon¹, Sterling Johnson², Ben Handen¹, Bradley Christian

¹University of Wisconsin-Madison, Madison, WI, USA ²University of Pittsburgh, Pittsburgh, PA, USA ³New York State Institute for Basic Research in Developmental Disabilities, New York City, NY, USA

Background: Amyloid PET studies in the Down syndrome(DS) population, or in autosomal dominant Alzheimer's disease(AD), demonstrate elevated striatal amyloid in nearly all amyloid-positive subjects, often appearing before elevated cortical amyloid. Therefore, special attention should be placed on the analysis of early elevated striatal amyloid, in these conditions characterized by amyloid- β overproduction.

Methods::Eighty-one non-demented adults with DS (37.2±7.0yrs;44M,37F) underwent up to 3 cycles of PiB scans for a total of 80 cycle1, 54 cycle2, and 11 cycle3 scans. Standard uptake value ratio (SUVR;50-70min;cerebellar gray matter reference region) images were normalized to MNI space via a DS-specific PiB template and mean SUVRs were extracted from hand-drawn (on T1 MRIs;nucleus accumbens 2328mm³) or atlas-based masks (WakeForestUniversity pickatlas, SPM8;caudate 8240mm³, putamen 13752mm³, globus pallidus 4928mm³). Region of interest(ROI) dilation was accomplished by smoothing with an 8mm Gaussian kernel and thresholding at various cutoffs to investigate the effects of ROI size on mean SUVR.

Results: Distributions of PiB SUVR in the caudate (overall mean \pm SD;1.16 \pm 0.41), putamen (1.52 \pm 0.42), nucleus accumbens (1.26 \pm 0.29), and globus pallidus (1.04 \pm 0.11) are shown in Figure 1. The change in PiB SUVR between cycles (3.0 \pm 0.7years apart) were 0.07 \pm 0.15, 0.10 \pm 15, 0.06 \pm 0.13, -0.01 \pm 0.09 for the caudate, putamen, nucleus accumbens, and globus pallidus, respectively. Mean SUVR was stable after ROI dilation (| Δ SUVR| at 0.1 threshold: caudate 0.02;putamen 0.01;nucleus accumbens 0.01;globus pallidus 0.06), despite the widening of voxel-wise distributions due to inclusion of adjacent ventricle space or white matter.

Conclusion: Combinations of caudate, putamen, or nucleus accumbens provide meaningful information about early amyloidogenesis in the DS population, but the degree of inclusion for each subregion affects the mean SUVR. ROI size has minimal impact on ROIs that fully encompass a striatal subregion, but inclusion of adjacent ventricle space or white matter introduces extreme values that will have a greater influence on the mean SUVR in partial ROIs, e.g., just a few axial slices.

Research Support:R01AG031110, U54HD090256, U01AG051406



Frequency histograms of mean [¹¹C]PiB standard uptake value ratios (SUVRs) for four striatal subregions: the caudate, putamen, globus pallidus, and nucleus accumbens. While the caudate, putamen, and nucleus accumbens demonstrate a similar distribution across subjects, the globus pallidus does not show elevated binding. The panel on the right shows the regions of interest color coded to match the histogram title, and a representative [¹¹C]PiB SUVR image.

Keywords: Down syndrome, preclinical Alzheimer's disease, PiB, amyloid, striatum

Head-to-head comparison of tau-specific tracers in Alzheimer's disease: [11C]THK5351 vs [11C]PBB3 PET imaging

<u>Konstantinos Chiotis</u>¹, Per Stenkrona², Ove Almkvist^{1,3}, Ryosuke Arakawa², Akihiro Takano², Vladimir Stepanov², Andrea Varrone², Makoto Higuchi⁴, Christer Halldin², Agneta Nordberg^{1,5}

¹Dept NVS, Center for Alzheimer Research, Translational Alzheimer Neurobiology, Karolinska Institutet, Stockholm, Sweden ²Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institutet, Stockholm,

Sweden ³Department of Psychology, Stockholm University, Stockholm, Sweden ⁴Molecular Imaging Contern National Institute of Padiological Sciences, 4,0,1 Anagawa, Inc.

⁴Molecular Imaging Center, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba, Japan

⁵Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden

Objective: During the past five years, the development of different tau-specific PET tracers has enabled the visualization of tau deposits in Alzheimer's disease (AD) as well as other tauopathies. In this study we evaluated *in vivo* THK5351 and PBB3, two tau-specific PET tracers that belong to different chemical families, in the same patients with AD.

Materials & Methods: A group of patients with clinical diagnoses of mild cognitive impairment and probable AD were recruited after thorough clinical assessment. All patients underwent multimodal imaging with the tau-specific tracers THK5351 and PBB3, the amyloid-specific tracer AZD2184 as well as a 3D T1 MRI sequence. In addition to the clinical assessment, all patients were evaluated for the purposes of the project with a detailed neuropsychological battery.

Results: All patients showed high widespread cortical binding of AZD2184. Binding of THK5351 and PBB3 was observed in the temporal lobes as well as other isocortical areas, however, distinct from the distribution pattern of AZD2184 binding. Compared to PBB3, THK5351 showed greater grey matter binding. Distinct areas showing off-target binding for every tracer were identified.

Significance: To date, this is the first study to investigate *in vivo* the comparability of two different tauspecific PET tracers in the same patients with AD. This study will shed new light into the regional binding properties of the tracers as well as the underlying interrelationship between the tau tracers' binding with markers of cognitive decline and amyloid burden in the AD brain. *Keywords: tau, amyloid, THK5351, PBB3*

Flow changes affect SUVr but not binding potential in an AD clinical trial

<u>Colin Groot</u>^{1,2}, Tessa Timmers^{1,2}, Rik Ossenkoppele^{1,2}, Maqsood Yaqub¹, Niels D Prins^{2,3}, Adriaan A Lammertsma¹, Philip Scheltens², Bart NM van Berckel¹

¹Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands ²Alzheimer Center & Department of Neurology, VU University Medical Center, Amsterdam, Netherlands ³Alzheimer Research Center, Amsterdam, Netherlands

Background: Clinical trials investigating changes in amyloid load in patients with Alzheimer's disease (AD) following treatment routinely make use of the semi-quantitative measure standardized uptake value ratio (SUVr). It has been shown, however, that PiB SUVr is sensitive to changes in blood flow, potentially leading to misinterpretation of therapy effects. The objective of the present study was to assess if blood flow changes during a clinical trial affect SUVr compared with the fully quantitative measure of amyloid load, which is binding potential (BP_{ND}).

Methods: 14 amyloid-positive patients with mild cognitive impairment (MCI) or AD (age 67 ± 5) underwent 90-minute dynamic PiB PET scans before and after a 12-week treatment period. A global cortical ROI was defined on (individual) structural MRI images using a probability map based template. BP_{ND} and SUVr (60-90 min post-injection) were calculated using cerebellar grey matter as reference region. In addition, an index of flow was obtained from the ratio of tracer deliveries to cortical and cerebellar regions (R₁). Changes between baseline and follow-up (Δ) were calculated for R₁, BP_{ND} and SUVr.

Results: Paired T-tests revealed no significant differences between baseline and follow-up values for any of the parameters (Table, Figure 1). ΔBP_{ND} showed good correlation with $\Delta SUVr$ (Spearman's $\rho=0.76$, p<0.01). ΔBP_{ND} did not correlate with ΔR_1 (Spearman's $\rho=0.37$, p=0.20), whilst $\Delta SUVr$ did (Spearman's $\rho=0.65$, p=0.01).

Conclusion: These results indicate that changes in SUVr, but not BP_{ND} , are affected by changes in blood flow. Although this had no effect on the interpretation of SUVr in the present study, the sensitivity of SUVr to changes in perfusion indicates that treatment effects in AD should preferably be assessed using fully quantitative methods such as BP_{ND} , especially if the interval between baseline and follow-up scans is longer and for drugs that have a direct effect on perfusion.

	Baseline	Follow-up
SUVr (60-90 min)	1.98 (0.36)	2.01 (0.41)
BPND	0.74 (0.24)	0.76 (0.27)
R ₁	0.85 (0.06)	0.85 (0.05)



Values are displayed as mean (standard deviation)

Keywords: SUVr, binding potential, flow, PiB, PET

Developing a tracer agnostic pipeline for amyloid and tau PET data

Zachary Hobel¹, Suzanne Baker², Matthew Ellis¹, Judy Pa

¹Stevens Neuroimaging and Informatics Institute, University of Southern California, Los Angeles, CA, USA ²Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA

Background: With the availability of sensitive and specific PET radioligands for beta-amyloid and tau aggregates, many studies are incorporating both markers in large-scale, within-subject designs. Thus, there is an increasing need to harmonize the analysis approach for amyloid and tau PET data to maximize biologically-relevant signals and minimize methodological noise. The goal of this project was to develop a tracer-agnostic analysis pipeline for amyloid and tau PET.

Methods: We utilized publicly available data from the Alzheimer's Disease Neuroimaging Initiative (ADNI). As of June 2016, there were 53 cognitively normal or mild cognitive impairment participants who had both amyloid and tau PET data available (24 women, age: 76.4 ± 7.5 years). We first constructed an amyloid PET analysis pipeline based by published studies from the ADNI PET Core, tested our pipeline on raw data downloaded from ADNI, and then developed a complementary tau PET pipeline.

Results: We produced an analysis pipeline with key features, including image realignment, coregistration, averaging, reslicing, and smoothing. Smoothing parameters were dependent on each scanner's resolution and performed to bring images acquired at different scanners to a common resolution. The reference regions were a composite of the whole cerebellum, brainstem/pons, and white matter for AV-45 and the whole cerebellum for AV-1451. Using our harmonized pipeline, we replicated the AV-45 SUVR composite scores processed by the ADNI PET Core with 10⁻³ accuracy. In proof of principal analyses, we found that 1) AV-1451 SUVR values in the right inferior temporal cortex were negatively associated with long-delay memory, and 2) APOE-e4 carriers had higher AV-45 SUVR values when compared to APOE-e4 non-carriers (all p's<0.01).

Conclusions: A flexible analysis pipeline for processing amyloid and tau PET data is feasible and enables combining datasets from different sources for large-scale analyses. Future work will include optimizing this pipeline for clinical trials, integrating other tracers, and standardizing to centiloids. *Keywords: Alzheimer's disease, AV-45, AV-1451, clinical trials, harmonization*

Kinetic modeling of the tau PET tracer [18F](S)THK-5351 in healthy controls and Alzheimer's disease subjects

<u>Olivier Barret</u>¹, Cristian Constantinescu¹, Christopher Buckley³, Grethe Dalsgaard³, Alex Gibson³, Ajay Purohit², John Beaver², John Seibyl¹, Gilles Tamagnan¹, Ken Marek¹, Danna Jennings¹, Cristian Salinas-Valenzuela²

¹Molecular NeuroImaging, LLC, New Haven, CT, USA ²Biogen Inc, Boston, MA, USA ³GE Healthcare, Amersham, United Kingdom

Objective: To perform kinetic analysis of (S)THK-5351 with arterial input function in healthy controls (HC) and Alzheimer's disease (AD) subjects, and assess test/retest variability of different measures.

Methods: PET brain imaging was completed in five HC (age 51-69), five mild AD (age 64-71, MMSE 21-26) and five moderate AD (age 54-75, MMSE 8-19). Subjects were administered 9.0 ± 0.7 mCi (S)THK-5351 and imaged twice for 3.0 hours with arterial blood sampling. PET data were analyzed with Logan graphical analysis (invasive (LGA) and non-invasive (NI-LGA)) to estimate the distribution volume ratio (DVR). SUVR curves were calculated over 180 min and compared to DVR for different time windows. The cerebellar cortex was used as reference region. DVR and SUVR were compared between the three groups.

Results: (S)THK-5351 is rapidly metabolized, with ~15-20% of parent remaining at 30 min. There was very good agreement between LGA and NI-LGA DVR estimates. SUVR curves plateaued around 40 min post injection. SUVR measurements correlated with DVR ($R^2>0.9$) but overestimated DVR by ~50-100%, with SUVR (40-60 min) showing highest correlation with DVR. DVR estimates were robust, with <5% change when truncating data from 180 to 90 min. NI-LGA DVR (90 min) test/retest variability was $3.4\pm2.8\%$ across regions and subjects. Variability of SUVR was lower for 40-60 min ($3.6\pm2.8\%$) compared to 60-90 min ($4.7\pm4.0\%$). NI-LGA DVR (90 min) for HC, mild AD and moderate AD was 1.32 ± 0.03 , 1.49 ± 0.05 and 1.55 ± 0.06 in inferior lateral temporal cortex and 1.66 ± 0.04 , 1.79 ± 0.05 and 1.75 ± 0.06 in hippocampus.

Conclusions: SUVR curves rapidly reach a plateau and SUVR at 40-60 min highly correlate with DVR while providing lower test/retest variability compared to later imaging windows. Small signal increase was measured in AD compared to HC in regions expected to exhibit tau pathology, while high signal was measured in HC in subcortical regions and hippocampus. *Keywords: PET, Tau, Kinetic analysis, Test/Retest, THK-5351*

Longitudinal changes in [18]F-RO6958948 Tau PET signal in four Alzheimer's subjects

<u>Dean Wong^{1,2,3}</u>, Hiroto Kuwabara¹, Robert Comley⁵, Gregory Klein⁴, Christina Vozzi⁴, Michael Honer⁴, Joshua Roberts¹, Kelly Kitzmiller¹, Lorena Gapasin¹, Edilio Borroni⁴

¹Johns Hopkins University Department of Radiology and Radiological Sciences, Baltimore, MD, USA ²Johns Hopkins University Department of Psychiatry and Behavioral Sciences, Baltimore, MD, USA ³Johns Hopkins University Department of Neurology, Baltimore, MD, USA ⁴Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel, Switzerland ⁵AbbVie (former employee of Roche Pharmaceutical Research and Early Development), North Chicago, USA

Objective: RO6958948, a novel radiopharmaceutical for imaging of tau deposits, has previously been evaluated in 11 AD, 5 YHC, and 6 OHC in PET imaging studies, determining kinetic and test-retest properties. Here we report preliminary longitudinal data from 4 AD subjects imaged at a second time point ranging from 8 to 22 months.

Methods: Four AD subjects (Age: 70 - 86; Baseline MMSE: 22 - 24) had baseline and follow up dynamic scans on a HRRT for 90 minutes after a bolus injection of RO6958948. Data were analyzed using the reference tissue graphical analysis and SUVR 60-90 minutes post-injection (reference region: cerebellum). Changes in DVR and SUVR between baseline and follow-up were examined in eleven brain regions (a total of 22 left and right regions) that showed higher binding in the 11 AD subjects (Age: 55 - 86; MMSE: 16 - 25), and/or are typically used for Braak staging of tau pathology. Paired t-test was used to examine whether DVR or SUVR increased in individual subjects.

Results: AD subjects showed changes of MMSE scores (baseline and follow-up MMSE / scan intervals in months) as: Subject A1: $24 \rightarrow 25$ / 18 months; A2: $20 \rightarrow 19$ / 8 months; A3: $23 \rightarrow 19$ / 22 months and A4: $22 \rightarrow 18$ / 21 months). Increase in DVR values of the 22 regions were observed in: A1 (up to 12%) and A4 (up to 23%), uncorrected p values: p>10-3 and p<10-4. SUVR values increased in subject A1 (up to 27%), A3 (up to 14%) and A4 (up to 27%) uncorrected p values: A1 p<10-5, A3 p<0.01 and A4 p<10-4. Data evaluation using other reference regions is ongoing.

Conclusions: Substantial increases between baseline and greater than one year follow-up PET scans were seen in 3 AD subjects suggesting that RO6958948 can detect Tau pathology progression.

Keywords: Tau, novel, radiopharmaceutical, Alzheimer's, longitudinal

Longitudinal Centiloid change in ADNI [18F]Florbetapir PET data: implications for clinical trials

Donald McLaren¹, Felix Carbonell¹, Vincent Auclair¹, Alex Zijdenbos¹, Abhinay Joshi², Micheal Navitsky², Mark Mintun², Ping Chiao³, Barry Bedell^{1,4}

¹Biospective, Inc., Montreal, QC, Canada
²Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA
³Biogen, Inc., Cambridge, MA, USA
⁴McGill University, Montreal, QC, Canada

Introduction: Alzheimer's Disease clinical trials routinely use Florbetapir positron emission tomography (PET) scans as imaging endpoints. However, it is important to understand the changes observed in response to therapeutic interventions relative to natural history data and to other clinical trials. To this end, we have determined the annual change in Amyloid PET, in both SUVR and Centiloids, in ADNI to provide context for clinical trials.

Methods: Data from 188 ADNI subjects with repeated Amyloid PET scans were utilized. Florbetapir PET and 3D T1-weighted MRI scans were processed through Biospective's PIANOTM pipeline. SUVR values were calculated using the whole cerebellum as a reference region and converted to Centiloids. The Centiloid conversion equation (Klunk, 2015) was generated using data from 43 subjects across the AD spectrum (provided by Avid Radiopharmaceuticals) with PiB PET, Florbetapir PET, and 3D T1-weighted MRI scans. Only subjects with an amyloid-positive Florbetapir baseline PET scan, based on visual reads, were used for longitudinal analysis.

Results: The annual SUVR changes (±s.d.) were 0.039 ± 0.065 and 0.014 ± 0.055 for cognitively normal and cognitively impaired groups, respectively (80% power). The corresponding annual Centiloid changes were 7.96±13.42 and 2.85±11.38. The sample sizes per arm needed to detect a halt in SUVR or Centiloid change over one year were 45 and 244 for cognitively normal and cognitively impaired groups, respectively. The sample size per arm needed to detect a 10 Centiloid (0.049 SUVR) reduction in annual change was \leq 30 subjects per group (80% power).

Discussion: Based on this analysis, the detection of significant effects of anti-amyloid therapies that only halt the accumulation of β -amyloid will be limited by the statistical power. However, if an anti-amyloid therapy results in a substantial reduction of β -amyloid burden, then the required sample sizes would be drastically reduced, thereby facilitating the use of Amyloid PET in early-phase, disease-modifying clinical trials. *Keywords: amyloid, longitudinal, ADNI, Centiloid, sample size*
FreeSurfer approach to the Centiloid standardization method: Evaluation of alternative cortical target regions and partial volume correction

Davneet Minhas¹, Brian Lopresti¹, Howard Aizenstein^{2,3}, Charles Laymon^{1,3}, Elizabeth Campbell¹, Zheming Yu¹, Dana Tudorascu⁴, Chester Mathis¹, William Klunk^{2,5}

¹University of Pittsburgh, Radiology, Pittsburgh, PA, USA ²University of Pittsburgh, Psychiatry, Pittsburgh, PA, USA ³University of Pittsburgh, Bioengineering, Pittsburgh, PA, USA ⁴University of Pittsburgh, Biostatistics, Pittsburgh, PA, USA ⁵University of Pittsburgh, Neurology, Pittsburgh, PA, USA

Background: Central to the Centiloid standardization process is the cortical target region (SPM-CTX), derived by warping the CTX subject set (19 Alzheimer's disease and 25 older-control subjects) to MNI space using the Unified method within SPM and identifying the region of maximum difference between groups. However, the warping may be susceptible to differences in cortical grey matter (GM) atrophy. Further, the method does not account for the partial volume effect (PVE). This work evaluates alternative methods for generating a standard cortical region using FreeSurfer.

Methods: An initial alternative cortical region was generated by warping the Centiloid CTX subjects to a common space using FreeSurfer's Talairach transform and identifying the region of maximum difference (FS-CTX). A second GM-only cortical region was generated that follows the pial surface and GM-WM tissue boundaries by combining FreeSurfer GM parcellation regions that best match the FS-CTX region (FS-GM-CTX).

18 subjects independent of the Centiloid CTX set with PiB and MRI acquisitions were selected having either high (SUVR > 2.50; n=11) or low (SUVR < 1.20; n=7) amyloid load based on hand-drawn ROIs. Cortical SUVR values were determined using 4 methods: SPM-CTX, FS-CTX, FS-GM-CTX, and FS-GM-CTX with geometric transform matrix (GTM) partial volume correction (+PVC). Effect sizes (Cohen's d) were evaluated for distinguishing high vs. low amyloid load.

Results: SPM-CTX, FS-CTX, and FS-GM-CTX VOIs are overlaid on a native-space MRI in FIGURE. Average high-amyloid SUVRs (Cohen's d) were: SPM-CTX=2.82±0.24 (9.62); FS-CTX=2.59±0.17 (11.14); FS-GM-CTX=2.28±0.17 (9.86); FS-GM-CTX+PVC=3.73±0.31 (11.18).

Conclusions: The FS-GM-CTX method generated the lowest average high-amyloid SUVR and lower effect size than FS-CTX, likely due to its increased susceptibility to PVEs at the pial surface. However, FS-GM-CTX+PVC resulted in a similar effect size to FS-CTX despite a significantly larger standard deviation in the high-amyloid group. These results suggest PVC should be explored as part of a standardized amyloid methodology.

Keywords: amyloid, PET, partial volume, Centiloid, FreeSurfer



72

The quantitative impact of emission-transmission scan misalignment and region selection upon amyloid measurement accuracy

Randolph Andrews¹, <u>Dawn Matthews</u>¹, Anne Smith²

¹ADM Diagnostics LLC, Northbrook, IL, USA ²Siemens Healthcare, Knoxville, TN, USA

Background: Statistically powered measurement of amyloid accumulation and removal is challenged by low biological accumulation rates and potentially subtle treatment reduction values. Several technical factors can overwhelm detection of these changes, including attenuation correction error due to misalignment between transmission scan and emission scan, but this has not been quantified. We systematically quantified emission-transmission misalignment impact upon Standardized Uptake Value Ratio, and the role of reference and target region selection.

Methods: Florbetapir PET-CT scans with negligible subject motion were obtained from three subjects with a range of clinical diagnoses, morphologies, and amyloid: Healthy Control amyloid negative (Am-), amnestic MCI Am+ threshold, and early AD Am+. The CT (mu-map) and emission scans of each were systematically misaligned and reconstructed using 56 different permutations including translational motion in each of x, y, and z directions of 0 to 10mm, and rotational motion relative to each axis of 0 to 10 degrees, and combined translation and rotation in all directions. Versions were also constructed that required realignment of the emission scans during processing vs. no realignment, to segregate realignment error from embedded attenuation correction error. Differences in measured regional values relative to the correctly aligned case were calculated and compared for different target regions of interest and reference region definitions, including regions based upon the AAL atlas and regions comprised of the Freesurfer segments applied in ADNI (Landau). Impact was compared across misalignment permutations, regions, and subjects.

Results: SUVR percent error ranged from 1% to over 50% depending upon motion and regions measured. Error increased notably after 4mm or 4 degrees. Subcortical white matter showed less error than gray cerebellum and pons in most cases, and certain cortical regions showed greatest change.

Conclusions: Emission-transmission scan misalignment must be minimized to assure accurate amyloid measurement. Reference and target regions can be selected to minimize misalignment related error.



Figure 1. Percent change in regional amyloid PET values associated with y-axis translation, xaxis rotation, and combined translation and rotation across all axes. Reference regions shown on left, and example target AAL-based regions on right.

Keywords: amyloid, attenuation, quantitation, SUVR, rates

High quantitative accuracy amyloid PET imaging with precision estimation

<u>Pawel Markiewicz</u>^{1,2}, Kjell Erlandsson², Jonathan Schott³, Catherine Scott¹, David Cash³, Frederik Barkhof¹, Nick Fox³, Sebastien Ourselin^{1,3}

¹Translational Imaging Group, CMIC, University College London, London, United Kingdom ²Institute of Nuclear Medicine, University College London, London, United Kingdom ³Dementia Research Centre, University College London, London, United Kingdom

We present an advanced infrastructure dedicated to quantification of amyloid imaging using PET/MR. The proposed software provides full control of list-mode data processing, image reconstruction and analysis leading to precise quantitative estimates of regional or voxel-level SUVr, and includes:

(1) generation of an atlas-based pseudo-CT (pCT) μ -map for attenuation correction which can be coregistered to any time frame of PET data to account for head motion;

(2) 3D scatter correction for long axial FOV scanners;

(3) voxel-based partial volume correction (PVC, iterative Yang) using T1w brain parcellations and upsampled PET image;

(4) full detector normalisation and reduced noise randoms correction.

The entire processing chain is implemented on high-throughput graphical processing units (GPU). This enables comprehensive investigation of the sources of uncertainty through 100-times bootstrap resampling of the list-mode data and consequent multiple image reconstructions and analyses.

This methodology allows for a critical evaluation of the impact of PET count statistics; different methods for attenuation correction (UTE, pCT), scatter correction, PVC, registration and interpolation; choice of reference region; and size and position of the region-of-interest relative to the scanner's field-of-view. We show that partial volume effects and attenuation correction inaccuracies are the biggest sources of error (accounting for up to 10% each) followed by the limited count statistics (error of up to 8%). The type of interpolation used in image up-sampling for PVC and ROI analysis may cause changes of up to 4% in SUVr. Coregistration of the mu-map to any given time frame PET image increases accuracy due to misalignment correction but is a source of additional uncertainty.

The proposed infrastructure enables very accurate estimates of amyloid deposition using static and dynamic PET imaging. Estimates of uncertainty estimated at voxel and ROI levels aid in the interpretation of cross-sectional data, and are likely to allow for increased precision in longitudinal analyses.





blue horizontal lines: standard global neocortex SUVr blue dots: standard regional SUVr red dots/box plots: bootstrapped distributions of SUVr (uncertainties)

acglt, mcglt, pcglt: anterior, middle, posterior cingulate precu: precuneus

tmprl: temporal, partl: parietal, neocx: neocortex

Keywords: amyloid quantification, PET, bootstrap resampling, uncertainty estimation, partial volume correction, scatter correction, attenuation correction

Comparison of region of interest segmentation methods for extraction of 11C-PiB SUVR in the Down syndrome population

<u>Tobey Betthauser</u>¹, Patrick Lao¹, Dana Tudorascu², Julie Price², Peter Bulova², Sigan Hartley¹, Regina Hardison², Rameshwari Tumuluru², Davneet Minhas³, Charles Laymon², Dhanabalan Murali¹, Chester Mathis², Annie Cohen², Todd Barnhart¹, Darlynne Devenny³, William Klunk², Sterling Johnson¹, Ben Handen², Bradley Christian¹

¹University of Wisconsin - Madison, Madison, WI, USA ²University of Pittsburgh, Pittsburgh, PA, USA ³Institute for Basic Research in Developmental Disabilities, New York, NY, USA

Introduction: Region of interest (ROI) segmentation can be problematic in populations with brain structure abnormalities, particularly for automated processing routines. Differences in ROI delineation could affect statistical outcomes when extracting PET binding measures. This work compares three methods of ROI delineation for ¹¹C-PiB SUVR extraction in the Down syndrome population.

Methods: Fifty-four individuals, selected from a larger cohort, with Down syndrome underwent ¹¹C-PiB PET (50-70 min) and T1-weighted MRI scans. Parametric SUVR images were generated (GM cerebellum reference) and coregistered to MRI (SPM8). Mean SUVRs were extracted from hand-drawn (HD) (Rasario2011), FreeSurfer 5.1.0 (FS), and Wake Forest University Pick Atlas (WFU) derived ROIs. HD and FS ROIs were defined in native MRI space. WFU ROIs were defined in MNI space. WFU SUVRs were extracted from SUVR images that were normalized from native MRI space (SPM8) to a study-specific PET template in MNI space. Between-method differences in mean SUVR were determined using a repeated measures analysis with a fixed method factor and a random subject effect (to account for within subject correlation). HD ROIs were the standard for comparison. Intra-class correlation coefficients (ICCs) were calculated using a one-way random effects model to assess agreement of the FS and WFU methods with the HD method.

Results: Compared to HD SUVRs, both WFU and FS SUVRs were significantly lower for all ROIs (Tables 1 and 2). ICCs indicated reasonable agreement with HD SUVRs for FS (except temporal cortex) and WFU methods, with WFU generally having slightly higher ICC's with HD (Table 3).

Conclusions: The use of a study-specific PET template in combination with the WFU PickAtlas improves agreement with hand drawn ROIs compared to using FreeSurfer and is a viable method for ROI delineation in the Down syndrome population. Normalizing to a PET template allows for regional SUVR extraction without requiring MRI data.

Region	Hand Drawn (n=54)	Pick Atlas (n=54)	Freesurfer (n=54)
Anterior Cingulate	1.44 (0.32)	1.28 (0.26)	1.29 (0.25)
Frontal Cortex	1.38 (0.32)	1.17 (0.27)	1.12 (0.23)
Parietal Cortex	1.30 (0.24)	1.20 (0.28)	1.22 (0.20)
Precuneus	1.35 (0.31)	1.27 (0.29)	1.25 (0.26)
Temporal Cortex	1.34 (0.24)	1.18 (0.20)	1.08 (0.19)
Striatum	1.42 (0.50)*	1.32(0.37)	1.35 (0.34)

Table 1 Descriptive statistics for computed SUVRs for each method and region. Values are presented as mean and standard deviation across all subjects. (*n=53)

Region	Pick Atlas vs Hand Drawn	Freesurfer vs Hand Drawn
Anterior Cingulate	-0.166 (-0.195, -0.136)	-0.158 (-0.187, -0.129)
Frontal Cortex	-0.209 (-0.243, -0.175)	-0.266 (-0.299, -0.232)
Parietal Cortex	-0.097 (-0.130, -0.065)	-0.176 (-0.208, -0.144)
Precuneus	-0.083 (-0.105, -0.060)	-0.095 (-0.118, -0.073)
Temporal Cortex	-0.158 (-0.184, -0.132)	-0.263 (-0.289, -0.236)
Striatum	-0.095 (-0.139 <i>,</i> -0.051)	-0.063 (-0.106, -0.019)

Table 2 Results from the repeated measures model represented as the mean estimated differences and 95% confidence interval using hand-drawn values as the reference method.

	Hand Drawn and Pick Atlas	Hand Drawn and Free Surfer
Region	ICC	ICC
	(Agreement)	(Agreement)
Anterior Cingulate	0.785	0.762
	(0.658, 0.869)	(0.623, 0.854)
Frontal Cortex	0.683	0.526
	(0.512, 0.803)	(0.304, 0.694)
Parietal Cortex	0.806	0.629
	(0.689, 0.883)	(0.437, 0.766)
Precuneus	0.925	0.889
	(0.875 <i>,</i> 0.956)	(0.817, 0.934)
Temporal Cortex	0.673	0.369
	(0.497, 0.796)	(0.116, 0.577)
Striatum	0.925	0.909
	(0.875, 0.956)	(0.848, 0.946)

Table 3 Intra-class correlation coefficients with 95% confidence intervals comparing agreement of FreeSurfer and WFU Pick Atlas SUVRs with hand-drawn SUVRs.

Keywords: Down Syndrome, Beta-amyloid, PET, PiB, SUVR

Comparison of tau distribution according to tau tracers in various neurodegenerative diseases: Using [18F]AV1451 and [18F]THK-5351

Young Koung Jang¹, Gil Rabinovich², Heejin Kim¹, Jin San Lee¹, Ko Woon Kim¹, <u>Sang Won</u> <u>Seo</u>

¹Samsung Medical Center, Seoul, Korea ²University of California, San Francisco, San Francisco, CA, USA

Tau accumulation is known to be core pathologic change in various neurodegenerative diseases including AD. Several tau tracers have been developed to detect tau deposition in vivo. Recently, AV1451 and THK-5351 are widespread tau tracers among many tau tracers. We evaluated how each tau tracer reflected tau distribution and weather there were some differences between two tracers or not in various neurodegenerative diseases including AD-spectrum tauopathies and non-AD neurodegenerative diseases.

Six participants performed Tau-PET using two tracers, FBB-PET, and MRI. The participants consisted of two bvFTD, one svPPA, one AD, one LPA, and one SMI patients. To compare regional tau tacers uptake, we used the standardized uptake value ratios (SUVR) which is uptake ratio of automated volume of interest to reference region.

We found that THK-5351showed higher amount and larger area of retention than AV1451 in non-AD neurodegenerative diseases. Conversely, in AD spectrum diseases, higher amount and larger area of uptake were shown in AV1451, compared to THK. We also found that off target binding in midbrain and basal ganglia was prominent in THK-5351 than AV1451.

This study revealed that AV1451 was more specific to AD tauopathies and less likely to present off target binding, while THK-5351 was more likely to reflect non-specific neurodegeneration. These results would provide better understanding to clinical application of AV1451 and THK-5351. *Keywords: tau, PET, tracer*

A comparison of DVR and SUVR methods for THK5317 and THK5351

<u>Tobey Betthauser</u>¹, Patrick Lao¹, Dhanabalan Murali¹, Todd Barnhart¹, Shozo Furumoto², Nobuyuki Okamura², Charles Stone¹, Sterling Johnson¹, Bradley Christian¹

¹University of Wisconsin - Madison, Madison, WI, USA ²Tohoku University, Sendai, WI, USA

Objectives: This work compared quantification strategies for estimating specific binding with dynamic and static imaging of PET tau radioligands ¹⁸F-THK-5351 and ¹⁸F-THK-5317.

Methods: Twenty-eight participants (mean=71±7 yrs) underwent 90-minute dynamic ¹⁸F-THK-5351 or ¹⁸F-THK-5317 PET scans and T1-w MRI. Ten participants were scanned with both tracers (321±46 days between PET scans). Participants included individuals at-risk for Alzheimer's disease (AD) (15 parental history, 18 APOE- ϵ 4 carriers) and included probable AD (n=6), amnestic MCI (n=3), cognitively declining (n=10), and cognitively stable (n=9) individuals. Regression and Bland-Altman analyses were carried out to compare SUVR and DVR estimates determined derived from Logan graphical analysis, MRTM2, and basis function SRTM. The effects of t* (and k₂ for Logan) were investigated for MRTM2 and Logan. Effects of scan duration and scanning window were determined for DVR and SUVR, respectively. Regressions analyses were performed to compare within-subject DVR and SUVR estimates for the ten participants that received both THK scans.

Results: MRTM2 and Logan DVR estimates were stable for $t^*=30$ min and $t^*=40$ min, respectively. The Logan method was sensitive to combinations of t^* and k_2 . Between-method DVR estimates were generally in agreement for 90-minute dynamic scans for both tracers, with the exception of SRTM, which failed to converge in some ROIs for THK-5317. Sixty-minute scan durations using MRTM2 and 70-minutes using Logan produced DVR estimates consistent with 90-minute derived estimates. SUVR became temporally stable 50-70 minutes post-injection and SUVR from 30-50 minutes post-injection had the highest correlation with DVR. Agreement was observed between THK-5351 and THK-5317 DVR and SUVR estimates for individuals scanned with both tracers with THK-5351 having higher binding estimates.

Conclusions: THK-5351 has more favorable imaging characteristics for tau imaging compared to THK-5317. Shortened 60-minute dynamic scans are suitable for DVR estimation using MRTM2 for both THK-5351 and THK-5317 in this subject population.



Figure 1: Comparison of parametric THK-5351 and THK-5317 DVR and SUVR images. Differences were most predominant in WM for THK-5317 where MRTM2 and SUVR methods showed higher signal compared to Logan. DVR and SUVR methods for THK-5351 were generally in agreement. THK-5351 had higher binding estimates in gray matter regions associated with tau pathology compared to THK-5317.

Keywords: THK, Tau, Quantification, DVR, SUVR

A cortical cluster-based measure of change in longitudinal 18F-T807 **FTP PET**

J. Alex Becker¹, Danielle Cosio^{1,3}, Chris Lee¹, Nick Andrea¹, Reisa Sperling², Keith Johnson^{1,2}

¹Massachusetts General Hospital, Boston, MA, USA ²Brigham and Women's Hospital, Boston, MA, USA ³Massachusetts Institute of Technology, Cambridge, MA, USA

Introduction: Post-mortem studies have shown that tau deposition in early Alzheimer's Disease occurs predominantly in inferior and middle temporal cortex, and in subject-specific patterns which do not respect anatomical boundaries. PET ligand 18F-T807 (FTP) allows measurement of intra-subject change in tau binding. We investigated rate of change of tau binding in cognitively-normal (CN) subjects using a surfacebased cluster approach.

Methods: Two time-points of FTP PET (10mCi, 80-100min) were acquired in each of 31 CN subjects (baseline age 76.2±6yr, interval 20.2±5 months). Time-points were registered to a subject-specific FTP template that was registered to baseline MPRAGE. FTP data was sampled at midpoint vertices of the Freesurfer-calculated grey-matter-ribbon, surface-smoothed at 10mm FWHM, and expressed as SUVR (cerebral white-matter reference). Clusters in the lateral and medial temporal lobes and spanning both timepoints were formed from vertices with FTP SUVR>=1.0 sharing a segment of the triangular surface mesh in each time-point, or occupying congruent positions across time-points. An FTP uptake measure (ClustSUVR) for each subject was computed as the average SUVR across all clusters with overlap between time-points of at least 20% of the number of cluster vertices in each time-point, to minimize error due to misregistration. Mixed-effect models were used to determine rate of change of ClustSUVR in CN subjects.

Results: The 31 CN subjects had average rate of change of ClustSUVR of 0.009 SUVR/yr (0.00012,0.015) (1st,3rd quartiles), with minimum/maximum -0.013/0.063 SUVR/yr. Modeled ClustSUVR rate of change was 0.007±0.0021 SUVR/yr (p<0.003).

Conclusions: Our initial findings with FTP Tau-PET a group of normal subjects suggest that most showed evidence of increases in tau binding over time in spatially associated temporal lobe clusters of vertices with FTP SUVR>=1.0.

Keywords: Clusters, T807, Tau

Selegiline reduces brain [18F]THK5351 binding

Kok Pin Ng^{1,3}, Gassan Massarweh², Jean-Paul Soucy², Paul Gravel², Tharick A. Pascoal¹, Sulantha Mathotaarachchi¹, Min Su Kang¹, Monica Shin¹, Joseph Therriault¹, Sophie Levasseurr¹, Kayla Horowitz¹, Serge Gauthier¹, Pedro Rosa-Neto¹

¹Translational Neuroimaging Laboratory - McGill University, Montreal, QC, Canada ²McConell Brain Imaging Center - McGill University, Montreal, QC, Canada ³National Neuroscience Institute, Singapore, Singapore

Introduction: Interactions between molecular imaging agents and their respective targets might be affected by the chronic or acute use of certain pharmacological interventions. Here we described changes in THK5351 binding elicited by a single dose of a widely used MAO-B inhibitor, selegiline.

Methods: Patients with mild cognitive impairment (MCI; N=3; 72±5.2 y.o; MMSE) and a progressive supranuclear palsy patient (PSP; 68 y.o; MMSE=29) had a baseline THK5351 scan (6.8 ± 0.1 mCi). All participants had two days later, a second THK5351 scan (6.6 ± 0.5 mCi) conducted 1h following an oral dose of 10mg of selegiline. Dynamic images were obtained using the ECAT HRRT (High Resolution Research Tomograph). A six-minute transmission acquisition was obtained for each scan. The primary outcome measure was the standardized uptake value (SUV). SUVs were obtained using tissue radioactivity concentration obtained 50 to 70 minutes following THK5351 injection, normalized by body weight and injected tracer dose.

Results: On baseline scans, all individuals showed high uptake in the frontal, temporal lobes, basal ganglia and thalamus (see Figure 1). These regions of uptakes were reduced in a range of 36.2% - 51.3% in the follow up scans, presumably due to the blocking of MAO-B binding sites by selegiline (Figure 2).

Conclusion: Quantification of THK5351 binding is affected by concomitant use of selegiline. These results merit careful studies focusing on the underlying basis of this phenomenon, particularly interactions between THK5351 and MAO-B binding sites.



[¹⁸F]THK5351 Standardized Uptake Value Declines after 10mg Selegiline



Figure 2: Plot shows the baseline (BL) and follow up (FU) SUVs 1 hour post 10mg selegiline of the 4 study individuals

Keywords: [18F]THK5351, PET, selegiline, MAO-B

SESSION 2: Novel Tau Tracers

SESSION 2 Novel Tau Tracers	CHAIRS: Julie Price Massachusetts General Hospital Robert Koeppe University of Michigan
Effects of [18F]AV-1451 binding in cerebellar gray and extra-cortical areas	Suzanne Baker Lawrence Berkeley National Laboratory
[18F]MK-6240, a novel neurofibrillary tangles PET tracer: Evaluation in healthy subjects and Alzheimer's Disease patients	Cyrille Sur Merck & Co., Inc.
Current efforts to overcome drawbacks of [11C]PBB3 by developing new PBB3 derivatives: first-in-human PET study with [18F]AM-PBB3	Hitoshi Shimada National Institute of Radiological Sciences
Evaluation of baseline and longitudinal tau burden in Alzheimer's disease using [18F]GTP1 (Genentech tau probe 1) PET imaging	Robby Weimer Genentech Inc.
Invited Lecture: Molecular imaging analysis for tracer validation and clinical trials	Roger Gunn Imanova Ltd
Discussion	

Effects of [18F]AV-1451 binding in cerebellar gray and extracortical areas

Suzanne Baker¹, Anne Maass^{2,3}, Susan Landau², Samuel Lockhart², William Jagust^{1,2}

¹Lawrence Berkeley National Laboratory, Berkeley, CA, USA
²University of California, Berkeley, Berkeley, CA, USA
³German Center for Neurodegenerative Diseases, Magdeburg, Germany

Objectives: Evaluate high AV-1451 uptake in cerebellar gray subregions and extra-cortical regions.

Methods: Subjects (Table) received AV-1451 scans from 80-100 min and structural MRIs. MRIs were segmented using FreeSurfer5.3 and SPM12. SUVR80-100 was calculated using cerebellar gray as the reference region and coregistered to the MRI. Seven controls received a second scan 1.9 ± 0.5 years later. SUIT cerebellum atlas was reverse-normalized to native space and masked by FreeSurfer cerebellar gray for gray matter subregions. Extra-cortical high-uptake (ECHU) regions (SUVR80-100>1.3 and k > 500 voxels) were created in soft tissue and bone masks from SPM12. Cerebellar gray subregions and ECHUs were smoothed by the scanner resolution to quantify their partial volume effects (PVE) on cortical ROIs.

Table: Subjects

	Age	f/m	# Subjects	2nd scan
Young Healthy Controls (yHC)	39.51/16.8	2/9	11	0
Healthy Controls (HC)	78.3 1 5.8	42/27	69	7
Mild Cognitive Impairment (MCI)	62.9+⁄_10.5	4/10	14	0
Alzheimer's Disease (AD)	66.9½8.9	14/13	27	0

Results: Figure 1 shows SUVR80-100 for cerebellar gray subregions by diagnosis. Superior subregions showed higher AV-1451 uptake, with no differences observed across diagnosis within subregion. Superior subregions showed PVEs from 1-3% on parahippocampal, fusiform, and lingual gyri. For the 7 HCs with longitudinal data, the superior portions of cerebellar gray (relative to inferior cerebellar gray) changed a small

amount $(0\pm 2\%)$. Figure 2 shows the mean ECHU across subjects and a modest partial volume effect on cortical regions. Of the voxels classified as ECHU regions in scan 1, 31±14% were classified as ECHU in scan 2, while number of ECHU voxels increased by 63±81% from scan 1 to scan 2.





Conclusion: AV-1451 uptake varies in cerebellar gray subregions, showing increased uptake in superior regions. Although this has minimal PVE on ROIs and is stable over time, the inclusion of superior portions of cerebellar gray in the reference region could add noise to cross-sectional analyses. ECHU has a moderate effect on regional SUVRs and is not stable over time, resulting in noise in analyses across diagnosis and longitudinal studies.

Keywords: [18F]AV-1451, tau, non-specific binding

[18F]MK-6240, a novel neurofibrillary tangles PET tracer: evaluation in healthy subjects and Alzheimer's disease patients

<u>Cyrille Sur</u>¹, Arie Struyk², Idriss Bennacef¹, Talakad Lohith¹, Cristian A Salinas⁵, Florestina Telan-Choing², Ruben Declercq⁴, Tom Reynders⁴, Sofie Celen⁸, Kim Serdons⁸, Guy Bormans⁸, Mathieu Vandenbulcke^{8,10}, Rik Vandenberghe^{9,10}, Jan de Hoon⁸, Corinne Vandermeulen⁸, Michel Koole⁸, Koen Van Laere^{8,10}, Gilles Tamagnan⁷, Danna Jennings⁷, Ken Marek⁷, Olivier Barret⁷, John Seibyl⁷, Ping Chiao⁵, Zhizhen Zeng¹, Abbas Walji³, Eric Hostetler¹, Richard J Hargreaves⁵, Rick Hiatt⁶, Mark Forman², Jeffrey Evelhoch¹

¹Translational Biomarkers, Merck & Co., Inc., West Point, PA, USA
²Translational Pharmacology, Merck & Co., Inc., North Wales, PA, USA
³Discovery Chemistry, Merck & Co., Inc., West Point, PA, USA
⁴Translational Pharmacology, MSD, Brussels, Belgium
⁵Biogen, Boston, MA, USA
⁶Enigma Biomedical Group Inc., Toronto, ON, Canada
⁷Invicro, New Haven, CT, USA
⁸KU Leuven, Leuven, Belgium
⁹Neurology department, University Hospitals Leuven, Leuven, Belgium
¹⁰Alzheimer Research Centre KU Leuven, research Institute for Neuroscience and Disease, Leuven, Belgium

Background: MK-6240 is a novel PET tracer for the detection of neurofibrillary tangles (NFT) in Alzheimer's Disease (AD) patients. Here, we present the pharmacological profile of MK-6240 and preliminary characterization in healthy elderly (HE) and AD subjects.

Methods: The pharmacological profile of MK-6240 was established and compared to AV-1451 in various preclinical models. Whole body images were collected over 5 hours in healthy volunteers to estimate biodistribution and effective dose (ED). HE and AD patients received a MK-6240 scan to determine tracer kinetics. After bolus injection of MK-6240 (153-349 MBq) dynamic scans were acquired for up to 180 minutes. Some of the dynamic scans were acquired with arterial input to perform tissue compartmental modeling.

Results: In vitro experiments using AD tissue homogenates showed that MK-6240 is a potent (K_D :0.3 nM) and selective NFT ligand. In contrast to AV-1451 no saturable MK-6240 in vitro binding was observed in control tissue sections. In vivo, self-block studies in rhesus showed no off-target binding for MK-6240. Dosimetry evaluation in human resulted in an effective dose of 29.4+/-0.6 μ Sv/MBq allowing several scans per year. MK-6240 showed high peak brain uptake of ~ 5 SUV followed by quick washout from all brain regions in HE but retention in medial temporal lobe and neocortical regions in AD. Tracer kinetics were best fitted by a 2-tissue-compartment model and a linear relationship was found between DVR and SUVR(60-90 min) using cerebellum as a reference region. In AD patients the distribution of MK-6240 signal was consistent with post-mortem pattern of NFT deposition with SUVR >3-4 in patients exhibiting neocortical signal.

Conclusion: MK-6240 is a novel selective and specific NFT PET tracer with a favorable radiation profile and a large dynamic range. These characteristics are promising for characterizing the pathological burden of low and high NFT expressing brain regions. *Keywords: Tau, PET, Alzheimer, clinical*

Current efforts to overcome drawbacks of [11C]PBB3 by developing new PBB3 derivatives: first-in-human PET study with [18F]AM-**PBB3**

Hitoshi Shimada¹, Soichiro Kitamura¹, Yasuyuki Kimura^{1,2}, Masanori Ichise¹, Maiko Ono¹, Hitoshi Shinotoh^{1,3}, Manabu Kubota¹, Keisuke Takahata¹, Sho Moriguchi¹, Tetsuya Ishii¹, Chie Seki¹, Ming-Rong Zhang⁴, Tetsuya Suhara¹, Makoto Higuchi¹

¹Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan ²Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Aichi, Japan ³Neurology Chiba clinic, Chiba, Japan ⁴Department of Radiopharmaceutics Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan

Background and aims: Accumulating evidence indicates that PBB3 can bind diverse tau conformations, such as Alzheimer's disease (AD), progressive nuclear palsy (PSP), corticobasal syndrome, Pick's disease, and transgenic mouse models. Meanwhile, it is gradually revealed that PBB3 have several issues including the short half-life of ¹¹C, limited dynamic range and off-target binding around basal ganglia and thalamus, leading to difficulty in wide use and early detection of tau pathology. Then, we have developed novel PBB3 derivatives, AM-PBB3 and PM-PBB3, to overcome such drawbacks. Here we present preliminary data of PET imaging with fluorinated PBB3 derivatives.

Methods: Four patients with AD and four age-matched cognitive healthy control (HC) subjects underwent a dynamic PET scan, arterial blood sampling, and free fraction measurements after injection of AM-PBB3. PBB3 and PiB PET scans were also performed within a month. Parametric AM-PBB3, PBB3- and PiBimages were generated by voxel-based calculation of standard standardized uptake value ratio (SUVR) to the cerebellum. Furthermore, one- and two-tissue compartment analyses (1TCM, 2TCM) and a reference tissue model (MRTM₀) were also applied to estimate binding potential (BP_{ND}).

Results: Since plasma parent free fractions decreased over time, we analyzed kinetics of ¹⁸F-AM-PBB3 using corrected plasma input functions with sequentially measured parent free fractions. 2TCM produced a better fit to tissue TACs than did 1TCM with corrected input functions, and was in good agreement with MRTM₀. AM-PBB3 yields a 1.5 - 2 fold higher dynamic range than PBB3 in visualizing AD tau lesions. Off-target binding of PBB3 is noticeable in the basal ganglia and thalamus, while AM-PBB3 does not produce prominent off-target signals in these areas.

Conclusions: Fluorinated PBB3 derivatives were promising novel tau PET ligands, which showed similar characteristics to PBB3 with long half-life, broad dynamic range and less off-target binding around the basal ganglia and thalamus.

Keywords: tau, PET, [11C]PBB3, [18]AM-PBB3, [18F]PM-PBB3

Evaluation of baseline and longitudinal tau burden in Alzheimer's disease using [18F]GTP1 (Genentech Tau Probe 1) PET imaging

<u>Robby Weimer^{1,2}</u>, Olivier Barret³, Gilles Tamagnan³, David Alagille³, Jan Marik¹, Gai Ayalon², Thomas Bengtsson⁴, Mike Ward⁵, Geoffrey Kerchner⁵, Danna Jennings⁵, John P. Seibyl³, Ken Marek³, Sandra Sanabria⁶

¹Department of Biomedical Imaging, Genentech Inc., South San Francisco, CA, USA ²Department of Neuroscience, Genentech Inc., South San Francisco, CA, USA ³Molecular NeuroImaging LLC, New Haven, CT, USA ⁴Biostats, Genentech Inc., South San Francisco, CA, USA ⁵Early Clinical Development, Genentech Inc, South San Francisco, CA, USA ⁶Clinical Imaging Group, South San Francisco, CA, USA

Objectives: In Alzheimer's disease (AD), the density and anatomical distribution of tau pathology in the brain correlates with cognitive dysfunction. GTP1 is a tau PET tracer that exhibits desirable pharmacokinetics, enabling the use of $SUVR_{60-90min}$ as a surrogate measure of specific binding, and robust test-retest reliability. We report preliminary results on the burden of tau pathology detected by GTP1 PET imaging in an AD cross-sectional cohort, and changes observed at 6 and 12 months in participants of a longitudinal 18-month natural history study.

Methods: Subjects (age 50 to 85, inclusive) were enrolled in an ongoing study; inclusion criteria: cognitively normal (MMSE 28-30, CDR 0), prodromal AD (amyloid(+), MMSE 24-30, CDR = 0.5), mild AD (amyloid(+), MMSE 22-30, CDR 0.5 or 1) and moderate AD (amyloid(+), MMSE 16-21, CDR 0.5 or 1 or 2). GTP1 images are acquired over 30 minutes starting 60 minutes post injection. The cerebellar gray reference tissue is used to calculate SUVR, and tau burden was assessed by exploratory metrics: a *density* metric (average SUVR) and an *extent* metric (% of voxels above a SUVR threshold).

Results: Baseline tau burden in gray matter, using both *density* and *extent*, generally increased as a function of disease state (prodromal, mild, moderate), yet varied in distribution between subjects and across cohorts, with *extent* providing greater dynamic range. Preliminary longitudinal data show that increases in tau burden could be detected in mild and moderate subjects within 6-9 months. In contrast, healthy controls show low baseline gray matter tau burden and no longitudinal change.

Conclusion: Preliminary analysis suggests that GTP1 imaging can detect baseline tau pathology and progression. Additional interim analysis from this ongoing study will be presented. *Keywords: Tau PET, Alzheimer's disease, longitudinal*

Invited Lecture:

Molecular Imaging Analysis for Tracer Validation and Clinical Trials

Roger N Gunn

Imanova & Imperial College London, UK

PET molecular imaging data, using tracers that bind to misfolded proteins, can be acquired as dynamic or static data, with or without associated blood data. The analysis of these data aims to derive an outcome measure that is proportional to the density of the misfolded protein, however the quantitative accuracy of the outcome measure derived is dependent on both the chosen acquisition and analysis method.

There are three types of approach: 1) Full tracer kinetic analysis of dynamic tissue data using an arterial input function and an appropriate tracer kinetic model to derive VT and DVR outcome measures, 2) Reference tissue analysis of dynamic tissue data using a reference tissue input function to derive a DVR outcome measure and 3) Tissue ratio analysis from static data at a particular time point to derive an SUVR outcome measure.

The utility of the different analytical approaches will be explored in the context of tracer validation studies and clinical trials of novel therapeutics. For validation of novel tracers the goal is to understand the tracers key characteristics, which includes an assessment of BBB penetration, target binding, selectivity and any metabolite liabilities. For clinical trials the goal is to select an approach that balances quantitative accuracy with an experimental design that is practical for phase II/III trials.

THURSDAY

Thursday, January 12, 2017 - 08:00 am - 08:45 am

SESSION 3: Neuropathology I: Tau PET Ligand Selectivity and Comparative Studies

SESSION 3 Neuropathology I: Tau PET Ligand Selectivity and Comparative Studies	CHAIRS: William Klunk University of Pittsburgh Milos Ikonomovic University of Pittsburgh
Evaluation of the selectivity of Tau PET radioligand THK5351 in AD brain in vitro and nonhuman primate brain in vivo	Qi Guo <i>AbbVie Inc.</i>
Characterizing the "off-target" binding of 18F-THK5351 in Alzheimer's disease: correlation between ante-mortem and post-mortem findings	Ryuichi Harada Tohoku University Graduate School of Medicine
In vitro binding properties comparison of the tau PET tracers THK5117, THK5351, PBB3 and T807 in autopsy brain from Alzheimer diseases cases	Laetitia Lemoine Karolinska Institute
An autoradiographic evaluation of THK-5351 compared to AV-1451	Melissa Murray <i>Mayo Clinic</i>
Discussion	

Evaluation of the selectivity of Tau PET radioligand THK5351 in AD brain in vitro and nonhuman primate brain in vivo

<u>Qi Guo</u>¹, Bernd Otterstätter², Simone Benninghoff², David Reuter¹, Jiquan Wang¹, Marc Skaddan¹, Ann Tovcimak¹, Cecelia Schroeder¹, Gokul Krishnan¹, Kyle Wilcox¹, Robert Comley¹, Paul Makidon¹, Martin Voorbach¹, Andreas Haupt², Manolo Mugnaini², Laurent Martarello¹

¹AbbVie Inc., North Chicago, IL, USA ²AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

Objectives: Tau deposition has been shown to be highly associated with cognitive impairment. Furthermore tau deregulation is a key mediator of neurodegeneration. Positron emission tomography (PET) with a selective tau radioligand allows disease progression monitoring as well as direct demonstration of the mechanism of action of new therapies. Multiple tau radioligands have been developed; however the question about their selectivity in vivo remains. Here, we evaluate the off-target binding of THK5351 in Alzheimer's Disease (AD) brain tissue in vitro and in cynomolgus macaques (cynos) in vivo.

Methods: Competitive binding assays were performed in homogenate from entorhinal cortex of an AD donor with THK5351 in the presence of various concentrations of THK5351 as well as clorgyline and selegiline, in order to evaluate the total specific binding and binding to monoamine oxidase A and B (MAO-A and MAO-B) respectively.

Ten young (8-10yrs) and four geriatric (24-26yrs) cynos went through 120 min dynamic THK5351 PET scan with arterial sampling. Three old cynos had a second scan post i.v. administration of 1mg/kg selegiline. The total volume of distribution (V_T) was estimated using kinetic modeling.

Results: The in vitro binding assay demonstrated strong specific binding of THK5351. 100nM selegiline blocked 70% of the total binding whilst clorgyline showed no blocking effect at that concentration(Figure 1). The V_T in aged cynos was 20% higher than in the young (Figure 2) in globus pallidus (p=0.02) and striatum (p=0.06). Following selegiline pretreatment, there was 20-60% reduction in V_T across brain regions in aged cynos (Figure 3), suggesting MAO-B binding.

Conclusion: A sizable fraction of total THK5351 binding in the brain is attributable to MAO-B, the level of which is reported to increase with age. To our knowledge this dataset provides the first in vivo evidence of THK5351 binding to MAO-B. This off target (non-tau) binding should be considered as a confounding effect in longitudinal clinical trials using THK5351.

Figure 1. In vitro competitive binding assay with [3H]THK5351 in AD brain



Figure 2. Comparison of [18 F]THK5351 V_T in young and aged cynos





Figure 3. V_T parametric maps of [¹⁸F]THK5351 in aged cyno brain with and without selegiline blockade

Keywords: PET, Tau, THK5351, MAO-B, Selegiline

Characterizing the "off-target" binding of 18F-THK5351 in Alzheimer's disease: correlation between ante-mortem and postmortem findings.

<u>Ryuichi Harada^{1,2}</u>, Aiko Ishiki³, Shozo Furumoto⁴, Katsutoshi Furukawa^{4,5}, Manabu Tashiro⁴, Hiroyuki Arai³, Kazuhiko Yanai^{1,4}, Yukitsuka Kudo², Nobuyuki Okamura^{4,5}

¹Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan ²Division of neuro-imaging, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan ³Department of Geriatrics and gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan ⁴Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan

⁵Tohoku Medical and Pharmaceutical University, Sendai, Japan

Objectives: ¹⁸F-THK5351 has been widely used for the *in vivo* detection of tau pathology in the Alzheimer's brain. In spite of this, "off-target" binding has not been characterized, nor has ante to post-mortem validation been reported. The aim of study was to examine the on- and off-target binding of ¹⁸F-THK5351 using postmortem brain sections.

Methods: We performed postmortem examination of brain samples from an autopsy-confirmed Alzheimer's disease case (81-yo male, MMSE 16) who underwent ¹⁸F-THK5351 PET 7 months before death. *In vitro* autoradiography (ARG) of ³H-THK5351 was performed using frozen brain sections. *In vitro* binding assay was also performed using the brain homogenates from the corresponding regions. We quantitatively measured tau aggregates in the brain tissue from autopsy and examined the correlation with regional tracer retention in ¹⁸F-THK5351 PET image.

Results: We observed a significant correlation between cortical ¹⁸F-THK5351 SUVR in ante-mortem PET image with tau pathology at postmortem examination. We also observed ¹⁸F-THK5351 retention in the basal ganglia that contained no remarkable tau pathology in this case. To identify off-target tracer retention, competitive screening was performed using ARG with several compounds. Although no remarkable competition was observed with dopamine transporter inhibitor, µ-opioid receptor agonist, and monoamine oxidase-A (MAO-A) inhibitors, MAO-B inhibitor completely displaced ³H-THK5351 binding in the basal ganglia. *In vitro* binding assay also indicated that ³H-THK5351 binds with high affinity to recombinant MAO-B.

Conclusions: These results suggest that cortical ¹⁸F-THK5351 signal reflects tau pathology in the brain. MAO-B seems to explain ¹⁸F-THK5351 off-target retention in basal ganglia. A human study to confirm the *in vitro* findings is currently ongoing.

Keywords: tau PET, Alzheimer's disease, imaging-autopsy, off-target binding

In vitro binding properties comparison of the tau PET tracers THK5117, THK5351, PBB3 and T807 in autopsy brain from Alzheimer's diseases cases

<u>Laetitia Lemoine</u>¹, Per-göran Gillberg¹, Marie Svedberg², Vladimir Stepanov², He Tian³, Makoto Higuchi³, Christer Halldin², Agneta Nordberg^{1,4}

 ¹Karolinska Institute, Department of neurobiology, Care sciences and society, Center for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Stockholm, Sweden
²Karolinska Institute, Department of Clinical Neuroscience, Center for Psychiatric Research, Stockholm, Sweden
³Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan

⁴Karolinska University Hospital, Department of Geriatrics, Stockholm, Sweden

During the past years, there has been a rapid development of radiotracers for visualizing tau deposition in human brain. Three families of tau ligands have been studied in patients after having shown good *in vitro* binding-properties. Due to the presence of different tau isomers in Alzheimer's disease and other tauopathies it is important to further characterize and compare the binding properties between different Tau PET tracers. In this study we aimed at comparing the two THK compounds, THK5117 and THK5351 with T807 and PBB3, head to head in the same human brain tissue, using both autoradiography and binding assay studies. We are reporting for the first time the binding in large frozen autoradiography of ¹¹C-THK5351.

Methods: Regional distribution comparison between ³H-THK5117 and ³H-THK5351 were performed in brain homogenate from 3 AD cases. Autoradiographies on large frozen section were done using ³H-THK5351, ³H-THK5117, ¹¹C-THK5351 and ¹¹C-PBB3. T807 was used as cold compound for the ¹¹C compound autoradiography. *In vitro* binding assay competition using ³H-THK5351 with THK5351, THK5117 and T807 respectively were performed in hippocampus homogenate.

Results: Binding studies with ³H-THK5117 and ³H-THK5351 showed similar regional distribution in AD brain. The autoradiography with ¹¹C-THK5351 showed similar binding distribution in brain compared to ³H-THK5351. *In vitro* binding assay using ³H-THK5351 in competition with THK5351, THK5117 and T807, respectively, showed two binding sites that were similar for the two THK compound and different for T807. Those results were also confirmed by inhibition experiment in autoradiography.¹¹C-PPB3 showed in comparison to ¹¹C-THK5351 autoradiographies corresponding binding pattern with lower binding in most brain areas.

Conclusion: Tau tracers from three different families showed different binding properties probably reflecting different binding site on tau. These results may have an influence on the outcome of the clinical use of *in vivo* PET study targeting different form of tauopathies.

Keywords: tau pathology, autoradiography, biomarker imaging, autopsy brain

An autoradiographic evaluation of THK-5351 compared to AV-1451

<u>Val Lowe</u>¹, Melissa Murray², Vidur Sarma¹, Geoffry Curran¹, Ping Fang¹, Mukesh Pandey¹, Tyler Bruinsma¹, David Jones¹, Casey Cook², Keith Josephs¹, Joseph Parisi¹, David Knopman¹, Bradley Boeve¹, Kejal Kantarci¹, Leonard Petrucelli², Clifford Jack¹, Dennis Dickson², Ronald Petersen¹

¹Mayo Clinic, Rochester, MN, USA ²Mayo Clinic, Jacksonville, FL, USA

Background: Several tau-PET imaging agents have been developed. Comparing the characteristics of these different agents is important to better understand future applications. We therefore compared the binding of THK-5351 to AV-1451 PET in the same brain tissue samples in a wide range of pathologies.

Methods: Serial sections were obtained from our research brain bank from multiple different pathologies (normal, n=2; pathologic aging (PA, Braak \leq 3), n=1; AD, n=4; FTD-TDP, n=2; AGD, n=1; CBD, n=1; PSP n=1, PART, n=1; MAPT N297K, n=2; MAPT R406W, n=1; and MAPT 301L, n=1). Adjacent sections were incubated with AV-1451 and THK-5351 using identical methods. Self-blocking with each respective cold tau-PET agent was performed. Adjacent sections were also stained with PHF-1 and CP-13 for comparison. Visual comparison of the autoradiography results with the immunohistochemistry findings was performed.

Results: Both AV-1451 and THK-5351 show binding to AD-tau (3R+4R) with THK-5351 showing less intense binding in some sections and similar binding in others (Figure 1). The binding of THK-5351 was similar to AV-1451 in the remaining sections except for discordant uptake in the case of PA, some of which may be "off-target" binding (see Figure 2), less uptake in the MAPT 406W case, and discordant uptake in the CBD case. Similar binding between the two agents was seen in common "off-target" sites such as neuromelanin.

Conclusions: Reduced binding of THK-5351 vs. AV-1451 in some AD cases may result in lower THK-5351 signal in AD dementia clinical imaging. Mild THK-5351 binding in non-AD tau cases, similar to AV-1451, was generally seen and argues for similar clinical imaging characteristics. While some "off-target" sites had similar appearances between the two agents, additional suspicious "off-target" binding by THK-5351 needs to be better characterized and, at least in some cases tested, has incremental potential over AV-1451 to falsely mimic tau pathology.

Figure 1. Autoradiography findings of THK-5351 (left) and AV-1451 (right) in a posterior hippocampal section of a case with AD-type tau (respective blocking studies are shown below each). Reduced binding is seen with THK-5351 in PHF-1 positive regions (red arrows) as compared to AV-1451.



Figure 2. Autoradiography findings of THK-5351 (left) and AV-1451 (right) in a posterior hippocampal section (respective blocking studies are shown below each) of a case staged as Braak \leq 3 with no more than sparse plaques (sometimes referred to as pathologic aging (PA)). Discordant binding is seen with THK-5351 in PHF-1 negative regions (red arrows) unlike AV-1451. In addition, focal sites of "off-target" binding are more prevalent on THK-5351.



Keywords: Tau, PET, Tauopathy, AD

Poster Session 2A

Leal, Stephanie - 1

Hippocampal activation is associated with longitudinal amyloid accumulation and cognitive decline

Stephanie Leal¹, Susan Landau¹, Rachel Bell¹, William Jagust¹

¹Helen Wills Neuroscience Institute, Berkeley, CA, USA

The amyloid hypothesis suggests that beta-amyloid deposition leads to alterations in neural function and ultimate cognitive decline, however, why beta-amyloid deposition occurs to begin with remains unclear. One proposed model suggests that patterns of neural activity, namely increased brain activity, may lead to beta-amyloid deposition. More specifically, hyperactivity in the hippocampus may be detrimental and could be one factor that drives beta-amyloid deposition. We were interested in examining the relationship between hippocampal activity during a memory task using fMRI and change in beta-amyloid using longitudinal PIB-PET imaging in humans. We found that greater hippocampal activation at baseline was associated with increased beta-amyloid over time. Furthermore, greater change in beta-amyloid was associated with worse memory performance over time, suggesting that increased levels of beta-amyloid mediate the relationship between hippocampal activation and memory decline. These findings support the model linking increased hippocampal activation to beta-amyloid deposition.

Keywords: hippocampus, PIB, hyperactivity, memory, longitudinal

Tau-PET imaging with [18F]AV-1451 in progressive apraxia of speech with and without aphasia

<u>Rene Utianski</u>¹, Jennifer Whitwell¹, Christopher Schwarz¹, Matthew Senjem¹, Nirubol Tosakulwong¹, Joseph Duffy¹, Heather Clark¹, Mary Machulda¹, Clifford Jack¹, Val Lowe¹, Keith Josephs¹

¹Mayo Clinic, Rochester, MN, USA

Background: Apraxia of speech (AOS) is a motor speech disorder characterized by combinations of a slowed speaking rate, abnormal prosody, distorted sound substitutions, and trial-and-error articulatory movements. AOS is due to the abnormal planning and/or programming of speech production. When AOS is a presenting symptom of a neurodegenerative condition in the presence of aphasia (a disorder of language), it is referred to as progressive apraxia of speech (PAOS); when AOS is the only symptom, it is referred to as primary progressive apraxia of speech (PAOS). Past reports suggest associations with a primary tau (e.g. progressive supranuclear palsy, corticobasal degeneration), rather than amyloid pathology.

Aim: The goal of the current study was to investigate tau-PET imaging in patients with progressive AOS. **Methods**: Five patients with PPAOS and four patients with PAOS underwent tau-PET imaging using the AV-1451 ligand and amyloid-PET imaging using Pittsburgh Compound B (PiB). Uptake of AV-1451 was assessed as cortical to cerebellar crus grey matter ratios (SUVr) in cortical regions of interest, measured using the automated anatomical labeling atlas. A global PiB ratio of 1.5 was used to define positivity on amyloid-PET.

Results: Regions of abnormal AV-1451 binding differed between patients with PAOS and PPAOS. While both groups demonstrated increased binding in the supplementary motor areas, there was increased uptake in the language network in patients with PAOS (e.g. left greater than right supramarginal gyrus and inferior frontal operculum). Data revealed 3/5 patients with PPAOS and 2/4 patients with PAOS were negative on amyloid-PET, with positive AV-1451 binding.

Conclusions: The study demonstrated AV-1451 PET uptake in PPAOS and PAOS patients, with no discernible relationship between PiB positivity and tau deposition. Results provide support that PPAOS is a distinct entity from PAOS and support the notion that PPAOS and PAOS are primary tauopathies.



Keywords: [18F]AV-1451, PiB, apraxia of speech, aphasia

Top Panel: PPAOS patient (female, 77 years old), demonstrating focal tau binding in the supplementary motor area. Bottom Panel: PAOS patient (male, 58 years old), demonstrating diffuse tau binding in regions associated with the language network.

Lower white matter integrity is associated with higher amyloid deposition in older adults without dementia in two independent samples

<u>Hwamee Oh</u>¹, Atul Narkhede¹, Qolamreza R. Razlighi¹, Yaakov Stern¹, Richard P. Mayeux¹, Adam M. Brickman¹

¹Department of Neurology and the Taub Institute for Research on Alzheimer's disease and the Aging Brain, Columbia University, New York, NY, USA

The accumulation of beta-amyloid (A β), a pathological hallmark of Alzheimer's disease (AD), is highly agerelated and regionally selective. Abnormality of white matter (WM) tracts is very common in clinically normal older adults and has been associated with a higher risk of developing AD. Furthermore, the regional variability in age-related deterioration in WM tracts has been noted, showing that long-range cortico-cortical connections undergo deterioration with aging more steeply than WM tracts constrained within lobes. Using two independent samples of older adults without dementia, we examined a relationship between long-range WM tract integrity and amyloid deposition. One hundred twenty-six nondemented, ethnically diverse, and community-dwelling older adults from the Washington Heights-Inwood Columbia Aging Project (WHICAP) underwent ¹⁸F-Florbetaben amyloid PET and diffusion-weighted scans that quantify brain amyloid burden and WM tract integrity, respectively. A global amyloid index was calculated by standardized uptake value ratio (SUVR) with a cerebellar gray matter reference region and Aβ positivity cutoff was determined using a K-means clustering method, which classified 89 subjects as "Amyloid-negative (A β -O)" and 37 as "Amyloid-positive (A β + O)". Figure 1A shows significant interactions between axial diffusivity of superior longitudinal fasciculus and the body of corpus callosum (higher values indicating lower WM integrity) and amyloid group predicting the level of global A β deposition, accounting for age and sex (*ps* < 0.05). The relationship between WM integrity and amyloid deposition was further confirmed in an independent sample of cognitively normal older adults (N=44) obtained from Alzheimer's Disease Neuroimaging Initiative (ADNI) II, as shown in Figure 1B. The consistent results from two independent samples suggest a strong relationship between long-range WM tract integrity and amyloid deposition in older adults without dementia. Future studies are warranted to determine a directionality of this relationship using longitudinal assessments.



Figure 1. Relationship between white matter integrity and global amyloid index from two independent samples (WHICAP [A] and ADNI2 [B]). WM measures of radial/axial diffusivity and fractional anisotropy assessed in superior longitudinal fasciculus and body of corpus callosum

Keywords: beta-amyloid deposition, white matter tract integrity, amyloid PET, Diffusion Tensor Imaging, non-demented older adults

Uncovering the local-to-distributed relationship between β -amyloid and glucose metabolism

Felix Carbonell¹, Donald G. Mclaren¹, Alex P. Zijdenbos¹, Barry J. Bedell^{1,2}

¹Biospective Inc., Montreal, QC, Canada ²McGill University, Montreal, QC, Canada

Background: Several PET studies have explored the relationship between β -amyloid burden and glucose metabolism. It has been reported that **global** cortical β -amyloid burden has little contribution to glucose hypometabolism in cognitively normal (NC) and mild cognitive impairment (MCI) subjects. It has been also reported that **regional** hypometabolism is unrelated to **regional** β -amyloid burden in NC and MCI subjects. We hypothesize that these measurements of β -amyloid burden do not provide the complete relationship with glucose metabolism. As such, we have sought to determine if **local** β -amyloid burden measures are related to a **distributed** pattern of glucose metabolism.

Methods: We utilized a voxel-wise correlation analysis (VCA) to assess patterns of cross-correlation structure between glucose metabolism, as measured by FDG PET, and β -amyloid, as measured by florbetapir PET, in 607 NC/MCI subjects from the ADNI study. VCA yields a set of regions where **local** β -amyloid burden is statistically related to **local** glucose metabolism. We then regressed the mean β -amyloid burden in local seeds against glucose metabolism data while controlling for age, gender, MMSE, and APOE ϵ 4 status.

Results: Significant negative relationships of β -amyloid burden with glucose metabolism in temporal-parietal regions and posterior cingulate cortex (**Figure 1**) in the VCA revealed localized cross-modality relationships.



Figure 1. False Discovery Rate (FDR)-thresholded t-statistic map associated with negative local-to-local correlations between β -amyloid burden and glucose metabolism.

Local measures of β -amyloid burden in the left inferior temporal sulcus (ITS) and the right angular gyrus (ANG) showed distinct distributed relationships with glucose metabolism (**Figure 2A, B**).

Amyloid vs. Metabolism



Figure 2. FDR-thresholded t-statistic maps of glucose metabolism corresponding to (A) left ITS amyloid seed, (B) right ANG amyloid seed, and C) global cortical amyloid burden. Pearson's correlations between local β -amyloid and local glucose metabolism in the left ITS and right ANG were r=-0.23 (p<0.001) and r=-0.25 (p<0.001), respectively.

The statistically significant pattern observed with ANG β -amyloid burden did not resemble the pattern found when using global β -amyloid burden (**Figure 2C**). These distributed negative patterns did not appear to be driven by the strength or spatial extent of the corresponding β -amyloid pattern of spread or "network" (**Figure 3**).

Conclusions: The β -amyloid network has hubs that contribute to distributed metabolic decreases, which, in turn, are not necessarily foci for β -amyloid deposition.

Keywords: β-amyloid, glucose metabolism, mild cognitive impairment, Alzheimer's Disease

Amyloid Correlation Network



Figure 3. The β -amyloid network corresponding to (A) left ITS β -amyloid seed, (B) right ANG β -amyloid seed, and (C) global cortical β -amyloid burden. Black arrows correspond to the left ITS and right ANG seed locations. Pearson's correlations between local β -amyloid in the left ITS/right ANG seeds and global β -amyloid burden were r=0.89 and r=0.93, respectively.

[F-18]-AV-1451 binding correlates with neurofibrillary tangle Braak staging in postmortem brain tissue samples

Marta Marquié-Sayagués^{1,2}, Alejandro Antón-Fernández^{1,2}, Michael Siao Tick Chong^{1,2}, Avery C. Meltzer^{1,2}, Nil Sáez-Calveras^{1,2}, Eline Verwer³, Prianca Ramanan^{1,2}, Marc D. Normandin³, Matthew P. Frosch⁴, Teresa Gómez-Isla^{1,2}

¹MassGeneral Institute for NeuroDegenerative Disease, Charlestown, MA, USA ²Massachusetts General Hospital, Department of Neurology, Boston, MA, USA ³Massachusetts General Hospital, Department of Radiology, Boston, MA, USA ⁴Massachusetts General Hospital,, C.S. Kubik Neuropathology Center, MA, USA

Introduction: -AV-1451, a PET tracer specifically developed to detect brain tau neurofibrillary pathology, has the potential to improve diagnostic accuracy for Alzheimer's disease (AD) and to allow reliable quantification of brain tau burden; something that may prove essential for evaluating disease progression and for assessing response to tau-targeted therapies. Recent PET studies show that patients with mild cognitive impairment and AD dementia exhibit significantly higher *in vivo* -AV-1451 retention than cognitively normal controls. Importantly, PET patterns of -AV-1451 correlate well with disease severity and seem to match the predicted topographic Braak staging of neurofibrillary tangles (NFTs) in AD, although this awaits confirmation.

Objectives: We studied the correlation of autoradiographic binding patterns of -AV-1451 and the stereotypical spatiotemporal pattern of progression of NFTs using legacy postmortem brain samples representing different Braak NFT stages (I-VI) (Braak and Braak, 1991).

Methods: We performed -AV-1451 phosphor-screen autoradiography and quantitative tau measurements (stereologically-based NFT counts and biochemical analysis of tau pathology) in four brain regions (entorhinal cortex, superior and inferior banks of the superior temporal sulcus and occipital cortex) in a total of 22 cases: low Braak (I-II, n=6), intermediate Braak (III-IV, n=7) and high Braak (V-VI, n=9).

Results: Strong and selective -AV-1451 binding was detected in all tangle-containing regions matching precisely the observed pattern of PHF-tau immunostaining across the different Braak stages. As expected, no signal was detected in the white matter or other non-tangle containing regions. Quantification of -AV-1451 binding was very significantly correlated with the number of NFTs present in each brain region and with the total tau and phospho-tau content as reported by Western blotting. <u>Conclusion</u>: AV-1451 is a promising biomarker for *in vivo* detection and quantification of brain tau burden in AD. Neuroimaging–pathologic studies conducted on postmortem material from individuals imaged while alive are now needed to confirm these observations.

Keywords: [F-18]-AV-1451, PET, postmortem, Braak, neurofibrillary tangles, tau

Measurement of pathological amyloid in routine clinical assessment: comparison of visual [18F]Flutemetamol PET and CSF

Nenad Bogdanovic¹, Enrico Fantoni², Gill Farrar²

¹University Hospital Oslo, Oslo, Norway ²GE Healthcare, Amersham, United Kingdom

Introduction: Amyloid PET and CSF beta-amyloid ($A\beta42$) are valid alternatives for determining pathological load. Accuracy of the two methods was found by Palmqvist *et al.*, 2015 to be comparable. However, the CSF A $\beta42$ threshold required to establish a "positive" diagnosis of β -amyloid plaque accumulation varies between sites. Assessment of a cohort from routine clinical practice compared CSF A $\beta42$ with flutemetamol PET reads to assess the concordance between PET and CSF measures.

Methods: 60 patients referred by their general practitioner to the Oslo University Memory Clinic with cognitive complaints (mean age 69; range 49 to 81 years) underwent lumbar CSF fluid sampling and PET scanning of approximately 185 MBq flutemetamol. CSF measures were determined in Akerhus University Hospital, Oslo using INNOTEST enzyme-linked immunosorbent assays (Fujirebio, Ghent, Belgium). flutemetamol images were classified by readers trained per the manufacturer's instructions as

either positive or negative.

Results: Flutemetamol PET scanning identified 38 subjects as being amyloid-positive, 15 of whom had CSF A β 42 below 550 pg/mL (Figure 1). Of the 22 patients with negative amyloid scans, 17 had CSF A β 42 values above 770pg/mL. The remainder of the 28 cases had A β 42 CSF measures between 550-770 pg/ml with 23 evaluated as amyloid positive in the PET image read and only 5 as amyloid negative.

Conclusion: A review of the ranked data suggests a threshold > 720pg/mL for CSF A β 42 captures 78% of PET negatives, whilst below a PET positivity rate of 89% is observed. This threshold is higher than previously observed (550 pg/mL), suggesting that the PET read is sensitive to the presence of early pathological amyloid observed when CSF A β 42 is starting to trend down. Further work will examine any centre dependent bias in the CSF analysis as well as a second PET scan read of the discordant cases.

Clinical diagnosis of these cases will also be examined.

Ref: Palmqvist et al (2015) Neurology; 85: 1-10

Keywords: [18F]flutemetamol, CSF Aβ42, routine clinical assessment, threshold





Negative (normal) amyloid PET scan;
Positive (abnormal) amyloid PET scan;

--- Current CSF A642 threshold; --- Revised CSF A642 threshold.
Metabolic syndrome and amyloid accumulation in the aging brain

Gabriela Gomez¹, <u>Lori Beason-Held</u>¹, Murat Bilgel¹, Yang An¹, Stephanie Studenski¹, Susan Resnick¹

¹Intramural Research Program, NIA, NIH, Baltimore, MD, USA

Introduction: Metabolic Syndrome (MetS) affects 35% of all adults and 50% of adults over 60yr. A growing body of evidence supports a link between MetS and the neuropathology of Alzheimer's disease (AD), yet key components of the relationship between MetS and AD remain unexplored. In this study of older adults, we investigated the association between MetS and global cerebral amyloid status (positivity) and longitudinal regional change of amyloid accumulation.

Methods: We followed 170 participants enrolled in the Baltimore Longitudinal Study of Aging Neuroimaging substudy (BLSA-NI) over a mean interval of 2.7 years (mean baseline age=76.7yr). Cerebral amyloid was measured using 11C-Pittsburgh compound B (PiB) dynamic positron emission tomography (PET). Participants were then separated into PiB+/- groups based on mean cortical distribution volume ratios (DVR). Fisher's exact test was conducted to assess whether PiB status differed by concurrent MetS diagnosis. A linear mixed effects model was then used in the PiB+ group (N=56, mean age at baseline=80.07, mean interval=2.3yr) to assess the cross-sectional and longitudinal relationship between baseline MetS and regional DVR in areas derived from the Desikan-Killiany atlas (p<0.05, FDR-corrected).

Results: We found that PiB positivity did not significantly differ by concurrent MetS diagnosis (odds ratio 0.93, p=0.87). Within the PiB+ group, a linear mixed model revealed no significant association between MetS diagnosis and concurrent regional DVR levels at baseline. However, diagnosis of MetS was associated with increased rates of A β accumulation in several regions over time, including the superior parietal lobe, precuneus, medial frontal cortex, and insula.

Conclusion: Although MetS was not associated with overall amyloid positivity, the disorder was associated with accelerated A β accumulation in individuals with preexisting cerebral amyloid levels. These findings suggest that MetS may be an important factor in the progression of AD, and highlight the importance of health-related preventative strategies for dementia.

Keywords: health, obesity, hypertension, diabetes, dementia

Left frontal global connectivity is a substrate of cognitive reserve in mild cognitively impaired patients with a high amyloid burden

<u>Nicolai Franzmeier</u>¹, Marco Duering¹, Michael Weiner², Martin Dichgans^{1,3,4}, Michael Ewers¹

¹Institute for Stroke and Dementia Research, Klinikum der Universität München, Munich, Germany ²University of California at San Francisco, San Francisco, CA, USA ³Munich Cluster for Systems Neurology, Munich, Germany ⁴German Center for Neurodegenerative Diseases, Munich, Germany

Background: Previous studies in Alzheimer's disease (AD) suggest, that higher cognitive reserve (CR) allows maintaining memory performance relatively well when facing AD pathology. However, the neural mechanisms underlying CR remain unknown. We assessed the lateral frontal cortex (LFC) - a hub region supporting cognitive control - as a potential substrate of CR in mild cognitively impaired subjects with increased levels of amyloid-PET uptake (MCI-Ab+). We hypothesized firstly, that higher global LFC functional connectivity (gLFC-connectivity) is associated with higher CR (i.e. years of education). Secondly, we hypothesized that greater gLFC-connectivity is associated with reduced effects of FDG-PET hypometabolism onto memory performance in MCI-Ab+.

Methods: We included 44 MCI-Ab+ and 24 amyloid-PET negative healthy controls (HC-Ab-). We assessed seed-based functional connectivity between an 8mm spherical LFC ROI (BA6/44) and each grey matter voxel. To yield gLFC-connectivity, all positive correlations were averaged across voxels. Using voxel-wise regression, we tested whether in MCI-Ab+ greater education was predicted stronger FDG-PET hypometabolism, controlling for memory performance. In further regression analyses, we tested whether higher gLFC-connectivity was associated with greater education and reduced effects of FDG-PET hypometabolism onto episodic memory (interaction FDG-PET metabolism x gLFC-connectivity).

Results: We found precuneus FDG-PET metabolism to be reduced in MCI-Ab+ compared to HC-Ab-(p=0.028), with stronger reductions observed in MCI-Ab+ with greater education (p=0.006), when controlling for memory performance. This suggests that MCI-Ab+ with greater education can better tolerate FDG-PET hypometabolism. In MCI-Ab+, greater education predicted higher gLFC-connectivity (Fig.1A). The interaction gLFC-connectivity x precuneus FDG-PET on memory was significant in MCI-Ab+ (p=0.027), such that at higher levels of gLFC-connectivity the association between precuneus hypometabolism and memory impairment was attenuated, suggesting a compensatory LFC effect (see Fig.1B).

Conclusion: Higher gLFC-connectivity is a functional substrate of CR that helps maintaining memory performance relatively well in the face of high Ab-deposition and emerging FDG-PET hypometabolism.



Association between education, gLFC-connectivity and precuneus FDG-PET metabolism in MCI-A β +. (A) Scatterplot of the association between years of education and gLFC-connectivity. (B) Scatterplot for the interaction gLFC-connectivity × precuneus FDG-PET metabolism on memory performance in MCI-A β +. Precuneus FDG-PET metabolism is plotted against the memory composite score for participants with high and low gLFC-connectivity. Groups of high and low gLFC-connectivity (defined via median split) are plotted separately for illustrational purposes.

Keywords: Alzheimer's disease, fMRI connectivity, Cognitive reserve, memory

Detection of radiologic and laboratory features of cerebral amyloid angiopathy in patients with Alzheimer's disease

Panagiotis Fotiadis¹, John Becker², Kristin Schwab¹, Jonathan Rosand¹, Anand Viswanathan¹, Reisa Sperling², Keith Johnson², Steven Greenberg¹, Edip Gurol¹, Alzheimer's Disease Neuroimaging Initiative³

¹J. P. Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA ²Department of Radiology, Athinoula Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, USA ³Alzheimer's Disease Neuroimaging Initiative, Los Angeles, CA, USA

Background Patients with Cerebral Amyloid Angiopathy (CAA) have posterior vascular amyloid deposition and lower Amyloid Beta (A β) levels when compared to patients with Alzheimer's Disease (AD). We hypothesized that similar findings would be observed in AD patients with strictly lobar microbleeds (LMB) and/or cortical superficial siderosis (cSS) attributable to CAA, when compared to AD patients with no hemorrhagic lesion(s).

Methods We reviewed MRIs of AD patients with T2*-, FLAIR and 3D T1-weighted MRI as well as Florbetapir PET, CSF Aβ-42 and tau levels, and APOE status within the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.

Results The CAA-AD (n=51) and NH-AD (n=85) groups were balanced for age, gender and history of hypertension (all p>0.2). The APOE4 was more frequently present in the CAA-AD group (78% vs 60%, p=0.038). Patients with CAA-AD had higher White Matter Hyperintensity (WMH) volumes (0.73 vs 0.49 % intracranial volume, p=0.035) and higher occipital-to-global Florbetapir ratio (0.98 vs 0.94, p=0.02) but similar mean cortical Florbetapir uptake (1.38 vs 1.36, p=0.57), cortical thickness (2.22 vs 2.20 mm, p=0.38), and hippocampal volume (0.37 vs 0.38 % of ICV, p=0.24) when compared to NH-AD. In multivariable regression models, higher occipital-to-global Florbetapir ratio (p=0.009) and presence of APOE4 (p=0.002) were associated with CAA-AD. In 117 patients with CSF data, CAA-AD (n=46) had lower Aβ-42 (127 vs 140 pg/ml, p=0.038) but similar tau levels (131 vs 136 pg/ml, p=0.68) when compared to NH-AD. Lower Aβ-42 was also associated with CAA-AD (p=0.024) in multivariable regression models.

Conclusions Over one-third of AD patients displayed CAA-induced hemorrhagic lesion(s). When compared to NH-AD, they presented higher occipital-to-global Florbetapir uptake, suggesting vascular amyloid binding, and lower CSF A β -42 levels potentially related to amyloid sequestering in cortical vessel walls. These results support the possibility that advanced CAA commonly accompanies clinically diagnosed AD, contributing to dementia pathogenesis, and potentially affecting clinical treatment decisions.

Keywords: Cerebral Amyloid Angiopathy, Alzheimer's Disease, Hemorrhagic Lesions, Beta Amyloid, CSF

Elevated 18F-AV-1451 PET tracer uptake detected in incidental imaging findings

<u>Samuel Lockhart</u>¹, Nagehan Ayakta², Joseph Winer³, Renaud La Joie², Gil Rabinovici², William Jagust¹

¹Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA ²Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA ³Department of Psychology, University of California, Berkeley, Berkeley, CA, USA

Objective: To assess elevations in AV-1451 (tau) PET tracer uptake colocalized with incidental imaging findings.

Methods: We discovered 5 cases (2 normal controls, 3 patients: 1 Alzheimer's Disease, 1 mild cognitive impairment, 1 Parkinson's disease) with surprising increases in AV-1451 uptake in regions of incidental neuroimaging findings. In each participant, we collected T1 and FLAIR MRI, 80-100 min 18F-AV-1451 PET SUVR images, and generated a global cortical average from 11C-PiB DVR images for amyloid positivity classification. PET images used a cerebellar grey matter reference region. AV-1451 and FLAIR were linearly aligned to T1 images and resliced. Target ROIs (9x9x9 mm cubes) were drawn on T1 images over the observed imaging findings, as were ROIs in the hemisphere contralateral to the findings.

Results: Participant A (Table) has T1 images (Figure) revealing right temporal hypointensity surrounded by hyperintensity on FLAIR images, consistent with chronic infarction. Participant B's MRI sequences reveal the characteristic appearance of a right cerebellar cavernous malformation. Participant C has imaging also consistent with a remote infarct, located in the right frontal lobe. Participant D's imaging reveals a right medial frontal meningioma, while participant E exhibits a left superior frontal meningioma. We found elevated AV-1451 signal associated with the chronic infarcts, cavernous malformation, and meningiomas. For all participants, AV-1451 signal is markedly increased in the location of the target ROI covering each incidental imaging finding, particularly compared to the contralateral ROI.

Conclusions: In certain conditions, tracer binding might complicate image interpretation. Here, we demonstrated tracer uptake in meningiomas, vascular malformations and remote infarcts. In studies using AV-1451 and other tau tracers to study aging and disease, researchers must carefully examine PET images for focal tracer accumulation and MRI images for incidental findings; these may produce spurious signal elevations not reflective of the presence of age or AD-related pathology.

	А	В	С	D	E
Age (y)	80	80	67	77	80
Sex	М	F	F	F	F
Diagnosis	Normal	Normal	PD	AD	aMCI
PiB+/-	_	+ (borderline)	+ (borderline)	+	+
PD = Parkins	on's Disease, AD	= Alzheimer's D	isease, aMCI = A	Amnestic MCI.	

Table. Participant demographics.

Figure. Elevated AV-1451 tracer uptake seen in incidental

neuroimaging findings. Axial images for participants A-E (columns). Images (radiological convention) are 18F-AV-1451 SUVR (1st row), FLAIR (2nd row), T1 (3rd row), and target and contralateral ROIs (red and blue masks in 4th row) on T1. Voxel histograms from target and contralateral ROIs are in 5th and 6th rows (dashed line = mean). Participant D exhibits strong cortical tracer retention, consistent with AD diagnosis. Participant E inset shows close-up of meningioma on T1.



Keywords: AV-1451, Imaging, Binding, Infarction, Meningioma

18F-AV-1451 PET demonstrates Braak stage-specific associations with limbic white matter integrity in normal aging

Samuel Lockhart¹, Anne Maass¹, Shawn Marks¹, Suzanne Baker², William Jagust¹

¹Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, USA ²Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA

Objectives: To evaluate associations of age, beta-amyloid (A β), and tau with white matter (WM) microstructure in cognitively normal older adults (OA).

Methods: 47 OA (Table) received 18F-AV-1451 (tau) PET, 11C-PiB (Aβ) PET, and T1 and diffusionweighted MRI. For each subject we calculated a global cortical PiB average. We segmented T1 MRIs using FreeSurfer v5.3, coregistered 18F-AV-1451 (80-100 min SUVR, cerebellar grey reference) scans to T1, partial volume corrected 18F-AV-1451 images (including a correction for choroid plexus), and calculated 18F-AV-1451 in ROIs that reflect Braak stages. Diffusion data were processed using FSL to generate nativespace fractional anisotropy (FA) and mean diffusivity (MD) images, and warped to MNI space using ANTS. Images were smoothed, and means for select limbic WM tracts (Hopkins atlas) calculated. We assessed statistical relations using non-parametric bivariate and partial Spearman correlation analyses.

Results: 18F-AV-1451 retention demonstrated a specific pattern of associations with limbic WM integrity. Mean 18F-AV-1451 retention in Braak stage 2 ROIs (bilateral hippocampus) showed negative associations with ventral cingulum bundle and fornix column/body FA (Figure), and positive associations with MD in the same tracts (|.30| < rho < |.37|). Age showed negative associations with limbic tract FA (-.34 > rho > -.44), and positive MD associations in all tracts (.43 < rho < .57). In a model controlling for age and global PiB, Braak 2 18F-AV-1451 significantly predicted reduced ventral cingulum FA (rho = -.30, p = .043). Controlling for age and ventral cingulum FA, Braak 2 18F-AV-1451 predicted reduced memory performance (CVLT long delay free recall; rho = -.30, p = .045).

Conclusions: Although the mechanisms by which late-life tau and amyloid accumulation influence brain structural connectivity and cognition are not well understood, these results suggest that early medial temporal tau accumulation is associated with reduced limbic tract integrity.

Table. Participant Demographics.

	Braak Stage		
	0	1/2	3/4
n	6	31	10
Age, y	80.7 (8.3)	78.1 (5.5)	79.3 (2.4)
Global PiB DVR	1.08 (0.1)	1.07 (0.1)	1.35 (0.3)
CVLT Long delay free recall	13 (2.1)	11 (3.1)	8.6 (5)

Figure. Spearman rho values for bivariate relations of AV-1451, PiB, and age with tract white matter microstructure. (a) Correlation matrix for associations between white matter tract FA (y-axis) and other measures (x-axis), with color indicating negative (red) and positive (blue) monotonic associations; (b) values for FA of rho > ± 0.3 . (c) Correlation matrix for similar MD associations and (d) values for MD of rho > ± 0.3 .



Keywords: AV-1451, DTI, Tau, Amyloid, Cingulum

Microglial activation correlates in vivo with tau aggregation and amyloid deposition in mild cognitive impairment and Alzheimer's disease

<u>Melanie Dani</u>¹, Melanie Wood¹, Ruth Mizoguchi¹, Zhen Fan¹, Richard Morgan², Zuzana Walker^{3,4}, Valeria Calsolaro¹, Grazia Femminella¹, Rainer Hinz⁵, David Brooks⁶, Paul Edison¹

¹Neurology Imaging Unit, Imperial College London, London, United Kingdom
 ²Chelsea and Westminster Hospital, London, United Kingdom
 ³Division of Psychiatry, University College London, London, United Kingdom
 ⁴North Essex Partnership University NHS Foundation Trust, London, United Kingdom
 ⁵Wolfson Molecular Imaging Centre, University of Manchester, Manchester, United Kingdom
 ⁶Department of Nuclear Medicine, Aarhus University, Aarhus, Denmark

Introduction: In addition to amyloid deposition and neurofibrillary tangle deposition, microglial activation plays a key role in the pathophysiological processes in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI). However, the exact relationship between microglial activation and protein aggregation is still debated. In this study, we examined voxel-level correlations between microglial activation, amyloid, and tau aggregation using ^{11C}-PBR28, ¹⁸F-flutemetamol, and ¹⁸F-AV1451 PET, respectively.

Methods: 20 AD, 23 MCI subjects and 21 healthy controls were included. Subsets of this group had ¹¹C-PBR28, ¹⁸F-flutemetamol, and ¹⁸F-AV1451 PET scans.

Biological parametric mapping in SPM was used to interrogate the voxel-level correlation between the pathologies. SPM t-maps were generated to localise differences between the MCI and AD patients with controls for each tracer. Correlations were performed at a voxel-level with a statistical threshold of significance set at P<0.01 and an extent threshold of 25 voxels. All clusters identified with a corrected p<0.05 were deemed significant.

Results:

<u>MCI</u>

There were clusters of positive correlations across the cortex between

- Microglial activation and amyloid deposition
- Microglial activation and tau aggregation
- Amyloid deposition and tau aggregation <u>AD</u>

There were clusters of positive correlations across the cortex between

- Microglial activation and tau aggregation
- Amyloid deposition and tau aggregation

Interestingly, there were clusters of negative correlations across the cortex between microglial activation and amyloid deposition.

Discussion: Microglial activation is associated with protein aggregations in MCI and AD. The distribution patterns differ between the pathologies, and also between the MCI and AD groups, indicating that the distribution of microglial activation may change later in the disease. These findings are compatible with all three pathologies playing a significant role in progressive neuronal damage, and a multi-targeted intervention may be necessary for effective disease prevention and cure.

Keywords: amyloid, tau, microglial activation, Alzheimer's

Correlation of regional amyloid load in cognitively healthy monozygotic twin pairs, measured using [18F]Flutemetamol

<u>Mara ten Kate</u>¹, Elles Konijnenberg¹, Anouk den Braber^{1,2}, Sofie Adriaanse³, Maqsood Yaqub³, Dorret Boomsma², Philip Scheltens¹, Bart van Berckel³, Pieter Jelle Visser^{1,4}

¹Alzheimer Center, Department of Neurology, VU University Medical Center, Amsterdam, Netherlands ²Department of Biological Psychology, VU University Amsterdam, Amsterdam, Netherlands ³Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands ⁴Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht, Netherlands

Background: Amyloid pathology precedes clinical dementia by decades. So far it remains unclear to what extent genetic and environmental influences play a role in amyloid pathology. Studies in monozygotic twins are useful to estimate the upper-limit of genetic contribution to a disease. The aim of this study is to estimate the concordance of regional amyloid load between cognitively healthy elderly monozygotic twin pairs.

Methods: We included 93 monozygotic twin pairs from the NTR-EMIF-AD PreclinAD study. Inclusion criteria were age ≥ 60 years and delayed recall score above -1.5 SD of normative data. Dynamic flutemetamol (FMM) scans were performed with combined data from two scans (30 minutes starting directly after FMM injection and 90-110 minutes post injection). Non-displaceable binding potential (BP_{ND}) with cerebellar grey matter as reference region was calculated for whole brain and various regions using the basis function implementation of the simplified reference tissue model (RPM1). Twin correlations for amyloid pathology were estimated with and without correcting for age and gender.

Results: Subjects were on average 70±7 years old and 57% were female. They had 15±5 years of education and an MMSE score of 29.0±1.1. Correlation of global BP_{ND} was 0.47 (p < 0.001). Regional correlations were 0.47 for parietal, 0.47 for frontal, 0.43 for temporal and 0.49 for posterior cingulate (all p < 0.001). When correcting for age and gender all correlations dropped by 0.05 on average. All remained significant.

Conclusion: We found a significant correlation between cognitively healthy monozygotic twins for global and regional amyloid pathology. These data suggest that in addition to a moderately-strong genetic background for amyloid pathology, also non-genetic factors substantially influence the occurrence of amyloid. Future studies on the causes of identical twin discordance may provide novel insights into the pathophysiology of amyloid depositions, thereby providing new treatment targets for AD. *Keywords: amyloid, Flutemetamol, twins, genetic*

In vivo tau imaging in Parkinson's disease using 18F-AV-1451 PET

Allan Hansen¹, Malene Damholdt², Peter Parbo¹, David Brooks^{1,3}, Per Borghammer¹

¹Dept of Nuclear Medicine, Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark ²Department of Psychology and Behavioural Sciences, Aarhus University, Aarhus, Denmark ³Division of Neuroscience, Newcastle University, Newcastle, United Kingdom

Background: Alzheimer disease (AD) co-pathology is common in Parkinson's disease (PD) at autopsy, particularly in PD dementia, which 80% of patients develop. In non-PD subjects diagnosed with mild cognitive impairment (MCI), increased tau deposition in neurofibrillary tangles (NFT) can be detected using the NFT tracer AV-1451. We hypothesized that AV-1451 PET would show tau aggregation in patients with early stage PD-MCI and that the signal would correlate with cognitive dysfunction.

Methods: 23 PD patients and 25 healthy age-matched controls had 18F-AV-1451 PET and comprehensive neuropsychometric assessment of memory, working memory, language, executive and visuospatial domains to detect the presence of MCI. Between-group comparisons of cortical AV1451 binding at a voxel level and correlations with cognitive domain z-scores were interrogated with SPM12. VOI-based analysis for group comparison and estimation of Braak tau stages (EBS) was performed using PMOD and Stata.

Results: 7 PD patients were identified as PD-MCI and 16 as PD-nonMCI. Voxel-wise analysis showed no significant group differences that survived a family wise error correction. No domain z-score was found to correlate with cortical 18F-AV-1451 signal. One PD-MCI patient was EBS 5, two healthy controls EBS 1, all other test subjects were EBS 0. No group differences were seen in VOIs used for Braak staging, including entorhinal cortex, middle and inferior temporal gyrus and visual cortical areas. Further, there were no group differences between PD and controls in pallidum, putamen or caudate nucleus, VOIs often examined for the differential diagnosis of progressive supranuclear paresis (PSP). PD patients had decreased signal in the midbrain compared to controls in contrast to the reported increases in PSP.

Conclusion: Our results indicate that tau pathology as detected by the 18F-AV-1451 tracer is uncommon in both PD-nonMCI and PD-MCI and show no significant correlation with cognitive function at this stage. *Keywords: AV-1451, tau, Parkinson, PD-MCI*

Tau PET imaging and atrophy in neurodegenerative dementias

<u>Brad Dickerson</u>¹, Scott McGinnis¹, Stephen Gomperts¹, Sara Makaretz¹, David Wolk², Aaron Schultz¹, Neil Vasdev¹, Keith Johnson¹

¹Massachusetts General Hospital/Harvard Medical School, Charlestown, MA, USA ²University of Pennsylvania, Philadelphia, PA, USA

Background: Using tau PET imaging, investigators have begun to demonstrate relationships between the magnitude of tau PET signal and the magnitude of FDG PET hypometabolism or MRI-derived atrophy. Here we investigate the relationship between atrophy and T807 signal in patients with MCI or dementia.

Methods: We have used T807 to scan a series of patients with MCI (PPA, PCA, amnesic MCI), AD dementia, FTLD dementia, and DLB dementia. We have compared them with cognitively intact controls, analyzing SUVR (cerebellum reference) data in comparison to % atrophy derived from quantitative analysis of MRI scans relative to controls.

Results: In areas of elevated T807 signal, atrophy is typically present when T807 SUVR is greater than 2.2. Areas with T807 SUVR between 1.8 and 2.2 may demonstrate atrophy. Areas with T807 SUVR below 1.8 usually do not demonstrate atrophy. Within each patient, the magnitude of T807 SUVR correlates with the magnitude of atrophy relative to controls.

Conclusions: In patients with neurodegenerative dementias, T807 signal is co-localized with atrophy and its magnitude correlates with the magnitude of atrophy.

Funding: R21 AG051987, R01 DC014296, P50 AG005134, R01 AG046396 Keywords: tau PET, atrophy, AD, FTD

Insulin resistance in midlife increases the risk for brain amyloid accumulation 15 years later

Laura Ekblad¹, Jarkko Johansson¹, Hanna Laine^{2,3}, Matti Viitanen^{2,4}, Antti Jula⁵, Juha Rinne^{1,6}

¹Turku PET Centre, University of Turku, Turku, Finland
 ²Turku City Hospital, University of Turku, Turku, Finland
 ³Department of Medicine, Turku University Hospital, Turku, Finland
 ⁴Clinical Geriatrics, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden
 ⁵National Institute for Health and Welfare, Turku, Finland
 ⁶Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland

Background: Diabetes is an acknowledged risk factor for Alzheimer's disease. Insulin resistance (IR) seems to be the key link between type 2 diabetes and the risk for Alzheimer's disease. Insulin resistance contributes to the neuropathological changes of Alzheimer's disease through multiple pathways. We hypothesized that midlife insulin resistance, estimated by the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) would increase the risk for brain amyloid accumulation 15 years later, and that this risk might be modulated by APOEɛ4 genotype.

Methods: We studied the possible presence of brain beta-amyloid accumulation in 60 cognitively healthy elderly individuals (mean age 70.4 years, 53.3 % women) from the Finnish, population based, nationwide Health 2000 study (n=5935) using -PIB-positron emission tomography (PET) imaging during 2015–2016. The study volunteers had been measured for fasting insulin and glucose values15–16 years before the PET scans. 30 individuals (IR+ group) belonged to the highest tertile of HOMA-IR in the Health 2000 study (HOMA-IR>2.16). The control group consisted of those belonging to the lowest tertile of HOMA-IR (IR- group, HOMA-IR<1.24). 50 % of participants in both groups were APOEɛ4 genotype carriers (ε 4/ ε 4 or ε 3/ ε 4). None of the participants had diabetes at baseline. The -PIB-PET scans were analyzed visually and rated as PIB+/PIB-.

Results: As expected, APOE ϵ 4 genotype was a greater risk factor for amyloid accumulation than insulin resistance. Insulin resistance in midlife increased the risk for amyloid accumulation both in APOE ϵ 4 carriers and non-carriers. In the IR-/APOE ϵ 4- group 2/15 (13.3 %) were PIB positive; in the IR+/APOE ϵ 4- 3/15 (20.0 %); in the IR-/APOE ϵ 4+ 10/15

(66.7 %), and in the IR+/APOEɛ4+ 12/15 (86.7 %).

Conclusions: The preliminary analysis of our PET data shows that insulin resistance in midlife is an additive risk factor for brain amyloid accumulation later in life both in non-carriers and carriers of APOEɛ4 genotype.

Keywords: Alzheimer's disease, insulin resistance, PIB-PET imaging, beta-amyloid, APOEepsilon4 genotype



Imaging tau deposition in the Lewy body diseases

<u>Stephen Gomperts</u>¹, Joseph Locascio¹, Sara Makaretz¹, Aaron Schultz², Christina Caso⁴, Vasdev Neil², Reisa Sperling^{1,3}, John Growdon¹, Brad Dickerson¹, Keith Johnson^{1,2}

¹Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ²Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ³Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA ⁴Department of Radiology, University of Washington, Seattle, WA, USA

Background: Although Lewy body inclusions define the Lewy body diseases - dementia with Lewy bodies (DLB), Parkinson disease (PD), and Parkinson disease dementia (PDD), Alzheimer's disease (AD) pathological changes of intracellular tau and extracellular amyloid deposition are also commonly observed. Neuropathological studies have implicated tau pathology in cognitive impairment in both DLB and PD. We set out to evaluate the contribution of tau pathologic changes to these diseases during life using Flortaucipir (FTP) PET and to relate FTP retention to PiB binding and cognitive function.

Methods: Twenty-four patients with Lewy body disease - 7 DLB (age 68 ± 2 years), 8 PD with cognitive impairment (PD-impaired, age 72 ± 2 years), and 9 PD without cognitive impairment (PD-normal, age 67 ± 3 years) - underwent FTP PET, PiB PET, and MRI, along with neurologic and neuropsychological evaluation, and were contrasted with an independently acquired group of 29 normal control subjects with minimal amyloid burden (age 69 ± 2 years). FTP retention was expressed as the SUVR using a cerebellar gray reference. PiB retention was expressed as the DVR using a cerebellar reference.

Results: FTP cortical uptake in DLB subjects exceeded NC, particularly in the inferior temporal gyrus and precuneus. Foci of elevated FTP binding were also observed in PD-impaired subjects, in a similar distribution, but not in PD-normal subjects. Four of seventeen Lewy body disease subjects had elevated FTP binding despite low cortical PiB uptake. FTP binding in the inferior temporal gyrus and precuneus correlated with MMSE and Clinical Dementia Rating scale sum-of-boxes-scores.

Conclusion: Cortical tau deposits are common in DLB and PD-impaired subjects, in an anatomical distribution reminiscent of AD, and contribute to cognitive impairment. In contrast with AD, it appears that high levels of amyloid burden are not necessary for tau deposition in the Lewy body diseases. *Keywords: Lewy, DLB, tau, Flortaucipir, amyloid*

Nonfluent variant of primary progressive aphasia: Tau deposition in the language network

<u>Belen Pascual</u>¹, Paolo Zanotti-Fregonara¹, Quentin Funk¹, Elijah Rockers¹, Neha Pal¹, Meixiang Yu², Bryan Spann¹, Paul Schulz³, Joseph C Masdeu¹

¹Department of Neurology, Houston Methodist Research Institute, Weill Cornell Medical College, Houston, TX, USA ²PET Core, Houston Methodist Research Institute, Weill Cornell Medical College, Houston, TX, USA ³Department of Neurology, UT Physicians, Houston, TX, USA

Background: The sporadic nonfluent/agrammatic variant of primary progressive aphasia (nfvPPA) is characterized by impaired speech sound production and distorted grammar. The core of the initial damage is localized to Broca's area. Tau imaging using ¹⁸F-AV-1451 PET provides a unique opportunity to determine the brain distribution of tau deposition in this syndrome.

Methods: We evaluated with ¹⁸F-AV-1451 PET six patients with nfvPPA and six normal controls. Both patients and controls were amyloid-negative, and they did not differ significantly in age and sex (nfvFTD: n = 6, 3 women, mean age = 64.2 ± 5.9 ; controls: n = 6, 3 women, mean age = 68.8 ± 7.6). ¹⁸F-AV-1451 images from 80 to 100 min were averaged, and standardized uptake value ratios were calculated using the mean activity in the cerebellar gray matter as the reference region. Additionally we determined functional connectivity with BOLD MRI in a group of 35 healthy volunteers group-matched to the patients, using as seed the volume of the largest tau cluster in the nfvPPA group.

Results: On voxel-wise analysis and compared to controls, patients with nfvPPA had increased tau uptake (p < 0.001 uncorrected) in two major clusters. The larger cluster was in Broca's area. The smaller cluster was located in the planum temporale of the superior temporal gyrus, extending to the supramarginal gyrus (Wernicke's area). As expected, on the MRI functional connectivity study, the seed in the location of the larger tau cluster showed the most significant connectivity with a region located in the same area as the smaller tau cluster.

Conclusions: In nfvPPA, ¹⁸F-AV-1451 PET showed abnormal tau deposition not only in Broca's area, but also, and separately, in Wernicke's area. This study provides direct *in vivo* evidence of network tau propagation in humans, postulated to occur in these neurodegenerative disorders and already documented in animal models.

Keywords: Primary Progressive Aphasia, Language, 18F-AV-1451, Frontotemporal Dementia

Longitudinal decrease of white matter PiB uptake in aging and Alzheimer's disease

<u>Yi Su¹</u>, Kewei Chen², Eric Reiman², John Morris¹, Tammie Benzinger¹

¹Washington University in St. Louis School of Medicine, St. Louis, MO, USA ²Banner Alzheimer's Institute, Phoenix, AZ, USA

Background: A number of recent studies reported that when WM as by itself, or part of, the reference region to quantify cerebral amyloid burden, improved sensitivity to longitudinal changes can be achieved. Hence, using WM as the reference region to quantify amyloid PET data is gaining popularity in aging and Alzheimer disease (AD) research community. On the other hand, lower white matter PiB binding is reported in regions with myelin damage in the context of multiple sclerosis. In this study we examine the longitudinal amyloid tracer binding in white matter regions.

Methods: A total of 183 participants (112 female; 64 APOE4 carriers; age 45~86; 137 amyloid negative and CDR=0; 36 amyloid positive and CDR=0; 10 CDR>0) from our local memory and aging studies who had longitudinal PiB imaging data were included in this preliminary analysis. Quantification of PiB PET imaging data was performed using standard procedure based on region of interest defined using T1-weighted MR scan during the same period and with cerebellar cortex as the reference region.

Results: Significant longitudinal decreases (p<0.05) in white matter SUVR was observed for the whole group ($p=1.34\times10^{-6}$), normal control ($p=1.09\times10^{-4}$), preclinical AD (p=0.029), and the cognitively impaired group ($p=4.35\times10^{-3}$) (Figure 1). The results hold with or without partial volume correction.

Conclusion: Longitudinal decreases in white matter PiB binding is observed in our memory and aging study cohorts, suggesting possible gradual white matter demyelination due to aging and AD pathology. White matter signal in amyloid imaging may serve as a biomarker for white matter integrity and the validity of using white matter as the reference region needs further investigation.



Figure 1. Longitudinal white matter SUVR changes in normal control, preclinical AD, and CDR+ groups.



18F-AV-1451 and 11C-PIB PET do not explain impairment in Parkinson's disease

<u>Joseph Winer</u>¹, Peter Pressman², Jordan Stiver², Anne Maass³, Daniel Schonhaut², Joel Kramer², Gil Rabinovici², William Jagust³

¹Department of Psychology, University of California, Berkeley, Berkeley, CA, USA ²Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA ³Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, USA

Background: Multiple pathologies contribute to impairment in Parkinson's disease (PD), including Lewy bodies, cerebrovascular disease, and Alzheimer's disease (AD). Emerging studies have reported increased tau deposition in PD dementia, but tau has not been characterized in cognitively normal PD and PD with mild cognitive impairment.

Methods: Here we compared *in vivo* AV-1451 and PIB retention in cognitively normal patients with PD (PD-CN, N=15, age 67 ± 6.6), PD patients with mild cognitive impairment (PD-MCI, N=14, age 67 ± 4.9), and PIB positive and negative normal controls (NC-PIB+, N=29, age 75 ± 4.7; NC-PIB-, N=29, age 77 ± 3.86). ¹⁸F-AV-1451 SUVRs (80-100 min, cerebellar gray reference) were normalized to template space for voxel-wise group contrasts, and regions of interest (ROIs) that paralleled AD Braak stages were created in native space using FreeSurfer. A global cortical ¹¹C-PIB DVR index was calculated for each subject.

Results: Six PD patients (21%, 1 PD-MCI, 5 PD-CN) were PIB positive and 23 PIB negative. Voxel-wise contrasts between PD-CN and PD-MCI, and additionally between PD and PIB- controls, did not reveal significant differences. AV-1451 binding did not differ between PD-MCI and PD-CN in AD Braak stages I/II, III/IV, or V/VI, and did not differ from PIB- healthy older adults (**Figure 1**). PD PIB+ and PD PIB- AV-1451 binding differed significantly in Braak stages III/IV and V/VI (**Figure 2**). PD PIB+ binding was similar to PIB+ controls, while PD PIB- binding was similar to PIB- controls.

Conclusions: These findings suggest that patterns of cortical A β and tau do not differ in PD-CN, PD-MCI, and healthy older adults. Age, A β , and tau do not differentiate PD-CN and PD-MCI. Tau deposition is related to A β status and age in both PD and healthy older adults. Cognitive deficits in PD-MCI do not appear to reflect AD pathology.



Keywords: Parkinson's disease, PD-MCI, tau, AV-1451, PIB

Longitudinal tau-PET imaging using [18F]AV-1451 in progressive supranuclear palsy

<u>Jennifer Whitwell</u>¹, Val Lowe¹, Bradley Boeve¹, Kejal Kantarci¹, Matthew Senjem¹, Nirubol Tosakulwong¹, Christopher Schwarz¹, Anthony Spychalla¹, Ronald Petersen¹, Clifford Jack¹, Keith Josephs¹

¹Mayo Clinic, Rochester, MN, USA

Background: Positron emission tomography (PET) imaging using a tau ligand could be a valuable biomarker of disease progression in a primary tauopathy like progressive supranuclear palsy (PSP), although it is unknown whether longitudinal change in tau-PET signal can be detected in PSP.

Methods: We performed serial tau-PET imaging using the AV-1451 ligand in two patients with PSP. Median AV-1451 uptake was calculated for six subcortical and brainstem regions (midbrain, dentate nucleus of the cerebellum, thalamus, pallidum, putamen, and caudate nucleus) and four cortical regions (supplementary motor cortex, precentral cortex, postcentral cortex and superior frontal cortex) that are typically involved pathologically in PSP. To account for age-associated confounds, regional values were converted into age-corrected z-scores representing difference from 71 healthy controls. The PSP patients were also compared to

four reference subjects who had a non-PSP clinical diagnosis and had also undergone serial tau-PET scans at our institution. **Results:** An increase in tau-PET signal over time was observed in all the subcortical and brainstem structures, except for the caudate nucleus, in PSP. Both PSP subjects showed an increased tau-PET signal over time in midbrain, dentate nucleus of the cerebellum. and thalamus, with one of the PSP subjects also showing an increase in signal over time in the pallidum and putamen (Figure). The PSP patients also showed greater involvement of the subcortical and brainstem structures than the four reference subjects. In contrast, no consistent increase over time in tau-PET signal was observed in the four cortical regions in PSP.

Conclusions: This data provides evidence that tau-PET measurements of subcortical and brainstem structures could prove to be useful longitudinal biomarkers in PSP.

Longitudinal tau-PET scans in two patients with PSP

Keywords: tau, PET, progressive supranuclear palsy, serial



Pittsburgh compound-B PET and MRI biomarkers of cognition in aging multiple sclerosis patients

<u>Burcu Zeydan^{1,2}</u>, Val J. Lowe¹, Scott A. Przybelski³, Christopher G. Schwarz¹, Nirubol Tosakulwong³, Samantha M. Zuk¹, Matthew L. Senjem⁴, Jeffrey L. Gunter⁴, Rosebud O. Roberts², Michelle M. Mielke², Eduardo E. Benarroch², Moses Rodriguez², Mary M. Machulda⁵, Timothy G. Lesnick³, David S. Knopman², Ronald C. Petersen², Clifford R. Jack Jr¹, Kejal Kantarci¹, Orhun H. Kantarci²

¹Mayo Clinic College of Medicine, Department of Radiology, Rochester, MN, USA ²Mayo Clinic College of Medicine, Department of Neurology, Rochester, MN, USA ³Mayo Clinic College of Medicine, Department of Health Sciences Research, Rochester, MN, USA ⁴Mayo Clinic College of Medicine, Department of Information Technology, Rochester, MN, USA ⁵Mayo Clinic College of Medicine, Department of Psychiatry and Psychology, Rochester, MN, USA

Background/Objective: Advanced MRI techniques used in imaging myelin of brain parenchyma are not myelin-specific. In contrast, amyloid tracers such as cortical Pittsburgh compound-B (PiB) are recently shown to target myelin. We studied the association of cognitive function with thalamic volume, lobar cortical thickness PIB positron emission tomography (PET) and white matter (WM) PiB binding as a potential myelin marker in an aging MS population.

Design/Methods: In the population-based Mayo Clinic Study of Aging, 24 of 4869 participants had MS, with a subset who underwent brain MRI (n=16) and PiB-PET (n=12). One MS patient fulfilled criteria for mild cognitive impairment while another fulfilled criteria for dementia and neither had PiB-PET. Controls from the same cohort were age- and sex-matched (5:1) to MS patients. Quantitative image analyses were performed using automated or semi-automated image processing pipelines.

Results: MS patients had lower cognitive z-scores for memory (p=0.03) and language (p=0.02) than controls. MS patients had smaller thalamic volumes (p=0.003), thinner temporal cortices (p=0.001) and thinner frontal cortices (p=0.045) than controls. Thalamic volume loss was associated with decreased attention-executive performance (p=0.02). PiB uptake was reduced in areas of WM hyperintensities compared to normal appearing WM in MS (p=0.0002) and controls (p<0.0001). Reduced PiB uptake in areas of WM hyperintensities was associated with decreased visuospatial performance in MS (p=0.02). There was no difference in global cortical PiB standardized uptake value ratios between MS and controls (p=0.39).

Conclusions: Late MS is characterized by reduced cognitive performance, cortical and thalamic atrophy, but normal PiB uptake in the cortex. The frontal and temporal multimodal association areas interconnected via a large number of WM tracts are prone to damage in MS. The correlation between thalamic atrophy and lower attention-executive function likely reflects WM injury in thalamo-cortical projections. The correlation between PiB-PET and visuospatial processing may reflect injury to association area connectivity. *Keywords: Pittsburgh compound-B, PET, multiple sclerosis, myelin, cognition*

Improved estimation of gray matter volume in presence of white matter hyperintensities in Alzheimer's and Down syndrome studies with amyloid burden

<u>Dana Tudorascu</u>¹, Helmet Karim¹, Lea Alhilali², Patrick Lao³, Tobey Betthauser³, Erica Tamburo¹, Rebecca Maccloud¹, Jeffrey James¹, Davneet Minhas¹, Annie Cohen¹, Beth Snitz¹, Julie Price⁴, Brian Lopresti¹, Chet Mathis¹, Oscar Lopez¹, Sterling Johnson³, Ciprian Crainiceanu⁵, Ben Handen¹, Brad Christian³, Howard Aizenstein¹, William Klunk¹

¹University of Pittsburgh, Pittsburgh, PA, USA ²Barrow Neurological Institute, Phoenix, AZ, USA ³University of Wisconsin, Madison, WI, USA ⁴Athinoula A. Martinos Center, Harvard Medical School, Charlestown, MA, USA ⁵Johns Hopkins University, Baltimore, MD, USA

Introduction: White matter hyperintensities (WMHs) appear as hyperintense areas in magnetic resonance imaging (MRI). WMHs present a challenge for standard segmentation algorithms that misclassify WMHs as gray matter (GM). Our objective was to investigate tissue class segmentation in two longitudinal samples: Down syndrome (DS, 3 years) and Alzheimer's disease (AD, 6 years).

Methods: Gray matter volume (GMV) was obtained in 39 ADs (14 PiB+) and 28 DS (13 PiB+) with three methods: *1) Standard*: MPRAGES are segmented into six tissue types: GM, white matter (WM), cerebrospinal fluid, and 3 non-brain tissues (SPM12); *2) Multi-spectral*: MPRAGE and FLAIR are used in the segmentation for more accurate classification; *3) Fill*: A WMH mask is obtained from FLAIR (Wu et. Al, 2006), MPRAGEs are filled with normal appearing WM, which are then segmented. GMV is computed (max of probabilities among tissue maps) for each subject, within each method. The GMV is compared using a repeated measures model with a fixed effect of method, time, PiB status and a random subject effect. To assess accuracy between methods, a neuroradiologist case investigation is presented in Figure1. **Results:** <u>AD Study:</u> Statistically significant differences were detected in GMV between the segmentation methods (p<0.0001), time (p<0.0001), and PiB status (p=0.0002) (Tables1.1, 1.2) with higher mean GMV for standard and fill method and lower for multi-spectral. <u>DS study:</u> Statistically significant differences were detected between GMV from different methods (p<0.0001) (Tables2.1, 2.2) with higher mean GMV for

standard and fill method and lower for multi-spectral. **Conclusion**: Our results suggest that GMV is more precisely estimated in the presence of WMH using fill or multispectral techniques. Without correctly accounting for WMH, GMV could be overestimated, thus affecting the analysis and conclusions. Moreover, in studies with heavy amyloid burden, additional caution should be taken due to differences between PiB



Figure 1. (A) MPRAGE at the level of the a lateral ventricle. (B) FLAIR image demonstrating WMH predominantly in the periventricular and deep white matter.(C) WMH map demonstrates excellent concordance with the FLAIR WMH, with the small exception of slight underestimation in the right posterior periventricular region (yellow arrowhead). (D)Standard segmentation, demonstrating large regions of periventricular WMH classified as gray matter around the frontal horn of the right lateral ventricle and in the posterior periventricular regions bilaterally (yellow arrow). (E) Multispectral: no misclassification of WMH as GM. (F) Fill: demonstrating small areas of WMH misclassified as GM, predominantly in the right posterior periventricular white matter, but also punctate regions in the left posterior periventricular white matter and around the right frontal horn (square yellow arrowheads). Segmentations were all performed using SPM12.

groups in GMV.

Table 1.1. AD study results (Descriptive statistics):

PiB status/Method	PiB (+)		PiB (-)		
,	GMV Time 1	GMV Time 2	GMV Time 1	GMV Time 2	
	(n=15)	(n=4)	(n=25)	(n=9)	
Standard	488.83	472.70	483.01	457.14	
	(88.80)	(45.30)	(54.05)	(39.08)	
Multispectral	478.93	459.30	470.72	445·37	
	(82.73)	(46.02)	(49.77)	(32.87)	
Fill	491.47	480.16	481.63	454.55	
	(90.51)	(42.70)	(55.51)	(34.54)	

Results are in mL and presented as mean (sd).

Table 1.2. AD study results (Model estimates):							
Effect	β (SE)	T (df)	p-value	95% CI for β			
Intercept	580.73 (11.41)	42.13 (46.8)	<0.0001	(457.77, 503.69)			
Fill (Standard=ref)	0.22 (1.66)	0.13 (115)	0.78	(-3.07, 3.52)			
Multispectral (Standard=ref)	-11.61 (1.66)	-6.98 (115)	<0.0001	(-14.90, -8.31)			
PiB Status (PiB (-)=ref)	-27.04 (9.75)	-3.88 (136)	0.0002	(-40.80, -13.27)			
Time (Time 2=ref)	14.65 (2.00)	7.29 (117)	<0.0001	(14.83, 25.77)			

 β coefficient for the method represents the difference in GMV mean between standard segmentation (reference method) and each other method when time and PiB status are fixed; β coefficient for the PiB status represents the difference in GMV mean between PiB (+) and PiB (-) when time and volume are fixed; β coefficient for time represents the difference in GMV mean between Time 1 and Time 2 when method and PiB status is fixed. GMV were computed by counting the number of voxels in which the GM tissue class was the highest (compared to other tissue), multiplying by their dimension and dividing by 1000 to represent it in mL.

Table 2.1. DS study results (Descriptive statistics):

PiB status/Method	PiB (+)		PiB (-)		
	GMV Time 1 (n=15)	GMV Time 2 (n=7)	GMV Time 1 (n =13)	GMV Time 2 (n=8)	
Standard	524.03 (41.73)	459.28 (67.44)	499.92 (62.67)	523.11 (49.28)	
Multispectral	417.30 (119.36)	416.29 (59.19)	446.74 (41.35)	439.83 (66.92)	
Fill	511.24 (46.41)	458.81 (67.74)	499.77 (62.87)	523.11 (49.18)	

Results are in mL and presented as mean (sd).

Effect	β (SE)	T (df)	p-value	95% CI for β
Intercept	505.16 (16.25)	31.08 (60.6)	<0.0001	(472.66, 537.67)
Fill (Standard=ref)	-3.99 (9.66)	-0.41 (96.7)	0.68	(-23.18, 15.19)
Multispectral (Standard =ref)	-73.25 (9.66)	-7.58 (96.7)	<0.0001	(-92.44, -54.06)
PiB Status (PiB (-)=ref)	-6.44 (16.81)	-0.38 (59.9)	0.70	(-40.06, 27.17)
Time (Time 2=ref)	5.61 (9.66)	0.58 (115)	0.56	(-13.54, 24.74)

 β coefficient for the method represents the difference in GMV mean between standard segmentation (reference method) and each other method when time and PiB status are fixed; β coefficient for the PiB status represents the difference in GMV mean between PiB (+) and PiB (-) when time and volume are fixed; β coefficient for time represents the difference in GMV mean between Time 1 and Time 2 when method and PiB status is fixed. GMV were computed by counting the number of voxels in which the GM tissue class was the highest (compared to other tissue), multiplying by their dimension and dividing by 1000 to represent it in mL.

Keywords: improved segmentations in amyloid (+), GM overestimation in presence of WMH,

Global white matter diffusion characteristics predict longitudinal cognitive change independently from amyloid accumulation in older adults

<u>Jennifer S. Rabin</u>¹, Rodrigo Perea⁴, Rachel Rachel Buckley^{3,5,6}, Keith A. Johnson^{3,4}, Reisa A. Sperling^{3,4,5}, Trey Hedden^{2,4}

¹Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
 ²Department of Radiology, Massachusetts General Hospital, Boston, MA, USA
 ³Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
 ⁴Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, USA
 ⁵Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia
 ⁶Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia
 ⁷Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Objective: Reduced white matter integrity has been proposed as one explanation for age-related cognitive decline. Here, we examined (1) whether diffusion characteristics of global versus tract-specific white matter predicted longitudinal cognitive decline in healthy older adults and (2) whether white matter diffusion characteristics affected cognition independently from amyloid accumulation or white matter hyperintensities (WMH).

Methods: Pittsburgh Compound B–positron emission tomography and diffusion tensor imaging (DTI) were performed at baseline in 259 clinically normal older adults (aged 63 – 89) from the Harvard Aging Brain Study. DTI data were processed with Tract-Based Spatial Statistics. Global white matter diffusion was measured as mean fractional anisotropy (FA) across the whole white matter skeleton. Tract-specific diffusion was measured as mean FA for 8 major white matter tracts. Factor scores derived from neuropsychological tests represented processing speed, executive function, and episodic memory. Baseline age, gender and education and their interactions with time were controlled in each model.

Results: Linear mixed models found that global white matter FA at baseline predicted longitudinal changes in processing speed and episodic memory but not executive function. After accounting for global white matter FA, no individual tracts significantly predicted a change in any cognitive domain. Next, we investigated whether the relationship between global white matter FA and cognitive change (for processing speed and memory) was independent of amyloid and WMH. In these models, global white matter FA remained a significant predictor of episodic memory and processing speed over time; amyloid significantly predicted a change in episodic memory, but not processing speed; and WMH did not predict a change in either domain.

Conclusion: These findings suggest that longitudinal changes in episodic memory and processing speed are associated with global, rather than tract-specific, white matter diffusion characteristics and that white matter FA and amyloid accumulation independently predict cognitive change. *Keywords: white matter, DTI, amyloid, cognition, white matter hyperintensities*

130

[18F]AV1451 tau PET distinguishes PSP from controls and Parkinson's disease

Daniel Schonhaut¹, Corey McMillan², Brad Dickerson³, Andrew Siderowf⁴, Michael Devous⁴, Richard Tsai¹, Joe Winer⁵, David Russell⁶, Irene Litvan⁷, Erik Roberson⁸, Joel Kramer¹, Peter Pressman¹, Ilya Nasrallah², Suzanne Baker⁹, Stephen Gomperts³, Keith Johnson³, Murray Grossman², William Jagust⁹, Adam Boxer¹, <u>Gil Rabinovici¹</u>

¹University of California San Francisco Memory & Aging Center, San Franscisco, CA, USA
 ²Dept. of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
 ³Dept. of Neurology, Harvard Medical School, Boston, MA, USA
 ⁴Avid Radiopharmaceuticals, Philadelphia, PA, USA
 ⁵Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA
 ⁶Institute for Neurology, University of California San Diego, San Diego, CA, USA
 ⁸Dept. of Neurology, University of Alabama Birmingham, Birmingham, AL, USA
 ⁹Lawrence Berkeley National Laboratory, Berkeley, CA, USA

Background: AV1451 binds selectively to neurofibrillary tangles in Alzheimer's disease, but studies assessing post-mortem binding to tau aggregates in progressive supranuclear palsy (PSP) have yielded mixed results. We compared *in vivo* AV1451 retention in patients with PSP (N=33, 12% Aβ PET+) compared to normal controls (NC, N=46, all Aβ PET-) and patients with Parkinson's disease (PD, N=26, 19% Aβ PET+). **Design/methods:** Participants were recruited in Avid-sponsored multi-site imaging trials (NCT #02167594 and #02016560) and independent studies at UCSF/LBNL and MGH (**Figure 1**). 80-100 mean AV1451 images were co-registered to subject-specific T1-weighted MRI, and SUVR images were derived referencing cerebellar gray matter (excluding dentate nucleus, DN). Voxel-wise and region-of-interest group comparisons were performed in template space (SPM12), covarying for age. Receiver Operator Characteristic (ROC) analyses were performed to assess single-subject discrimination.

Results: On voxel-wise analysis, PSP showed elevated binding compared to NC and PD in bilateral globus pallidus (GP), dorsal midbrain, subthalamic nucleus (STN), and DN (p(FWE)<0.05, Figure 2). Mean SUVR were increased in PSP vs. NC and PD in GP, STN and DN (p<0.001), and in PSP vs. PD in substantia nigra (SN, p<0.001) (Figure **3**). There were no differences in AV1451 retention between PD and NC. On ROC analyses, Areas Under the Curve were 0.862 for PSP vs. NC (sensitivity 84.8% specificity 78.3%) and 0.879 for PSP vs. PD (sensitivity 90.9%, specificity 80.8%). Regional and voxel-wise AV1451 SUVR did not correlate with disease severity as measured by PSP Rating Scale.

Figure 1

	N	Site	Age	Sex	PSPRS
PSP	33	10 UCSF/LBL 19 Avid A09 study 4 MGH	69.6 ± 5.7	23 Male 10 Female	34.7 ± 11.6
PD	26	26 UCSF/LBL	67.1 ± 5.4	14 Male 12 Female	
NC	46	20 UCSF/LBL 17 Avid A05/A09 studies 9 MGH	69.6±5.4	25 Male 21 Female	

PSP-RS: PSP Rating scale (0-100, higher scores relate to worsening disease)

Conclusions: AV1451 uptake is elevated in PSP compared to NC and PD in a pattern that matches the expected distribution of tau aggregates. Longitudinal studies with autopsy confirmation are needed to further assess the utility of AV1451 as a biomarker of tau pathology in PSP and other non-AD tauopathies.



Sponsors: Avid Radiopharmaceuticals, Tau Consortium, Michael J. Fox Foundation.

SN

PUT

Keywords: AV1451, PSP, non-AD tauopathies, Parkinson's disease

nigra, THAL - thalmus; CAUD - caudate

DN

STN

0.4

GP

THAL

PONS

CAUD

Antemortem-postmortem correlation of florbetapir (18F) PET amyloid imaging with quantitative biochemical measures of Aβ40 and Aβ42

Thomas Beach, Chera Maarouf, Anthony Intorcia, Lucia Sue, Geidy Serrano, Alex Roher

¹Banner Sun Health Research Institute, Sun City, AZ, USA

Amyloid imaging effectively demonstrates the *in vivo* presence of amyloid-beta (AB) deposits in the aging human brain but it is still unknown which of the many structural forms and modifications of AB are detected. In Alzheimer's disease, most amyloid deposits are predominantly composed of AB ending at amino acid residues Val40 or Ala42. The relative abundance of these two major forms differs between individuals but in general it has been reported that AB40 is largely restricted to neuritic plaques and larger blood vessels while AB42 may be deposited in senile plaques and vascular amyloid of all types, and is often the sole component of diffuse plaques. The distinction is important as it is mainly the neuritic plaques that correlate with cognitive impairment while diffuse plaques may be the initial type of AB deposited. Whether PET amyloid ligands such as florbetapir-¹⁸F (Amyvid) are partially or wholly selective for brain deposits of AB40 or AB42 is currently unknown. We compared antemortem florbetapir PET cortical/cerebellar signal intensity (SUVr) of 55 subjects with postmortem biochemical (ELISA) measurements employing specific antibodies against AB1-40 and AB1-42. Correlation analyses were significant for both AB40 and AB42, but were much stronger for AB42. Despite this, SUVr in these 55 individuals was not dependent on the AB40/42 concentration ratio. These results suggest that, while florbetapir binds to both species in the human brain, the interaction with AB42 dominates over that with AB40. This may be in large part due to the generally higher AB42 concentrations, but may be partially due to preferential AB42 binding, possibly due to its higher likelihood to be present in a β -pleated sheet tertiary structure, or to differences in β -pleated sheet tertiary or quaternary structure.

Keywords: Alzheimer's disease, autopsy, diagnosis, neuritic plaque, diffuse plaque

Proteomics signatures of Alzheimer's disease: gender differences and relationship to pathological markers

Shantanu Srivatsa¹, Joseph Lucas¹, Murali Doraiswamy¹

¹Duke University, Durham, NC, USA

Background: Women may have a greater risk for Alzheimer's disease (AD) and there is interest in examining potential gender differences in AD biomarkers. While prior studies have focused on brain imaging or cerebrospinal fluid, there is also a need to validate personalized blood biomarkers.

Methods and results: We analyzed baseline clinical and cognitive data from the Alzheimer's Disease Neuroimaging Initiative (ADNI-1) as well as baseline proteomics data in individuals with MCI, AD or normal cognition. The Biomarkers Consortium Plasma Proteomics Project RBM multiplex data, referred to as the human discovery map, was developed on the Luminex xMAP platform by Rules-Based Medicine (RBM) to contain proteins previously reported in the literature to be altered as a result of cancer, cardiovascular disease, metabolic disorders and inflammation. Details of the assay technology and validation has been described elsewhere. We conducted statistical analyses to examine if there were gender differences in plasma protein signatures and whether such signatures were related to diagnosis and pathological markers.

Conclusions: In initial analyses, a number of protein markers differed by diagnosis and gender. Full results of our analyses and analyses will be presented. Discovering gender specific biomarkers may provide novel mechanistic insights into disease modification in subjects at risk. *Keywords: Proteomics, amyloid, tau, sex differences*

Tau PET in subjects at risk for chronic traumatic encephalopathy

<u>Nicolas Andrea</u>¹, Jonathan Alverio¹, Christopher Lee¹, Christopher Nowinski², Heidi Jacobs¹, Ann McKee², Keith Johnson¹, David Jin¹

¹Departments of Radiology and Neurology, Massachusetts General Hospital, Boston, MA, USA ²Center for the Study of Traumatic Encephalopathy, Boston University School of Medicine, Boston, MA, USA

Background: Chronic traumatic encephalopathy (CTE) is a progressive tauopathy resulting from repetitive brain trauma. Tau deposition is widely scattered in neocortical sulci, but by Stage III, medial temporal lobe (MTL) is typically involved. We tested whether MTL tau PET measures were elevated in 10 former american football players with histories of multiple trauma exposure (TE) compared to non-exposed control subjects (CS).

Methods: TE (n=10, aged $45.2 \pm 8.7y$; 10.4 ± 2.8 football seasons played) and CS (n=10, aged $49.4 \pm 7.1y$) participants underwent clinical evaluations, MRI, 18F Flortaucipir (FTP)-PET, and PiB-PET. Group differences in FTP SUVR (80-100min) defined individually in 4 MTL ROIs (Freesurfer) were assessed with robust linear regression, adjusting for age.

Results: TE and CS groups were similar in age, education, MMSE, ICV-adjusted total hippocampal volume, and amyloid burden assessed with PiB FLR (all p > 0.2), but differed in Ohio State Traumatic Brain Injury score (p<0.05). FTP SUVR was greater in TE compared to CS in parahippocampal gyrus and hippocampus (p<0.05) and at trend level in entorhinal cortex and amygdala (p<0.07) (Figure 1). Age by group interaction was seen in parahippocampal gyrus (p<0.01, CTE>CS), and trending in entorhinal cortex (p<0.1).

Conclusions: These preliminary data suggest that PET measures of tau deposition in MTL may be elevated in individuals with a history of repeated brain trauma, consistent with postmortem observations. While the binding properties of FTP to cortical CTE lesions are at present incompletely understood, our data are consistent with autopsy data in CTE that indicate greater MTL tauopathy than expected for age. While these trauma-exposed participants were non-demented, further evaluations of tau PET in relation to features of putative CTE clinical phenotypes may yield important insights.

Keywords: PET, CTE, Tau





^{**} p < 0.05

PET staging of brain amyloidosis using striatum

<u>Bernard Hanseeuw</u>¹, Rebecca Betensky², Beth Mormino¹, Aaron Schultz¹, Kate Papp^{1,3}, Rachel Buckley¹, Jasmeer Chhatwal¹, Gad Marshall^{1,3}, Dorene Rentz^{1,3}, Reisa Sperling^{1,3}, Keith Johnson^{1,3}

¹Massachusetts General Hospital, Boston, MA, USA ²Harvard School of Public Health, Boston, MA, USA ³Brigham and Women's Hospital, Boston, MA, USA

Objective: To disentangle neocortical and striatal $A\beta$ contributions to cognitive decline in CN and MCI from HABS and ADNI, and evaluate how much power clinical trials would gain by selectively enrolling participants with striatal amyloidosis.

Methods: We included 643CN and 573MCI with baseline A β -PET and longitudinal MMSE over an average 3.3-year follow-up. We classified subjects in three A β -Stages. Stage 0: Low-A β ; Stage1: High-neocortical, low-striatal A β ; and Stage2: High-neocortical, high-striatal A β . We used mixed-models to assess the association between A β -Stages and subsequent MMSE decline, adjusting for demographics and cohort. We also tested whether use of a PET staging system including striatal A β would improve power in a clinical therapeutic trial.

Results: MMSE declined faster in Stage2-CN (0.28points/y) than in Stage1-CN (0.16points/y; p=0.026) and faster in Stage1-CN than in Stage0-CN (0.04points/y; p=0.002). MMSE declined faster in Stage2-MCI (1.2points/y) than in Stage1-MCI (0.25points/y; p<0.00001) and faster in Stage1-MCI than in Stage0-MCI (0.07points/y; p=0.003). To compare striatal- and neocortical-A β contributions within the high-A β group, we used a 2-by-2design based on striatum (Stage1/Stage2) and neocortex (high/very high: +/++). Decline rates were 0.17 (Stage1+), 0.43 (Stage1++), 0.65 (Stage2+), and 0.95 (Stage2++) MMSE-points/y. All pairwise comparisons were significant (p<0.050), indicating faster progression associated with high-striatal A β (Stage2+) than very high neocortical A β (Stage1++). A 300-CN trial (2 arms over 3-year duration; 80% power; alpha=0.05) would detect a drug effect on MMSE (PACC) of 52.8% (30.5%) or greater in Stage2-CN compared to 93.8% (45.9%) in unselected A β +. A 300-MCI trial would detect a drug effect on MMSE of 24.7% or greater in Stage2 compared to 51.3% in unselected A β +.

Conclusions: Striatal A β -PET signal indicates increased risk of subsequent decline amongst high-A β nondemented individuals. PET staging including both striatal and neocortical A β measures may be useful in the context of anti-A β trials as a biomarker of progression, and potentially as an endpoint for assessing drug efficacy.





HABS and ADNI, CN and MCI pooled: Total n=1216



Keywords: Amyloid-PET, Striatum, Clinically normal, Mild Cognitive Impairment, Anti-amyloid therapeutic trial

Tau PET imaging tracks both pathology and brain perfusion in non-AD tauopathies: a multimodal study

<u>Elena Rodriguez-Vieitez</u>¹, Antoine Leuzy¹, Konstantinos Chiotis¹, Laure Saint-Aubert¹, Ove Almkvist¹, Anders Wall², Agneta Nordberg^{1,3}

¹Translational Alzheimer Neurobiology, Center for Alzheimer Research, Dept. NVS, Karolinska Institute, Stockholm, Sweden ²Section of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden ³Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden

Objectives: We have recently shown that THK5317 tau PET may prove a potential dual biomarker, describing both molecular pathology and brain perfusion in Alzheimer's disease (AD). The aim of this study was to illustrate the dual-use of THK5317 in non-AD tauopathy cases, in relation to biomarkers including glucose metabolism, amyloid and cognition.

Methods: Non-AD patients were recruited, including three patients with clinical diagnoses of frontotemporal dementia, one with semantic dementia, one with corticobasal syndrome (CBS), and two amyloid-negative mild cognitive impairment (MCI) patients. All patients underwent T1 MRI, PET imaging with THK5317, PIB and FDG, and comprehensive neuropsychological assessments. The CBS patient, and one of the amyloid-negative MCIs, were longitudinally followed-up (at 23 and 17 months, respectively) with the same multimodal protocol (except PIB); both were diagnosed as CBS at follow-up. Brain perfusion was estimated using the simplified reference tissue model R₁ and the early-phase (0-3 min) standardized uptake value ratio (SUVR), with cerebellum grey matter (GM) as reference. PET quantification (THK5317 Logan DVR, PIB SUVR, FDG SUVR and perfusion parameters) was performed using the cerebellum GM as reference. Regional and voxel-wise comparisons were performed with respect to groups of young (n=5; 22-28 years) and elderly healthy volunteers (n=4; 60-65 years), and of AD patients (n=20, 60-74 years).

Results: All non-AD patients were amyloid negative (<1.40 SUVR cortical composite PIB PET) and showed heterogeneous brain distributions of THK5317 retention, with significantly greater retention than in young healthy controls. Heterogeneous regional patterns of both hypometabolism and hypoperfusion were observed in these patients, corresponding to their diverse clinical phenotypes.

Conclusion: The findings suggest the usefulness of THK5317 as a dual biomarker, capable of tracking the different pathology and brain perfusion patterns in non-AD patients, and supporting its potential applicability to help discriminate between AD and non-AD tauopathies using a single PET scan. *Keywords: tau; perfusion; tauopathies; corticobasal syndrome; frontotemporal dementia*

Hippocampal cingulum integrity predicts change in tau accumulation in a downstream-connected region in amyloid-positive normal older individuals

<u>Heidi Jacobs</u>^{1,3}, Aaron Schultz³, Rebecca Amariglio⁴, Trey Hedden³, Kathryn Papp⁴, Rodrigo Perea³, Dorene Rentz⁴, Jorge Sepulcre³, Reisa Sperling^{2,3,4}, Keith Johnson^{1,2,3}

¹Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ²Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ³Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ⁴Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Introduction: Neuropathology studies suggest that tau pathology propagates via connections in a process potentiated by amyloid pathology. We examined longitudinally whether hippocampal volume (HV) predicts tau accumulation in a connected area, the isthmus, via its anatomic connection, the hippocampal cingulum (HC) bundle. Furthermore, we examined whether amyloid deposition moderates this process (fig1).



Methods: Two hundred fifty-six clinically normal participants from the Harvard Aging Brain Study completed baseline DTI, PIB-PET scanning and neuropsychological assessment (mean age:73.45 years; mean cognitive follow-up:5.11 years; mean MRI follow-up:2.89 years) Of these participants, 110 subjects underwent Flortaucipir-PET scanning at ~2.32 \pm 1.32 years from MRI baseline (mean follow-up:2.75 years (n=41)). Tract of interest was the HC and control tract was the uncinate fasciculus (UF). Tau region of interest was the isthmus; inferior temporal (IT) cortex the control region. Linear mixed models examined whether i) baseline HV predicts change in HC diffusion, ii) baseline HC diffusion predicts isthmus tau accumulation and interacts with amyloid status and iii) HC diffusion predicts memory in high isthmus tau persons. Memory scores were derived from a factor analysis. Age, gender and education were included as covariates.

Results: Baseline HV predicted diffusion changes in the HC, not in the UF. Baseline HC, not UF, diffusion predicted changes in isthmus tau, not IT tau. Amyloid positive individuals showed a stronger association between HC integrity and isthmus tau change then amyloid negative. HC diffusion predicted change in memory performance in high isthmus tau compared to low tau persons. All associations were right lateralized (fig2, table).

Effect of tract integrity on tau accumulation is amyloid-driven



LME Models	Hippocampal cingulum		Uncinate fasciculus	
	Estimate (SE)	p-value	Estimate (SE)	p-value
I. HCV predicting diffusion				
(observations=392)				
 Left 	-6.2e ⁻⁰⁴	0.396	2.3e ⁻⁰⁴	0.194
	(7e ⁻⁰⁴)		(1.8e ⁻⁰³)	
 Right 	-1.80e ⁻⁰³	0.027	4.9e ⁻⁰⁴	0.312
C C	(8e-04)		(4.8e ⁻⁰⁴)	
II. Diffusion predicting isthmus tau				
(observations=151)				
• Left	0.217 (0.26)	0.417	-0.022 (0.08)	0.789
 Right 	0.213 (0.09)	0.037	0.126 (0.14)	0.379
III. Diffusion x amyloid predicting				
isthmus tau (observations =149)				
• Left	-0.183 (0.55)	0.739	0.393 (0.34)	0.252
 Right 	0.513 (0.23)	0.030	0.563 (0.38)	0.148
VI. Diffusion predicting IT tau				
(observations = 151)				
 Left 	0.014 (0.22)	0.952		
 Right 	0.066 (0.11)	0.565		
V. Diffusion x tau predicting memory				
(observations = 600)				
• Left	0.239 (0.35)	0.497		
Right	-0.599 (0.25)	0.015		

Note: Linear Mixed effects models for the chain of events and their control regions. All models were covaried for age, gender and education and their interaction with time (if p<0.10). Age was centered at 73.45 years, education at 15.80 and female was the reference for gender. Abbreviations: LME: Linear Mixed Effects models; HCV: Hippocampal volume; IT = inferior temporal. All shown models use the mean diffusivity metric (multiplied by 1000, threshold at FA > 0.2). Tau values are in standardized uptake value ratio's with the cerebellum grey as reference region and corrected for partial volume effects. Amyloid deposition (PIB) is dichotomized at DVR-FLR=1.20

<u>Discussion</u>: These findings suggest that tau pathology propagates from the medial temporal to the limbic lobe via specific connections and this is potentiated by amyloid. This chain of events is associated with memory decline. Exploring these relationships in patient populations will be the next step in understanding the spatial pattern of tau propagation.

Keywords: Tau, propagation, connectivity, memory, longitudinal

Greater regional cortical thickness is associated with selective vulnerability to atrophy in Alzheimer's disease, independent of regional amyloid load

Chunfei Li¹, <u>Ranjan Duara</u>^{2,4}, David A. Loewenstein^{3,4,5}, Mercedes Cabrerizo¹, Warren Barker^{2,4}, Malek Adjouadi^{1,4}

¹Center for Advanced Technology and Education, School of Engineering, Florida International University, Miami, FL, USA

²Wien Center for Alzheimer's Disease & Memory Disorders, Mount Sinai Medical Center, Miami, FL, USA ³Psychological Services and Neuropsychology Laboratory, Mount Sinai Medical Center, Miami, FL, USA ⁴Florida ADRC (Florida Alzheimer's Disease Research Center at Gainesville, Miami Beach, Miami and Boca Raton, FL), Gainesville, Miami and Boca Raton, FL, USA

⁵Center on Aging and Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, FL, USA

Background/Objective: Thinning of the cortex in specific brain regions has been described in both early and preclinical Alzheimer's disease (AD)¹, whereas among cognitively normal (CN) elderly, greater amyloid load has been associated with greater temporal lobe volumes². We further explored these observations by studying the relationships between cortical thickness (CTh), amyloid load and the severity of regional atrophy in AD.

Methods: MRI scans (3-D, T1-weighted) were used to delineate 68 cortical regions among CN (n=251; age = 75.3 ± 6.6 years) and AD (n=162; age= 74.7 ± 7.8 years) subjects in the ADNIGO/ADNI2 cohort. The severity of regional atrophy from CN to AD (Atr(%)^{CN-AD}) was calculated for each brain region. AV45 PET were linearly registered onto post-processed T1-weighted MRI images, and regional Uptake Value Ratios (rSUVR) (target to cerebellum) were calculated, following segmentation and parcellation. Pearson Partial Correlation (PPC) were calculated to examine the association of the mean regional CTh among CN individuals to Atr(%)^{CN-AD}, correcting for regional mean SUVR in corresponding regions.

Results: Regions with the greatest CTh among CN subjects were aggregated in limbic regions (e.g. entorhinal cortex, temporal pole, insula cortex) which also tended to have the lowest rSUVRs. In contrast, CTh was lower in many neocortical regions (e.g., pericalcarine, precuneus, superior parietal), which had the highest rSUVRs (Figs.1 and 2). Regional CTh was positively correlated to the severity of atrophy in each region , before (r = 0.662, p = 4.309e-10), as well as after (r = 0.535, p = 2.226e-06) partitioning out the effect of regional SUVR (Fig. 1).

Conclusions: Brain regions with greater cortical thickness at baseline have greater regional neurodegeneration, not mediated by regional amyloid load. This phenomenon may represent an aspect of brain/cognitive reserve. Alternatively, genetic factors mediating regional cortical thickness developmentally, may also mediate selective vulnerability to atrophy.





Fig. 1. Plot of regional Cortical Thickness and % Atrophy with the estimated linear regression model. Results were similar for the left and right hemisphere, so only left hemisphere ROI's were plotted. Atrophy Rate = -11.287+6.775*CTh; r = 0.662, adjusted R-squared = 0.4302



SUVR_CN vs CTh Atrophy Rate

Fig. 2. Plot of regional SUVR and % Atrophy with the estimated linear regression model. Only left hemisphere ROIs are plotted. AtrophyRate = 33.627-26.33*SUVR_CN; r = -0.570, adjusted *R*-squared: 0.315

Keywords: Alzheimer's disease, selective vulnerability, cortical thickness, regional amyloid load, regional atrophy
Distinctive clinical significance of hemorrhagic and amyloid imaging markers in patients with clinical-radiological cerebral amyloid angiopathy in memory clinic patients

Young Kyoung Jang¹, Jin San Lee¹, Ko Woon Kim¹, Sang Won Seo^{1,2}

¹Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

²Neuroscience Center, Samsung Medical Center, Seoul, Korea

Cerebral amyloid angiopathy is a cerebrovascular disease caused by amyloid β accumulation in the cortical and leptomeningeal vessel walls. However, only few studies examined the clinical significance of hemorrhagic and amyloid β imaging markers in patients with clinical cerebral amyloid angiopathy. We, therefore, aimed to investigate the effects of lobar cerebral microbleeds and cortical superficial siderosis on cortical thickness and cognitive impairment.

372 participants were divided into two groups according to the median number of lobar cerebral microbleeds and cortical superficial siderosis. Cortical thickness was measured by surface based methods. We also included 114 clinical-radiological cerebral amyloid angiopathy patients who underwent amyloid β PET and neuropsychological tests. Linear mixed effects model was performed in order to investigate the longitudinal effects of parenchymal amyloid β positivity.

Older age, Apolipoprotein E ϵ 4 allele, poorer cognitive status, and more severe deep and periventricular white matter hyperintensities were the most prominent in probable cerebral amyloid angiopathy followed by possible cerebral amyloid angiopathy and non-cerebral amyloid angiopathy groups. Multiple lobar cerebral microbleeds were associated with impairment in all cognitive domains, while cortical superficial siderosis was associated with impairment in attention, frontal executive function and mini mental state examination. Furthermore, 58.9% of clinically diagnosed cerebral amyloid angiopathy patients showed amyloid β PET positivity, which also affected baseline memory function and progressive decline in multiple cognitive domains. Taken together, our findings suggest that multiple lobar cerebral microbleeds and cortical superficial siderosis affect distinctively clinical features, providing new insights into their underlying pathomechanisms.

Our findings suggested that CAA might be classified into several phenotypes according to kinds of hemorrhagic markers or the A β PET positivity. Therefore, these results emphasize the need for further prospective therapeutic trials to determine how prevention strategies targeting CAA related neuroimaging markers might modify the natural history of cognitive impairment. *Keywords: CAA, amyloid PET*

Is tau accumulation detectable before neuronal injury markers? – Analysis from tau PET imaging with [C-11]PBB3 in clinical variants of Alzheimer's disease

<u>Masamichi Imai</u>^{1,2}, Kenji Ishii¹, Mika Tanaka¹, Kenji Ishibashi¹, Kei Wagatsuma¹, Muneyuki Sakata¹, Tetsuro Tago¹, Jun Toyohara¹, Shigeo Murayama³, Hirotaka Maruno^{2,4}, Hitoshi Shimada⁵, Makoto Higuchi⁵, Tetsuya Suhara⁵

¹Neuroimaging Research, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
²Department of Radiology, Toranomon Hospital, Tokyo, Japan
³Department of Neurology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan
⁴Okinaka Memorial Institution for Medical Research, Tokyo, Japan
⁵Clinical Research Cluster, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan

Background: Past clinico-pathological studies and recent tau PET imaging studies have suggested that neurofibrillary tangle or tau pathology is closely linked to clinical symptoms. Current neuropathological model of Alzheimer's disease (AD) assumes that tau accumulation may precede neuronal injury. The purpose of this study is to examine if tau PET imaging with ¹¹C-PBB3 can detect tau pathology concurrently or separately with hypometabolism/atrophy with ¹⁸F-FDG PET/structural MRI. We focused on patients with local variant of AD in which different stages of AD pathology are most likely to coexist region by region.

Methods: We studied two cases of posterior cortical atrophy (PCA) and two cases of logopenic variant of primary progressive aphasia (lvPPA) meeting the criteria for probable AD dementia or mild cognitive impairment due to AD, and 23 amyloid negative cognitively normal subjects as control. In each subject PET images with ¹¹C-PBB3, ¹¹C-PiB, ¹⁸F-FDG and 3D MRI images were obtained. All the images were corregistered and SUVR PET images in reference to cerebellar cortex were used for further evaluation with visual inspection, ROI analysis, and SPM statistical analysis.

Results: In PCA patients, ¹¹C-PBB3 accumulation was detected in bilateral occipito-parietal region. In lvPPA patients, remarkable ¹¹C-PBB3 accumulation was observed in bilateral temporo-parietal cortex left-side dominantly. Hypometabolic and atrophic area appeared to be more restricted to the area with tau deposition (Figure 1). On the other hand, in the most severely hypometabolic/atrophic regions ¹¹C-PBB3 accumulation did not necessarily be the highest, but seemed to be relatively declined (Figure 2).

Biomarker Imaging of Variant AD



Correlation of Tau Burden and Glucose Metabolism



Conclusion: Our results suggest that tau related pathology in AD evaluated by ¹¹C-PBB3 is detectable before the emergence of hypometabolism and atrophy. In the regions with advanced stage of AD pathology, ¹¹C-PBB3 binding may decline presumably due to atrophy and/or tracer's binding characteristics against variable tau conformations. Further longitudinal and histopathology studies are required.

Keywords: tau. PBB3. clinical variant of Alzheimer's disease.

Investigation of gait speed and ß-amyloid in older adults from the Harvard Aging Brain Study

Dylan R. Kirn¹, Rachel F. Buckley^{1,3,4,5}, Bernard J. Hanseeuw¹, Rebecca E. Amariglio^{1,2,3}, Reisa A. Sperling^{1,2,3}, Keith A. Johnson^{1,2,3}

¹Department of Neurology, Massachusetts General Hospital, Boston, MA, USA ²Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA ³Harvard Medical School, Boston, MA, USA ⁴Florey Institutes of Neuroscience and Mental Health, Melbourne, Australia ⁵Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia

Background: Recent evidence from post-mortem studies suggest that AD pathology may not only influence decline in cognition, but physical functioning as well. A negative relationship between gait speed(GS) and striatal β-Amyloid(Aβ) has been shown cross-sectionally, and so we aimed to investigate the effect of baseline neocortical and striatal Aβ on GS change. We hypothesized that increasing baseline Aβ would relate to poorer cross-sectional GS, and also slower GS over four years.

Methods: 287 older adults(73yrs±6.4) underwent baseline PiB-PET imaging and GS measurements, and had an additional GS measurement at their third yearly assessment. GS(meters/second) was measured using a 30ft course, with one turn. GS change slopes were extracted from a GS-by-time linear mixed model. Neocortical Aß burden was represented by a summary distribution volume ratio (DVR) of frontal, lateral and retrosplenial(FLR) tracer uptake, while striatal Aß reflected a composite of caudate and putamen DVRs. PiB groups were calculated according to both FLR/STR status (FLR-,FLR+/STR-,FLR+/STR+). Linear regression analyses were run to determine whether GS (cross-sectionally or longitudinally) would be predicted by either neocortical or striatal Aß, after accounting for age and gender.

Results: Neither neocortical nor striatal Aß were found to associate with cross-sectional GS (β =0.03, p=0.46, β =0.08, p=.12, respectively). In addition, no relationship was observed between neocortical Aß and GS change (β =0.003, p=.15; β_{age} =-.0006, p<.001), or striatal Aß and GS change (β =.004, p=.16; β_{age} =-.0006, p<.001). An ANCOVA showed that GS change did not differ according to PiB group (F=0.96, p=.39).

Conclusion: This is the first study to examine the longitudinal relationship between GS and AB. Our analysis did not reveal an association between these outcome measures, however, this may be due to relatively subtle changes in gait speed over four years. While our preliminary findings support age-associated decline in gait speed, a longer follow-up will be needed to elucidate the involvement of proteinopathy. *Keywords: amyloid, gait speed, striatum, older adults*

Greater [F-18]THK-5351 binding in medial and ventral temporal lobe is associated with altered microstructure and reduced myelin

<u>Andrew Merluzzi</u>¹, Nagesh Adluru¹, Andrew Schoen¹, Douglas Dean¹, Vikas Singh¹, Bradley Christian¹, Tobey Betthauser¹, Patrick Lao¹, Todd Barnhart¹, Murali Dhanabalan¹, Sanjay Asthana¹, Andrew Alexander¹, Sterling Johnson¹, Barbara Bendlin¹

¹University of Wisconsin - Madison, Madison, WI, USA

Background: Amyloid plaques and neurofibrillary tangles (NFTs) are not unilateral predictors of dementia, suggesting that other mechanisms contribute to the development of cognitive decline. Neuronal microstructure and brain connectivity may play an important role in this process, particularly as NFTs begin to develop. As such, we hypothesized a relationship between NFTs measured by THK-5351 binding in temporal lobe structures and altered microstructure and myelin in adjacent regions.

Methods: Cognitively healthy participants underwent THK-5351 PET imaging, diffusion tensor imaging (DTI), and mcDESPOT to detect myelin water fraction (MWF Analysis: n=11, age=67.2 \pm 2.2 years, 54% female, 45% *APOE* ϵ 4 positive; DTI Analysis: n=17, age=68.8 \pm 1.6 years, 59% female, 41% *APOE* ϵ 4 positive). Distribution volume ratios (DVR) of THK-5351 binding were obtained from bilateral hippocampus and fusiform gyrus, and were used as predictors in voxelwise linear regressions for fractional anisotropy (FA), mean diffusivity (MD), and MWF in SPM12 (controlling for age, sex, and *APOE* ϵ 4). Biological Parametric Mapping (BPM) in SPM8 was used to ascertain the effect of tau on the microstructural metrics on a regional basis.

Results: Significant associations were found between hippocampal and fusiform THK-5351 binding and microstructure and myelin. Specifically, on a regional basis, THK-5351 was associated with reduced MWF in several temporal lobe structures, including the hippocampus and cingulum bundle (Figure 1 A/B). Similarly, on a voxelwise basis, THK-5351 was associated with reduced FA in the cingulum bundle (Figure 1 C/D). THK-5351 was also associated with increased MD in the left hippocampus (Figure 1 E/F).

Conclusions: THK-5351 binding was associated with altered microstructure and reduced myelin in a cognitively healthy middle-aged population, findings that may prove useful in identifying the early processes leading to cognitive decline in those with tau accumulation. This provides insight into the relationship between Alzheimer's disease pathologies and brain microstructure in the preclinical stage.



Keywords: THK5351, connectivity, DTI, myelin, tau

Contribution of neuritic and diffuse plaques to signal derived from CN-Flutemetamol: a preliminary study in AD autopsy brains

<u>Milos Ikonomovic¹</u>, Eric Abrahamson¹, Christopher Buckley², Chester Mathis¹, WIlliam Klunk¹, Gill Farrar²

¹University of Pittsburgh, Pittsburgh, PA, USA ²GE Healthcare, Amersharm, United Kingdom

Background: Specificity and sensitivity of Flutemetamol (Vizamyl) PET are high for detecting neuritic amyloid-beta plaques (NP), however several false-positive results indicate that this radiotracer may also detect diffuse plaques (DP). Using the fluorescent derivative of Flutemetamol (CN-Flutemetamol) applied to AD brain tissue sections, we have detected both NP and DP, although NP appeared to have brighter fluorescence than DP. The current study explores quantitatively this relation in brain areas affected differentially by NP and DP.

Methods: Tissue sections from the frontal cortex (FC, variable proportions of NP and DP) and caudate (CD, all DP) from ten AD cases were processed using CN-Flutemetamol. We measured CN-Flutemetamol positive plaque load, expressed as percent area occupied by plaques, and integrated density, a measure that integrates both size and fluorescence intensity of labeled plaques per defined field.

Results: All plaques (DP and NP in the FC and DP in the CD) were labeled with CN-Flutemetamol. CN-Flutemetamol-labeled total plaque load was similar in CD and FC (CD = 3.79 ± 0.64 ; FC = 5.81 ± 1.18 ; 2-tailed t-test p = 0.15), however, the integrated density in FC was greater than in the CD (CD= 5024 ± 490.3 ; FC= 11742 ± 568.2 ; 2-tailed t-test p<0.0001).

Discussion: For two regions with comparable plaque area coverage, but with different involvement of NP and DP, the region with a preponderance of NP yields greater overall CN-Flutemetamol fluorescence signal when area coverage and signal intensity are calculated as a single value (integrated density). This implies that in PET imaging studies, brain regions with high densities of NP exhibit greatest Flutemetamol retention. However, DP can contribute to Flutemetamol PET signal in regions with very high DP area coverage. Thus, Flutemetamol PET may correlate better with NIA-AA 2012 AD neuropathology criteria that incorporate both CERAD (NP) and Thal phases (all types of A β plaques).

Keywords: Flutemetamol, amyloid-beta, diffuse plaques, neuritic plaques, PET

PET tau and amyloid synergy in default mode network determines the clinical status in predementia stages of Alzheimer's disease

<u>Tharick Pascoal</u>, Sulantha Mathotaarachchi, Min Su Kang, Kon Pin Ng, Jean-Paul Soucy, Serge Gauthier, Pedro Rosa-Neto

¹Mcgill University, Montreal, QC, Canada

Although abnormal levels of amyloid- β and tau proteins have been constantly associated with dementia, the link between amyloid-ß plaques and neurofibrillary tangles as determinants of clinical status remains an unsolved question in Alzheimer's disease (AD). Here, we tested the hypothesis that the synergistic interaction between, rather than the independent or additive effects of, amyloid-β plaques and neurofibrillary tangles determines clinical status in the predementia stages of AD. We assessed 80 ADNI individuals (41 cognitively normal individuals and 39 mild cognitive impairment) with magnetic resonance, florbetapir amyloid-ß and AV1451 tau positron emission tomography imaging as well as clinical status assessed with the Clinical Dementia Rating Scale Sum of Boxes. A voxel-based interaction model assessed the main and interactive effects of amyloid- β and tau positron emission tomography on clinical status, accounting for age, gender, years of education, APOE $\varepsilon 4$ status, diagnosis and grey matter density at every voxel. We further carried out an analysis of variance to compare the synergistic model with the mediation and additive models. We found that the synergism between amyloid- β and tau pathologies in the precuneus, posterior cingulate, inferior parietal, lateral temporal and medial prefrontal cortices were associated with worse clinical status in the predementia stages of AD (P < 0.001). In addition, analysis of variance strongly supported that the model with the interaction term best described clinical status, as compared to reduced models testing (1) only amyloid- β ; (2) only tau; and (3) amyloid- β plus tau with P values < 0.0001 in all three cases. These results highlight the concept that the synergy between amyloid- β and tau determines clinical status in the predementia stages of AD. Importantly, the regions where such a synergy determined worse clinical status were confined to the functional hubs of the brain's default model network, which are postulated fundamental to the large-scale brain organization.

Keywords: Amyloid PET, tau PET, protein-protein interaction



Staging of amyloid- β , tau, regional atrophy rates and cognitive change in a non-demented cohort

Evan Fletcher Fletcher^{1,2}, Alice Renaud³, Abhninandan Nandi¹, Charles DeCarli^{1,2}

¹IDeA Laboratory, UC Davis, Davis, CA, USA ²Department of Neurology, UC Davis, Sacramento, CA, USA ³Northeastern University, Boston, MA, USA



Figure 2



Figure 3

Background: Despite extensive study, questions remain about the sequencing of biomarker events, including amyloid- β , tau, atrophy and cognitive decline, in association with the progression of Alzheimer's pathology. Moreover, current models emphasize the temporal nature of evolution in biomarker abnormalities while neglecting the issue of differences in anatomical distribution known to accompany Alzheimer's pathology.

Subjects and Methods: We tested both biomarker chronology and anatomical variation in a non-demented cohort of ADNI-2, using regressions and serial mediation models (Fig. 1), incorporating baseline CSF tau with regional 2-year longitudinal atrophy, to mediate the effects of baseline CSF amyloid- β (A β) concentration on 2-year cognitive change.

Results: In cognitive normals there were no mediations but $A\beta$ correlated with atrophy rates in medial temporal (MTL: amygdala, entorhinal cortex, parahippocampal gyrus and hippocampus), lateral temporal regions (LTR: inferior, middle and superior temporal gyri) and also with change in executive and memory function.

In mild cognitive impairment (MCI) different mediation models of A β effects on cognitive change were significant for anatomically distinct regions that may reflect different dynamics of the interaction of A β , tau and atrophy (Figs 2-3). These regions corresponded roughly with the Braak stages of tau deposition. Mediation by MTL atrophy alone (without tau) was significant in both early and late MCI. Mediation by tau -> neocortical atrophy was seen first in LTR in early MCI (Fig. 2), spreading to many other neocortical regions of atrophy by late MCI (Fig. 3).

Discussion: Our results thus suggest that different mediation models are sensitive to differing interactions of $A\beta$, tau and longitudinal atrophy by brain location, pointing to topographical as well as disease state differences in the sequencing of the effects of $A\beta$ and tau on atrophy and cognition. These differences suggest that future sequential biomarker models should take into account both temporal (i.e. disease stage) and spatial (anatomical regions) dimensions.

Keywords: mediation, amyloid-beta, tau, regional atrophy, biomarker models

Increased level of CSF neurofilament light chain is associated with amyloidosis in transgenic rat model of Alzheimer's disease

<u>Min Su Kang</u>^{1,2,6}, Eduardo R. Zimmer^{1,5}, Monica Shin^{1,2,6}, Sulantha Mathotaarachchi^{1,2}, Tharick Pascoal^{1,2}, Kok Pin Ng^{1,2}, Henrik Zetterberg⁷, Jean-Paul Soucy³, Judes Poirier⁶, Serge Gauthier^{1,2,6}, A. Claudio Cuello⁴, Pedro Rosa-Neto^{1,2,3,6}, Kaj Blennow⁵

¹Translational Neuroimaging Translational laboratory, Montreal, QC, Canada
²McGill University Research Centre for Studies in Aging, Verdun, QC, Canada
³McConnell Brain Imaging Centre - McGill University, Mont, QC, Canada
⁴McGill University - Department of Pharmacology, Mont, QC, Canada
⁵Department of Biochemistry, Federal University of Rio Grande do Sul, Porto Alegre, BR
⁶Douglas Mental Health Institute, Verdun, QC, Canada
⁷Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disease that has the characteristics of multiple pathologies: amyloidosis, neurofibrillary tangles (NFTs), and atrophy. Recent findings revealed higher cerebrospinal fluid (CSF) neurofilament light (NfL) levels of AD patients and APPPS1 mouse model. NfL is a novel fluid biomarker for neuronal injury as it is part of major cytoskeleton proteins. However, its association with regional amyloidosis needs further investigations. Here, we utilized McGill-R-Thy1-APP transgenic rat (Tg) model that accumulates amyloid pathology without NFTs or cell depletion. Our aim of the study is to investigate the increased level of CSF-NfL and its association with amyloid accumulation. We hypothesized that the level of CSF-NfL is greater in Tg compared to WT and it is associated with amyloidosis in the AD vulnerable regions.

Methods: A total of 28 (11 WT, 17 Tg) rats underwent CSF collection (10 to 17 months). A subset of Tg (6) also received a PET scan with NAV4694 at 17 months. CSF-NfL concentration was measured using a novel ultrasensitive Single molecule array (Simoa) method based on two UmanDiagnostics antibodies directed against the rod domain of NfL that is conserved in rodents. NAV4694-PET was acquired with a 90-minute dynamic scan followed by 9-minute transmission scan. The non-displaceable binding potential was generated using cerebellar grey matter as a reference region. The PET image was processed using MINC-toolkit. The statistical analysis of group comparison and voxel-wise parametric map were performed using R and glim_image, respectively.

Results: CSF-NfL was increased in Tg compared to WT; t(193)=2.539, p=0.0119. CSF-NfL was significantly associated with the amyloidosis in corpus callosum, fornix, hippocampus, entorhinal cortex, thalamus and striatum.

Conclusion: Our results revealed that the amyloid pathology alone is sufficient to cause neuronal degeneration, monitored as increased CSF-NfL that also correlates with amyloidosis in AD vulnerable regions in the rat model.



Keywords: CSF, neurfilament light chain, amyloidosis, animal model, biomarker

Thursday, January 12, 2017 - 10:15 am - 10:45 am

SESSION 4: Nauropathology II: PET to Autopsy Correlations

SESSION 4 Nauropathology II: PET to Autopsy Correlations	CHAIRS: Melissa Murray, <i>Mayo Clinic</i> Teresa Gomez-Isla, <i>Massachusetts General</i> <i>Hospital</i>		
Neuropathology and biochemical correlations of [F- 18]AV-1451 and [C-11]PiB PET imaging in a subject with Alzheimer's disease	Milos Ikonomovic University of Pittsburgh		
Neuroimaging-pathologic correlation of [F-18]-AV-1451 in an autopsy confirmed Parkinson's disease case	Marta Marquie-Sayagues MassGeneral Institute for Neurodegenerative Disease		
Multimodal evaluation of 18F-AV-1451 PET in an autopsy-confirmed corticobasal degeneration patient	Corey McMillan Perelman School of Medicine at the University of Pennsylvania		
Discussion			

Neuropathology and biochemical correlations of [F-18]AV-1451 and [C-11]PiB PET imaging in a subject with Alzheimer's disease

<u>Milos Ikonomovic</u>, Eric Abrahamson, Julia Kofler, William Paljug, Manik Debnath, Julie Price, Carl Becker, Chester Mathis, Oscar Lopez, William Klunk

University of Pittsburgh, Pittsburgh, PA, USA

Objectives: Imaging-autopsy analyses show that PiB PET corresponds to fibrillar amyloid-beta (Abeta) plaques. Neuropathology validation of AV-1451 PET in subjects with Alzheimer's disease (AD) is lacking. We report the first postmortem neuropathology evaluation of AV-1451, and comparison to PiB PET, in an AD subject.

Methods: The brain of a 94 y.o. subject with clinically probable AD and a history of PiB and AV-1451 PET scans (two years and one year prior to death, respectively) was examined postmortem. Abeta, Tau, and p-Tau immunoreactive pathology by area fraction (fixed left hemisphere, LH), and ELISA concentrations of insoluble Abeta, Tau, and p-Tau (frozen right hemisphere, RH), were correlated with region-matched, atrophy-corrected SUVR values.

Results: Subject was PiB+ (GLB6~2.16). AV-1451 retention was highest in striatum and insular, cingulate and temporal cortex. Neuropathology was complex, with age-related tau astrogliopathy, hippocampal sclerosis, TDP-43 and α -synuclein inclusions, and cerebral vascular pathology in addition to Abeta and tau pathologies (Thal phase=3, Braak stage=5, CERAD score=2). In the LH, PiB correlated with Abeta plaque load (r=0.41, p=0.031) but not tau pathology, while AV-1451 correlated with PHF-1 (r=0.66, p=0.0002), AT180 (r=0.54, p=0.004), and AT8 (r=0.42, p=0.025) pathology, and Abeta plaque load (r=0.47, p=0.01). In the RH, PiB correlated with insoluble Abeta1-42 ELISA (r=0.61, p<0.001) and weakly with pSer199 and pSer396 ELISA (r=0.37 and 0.39, both p=0.05). AV-1451 correlated with total tau (0.64, p=0.0003), pSer396 (0.61, p=0.001), pSer199 (r=0.42, p=0.03), and insoluble Abeta1-42 (r=0.75, p<0.0001) ELISAs. PET retention values of the two ligands correlated in the LH (0.38, p=0.0038) and the RH (0.65, p=0.0002).

Conclusions: AV-1451 PET corresponded to measures of p-Tau pathology load and brain concentration. Associations of AV-1451 with PiB and measures of Abeta could be related to substantial co-distribution of Tau and Abeta pathology in this case.

We thank Avid Radiopharmaceuticals for the provision of AV-1451 precursor. Keywords: [F-18]AV-1451, [C-11]PiB, amyloid, tau, PET

Neuroimaging-pathologic correlation of [F-18]-AV-1451 in an autopsy confirmed Parkinson's disease case

<u>Marta Marquie-Sayagues</u>^{1,2}, Avery C. Meltzer^{1,2}, Eline Verwer³, Marc D. Normandin³, Michael A. Schwarzschild^{1,2}, Stephen N. Gomperts^{1,2}, Keith A. Johnson², Matthew P. Frosch⁴, Teresa Gomez-Isla^{1,2}

¹MassGeneral Institute for Neurodegenerative Disease, Charlestown, MA, USA ²Massachusetts General Hospital, Department of Neurology, Boston, MA, USA ³Massachusetts General Hospital, Department of Radiology, Boston, MA, USA ⁴Massachusetts General Hospital, C.S. Kubik Neuropathology Center, Boston, MA, USA

Introduction: PET tracer -AV-145 preferentially binds to neurofibrillary tangles in Alzheimer's brains and those that form as a function of age. Its ability to bind tau lesions in other tauopathies remains controversial. Some studies report increased *in vivo* -AV-1451 retention, predominantly in basal ganglia and midbrain, in patients clinically diagnosed with PSP and CTE, but others notice similar patterns in older adults regardless of their clinical diagnosis, including controls whose brains are not expected to harbor tau pathology. While midbrain signal seems heavily influenced by -AV-1451 off-target binding to neuromelanin-containing neurons in substantia nigra, the underlying substrate of *in vivo* -AV-1451 retention in basal ganglia remains intriguing. <u>Objective</u>: We examined the correlation of *in vivo* and postmortem AV-1451 binding patterns in an autopsy-confirmed Parkinson's disease (PD) case who underwent imaging 12 months prior to death and exhibited elevated *in vivo* retention predominantly in basal ganglia.

Methods: We quantified *in vivo* retention of -AV-1451 and performed autoradiography and quantitative tau measurements in multiple brain regions.

Results: PET scan showed bilateral elevated -AV-1451 retention in basal ganglia. Lower retention was also noticed in midbrain, left frontal lobe and inferior temporal lobes. Postmortem exam showed the expected neuropathologic lesions of PD and scattered neurofibrillary tangles in medial temporal lobe. No tau pathology was present in basal ganglia. Autoradiography failed to show -AV-1451 binding in multiple brain regions with exception of incidental age-related tangles in medial temporal lobe and off-target binding in substantia nigra. There was no detectable -AV-1451 binding in the basal ganglia, where the highest *in vivo* signal was observed. *In vivo* -AV-1541 retention did not correlate with postmortem biochemical tau measures.

Conclusion: *In vivo* -AV-1451 retention in basal ganglia may represent, at least in part, non-specific binding influenced by biological or technical factors that occur *in vivo* rather than underlying tau pathology. *Keywords:* [F-18]-AV-1451, PET, tau, postmortem, Parkinson, basal ganglia

Multimodal evaluation of 18F-AV-1451 PET in an autopsyconfirmed corticobasal degeneration patient

<u>Corey McMillan</u>¹, David Irwin^{1,3}, Ilya Nasrallah², Jeffrey Phillips¹, Meredith Spindler¹, Katya Rascovsky¹, Kylie Ternes¹, Charles Jester¹, David Wolk¹, Linda Kwong³, Virginia Lee³, Andrew Siderowf⁴, Edward Lee³, John Trojanowski³, Murray Grossman¹

¹Perelman School of Medicine at the University of Pennsylvania, Department of Neurology, Philadelphia, PA, USA
²Perelman School of Medicine at the University of Pennsylvania, Department of Radiology, Philadelphia, PA, USA
³Perelman School of Medicine at the University of Pennsylvania, Department of Pathology & Laboratory Medicine and Center for Neurodegenerative Disease Research, Philadelphia, PA, USA
⁴Avid Radiopharmaceuticals, Philadelphia, PA, USA

Background: Autoradiographic evidence suggests that the ¹⁸F-AV-1451 PET radioligand binds to paired helical filaments in Alzheimer's disease (AD), but there is mixed evidence related to binding to 4-repeat misfolded tau (4Rtau) in corticobasal degeneration (CBD). Thus, *in vivo* evaluations of ¹⁸F-AV-1451 in patients with autopsy-confirmation are needed.

Method: A multimodal evaluation of a 58 year-old male who participated in baseline (15 months pre-death) clinical, ¹⁸F-AV-1451 PET, ¹⁸F-florbetapir PET, MRI, and DTI and longitudinal (5 months pre-death) ¹⁸F-AV-1451 PET. At autopsy, immunohistochemistry confirmed a diagnosis of CBD.

Results: Baseline ¹⁸F-AV-1451 PET revealed the highest retention in deep grey matter areas commonly associated with CBD pathology including bilateral substantia nigra, globus pallidus, and midbrain (Figure 1.a). Follow-up ¹⁸F-AV-1451 PET revealed more visible retention in bilateral frontal and posterior temporal cortical regions along with midbrain and pons (Figure 1.b). An assessment of annualized change revealed a 1-9% increase in ¹⁸F-AV-1451 PET retention, which was highest in the pons, medulla, and midbrain along with bilateral frontal and right temporo-parietal cortices (Figure 1.c). Baseline ¹⁸F-AV-1451 PET uptake was inversely correlated with MRI gray matter volume (r_s =-0.209;p=0.016;Figure 2.a) and DTI mean diffusivity of white matter (r_s =-0.329;p=0.032;Figure 2.b). Percent area occupied (%AO) of tau pathological inclusions was related to follow-up ¹⁸F-AV-1451 PET retention (r_s =0.768;p=0.001; Figure 2.c). Specifically, a SUVR≥1.2 captured all regions with high-tau pathology (%AO≥5.0) and did not capture any regions with low-tau pathology (%AO<5.0). Additionally, ¹⁸F-AV-1451 PET uptake was more highly related to thread (r_s =0.712;p=0.004) than tangle (r_s =0.630;p=0.022) pathology.

Conclusions: This multimodal assessment demonstrates that ¹⁸F-AV-1451 PET correlates with 4Rtau inclusions along with MRI and DTI measures. Single case data should be interpreted cautiously and future cohort studies including direct comparisons between CBD and AD are necessary to validate ¹⁸F-AV-1451 PET.





Figure 2. 18F-AV-1451 PET associations

Support: NIH (AG043503;AG017586;AG10124), Dana Foundation & Avid Radiopharmaceuticals.

Keywords: 18F-AV-1451 PET, Corticobasal Degeneration, tau, neuropathology, MRI

Keynote Lecture: Thomas Beach

Tau PET for Alzheimer's Disease: Possible Promise and Pitfalls

Thomas Beach

Sun Health Research Institute, Sun City, AZ, USA

This investigative review will utilize a comparative clinicopathological viewpoint to speculate on the potential benefits, as well as the possible obstacles, for tau PET imaging of Alzheimer's disease (AD). Etiologically, the amyloid hypothesis has been dominant for 25 years but this relies largely on the existence of autosomal dominant forms of AD that are caused by mutations in genes that affect the amyloid-beta (A β) peptide. The universal occurrence of tangles in aging humans raises the possibility of a tangle-first scenario for most sporadic AD cases, with plaque-bearing individuals representing only a subset. The dominance of tangles over plaques, in terms of impact on cognition, is firmly established. The typical clinical presentation of AD with a simple amnestic deficit is very likely a direct effect of tangle development in the entorhinal area and hippocampus, while the progression to dementia is most strongly associated with tangle spread throughout the cerebral neocortex. Despite this, it is clear that widespread neocortical tangles in AD do not occur without widespread neocortical plaques, presenting difficulties for a simple, unifying theory. The clinical diagnosis of AD is inaccurate using neurological examination alone but biomarkers have improved this and PET imaging of Aβ and/or tau will soon allow pathology-based clinical staging of AD. These developments are expected to greatly improve clinical trial efficiency and hence progress towards diseasemodifying therapies. Off-target binding of tau PET tracers is an enigma; this is not expected to seriously affect their usefulness for staging AD but may impair their application to non-AD tauopathies. Binding to iron-containing macromolecules such as hemosiderin and hemoglobin may be most explanatory but binding to melanin, mineralized deposits and lipopigments are alternate possibilities. Theoretically, molecular therapies directed against pathological tau hold at least equivalent promise as those directed against A^β but highly prevalent comorbid pathologies, especially Lewy body disease, cerebrovascular disease and stillmysterious intrinsic aging processes may hinder any single-agent approach. Imaging-to-autopsy studies, as well as prolonged longitudinal observational studies, will be needed to determine the long-term prognostic value of both amyloid and tau PET and hence identify appropriate stages for intervention initiation. Primary prevention will have to be virtually free of serious adverse effects, and be relatively inexpensive, as treatment periods of several years will probably be needed. Secondary and tertiary prevention could utilize progressively less-innocuous and more expensive agents.

Thursday, January 12, 2017 - 01:45 pm - 02:45 pm

SESSION 5: Tau PET: Non-AD Targets

SESSION 5 Tau PET: Non-AD Targets	CHAIRS: Gil Rabinovici University of California, San Francisco Brad Dickerson Massachusetts General Hospital
18F Flortaucipir binding in choroid plexus: association with race and hippocampus binding	Christopher Lee Massachusetts General Hospital, Harvard Medical School
[18F]Flortaucipir, aka [18F]AV-1451, Autoradiography Matches Immunofluorescent Staining From AT8 Tau Antibody in Chronic Traumatic Encephalopathy (CTE) Post-Mortem Brain Tissue Sections	Yin-Guo Lin Avid Radiopharmaceuticals, Inc.
Microscopic neuropathological evaluation of the binding profile of tau selective PET ligands in Alzheimer's disease and primary tauopathies	Melissa Wren University College London
AV-1451 tau-PET uptake in MAPT mutation carriers varies by tau isoforms	David Jones Mayo Clinic
18F-AV-1451 binding in familial frontotemporal lobar degeneration with tau pathology	William Kreisl Columbia University
Discussion	

18F Flortaucipir binding in choroid plexus: association with race and hippocampus binding

<u>Christopher Lee</u>¹, Marta Marquie¹, Nicolas Andrea¹, Molly LaPoint^{1,2}, David Jin¹, Heidi Jacobs¹, Aaron Schultz¹, Matthew Frosch¹, Teresa Gomez-Isla¹, Reisa Sperling^{1,2}, Keith Johnson^{1,2}

¹Departments of Neurology, Radiology, and the Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ²Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Background: On-target ¹⁸F-Flortaucipir (FTP) binding of Alzheimer's tau aggregates and off-target binding of melanocytes have been demonstrated with autoradiography (Marquie 2015). We hypothesized that if FTP binding in choroid plexus (CP) was associated with melanocytes, then FTP PET measures would be elevated in Black/African American (B/AA) participants compared to White (W).

Methods: FTP (SUVR; 80-100min,) and PiB PET were acquired in a total of 159 clinically normal participants in the Harvard Aging Brain Study, 26 B/AA and 133 W. Freesurfer FTP ROIs were sampled in CP, hippocampus (HC), amygdala (AM), inferior temporal gyrus (IT), entorhinal cortex (ER), and fusiform (FF) and corrected for the partial volume effect using GTM.

Results: Mean FTP SUVR, unadjusted for covariates, in CP was higher in Black/AA compared to White subjects (mean difference 0.47, +/-0.17, p=0.011) but did not differ in HC (p>0.17), AM (p>0.05), IT (p>0.6), ER (p>0.8) or FF (p>0.7). Elevated CP SUVR was independently associated with Black/AA race (p=0.001) and age (p=0.0003), covarying education, gender, PiB DVR and MMSE. In contrast, AM (p>0.76), IT (p>0.5), ER (p>0.1), and FF (p>0.2) SUVR were not associated with Black/AA race. However, HC SUVR was associated with Black/AA race (p=0.003), covarying age (p<10⁻¹²), PiB DVR (p=0.018), gender, education, and MMSE; the association did reach significance when CP was included in the model.

Conclusions: These findings suggest that melanocyte binding of Flortaucipir may account for high PET signal in CP. As off-target binding affects FTP HC measurement, hippocampus FTP levels should be interpreted with caution.

Keywords: Alzheimer's disease, tau PET, choroid plexus, race

[18F]Flortaucipir, aka [18F]AV-1451, autoradiography matches immunofluorescent staining from AT8 tau antibody in Chronic Traumatic Encephalopathy (CTE) post-mortem brain tissue sections

<u>Yin-Guo Lin¹</u>, Qianwa Liang¹, Felipe Gomez¹, Ann Mckee², Mark A. Mintun¹, Giorgio Attardo¹

¹Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA ²Boston University School of Medicine, Boston, MA, USA

Objective: CTE is a progressive tauopathy characterized by abnormal tau aggregates in widespread brain regions that can occur in those with history of repetitive brain trauma. We previously evaluated the potential of AV-1451 to detect tau of CTE with fluorescent surrogates that bound tau inclusions in CTE brain sections. The use of high μ M tracer concentration and alternative structures limited confidence in this previous data. Therefore, this study directly compares the autoradiography signal obtained from low M concentration of AV-1451 with AT-8 tau immunohistochemistry in CTE brain sections.

Methods: This study used sections of temporal cortex and striatum from 9 CTE brain sections (staged II, III and IV from Boston University) as well as negative and positive control brain slices from normal and Alzheimer's disease (AD), respectively, from National Disease Research Interchange. AV-1451 (20 μ Ci) was added to fresh frozen brain sections (10 μ m thick) to obtain autoradiography images. The same brain sections were stained with phospho-Tau antibody AT8 and imaged using a NanoZoomer 2.0HT (Hamamatsu).

Results: Autoradiography signal of stage III-IV CTE sections was moderate to high in temporal cortex and well matched to AT-8 tau staining. It was low to moderate in the striatal area and matched to AT-8 in gray matter but not in white matter. Relative quantitation of autoradiography signal showed stage III-IV CTE sections with clearly more signal than normal brain sections, but at least 5-fold lower intensity than in the AD brain sections.

Conclusion: AV-1451 autoradiography demonstrates tau deposits in temporal cortex and striatum from advanced CTE brain tissue sections. However, the intensity of binding was much less in CTE than in AD sections raising the possibility that the number of tau binding sites in CTE is much lower than in AD which could make PET imaging of tau deposits difficult to achieve reliably. *Keywords:* [18F]Flortaucipir, [18F]AV-1451, Autoradiography, Tau, CTE

Microscopic neuropathological evaluation of the binding profile of tau selective PET ligands in Alzheimer's disease and primary tauopathies

Melissa Wren^{1,2}, Kerstin Sander¹, Tammaryn Lashley², Nick Fox³, Erik Arstad¹

¹University College London, Institute of Nuclear Medicine and Department of Chemistry, London, United Kingdom ²University College London, Institute of Neurology, Queen Square Brain Bank for Neurological Disorders, London, United Kingdom ³University College London, Institute of Neurology, Dementia Research Centre, London, United Kingdom

Background: Molecular imaging with positron emission tomography (PET) using tau-selective ligands may facilitate early diagnosis of the dementias and allow for assessment of potential disease-modifying interventions. Structurally diverse tau PET tracers have now been translated into clinical trials; however, it remains unclear what type of pathology the different compound classes depict, and at which sensitivity.

Aims: To understand the factors that govern tau tracer binding, and their implication for *in vivo* PET imaging.

Methods: Tau selective ligands from two of the leading compound classes, the carbazole AV-1451, and its fluorescent analogue T726, and the quinoline THK-5117, were used to assess regional binding profiles by fluorescence microscopy, nuclear emulsion autoradiography and phosphor imaging. We used pathologically characterised tauopathy cases including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick's disease and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), together with age-matched controls. Results were correlated with underlying pathological tau immunostaining.

Results: In contrast to immunohistochemistry with the tau selective antibody AT8, imaging with T726 and THK-5117 in an AD cohort revealed large variations in the frequency of tracer binding to different types and maturities of pathological tau inclusions, and this binding varied between brain regions analyzed. Tracers from both compound classes were able to delineate neurofibrillary tangles from a mixed tau repeat FTDP-17 MAPT case, but binding was not detected in the microscopic inclusions of tissue from PSP, CBD, Pick's disease, or tau isoform specific FTDP-17 cases.

Conclusions: The results suggest that binding of tau selective ligands to the pathological inclusions found in the different tauopathies is not solely dictated by isoform composition or by the respective disease strain. Therefore, it cannot be assumed that *in vivo* PET truly reflects the distribution of tau pathology across brain areas.

Keywords: AV-1451, THK-5117, tau, PET, microscopy

AV-1451 tau-PET uptake in MAPT mutation carriers varies by tau isoforms

<u>David Jones</u>¹, Val Lowe¹, Jonathan Graff-Radford¹, Jeremy Syrjanene¹, Matthew Senjem¹, Christina Dheel¹, Zbigniew Wszolek², Rosa Rademakers², David Knopman¹, Ronald Petersen¹, Clifford Jack¹, Bradley Boeve¹

¹Mayo Clinic, Rochester, MN, USA ²Mayo Clinic, Jacksonville, FL, USA

Background: Tau positron emission tomography (Tau-PET) ligands have shown strong binding in Alzheimer's disease (AD) dementia cases *in vivo*. However, it is uncertain how well Tau-PET imaging performs in *MAPT* gene mutation carriers. Some *MAPT* mutations result in 3- and 4-repeat tau aggregates that are very similar to the aggregates seen in AD, while other mutations may result in tau aggregates that differ from AD.

Methods: We quantitatively (i.e., ROIs) and qualitatively (i.e., visual inspection) compared Tau-PET (AV-1451) SUVR values (cerebellar crus reference) in 9 symptomatic and 1 asymptomatic *MAPT* mutation carriers (n = 10, age range 42-67) with AD dementia subjects (n = 24, age range 54-90) and age-matched clinically normal (CN) subjects (n = 9, age range 42-67). Eight subjects had *MAPT* mutations that involved exon 10 (N279K, n=5; S305N, n=2; P301L, n=1) and two did not (V337M, n=2).

Results: Tau-PET signal was qualitatively and quantitatively different between AD, CN, and MAPT with the greatest signal intensity in AD and minimal regional signal in *MAPT* mutation carries with mutations in exon 10, each of which have primarily 4-repeat tau aggregates. However, *MAPT* mutation carriers with the mutations outside of exon 10 associated with 3- and 4- tau aggregates (V337M, n=2) had higher levels of signal relative to *MAPT* mutation carriers with mutations in exon 10 and greater than controls, but fell within the AD range (Figure 1).



Figure 1: AV-1451 in MAPT mutation carriers and reference clinically normal (CN) and Alzheimer's disease (AD) dementia subjects. Some MAPT mutation show elevated signal in affected brain regions, but the magnitude is typically within the control range. Subjects 8 and 9 however show a higher magnitude of signal that falls in the AD range. **Conclusions:** AV-1451 shows higher magnitude of binding in *MAPT* mutation carriers that harbor mutations that are more likely to produce AD-like tau pathology. Exon 10 splicing determines the balance of 3R and 4R

tau isoforms with mutations in exon 10 predisposing to a greater proportion of 4R aggregates and

consequently a lower level of AV-1451 binding (Figure 2), supporting the notion that AV-1451 has specific binding properties for AD-like tau pathology.



Figure 2: *MAPT* mutation location and representative AV-1451 scans. A schematic of the *MAPT* gene is displayed, highlighting the role of exon 10 splicing in determining 3R and 4R tau isoforms. The approximate mutation location and representative AV-1451 scans are indicated above for four subjects included in this analysis and one subject from the literature (adapted from Smith et. al., Brain [2016]). This schematic highlights the lack of significant AV-1451 signal in *MAPT* mutation carriers that harbor mutations that may disrupt exon 10 splicing.

Keywords: Tau-PET, AV-1451, MAPT, FTD

18F-AV-1451 binding in familial frontotemporal lobar degeneration with tau pathology

William Kreisl, Jill Goldman, Edward Huey

¹Columbia University, New York, NY, USA

Background: *MAPT* mutations cause familial frontotemporal lobar degeneration with tau pathology (FTLDtau). Alternative slicing of *MAPT* results in aggregates that are composed of different tau isoform conformations. ¹⁸F-AV-1451 was developed to bind to tau aggregates found in Alzheimer's disease, which are composed of both 3-repeat (3R) and 4-repeat (4R) tau isoforms. We sought to evaluate the ability of ¹⁸F-AV-1451 to detect tau aggregates in familial FTLD-tau caused by different *MAPT* mutations.

Methods: A total of seven members of three different families with *MAPT* mutations underwent PET imaging with ¹⁸F-AV-1451. *MAPT* mutations were associated with either predominantly 4R (P301L) or 3R + 4R (V337M and R406W) tau aggregates. Symptomatic (n = 4) and asymptomatic carriers (n = 1) and non-carriers (n = 2) were included. PET images were acquired 80-100 min after injection of 10 mCi ¹⁸F-AV-1451. Regional standardized uptake value ratios (SUVRs) were obtained by dividing uptake in target regions to that in cerebral gray matter.

Results: The three symptomatic V337M carriers (age 50-59 years, CDR = 0.5) had the greatest amount of ¹⁸F-AV-1451 binding (Table 1), with highest SUVRs in orbitofrontal cortex, anterior and ventral temporal cortex, and amygdala. The asymptomatic V337M carrier (age 33 years) and the symptomatic P301L carrier (age 56 years, CDR = 1) had ¹⁸F-AV-1451 binding similar to that in the two non-carriers (ages 28 and 60 years).

Conclusion: ¹⁸F-AV-1451 detects tau aggregates in V337M mutation carriers and therefore may be helpful in monitoring progression in patients with 3R + 4R tauopathies. Additional scans are required to confirm the conformational specificity of ¹⁸F-AV-1451 in FTLD-tau and to determine the threshold for PET positivity in 3R + 4R mutation carriers.

	Non-c	arriers			Carriers		
Age (years)	28	60	33	50	57	59	56
Family Mutation	R406W	V337M	V337M	V337M	V337M	V337M	P301L
Tau isoform	3R+4R	3R+4R	3R+4R	3R+4R	3R+4R	3R+4R	4R
CDR score	0	0	0	0.5	0.5	0.5	1
Ventral temporal ¹⁸ F-AV-1451 SUVR	0.99	1.09	1.1	1.36	1.52	1.81	1.05

Table 1. Clinical characteristics, mutation type, and ¹⁸F-AV-1451 binding for *MAPT* mutation family members

Abbreviations: CDR = Clinical Dementia Rating scale, SUVR = standardized uptake value ratio

Keywords: AV-1451, FTLD-tau, MAPT

Thursday, January 12, 2017 - 03:30 pm - 04:15 pm

Poster Session 2B - see 2A

Thursday, January 12, 2017 - 04:15 pm - 04:30 pm

SESSION 6: Thresholds and Centiloids

SESSION 6 Thresholds and Centiloids	CHAIRS: Keith Johnson Massachusetts General Hospital Sylvia Villeneuve McGill University	
Defining cut-points for imaging biomarkers used in brain aging and Alzheimer's disease research	Clifford Jack Mayo Clinic	
Further Adventures in the World of Centiloids	Robert Koeppe University of Michigan	

Defining cut-points for imaging biomarkers used in brain aging and Alzheimer's disease research

<u>Clifford Jack</u>¹, Heather Wiste¹, Stephen Weigand¹, Terry Therneau¹, Val Lowe¹, David Knopman¹, Jeffrey Gunter¹, Matthew Senjem¹, David Jones¹, Kejal Kantarci¹, Mary Machulda¹, Michelle Mielke¹, Rosebud Roberts¹, Prashanthi Vemuri¹, Denise Reyes¹, Ronald Petersen¹

¹Mayo Clinic, Rochester, MN, USA

Introduction: Every biomarker exists on a continuum; however, normal/abnormal cut-points are necessary in certain situations. Our goal was to develop cut-points for amyloid PET, tau PET, FDG PET, and cortical thickness.

Methods: Clinically normal (CN) individuals in this study were participants in the Mayo Clinic Study of Aging. Cognitively impaired individuals (MCI or AD dementia) were participants in either the Study of Aging or the Alzheimer's Disease Research Center. We examined five methods for determining cut-points (**Fig 1**): (1) the threshold value beyond which the biomarker rate of change worsens reliably, (2) 95% specificity in young CN, (3) 90% sensitivity in amyloid PET positive clinically impaired, (4) accuracy in distinguishing amyloid PET positive clinically impaired from young CN, (5) accuracy in distinguishing amyloid PET positive clinically impaired from age-matched amyloid PET negative CN.

Results: The reliable worsening method produced a cut-point for amyloid PET but not for FDG PET or cortical thickness. The specificity, sensitivity, and accuracy of clinically impaired versus young CN methods all gave similar cut-points for tau PET, FDG PET and cortical thickness (**Fig 2**). These labeled the most people positive and thus we refer to these cut-points as "lenient". Cut-points defined using the accuracy of clinically impaired versus age-matched CN method labeled fewer people positive and therefore were more conservative for tau PET, FDG PET and cortical thickness (**Fig 3**). Lenient cut points do not while conservative cutpoints do incorporate the notion of "age norming."

Discussion: In the future, we will employ a single cut-point for amyloid PET (SUVR 1.42, centiloid 19) based on the reliable worsening cut-point method. We will base lenient cut-points for tau PET, FDG PET and cortical thickness on the accuracy of clinically impaired vs young CN method and base conservative cut-points on the accuracy of clinically impaired vs age-matched CN method.



Figure 1. Cut-point methods. Graphical summary of the five methods used for determining cut-points. In each panel, increasing numeric values of the biomarker correspond to biomarker worsening. A biomarker's cumulative distribution function (CDF) indicates a biomarker value x on the horizontal axis and the proportion of observations less than or equal x on the vertical axis.



Figure 2. Specificity, sensitivity, and accuracy cut-points. Cumulative distribution function (CDF) plots for young CN individuals (light grey), cognitively impaired individuals (black), and older CN individuals that were age- and sex-matched to the cognitively impaired group (dark grey). The arrows indicate cut-points chosen corresponding to 95% specificity (CDR = 0.95, dark green arrow), 90% sensitivity (CDF = 0.10, dark red arrow), accuracy in discriminating between young CN and cognitively impaired individuals (purple arrow). Accuracy was defined as the point of maximum difference between two CDFs. Amyloid PET was used in the definition of the cognitively impaired group so only the specificity cut-point is shown. For amyloid PET (panel A), values are shown in both SUVR and centiloid units. Panel B tau PET; panel C FDG PET; panel D MRI.



Figure 3. Biomarkers vs age. Scatter plots of each biomarker versus age among all MCSA CN individuals with box plots of the cognitively impaired group shown for reference. The horizontal lines indicate cut-points chosen from the five methods. The colors used were as follows: reliable worsening (RW), blue (only in panel A); specificity (Spec.), green; sensitivity (Sens.), red; accuracy of cognitively impaired versus young CN (Acc-Young), orange; accuracy of cognitively impaired versus matched CN (Acc-Matched), purple. Using each of these five cut-point methods, we then label individuals as normal or abnormal and show the percent abnormal as estimated from logistic regression models. For amyloid PET (panel A), values are shown in both SUVR and centiloid units. Panel B tau PET; panel C FDG PET; panel D MRI.

Keywords: Amyloid PET, tau PET, MRI, Alzheimer's biomarkers, Alzheimer's imaging

Koeppe, Robert

Further Adventures in the World of Centiloids

Robert A. Koeppe¹, Julie C. Price², Centiloid Working Group

¹University of Michigan, Ann Arbor, MI ²Harvard University, Cambridge, MA with Contributions from Eli Lilly/Avid, GE Healthcare, Navidea Biopharmaceuticals, and Piramal Imaging

The original Centiloid project provided a standardized method for scaling PiB data onto a 100-point scale, with "0" being the amyloid load for an "average" young control and "100" being the load for a "typical" AD patient. The original work had primary aims of providing a method for conversion of other "non-standard" methods of analysis (e.g. dynamic instead of static) or other amyloid tracers (e.g. the commonly used [¹⁸F]-labeled radiopharmaceuticals) to the same 0-100 Centiloid scale.

This talk will be divided into two sections:

- 1) the conversion of [¹⁸F]-labeled radiotracers into Centiloids, and
- 2) further investigation into potential sources of variability and error in the original Centiloid method.

<u>Conversion of [¹⁸F]-radiotracers</u>: The key step in the conversion of [¹⁸F]-tracers to the Centiloid scale is to acquire paired PET studies using both [¹¹C]-PiB and an [¹⁸F]-compound in group of subjects including both amyloid negative and amyloid positive individuals. The standard Centiloid target VOI and reference regions are then applied to both scans to calculated pairs of SUVr measures for each individual. The regression coefficients of the relationship between the F-18 measures and the C-11 PiB measures provide the conversion of F-18 SUVr values to "PiB-equivalent" SUVr values, and hence the subsequent conversion of F-18 SUVr to Centiloids. Regression equations from studies perform by each of the companies will be presented, with emphasis on the slope of the regression line between the F-18 tracer and PiB (as a measure of signal), and the standard deviation of the amyloid-negative controls (as a measure of noise).

<u>Centiloid 2.0</u>: The second portion of this talk will be a brief introduction to a soon to be submitted grant to the Alzheimer's Association titled "Further Validation of Centiloid Scaling for Amyloid PET Standardization: Centiloid 2.0." The original Centiloid project did not examine the impact of different scanner platforms or of the wide anatomical variation across young to elderly and diseased brains on the original Centiloid scaling process. The two primary specific aims of the grant will be to 1) evaluate the impact of PET scanner model differences on the scaling process by scanning subjects (both control, MCI and AD) on multiple scanner models and 2) identify an advanced image normalization/VOI sampling method for the scaling process that minimizes that problems associated with varying brain anatomy in aging and disease.

Friday, January 13, 2017 - 08:00 am - 08:45 am

SESSION 7: Amyloid and Tau PET in Clinical Trials

SESSION 7 Amyloid and Tau PET in Clinical Trials	CHAIRS: Bill Jagust University of California, Berkeley Susan Resnick National Institutes of Health
The A4 Study: Preliminary Analyses of Baseline Tau PET Imaging	Reisa Sperling Harvard Medical School
Conversion of aMCI subjects to AD in relation to [18F]flutemetamol Amyloid status, and hippocampal volume in a phase III longitudinal study	David Wolk Perelman School of Medicine at the University of Pennsylvania
Baseline 18F Flortaucipir SUVR, but not amyloid or cognition, predicts cognitive decline over 18 months in Phase 2 trial subjects	Michael Devous, Sr. Avid Radiopharmaceuticals
PET amyloid and tau imaging in a Phase 3 study of solanezumab	Mark Mintun Avid Radiopharmaceuticals
Discussion	·

The A4 Study: Preliminary Analyses of Baseline Tau PET Imaging

<u>Reisa Sperling</u>^{1,2}, Aaron Schultz², Dorene Rentz¹, Elizabeth Mormino², Eric Siemers³, Roy Yaari³, Sergey Schcherbinin³, Adam Schwarz³, Michael Devous⁴, Mark Mintun⁴, Michael Donohue⁵, Paul Aisen⁵, Keith Johnson²

¹Brigham and Women's Hospital, Boston, MA, USA
²Massachusetts General Hospital, Boston, MA, USA
³Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indianapolis, IN, USA
⁴Avid Radiopharmaceuticals, Philadelphia, PA, USA
⁵Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA, USA

Background: The advent of Tau PET imaging allows the *in vivo* detection and tracking of paired helical filament tau pathology, which may prove to be a particularly relevant outcome in secondary prevention trials in preclinical Alzheimer's disease (AD). The Anti-Amyloid Treatment in Asymptomatic AD (A4) Study is a Phase 3 trial of solanezumab vs. placebo in clinically normal older individuals with evidence of elevated amyloid accumulation on screening Florbetapir (FBP) imaging.

Methods: Tau PET imaging with 18F-Flortaucipir (FTP, aka AV1451/T807) is being acquired in a subset of participants at baseline, 18 and 36 months. FTP SUVr is evaluated in anatomically defined regions of interest (ROI) and with whole brain analyses, examining associations with FBP mean cortical SUVr and screening cognitive measures (Free and Cued Selective Reminding Test (FCSRT), Logical Memory Delayed Recall, Digit Symbol, and MMSE) with age, education, and gender covaried.

Results: FTP data (n=185; mean age=72.2 \pm 5.0; 99F/86M; MMSe=28.6 \pm 1.4) revealed a range of neocortical signal with 103/185 (56%) demonstrating SUVr >1.2 in inferior temporal regions. Significant positive associations between FBP and FTP were found in entorhinal, parahippocampal, fusiform, inferior and middle temporal, isthmus, and posterior cingulate ROI (partial r =.30 to.42; p<0.001).

Conclusion: Ongoing analyses suggest that regional Tau accumulation is significantly associated with cortical amyloid deposition and memory performance, even within the restricted ranges seen in the amyloid-positive clinically normal population eligible for A4. These preliminary findings suggest that we will be able to test the hypothesis whether decreasing amyloid accumulation can slow the spread of tau pathology and memory decline during preclinical AD.



Figure. Left: Whole brain map of 18F-Flortaucipir demonstrating the voxel-wise association with mean cortical 18F-Florbetapir SUVr, adjusted for age. <u>Right:</u> Regression plot of 18F-Flortaucipir (tau) vs. 18F-Florbetapir (amyloid) extracted from peak voxel in left inferior temporal region (partial r=.42; p<0.00001).

Keywords: Tau PET, Amyloid PET, prevention, clinical trials, memory

Conversion of aMCI subjects to AD in relation to [18F]flutemetamol Amyloid status, and hippocampal volume in a phase III longitudinal study.

Wolk David¹, Andrea Cherubini², Chris Buckley³, Michelle Zanette⁴, Paul Sherwin⁴

¹University of Pennsylvania, Philadelphia, PA, USA ²Institute of Molecular Bio-imaging and Physiology, Rome, Italy ³GE Healthcare, Amersham, United Kingdom ⁴GE Healthcare, Marlborough, MA, USA

Introduction: GE Healthcare conducted a study in which 232 patients with amnestic mild cognitive impairment (aMCI) underwent baseline MRI and amyloid PET imaging with flutemetamol to determine time to conversion to dementia in relation to baseline amyloid status. Conversion was determined by an independent committee, which reviewed the results of 6-monthly neuro-psychiatric testing for up to 36 months. While amyloid positivity was a significant and independent predictor of conversion, in a post-hoc analysis we also determined the association of hippocampal atrophy with conversion with the ultimate-aim of combining biomarkers to improve conversion prediction.

Methods: Baseline 3D T1 MRI scans from the study cohort were analysed quantitatively for hippocampal volume (hvol) estimation¹ in a post-hoc analysis. ANOVA was used to compare hvol by conversion to dementia status and amyloid status by flutemetamol image as positive/negative for amyloid by majority visual-read by five independent readers. The derived hvols were considered high if greater than-or-equal to 4.5cm³ and low if below this value².

Results: Among amyloid-*negative* patients, converters had a significantly lower hvol (p<0.0001) than non-converters. For amyloid-*positive* patients, converters had a significantly lower hvol than non-converters (p=0.014).

Using PET images alone, the hazard ratio for conversion over 3y for amyloid positive subjects compared to amyloid negative subjects was 2.5:1. However, when the PET & MRI biomarkers were combined, the Hazard ratio for subjects who were amyloid positive and of low hvol compared to those who were amyloid negative and high hvol was 5.6:1, see figure 1. These results stratify the risk and rate of progression from aMCI to pAD over three years using baseline assessments of flutemetamol PET and MRI scans and demonstrate the utility of combining A β PET and MRI biomarkers.

References:

1. Coupé et al., NeuroImage, 54 (2011), 940–954



Kaplan-Meier survival plot of aMCI -> pAD conversion for majority flutemetamol visual read of amyloid PET status and threshold (4.5cc) hippocampal volume (n=222).

Keywords: aMCI, hipocampal volume, risk, conversion

Baseline 18F Flortaucipir SUVR, but not amyloid or cognition, predicts cognitive decline over 18 months in Phase 2 trial subjects

<u>Michael D. Devous, Sr.¹</u>, Navitsky Michael¹, Andrew Siderowf¹, Ian Kennedy¹, Abhinay D. Joshi¹, Sudeepti Southekal¹, Ming Lu¹, Michael J. Pontecorvo¹, Mark A. Mintun¹

¹Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA

Background: Literature suggests that neuropathologic tau correlates with cognitive impairment. It is unknown whether tau distributions relate to the evolution of cognitive deterioration. We examined relationships between Flortaucipir uptake and changes in cognition or function over time.

Methods: Flortaucipir scans (acquired 80-100 min post 370 MBq injection) were obtained in amyloidpositive healthy (n=5), MCI (n=47) or AD (n=30) subjects. VOI SUVr values were obtained from 1) a VOI determined by discriminant analysis to distinguish diagnostic groups (MUBADA) and 2) VOIs defined at baseline by the correlation between tau and domain-specific cognitive tests (correlation maps). SUVR values were normalized to a parametrically-derived white matter reference region. Assessments included MMSE, ADAS-Cog, a neuropsychological battery and the Functional Activities Questionnaire (FAQ). Correlations were used to compare baseline Flortaucipir SUVr, amyloid SUVR (Florbetapir) or cognitive scores to changes in cognition after 18 months.

Results: Strong correlations at baseline were seen between both Flortaucipir and Florbetapir SUVr relative to MMSE, ADAS-Cog and FAQ (Table 1). Baseline Flortaucipir MUBADA SUVr was also correlated with all 18-month cognitive and functional change measurements (ADAS p=0.047, MMSE p=0.0007, FAQ p=.0006; Table 1). However, amyloid SUVR was not correlated with 18 month changes in cognition or function, nor were baseline cognitive or functional measures correlated with changes with their respective measure. Heat map analysis (Table 2) demonstrated that for most cognitive domains, MUBADA SUVR was at least as effective as the cognitive-correlation-derived VOIs at predicting 18 month changes.

Conclusions: Baseline tau was strongly correlated with 18 month change in MMSE, ADAS-Cog and FAQ. However, neither baseline amyloid, cognitive nor functional scores related to changes at 18 months. These data suggest that tau is relevant to the evolution of cognitive and functional decline in ways not evident for either amyloid or the cognitive/functional measures themselves in MCI and AD patients.
Table 1: Relationships between tau and cognition. Baseline correlations are modeled to adjust for effects of age. 18 month change data models include both age and baseline cognition.

SUVr	ADAS	MMSE	FAQ
	(n=82)	(n=82)	(n=77)
Tau MUBADA	0.52	-0.46	0.35
	<.0001	<.0001	0.0023
Tau Precuneus	0.52	-0.44	0.30
	<.0001	0.0001	0.0088
Amyloid	0.46	-0.41	0.26
(Florbetapir)	<.0001	0.0002	0.0245

Baseline tau or amyloid vs baseline cognition or function

Baseline tau, amyloid, cognition or function vs 18 mo. Δ cognition or function

Baseline SUVr	ADAS Change	MMSE Change	FAQ Change
	(n=49)	(n=53)	(n=52)
Tau MUBADA	0.28	-0.46	0.48
	0.0468	0.0007	0.0006
Tau Precuneus	0.21	-0.41	0.46
	0.1529	0.0032	0.0009
Amyloid	0.09	-0.08	-0.03
(Florbetapir)	0.5391	0.5870	0.8301
Baseline ADAS, MMSE	0.22	-0.04	0.02
or FAQ scores	0.1623	0.22	0.8915

Table 2. Relative predictive strength of baseline tau for either the MUBADA VOI or for the cognitionspecific VOIs relative to 18-month change in cognition. Correlation coefficients derived from Pearson's R. Cog VOI = VOI derived from tau / cognitive test correlation maps. Red = $r \ge 0.3$; yellow = $0.2 \ge r < 0.3$; green = r < 0.2.

R	ADAS	Clock Draw	Construct praxis	DSST	Delayed Recall	Digit Span	Ideational Praxis	Immed Recall	MMSE	Orientatn	Remembr Instructns	Trails A	Trails B	Word Recall	Word Recog
MUBADA	0.30	-0.20	0.28	-0.43	-0.33	-0.20	0.29	-0.22	-0.50	0.21	0.41	0.17	0.31	0.17	-0.07
COG VOI	0.34	-0.21	0.13	-0.38	-0.26	-0.18	0.22	-0.18	-0.50	0.13	0.26	0.13	0.30	0.15	-0.05

Keywords: tau imaging, cognitive decline, progression, Amyloid, flortaucipir

PET amyloid and tau imaging in a Phase 3 study of solanezumab

<u>Mark A Mintun</u>¹, Michael D Devous, Sr.¹, Ming Lu¹, Michael J Pontecorvo¹, Abhinay D Joshi¹, Sudeepti Southekal¹, Andrew Siderowf¹, Mark J Lowrey¹, Marybeth Devine¹, Tyler E Benedum¹, Caitlin Pearson¹, Nathaniel C Lim¹, Adam S Fleisher², Karen L Sundell², Eric R Siemers²

¹Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA ²Eli Lilly and Company, Indianapolis, IN, USA

Background: EXPEDITION3 is a placebo-controlled Phase 3 study assessing the effect of solanezumab, an IgG1 humanized monoclonal antibody that binds soluble amyloid-beta (A β) peptides, on cognitive decline over 80 weeks in patients with mild Alzheimer's disease (AD). A subset of subjects underwent amyloid PET imaging with -florbetapir (N=1839), and a subset of those also underwent tau PET imaging with -flortaucipir (N=206).

Methods: Amyloid PET scanning (20 min scans at 50 min post injection of 10 mCi -florbetapir) was done at screening and at week 80. SUVr values are calculated from standard atlas-based cortical and whole cerebellar regions. Longitudinal measures are normalized by a subject-specific MRI-derived white matter region to reduce variability in longitudinal amyloid PET estimate.

Tau PET scanning (30 min scans, 75 min post injection of 6.5 mCi 18F-flortaucipir) was done at baseline, week 40 and week 80. Flortaucipir SUVr will be calculated using a large atlas-based cortical region normalized by a parametrically derived subject-specific white matter reference region.

Solanezumab treatment effects on florbetapir amyloid and flortaucipir tau PET imaging will be evaluated with analysis of co-variance (ANCOVA) and mixed effects model repeat measurement (MMRM), respectively.

Results: Power was estimated from exploratory analyses of previous Phase 3 solanezumab amyloid PET studies and was calculated to be >90% for detection of a reduction in amyloid load as small as 2% from baseline in the treatment arm, assuming the placebo arm had no change. Based on data from a longitudinal flortaucipir Phase 2 study (Figure 1), the power for detecting the slowing of accumulation of tau deposits ranged from 28% to over 80% depending on the magnitude of the treatment effect and number of subjects completing the substudy (Table 1).

Conclusions: Imaging biomarkers are poised to play an increasing role in understanding the effect of therapeutic drugs on underlying AD pathology. Methodologies designed for assessing these results will be discussed.

Figure 1: PET Tau signal measured by [18F]-flortaucipir by age in subjects enrolled in a Phase 2 trial. Data points are from subjects completing flortaucipir PET scans at baseline, 9 month and 18 month visits. Not all subjects were able to complete all visits. The SUVr on the y-axis was calculated using an atlas-based large cortical region (created with a diagnostic group discriminant analysis and labeled MUBADA) normalized by a parametrically derived subject-specific white matter reference region. The red data is for subjects with positive amyloid PET scans at baseline and the blue data are subjects with negative amyloid PET scans. In amyloid positive subjects the change in flortaucipir SUVr at the 18 month visit compared to baseline was $+0.051 \pm 0.0053$ (LS Mean \pm SE) and was statistically significant (p<0.0001).



Table 1. Statistical Power to Detect the Possible Treatment Effect of Slowing of Tau Accumulation given Different Sample Sizes

	% Slowing in Tau Accumulation from Treatment				
Total Number of Completers	20% slowing	30% slowing	40% slowing		
100	28%	53%	78%		
150	39%	71%	92%		
200	49%	83%	97%		

*Each cell displays the statistical power to detect the treatment effect with specified sample size. For example, 100 completers in total will have 78% power to detect a treatment effect of 40% slowing, between treatment and placebo groups.

Keywords: solanezumab, mild dementia, the rapeutic trial, amyloid, tau

Poster Session 3A

Niemantsverdriet, Ellis - 40

Concordance improves between amyloid-PET and CSF amyloid- β for diagnosing Alzheimer's disease in a clinical setting by applying A β 1-42/A β 1-40 ratio

<u>Ellis Niemantsverdriet</u>¹, Julie Ottoy², Jeroen Verhaeghe², Charisse Somers¹, Ellen De Roeck¹, Hanne Struyfs¹, Femke Soetewey¹, Maria Bjerke¹, Tobi Van den Bossche^{3,4}, Sara Van Mossevelde^{3,4}, Johan Goeman⁴, Peter Paul De Deyn⁴, Peter Mariën^{4,5}, Jan Versijpt⁶, Paul Parizel⁷, Kristel Sleegers³, Christine Van Broeckhoven³, Leonie wyffels^{2,8}, Adrien Albert⁸, Sarah Ceyssens⁸, Sigrid Stroobants^{2,8}, Steven Staelens², Sebastiaan Engelborghs^{1,4}

 ¹Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, UAntwerp, Antwerp, Belgium
 ²Molecular Imaging Center Antwerp (MICA), UAntwerp, Antwerp, Belgium
 ³Department of Molecular Genetics, VIB, Antwerp, Belgium
 ⁴Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium
 ⁵Clinical and Experimental Neurolinguistics, CLIN, Vrije Universiteit Brussel, Brussels, Belgium
 ⁶Department of Neurology, University Hospital Brussels, Brussels, Belgium
 ⁷Department of Radiology, Antwerp University Hospital, Antwerp, Belgium
 ⁸Department of Nuclear Medicine, Antwerp University Hospital, Antwerp, Belgium

Background: In order to investigate the concordance between different biomarkers for Alzheimer's disease (AD) in a clinical setting, we set up a prospective longitudinal study. Evidence suggests that the concordance between amyloid PET and cerebrospinal fluid (CSF) A β increases when the CSF A $\beta_{1-42}/A\beta_{1-40}$ ratio is used as compared to CSF A β_{1-42} levels alone. The present study tests this hypothesis.

Methods: Sixty-seven subjects (dementia (n=15), MCI (n=39), and cognitively healthy controls (n=13)) underwent a -AV45 (Florbetapir) PET scan, -FDG PET scan, MRI scan, and an extensive neuropsychological examination. In a subset (n=57), a lumbar puncture was performed and AD cerebrospinal fluid (CSF) biomarkers were analyzed (A β_{1-42} , A β_{1-40} , T-tau, P-tau₁₈₁).

Results: We detected an increased concordance in the visual, both SUVR (cerebellum (CB) or total brain white matter (WM) as reference regions), and V_t AV45 PET values when $A\beta_{1-42}/A\beta_{1-40}$ was applied. In here, no difference was found between both cortical mean SUVR values by applying the ratio. CSF biomarkers were stronger associated to AV45 PET scans with total brain WM as reference region compared to SUVR_{CB}.

Conclusions: The concordance between CSF A β and AV45 PET increases when the CSF A β_{1-42} /A β_{1-40} ratio is applied. This finding is of most importance for the biomarker-based diagnosis of AD as well as for selection of subjects for clinical trials with potential disease-modifying therapies for AD. *Keywords: Florbetapir, dynamic [18F]-AV45 PET-scan, magnetic resonance image (MRI), cerebrospinal fluid (CSF), A\beta1-42/A\beta1-40 ratio*

Regional visual read inspection of [18F]Flutemetamol brain images from end-of-life and amnestic MCI Subjects

<u>Gill Farrar</u>¹, Michelle Zanette²

¹GE Healthcare, Amersham, United Kingdom ²GE Healthcare, Marlborough, MA, USA

Introduction: Visual interpretation of flutemetamol images relies upon review of 5 brain regions (frontal, parietal, posterior cingulate & precuneus, striatum and lateral temporal lobes). In an 'amyloid-positive' brain an elevated signal is observed in at least one region. Two different populations (end-of-life and amnestic MCI) were examined to investigate the pattern of regional read positivity in the two cohorts.

Methods: 180 EoL (mean age 81; range 59 to 95) and 232 amnestic MCI subects (mean age 71; range 53 to 91) were scanned following 185-370 MBq of intravenous flutemetamol. Images from both studies were read by two groups of 5 blinded readers who independently classified as positive or negative in each of the 5 brain regions. The majority interpretation (by at least 3 of the 5 readers) was used as the imaging endpoint.

Results: 71 positive images from the EoL study (from 106 coming to autopsy) and 97 positive images in the aMCI cohort were included in the assessment. In the EoL study widespread deposition of amyloid was observed with 76% of images positive in all 5 regions and a further 20% positive in 4 regions. In the aMCI group similar results were observed with 87% positive in 5 regions and a further 5% positive in 4 regions. In both groups, there was only a minority of cases where read positivity was observed in only 3, 2, or 1 region.

Conclusion: aMCI is one of the main patient groups assessed in clinical practice. Currently the methods for assigning a brain positive or negative for amyloid are via visual reading only. Even in this early phase of dementia the deposition of amyloid is widespread in terms of amount and topographical progression. Attempts to observe potential initial signs of amyloid deposition would have to focus on earlier populations in the dementia spectrum such as subjective cognitive decline or even earlier at risk subjects. *Keywords:* [18F]flutemetamol, visual inspection, regional reads, amnestic MCI, end-of-life

Tau mediates temporal lobe structure-function relationships and disrupts memory encoding in normal aging

<u>Shawn Marks</u>¹, Samuel Lockhart¹, Taylor Mellinger¹, Kaitlin Swinnerton¹, Andy Horng¹, Suzanne Baker², William Jagust^{1,2}

¹*Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, USA* ²*Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA*

Hippocampal hyperactivity has been associated with memory impairment in both cognitively normal older adults and mild cognitive impairment. Alzheimer's pathology preferentially targets structures within the hippocampal memory network, and β -amyloid has been linked to aberrant brain activity. The role of tau in network dysfunction remains unclear. This study sought to investigate the impact of both β -amyloid and tau on the hippocampus and associated structures during episodic memory.

Forty-three cognitively normal older adults and 20 young controls participated in a functional MRI paradigm designed to emphasize lure discrimination. Participants were shown color photographs of novel, repeated, and similar (i.e. lure) objects, and told to identify them as such. A subset of elderly participants underwent PIB and AV-1451 PET scans.

Older adults performed worse on the memory task, incorrectly identifying lure stimuli as repetitions more frequently than young controls. Individual patterns of activation were identified for three trial types during memory encoding: hits (repetitions correctly identified as "old"), correct rejections (lures correctly identified as "similar"), and false alarms (lures incorrectly identified as "old"). β -amyloid was positively associated with hit deactivations, such that older adults who deactivated less had more pathology; whereas, tau was positively associated with false alarm activations. Hit deactivations and false alarm activations were combined into a composite pathological activation measure to describe memory network dysfunction. Pathological activation was negatively associated with overall task performance. Atrophy of the hippocampus and entorhinal cortex was also associated with pathological activation. Furthermore, the presence of tau, specifically in the hippocampus and entorhinal cortex, mediated the relationship between pathological activation and entorhinal cortical thickness.

These results suggest that the co-occurrence of β -amyloid and tau play a critical role in the development of age-related memory decline, particularly by leading to aberrant activity throughout the hippocampal memory network and to atrophy of crucial brain structures. *Keywords: Episodic Memory, Amyloid, Tau, fMRI*

AMYPAD: A European public-private partnership to investigate the value of β -amyloid brain scans as a diagnostic and therapeutic marker for Alzheimer's disease

Frederik Barkhof^{1,2}, <u>Gill Farrar</u>³

¹VuMC, Amsterdam, Netherlands ²University College London, London, United Kingdom ³GE Healthcare, Amersham, United Kingdom

Background: 'Amyloid imaging to prevent Alzheimer's disease' (AMYPAD) is a collaborative research initiative to improve the understanding, diagnosis and management of AD through the utilisation of β -amyloid PET imaging. The 5-year programme is part of the Innovative Medicines Initiative, a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA. AMYPAD will have close links with its sister program EPAD (European Prevention of Alzheimer's Disease).

Goals: AMYPAD has 3 major goals: 1) improve the diagnostic workup of people suspected to have AD and their management; 2) understand the natural history of AD in the pre-symptomatic stage; 3) select people for treatment trials aiming at preventing AD by ensuring a more homogeneous and appropriate enrollment. Through engagement with regulators and health technology agencies, AMYPAD aims to maximize the value of its findings for pharmaceutical companies, healthcare providers, and patients.

Methods: The above goals will be achieved via 2 large studies where amyloid scanning is the major component. Study one is a diagnostic and patient management study with 900 subjects recruited from memory clinics (300 subjective cognitive decline, 300 mild cognitive impairment and 300 possible Alzheimer's dementia).

Study two will be a natural history cohort with 3000+ subjects coming from feeder EPAD cohorts. In both cohorts repeat amyloid scanning will be performed in up to 50% of the cases to enable methodology to be developed for the longitudinal measurement of amyloid change. A total of 6000 scans will be performed split 50:50 between Neuraceq (Piramal Imaging) and Vizamyl (GE Healthcare).

Biomarker characterisation over the full dementia spectrum will support EPAD in developing clinical trial readiness cohorts to be fed into therapeutic intervention studies.

AMYPAD will also investigate areas of novel scientific interest such as the integration of MR-PET with ASL to improve quantification, integrated biomarker modelling, quantitative PET outcomes for treatment trials and diagnostic value in SCD.

Keywords: AMYPAD, amyloid PET imaging, diagnostic work-up, natural history cohorts, trial readiness

Amyloid positivity is associated with steeper declines in prospective verbal episodic memory independent of neurodegeneration in cognitively normal older adults

<u>Murat Bilgel</u>¹, Yang An¹, Gabriela Gomez¹, Jessica Helphrey¹, Wendy Elkins¹, Dean Wong², Susan Resnick¹

¹Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, MD, USA ²Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Introduction: It is important to understand the distinct contributions of amyloidosis and neurodegeneration to cognitive decline in preclinical Alzheimer's disease (pcAD).

Methods: We assessed the effects of amyloid positivity as measured by Pittsburgh compound B positron emission tomography (PiB-PET) and hippocampal volume adjusted for intracranial volume (HVa) on prospective cognitive performance among 128 Baltimore Longitudinal Study of Aging (BLSA) participants (mean baseline age 76.2, SD 7.8) using data from 424 cognitively normal visits spanning 3.5 years on average. For each cognitive test, we conducted a linear mixed effects analysis whose predictors included baseline age, PiB group, HVa as well as their interactions with time, and covariates included sex, race, and cognitive reserve (computed using years of education and Wide Range Achievement Test). We also investigated the relationship between PiB positivity and prospective HVa.

Results: Baseline PiB positivity and lower HVa were independently associated with steeper longitudinal declines in verbal episodic memory and learning as measured by the California Verbal Learning Test (CVLT) sum of 5 learning trials (p=0.0004 for PiB, p=0.011 for HVa) and long-delayed free recall (p=0.017 for PiB, p=0.012 for HVa). Lower baseline HVa was also associated with steeper decline on CVLT short-delayed free recall (p=0.048). There were no associations with tests of executive function, processing speed, visual ability, or mental state. There were no differences in baseline HVa or its rate of change between the PiB groups.

Discussion: Episodic memory has consistently been shown to be the earliest cognitive domain impaired in pcAD. Given that amyloidosis and neurodegeneration are hypothesized to occur early in pcAD, our finding that amyloid positivity and lower HVa are associated with steeper declines on CVLT but not on other cognitive tests is consistent with current preclinical models. Our results suggest that amyloidosis is associated with memory decline independent of neurodegeneration.



Average longitudinal cognitive trajectories as a function of age. Solid and dotted lines indicate baseline HVa one standard deviation above and below the mean, respectively. Blue and orange lines indicate PiB- and PiB+ groups, respectively. *y*-axis limits correspond to the extrema in the analyzed sample. CVLT = California Verbal Learning Test, HVa = Hippocampal volume adjusted for intracranial volume.

Keywords: PiB, cognition, hippocampus, memory

Tau burden localized in functional brain networks is associated with cognitive performance in beta amyloid positive subjects across the Alzheimer's spectrum

<u>Arnaud Charil</u>¹, Sergey Shcherbinin¹, Sudeepti Southekal², Abhinay D Joshi², Michael D Devous², Bradley B Miller¹, Adam J Schwarz¹

¹Eli Lilly and Company, Indianapolis, IN, USA ²Avid radiopharmaceuticals, Philadelphia, PA, USA

Objectives: Cognitive functions are subserved by networks of connected regions. We sought to determine whether overall tau levels within a set of predefined functional networks (FNs) predicted cognitive performance in beta amyloid positive subjects across the Alzheimer's spectrum.

Methods: Flortaucipir F18 PET (-AV-1451) images were acquired from 85 amyloid-positive subjects, and converted into SUVR units using a cerebellar crus reference region. Mean SUVR values were extracted from ROIs within 12 functional networks (FNs) independently defined based on rsfMRI (http://findlab.stanford.edu/functional_ROIs.html). Subjects underwent a battery of cognitive tests. Linear models were built to predict cognitive performance based on 1) regional (FN) SUVRs and 2) weighted whole-brain (MUBADA) SUVR as a comparator. For 1) we performed backward stepwise model selection to identify the set of FNs that best predicted variance in any given cognitive test. R² values were adjusted for number of predictors.

Results: The sample included 3 cognitively normal controls, 53 MCI and 29 AD subjects. Overall, more variance in cognitive scores was explained by a combination of FN predictors $(0.07 < R^2 < 0.40)$ than weighted global SUVR $(0.03 < R^2 < 0.28)$. The FN model yielded increased R^2 over weighted global SUVR in 15/17 cognitive tests, with increases of >0.1 for 8 tests (Figure). The visuospatial, ventral default mode and executive control networks were most often found to be the strongest predictors. Different tests were associated with different network tau profiles. When the weighted global SUVR was included in the same model alongside the FNs, it was retained as a significant predictor for 4/17 tests, and in all 17 the full model increased the adjusted R^2 .

Conclusion: Compared to a weighted whole-brain flortaucipir SUVR measure, linear combinations of mean SUVRs from individual FNs increased the percent variance explained for different cognitive tests. Future work will examine the validity of these models in independent patient samples.



Figure: (Left) combination of functional networks whose tau burden was identified as significantly associated with the cognitive scores for each test; (right) results for the MUBADA SUVR model. Red squares represent a significant association with the cognitive test scores. [Abbreviations: JOLO = judgment of line orientation; DSST = digit symbol substitution test; SMN = sensorimotor network; Aud = auditory network; pVis = primary visual network; hVis = higher visual network; aSal = anterior salience network; Lang = language network; LECN = left executive control network; RECN = right executive control network; preQ = precuneus network; dDMN = dorsal default mode network; vDMN = ventral default mode network; vSpat = visuospatial network.]

Keywords: Flortaucipir, Tau, Functional Networks, Cognition, Alzheimer's Disease

Tian, Qu - 52

Gait variability, an indicator of subclinical amyloid burden

Qu Tian¹, Woei-Nan Bair¹, Murat Bilgel¹, Dean Wong², Susan Resnick¹, Stephanie Studenski¹

¹National Institute on Aging, Baltimore, MD, USA ²Johns Hopkins Medical Institutions, Baltimore, MD, USA

Introduction: Mobility decline precedes cognitive impairment and dementia. Recent amyloid imaging evidence suggests that higher amyloid burden predicts future decline in mobility in older adults but is not associated with concurrent mobility deficits. Increased gait variability, which may precede gait slowing, may be more sensitive to increased concurrent amyloid burden.

Methods: In the Baltimore Longitudinal Study of Aging, 75 older participants without mild cognitive impairment, Alzheimer's disease, Parkinson's disease or stroke had concurrent data on amyloid imaging and gait lab characteristics (mean age=78.2yr). β -amyloid burden was measured using ¹¹C-Pittsburgh compound B (PiB) dynamic positron emission tomography. PiB+/- status was based on a previously defined mean cortical distribution volume ratio cutoff. Mean and variability (CoV=SD/mean) in gait by 3D motion analysis was determined for four domains (pace, rhythm, variability and postural control). Cross-sectional associations between PiB status and each gait characteristic were examined using linear regression models, adjusted for age, sex, body mass index, height, gait speed, and covariates related to mobility one at a time (memory, executive function, psychomotor speed, depressive symptoms, cardiovascular risk, peripheral arterial disease, ApoE ϵ 4 status, cerebrovascular disease, knee pain).

Results: Compared to PiB-, PiB+ had higher gait speed variability and higher gait cycle time variability, independent of demographics, gait speed, and other covariates (all p<0.05). There were no significant associations with other gait variability measures (all p>0.05). Mean gait performance did not differ by PiB status, although there was a trend toward slower gait speed in PiB+ vs. PiB- (p=0.075).

Conclusion: This is the first evidence suggesting that in usual aging, gait speed variability and gait cycle time variability, but not mean performance, is related to amyloid positivity cross-sectionally. Increased gait variability may be a subclinical indicator of amyloid positivity. *Keywords: gait variability, subclinical amyloid burden, usual aging*

Does the tau signal increase over time differ across brain regions and stage of impairment in Alzheimer's disease?

<u>Sergey Shcherbinin</u>¹, Mark Mintun², Claire Brittain³, Ming Lu², Abhinay Joshi², Sudeepti Southekal², Michael Devous², Adam Schwarz¹

¹Eli Lilly & Co, Indianapolis, IN, USA ²Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA ³Eli Lilly & Co, Windlesham, United Kingdom

Objectives: We sought to examine longitudinal changes of regional tau accumulation over time using ¹⁸F-Flortaucipir PET imaging in MCI and AD subjects.

Methods: Longitudinal ¹⁸F-Flortaucipir tau images were compared to baseline images in amyloid positive MCI (N=28) and AD (N=17) subjects. SUVR values were calculated in four pre-defined atlas-based bilateral cortical (lateral temporal, occipital, frontal, and parietal) regions normalized to a white matter-based reference region (PERSI). A global weighted SUVR was calculated to approximate total tau signal for the whole cortex.

Results: At baseline, regional and global SUVR for the AD group were nominally (7-15% across regional mean values) and non-significantly larger than those for the MCI group. The largest mean signal was seen in the lateral temporal region (SUVR= 1.33 ± 0.33 for AD and 1.19 ± 0.30 for MCI) while the frontal signal was the lowest (SUVR= 1.04 ± 0.26 for AD and 0.97 ± 0.31 for MCI). Over 18 months, the AD group demonstrated higher increases in tau signal (in all regions and whole cortex) and the increase was more heterogeneous across regions than the MCI group. Compared with MCI, the AD group exhibited a significantly larger increase in frontal (Δ SUVR= 0.06 ± 0.05 for AD and 0.03 ± 0.04 for MCI, p<0.05) and parietal (Δ SUVR= 0.07 ± 0.06 for AD and 0.03 ± 0.05 for MCI, p<0.03 lobes. The strength of the signal change measured in the AD group using a mean/SD ratio of Δ SUVR (SNR) in the frontal (SNR=1.30) and parietal (SNR=1.25) lobes exceeded those pertaining to global (SNR=1.13), occipital (SNR=1.10) and temporal (SNR=0.97) Δ SUVR.

Conclusions: We observed an accelerated and less spatially uniform tau accumulation as cognitive impairment advances. In the AD group, signal in frontal and parietal regions increased more strongly than in temporal lobe and whole cortex and this frontal-parietal signal change was significantly larger than in the MCI group. Further investigation to support this preliminary analysis and to understand the possible relationship to the symptom progression is warranted.

Keywords: tau, longitudinal, accumulation, flortaucipir, heterogeneity

MRI-based amyloid imaging in Alzheimer's disease on clinical scanner

Dmitriy Yablonskiy, Yue Zhao, Tammie Benzinger, Anne Fagan, Jason Hassenstab, Nigel Cairns, Jie Wen, Andrei Vlassenko, Serguei Astafiev, Marcus Raichle, John Morris

¹Washington University in St. Louis, St. Louis, MO, USA

Rational: While the primary role of the $A\beta$ peptide in the development of Alzheimer's disease (AD) is now almost universally accepted, only PET-based measurements currently allow *in vivo* quantitative estimate of human brain amyloidosis. The aim of this presentation is to report preliminary validation of the MRI-based Gradient Echo Plural Contrast Imaging (GEPCI) technique as an efficient and non-invasive tool providing surrogate measure of $A\beta$ accumulation in the brain.

Methods: 19 human participants with various level of cognitive decline (from normal, to preclinical, to mild AD) selected from ongoing studies of aging and dementia at the Knight ADRC at Washington University underwent GEPCI (Siemens 3T MRI) and PET PiB A β (Siemens PET) measurements.

Results: The correlation analysis between GEPCI measurements of $R2^*$ relaxation rate constant and amyloid PET measurements (using PiB standardized uptake value ratio) revealed positive correlations in most cortical brain regions (Figure). The data show significant correlations not only in the areas of high amyloid accumulation (e.g. precuneus) but also in the areas of MTL. Remarkably, the strongest and most significant correlation exists in the parahippocampal cortex – the area of low amyloid accumulation in early AD stages. This shows the high sensitivity of GEPCI $R2^*$ to A β accumulation in this very important area of pathological changes in early AD particularly as it relates to the formation of amyloid plaques in the cerebral cortex.

Conclusion: For the first time we demonstrate that in vivo MRI-based measurements obtained on a clinical MRI scanner can provide information on brain $A\beta$ accumulation in human participants. Since MRI is a widely available technology, the GEPCI technique has great potential for widespread use in differential diagnosis, tracking early pathological brain changes and the evaluation of new disease-modifying therapies.



Figure. Correlations in several brain regions and on brain surface. Shaded areas are 95% confidence intervals. *Keywords: Alzheimer disease, Amyloid, MRI, GEPCI*

Years to parental symptom onset predicts amyloid burden, neurodegeneration and resting state connectivity changes in healthy elderly with a parental history of Alzheimer's disease

<u>Sylvia Villeneuve</u>^{1,3,4}, Jacob W. Vogel^{3,4}, Julie Gonneaud^{1,4}, Judes Poirier^{1,4}, Pedro Rosa-Neto⁵, Anne M. Fagan^{1,2,4}, Randall Bateman⁵, John Morris⁷, Alexa Pichet Binnette^{1,3,4}, Etienne Vachon-Presseau¹⁰, Tammie L. Benzinger^{6,7}, Sterling Johnson^{9,10}, John C. Breitner^{1,3}, for the PREVENT-AD Research Group .³

 ¹Department of Psychiatry, McGill University, Montreal, QC, Canada
 ²Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada
 ³Douglas Mental Health University Institute, Centre for Studies on Prevention of Alzheimer's Disease, Montreal, QC, Canada
 ⁴McGill Centre for Integrative Neuroscience, McGill University, Montreal, QC, Canada
 ⁵Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
 ⁶Department of Radiology, Washington University School of Medicine, St Louis, MO, USA
 ⁷Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO, USA
 ⁸Northwestern University, Chicago, IL, USA
 ⁹Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA

Health, Madison, WI, USA

Background In dominant genetic forms of Alzheimer's disease (AD), biomarker changes follow a predictable course, with mutation carriers showing progressive biomarker change as their age approaches their family's typical age of onset. We assessed whether $A\beta$ burden, neurodegeneration and alterations in functional connectivity appeared in a similarly predictable fashion among cognitively normal persons with a parental history of "sporadic" AD.

Methods We estimated each individual's proximity to their parent's symptom onset by subtracting their index relative's onset age from their current age . We then assessed the relationship between proximity to parental onset and cerebrospinal fluid (CSF) $A\beta_{1-42}$ (n = 102), MRI grey matter density (n = 271) and resting state functional connectivity (n = 221) in the PREVENT-AD cohort, while testing for *APOE* and gender interactions. The A β analyses were repeated in two independent cohorts using CSF and PIB-PET A β biomarkers.

Findings In PREVENT-AD, CSF A β_{1-42} (Fig.1), grey matter density (Fig.2) and functional connectivity (Fig.3) showed increasing abnormality with greater proximity to parental onset. Interaction analyses showed that the trend for CSF A β_{1-42} , was stronger in both *APOE* e4 carriers and women. The A β findings were replicated in the Adult Children Study and in the Wisconsin Registry for Alzheimer's Prevention Study (Fig. 1).

Interpretation Proximity to parental symptom onset might be useful in clinical trials to track AD biomarker changes in asymptomatic individuals. As is the case in autosomal dominant AD, these results suggest that parental onset can help estimate individuals' years before onset of symptoms.



"Estimated Years from Symptom Onset" and amyloid burden in sporadic AD. pink=gender interactions; green=APOE interactions; * p<0.05; ** p<0.01.



Keywords: amyloid, neurodegeneration, resting state, sporadic AD, parental onset

Clinical significance of visually equivocal amyloid PET on ADNI cohort

<u>Minyoung Oh</u>¹, Minjung Seo², Sun Young Oh³, Jungsu S. Oh¹, Jee Hoon Roh⁴, Jae-Hong Lee⁴, Jae Seung Kim¹

¹Department of Nuclear Medicine, Asan Medical Center, Seoul, Korea ²Department of Nuclear Medicine, Ulsan University Hospital, Ulsan, Korea ³Department of Nuclear Medicine, National Police Hospital, Seoul, Korea ⁴Department of Neurology, Asan Medical Center, Seoul, Korea

Objective: We aimed to describe the clinical and imaging characteristics of subjects with visually equivocal amyloid PET images from the Alzheimer's Disease Neuro-imaging Initiative (ADNI), a prospective cohort study.

Methods: We choose subjects with florbetapir PET both at baseline and 24 month on ADNI cohort. Florbetapir PET images were visually assessed by three nuclear medicine physicians and classified as positive or negative. Images not reached consensus reclassified as equivocal. We compared the clinical and imaging characteristics according to their florbetapir PET results.

Results: Among 347 subjects, the numbers of negative/equivocal/positive florbetapir PET images were 207 (71.2 \pm 7.4y, M:F=110:97), 40 (73.4 \pm 6.6y, M:F=22:18), and, 100 (73.3 \pm 6.6y, M:F=54:46) for each. About 10% of subjects with normal cognition (CN, N=14/127), MCI (N=24/198), and AD (N=2/22) showed equivocal florebetapir PET for each. Among negative/equivocal/positive groups, CSF A β 1-42 were positive in 25%, 80% and 98% for each. Baseline SUVR of florbetapir PET were 1.04 \pm 0.09, 1.22 \pm 0.17, 1.45 \pm 0.16, for each (p<0.001). During 24 month of F/U, they increased 0.93 \pm 2.88 %, 2.75 \pm 3.25 %, 2.03 \pm 3.64 % for each (p<0.05). SUVR of FDG PET were 6.58 \pm 0.51, 6.34 \pm 0.64, and 5.50 \pm 0.64 for each (p<0.001 for positive group and others). They were decreased 1.22 \pm 4.01%, 2.75 \pm 6.72% and 4.65 \pm 5.71% for each (p<0.001). Hippocampal volume were 7430.2 \pm 1007.3, 7105.7 \pm 1081.1, and 6565.5 \pm 1081.9 for each (p<0.001 for positive group and others). They were decreased 2.78 \pm 3.89%, 5.60 \pm 5.80% and 7.21 \pm 5.14% for each (p<0.001). Immediate recall of Rey auditory verbal learning test scores were 42.39 \pm 11.72, 38.42 \pm 13.78, and 32.75 \pm 10.16 for each (p<0.05). They decreased -1.17 \pm 8.39, -0.90 \pm 7.50, and 2.69 \pm 7.35 (p<0.05). In the equivocal group, subjects with MCI (N=24/40) showed more rapid change of SUVR of florbetapir PET and hippocampal volume than CN (N=14/40).

Conclusion: About 10% of subjects showed visually equivocal result of amyloid PET. They represented moderate amyloid accumulation and intermediate neurodegeneration with relatively rapid aggravation. *Keywords: Florbetapir, amyloid PET, equivocal, ADNI*

Severity of lifetime trauma is related to hippocampal tau deposition in Vietnam war veterans with PTSD

<u>Susan Landau</u>¹, Andy Horng¹, Thomas Neylan², William Jagust¹, Jacqueline Hayes², Paul Aisen⁴, Ronald Petersen⁵, Dallas Veitch², Clifford Jack⁵, Charles DiCarli⁸, Andrew Saykin⁶, Jordan Grafman⁷, Duygu Tosun², Michael Weiner²

¹Univ of California, Berkeley, CA, USA
 ²Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA
 ³Univ of California, San Francisco, CA, USA
 ⁴Alzheimer's Therapeutic Research Institute, University of Southern California, Los Angeles, CA, USA
 ⁵Mayo Clinic, Rochester, MN, USA
 ⁶Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA
 ⁷nPsychiatry and Behavioral Sciences & Cognitive Neurology/Alzheimer's Disease Research Center, Northwestern University, Chicago, IL, USA
 ⁸kImaging of Dementia and Aging (IDeA) Laboratory, University of California, Davis, CA, USA

Objective: Posttraumatic stress disorder (PTSD) is associated with poor cognitive performance, structural and functional abnormalities in several regions including the hippocampus, and an increased risk of dementia late in life. Here we examined AV1451 PET and other neuroimaging biomarkers in Vietnam War Veterans with PTSD (and traumatic brain injury (TBI) in some cases) to determine the possible contribution of tau to PTSD symptoms.

Methods: Veterans with and without a history of PTSD (and/or TBI) participated in neuroimaging (florbetapir-PET, AV1451-PET, MRI) and clinical evaluations that were similar to ADNI. Partial volume corrected AV1451 means were calculated within a bilateral medial temporal region (entorhinal cortex, hippocampus) and neocortical regions relative to cerebellar cortex. Current and lifetime traumatic stress symptoms were assessed with the Clinician-Administered PTSD Scale (CAPS).

Results: In 24 individuals with AV1451 (4 control, 18 PTSD with/without TBI, 2 TBI), medial temporal AV1451 did not differ across subject groups (Figure 1). In 18 individuals with PTSD (14 cognitively normal, 4 MCI; all male, age=68.8+/-3.2yrs, edu=14.4+/-2.5yrs), lifetime (but not current) PTSD symptom severity correlated with medial temporal AV1451 retention (p=0.05; Figure 2) but not neocortical AV1451, while adjusting for age, education, and hippocampal volume. Finally, medial temporal AV1451 retention in PTSD subjects was not related to amyloid positivity, presence of TBI, degree of self-reported lifetime alcohol use, antidepressant use, depression, or memory function.

Conclusion: These preliminary findings show a relationship between medial temporal tau and PTSD severity, suggesting that chronic PTSD may increase vulnerability to tau accumulation in regions relevant to memory and emotional processing, which may underlie future risk of cognitive decline and/or dementia. Alternatively, medial temporal tau accumulation that is common in mid to late life may predispose individuals with stress exposure to manifest PTSD symptoms.

Figure 1.



Figure 2. Datapoints with no border indicate cognitively normal subjects, datapoints with a black border indicate MCI subjects.



Keywords: Tau, Hippocampus, PTSD

Relationships between tau and glucose metabolism differ by amyloid status in aging

Jenna Adams¹, Samuel Lockhart¹, William Jagust^{1,2}

¹Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, USA ²Lawrence Berkeley National Laboratory, Berkeley, CA, USA

Relationships between tau and glucose metabolism may offer insights into how neurodegeneration evolves. We performed tau PET imaging using AV-1451, and FDG- and PIB-PET in a sample of 50 cognitively normal older adults (PIB- n=28; PIB+ n=22). We extracted partial volume corrected SUVRs for AV1451 and FDG in 62 cortical ROIs defined in native space with FreeSurfer. We performed partial correlations controlling for age and sex across all ROI combinations to determine associations between tau and FDG in the PIB- and PIB+ groups separately. Results showed that compared to the PIB- group, the PIB+ group demonstrated negative correlations between tau and FDG in many cortical ROIs; the strongest included significant (p < 0.05) negative associations between tau in the entorhinal cortex and FDG in regions such as the is thmus cingulate (r=-0.51), precuneus (r=-0.55), and inferior parietal lobe (r=-0.51). Within MTL ROIs (bilateral entorhinal, hippocampus, parahippocampal gyrus), we found both significant positive and negative associations between tau and FDG which depended upon PIB status and differed by ROI. To examine these relationships, we used linear regression models predicting FDG, with tau, PIB classification (+/-), and the tau*PIB interaction as predictors. We found significant tau*PIB interactions (model p<0.05, interaction p < 0.01) in most MTL ROIs. These interactions were particularly interesting in the left hippocampus, where tau in multiple MTL regions was associated with increased hippocampal metabolism in PIB+ (with positive b values 0.24 to 0.51) but decreased hippocampal metabolism in PIB-. These results indicate that tau may have different effects in different parts of the brain, and that this relationship depends on A^β. In cortical regions, regardless of A β , tau is associated with reduced metabolism. In the hippocampus, tau in multiple MTL regions is associated with reduced hippocampal metabolism in the absence of A β , but with increased hippocampal metabolism in the presence of $A\beta$.

Keywords: tau, glucose metabolism, amyloid beta, older adults

Relationships between NREM-sleep fragmentation and changes in brain structure, metabolism, amyloid burden and cognitive performance in healthy older adults

<u>Géraldine Rauchs</u>¹, Claire Andre¹, Cléménce Tomadesso¹, Florence Mezenge¹, Pierre Branger², Morgane Fossey¹, Robin de Flores¹, Alice Laniepce¹, Francis Eustache¹, Gaël Chetelat

¹Inserm-EPHE-University of Caen Normandy, research unit U1077, GIP Cyceron, Caen, France ²Neurology Department, Caen University Hospital, Caen, France

Background: Sleep fragmentation (SF) increases with age, and is related to cognitive impairment and a heightened risk of dementia. The mechanisms underlying these associations are still unclear, but emerging evidence suggests that a disruption of non-rapid eye movement (NREM) sleep, prevailing during the first half of the night, could exacerbate amyloid deposition. Our objective was to investigate the relationships between NREM-SF, changes in brain structure, metabolism and amyloid deposition, and cognitive performance.

Methods: 30 healthy older adults (mean age \pm SD: 72.4 \pm 7 y) underwent a detailed neuropsychological assessment, a structural MRI, FDG and florbetapir-PET scans (n=25 for this latter) to assess grey matter (GM) volume, brain glucose metabolism, and amyloid deposition respectively. Sleep-wake activity was recorded for one week with actigraphy (MotionWatch8, CamNtech). We computed the mean level and the variability of SF across nights, over the first half of the night. Correlations with neuroimaging data were performed using the SPM12 software, controlling for age, body mass index, anxiety, depression, and the other SF parameter (i.e. variability when the mean level was considered, and conversely).

Results: The mean level of NREM-SF was negatively correlated to brain glucose metabolism in the ventromedial prefrontal cortex (VMPFC), the accumbens and caudate nuclei, and the hypothalamus (p<0.001), and was associated to lower cognitive performance, especially for executive functioning and episodic memory (p<0.05). Variability of NREM-SF was negatively correlated to VMPFC GM volume, and positively correlated to amyloid burden in the VMPFC (p<0.001).

Discussion: These results suggest that, in cognitively normal older adults, a higher NREM-SF is related to brain alteration, mainly in the VMPFC known to be early affected in ageing, and by amyloid deposition in Alzheimer's disease. This may increase the risk of cognitive decline, further highlighting the importance of screening for sleep disturbances and of preserving sleep quality in elders. *Keywords: sleep; amyoid; atrophy; hypometabolism; cognition*

Is microglial activation protective in mild cognitive impairment?

<u>Grazia Daniela Femminella</u>¹, Melanie Dani¹, Melanie Wood¹, Zhen Fan¹, Valeria Calsolaro¹, Ruth Mizoguchi¹, Rebecca Atkinson¹, Trudi Edginton², Adam Waldman¹, Rainer Hinz³, David Brooks^{1,4}, Paul Edison¹

¹Department of Medicine, Imperial College London, London, United Kingdom ²Department of Psychology, University of Westminster, London, United Kingdom ³Wolfson Molecular Imaging Centre, University of Manchester, Manchester, United Kingdom ⁴Department of Nuclear Medicine, Aarhus University, Aarhus, Denmark

Introduction. Amyloid plaques and neurofibrillary tangles are characteristic features of Alzheimer's disease, and neuroinflammation has been proposed to be the link between amyloid deposition, tangle formation and neuronal damage. While microglial activation plays a significant role in Alzheimer's disease, the *in vivo* relationship between neuroinflammation and amyloid deposition and its role in mild cognitive impairment subjects is still debated. Here we investigated the role of microglial activation in mild cognitive impairment subjects using a second-generation translocator protein PET tracer, PBR28.

Methods. Thirty subjects (nine controls and twenty-one with mild cognitive impairment) underwent PBR28 and Flutemetamol PET scans, structural MRI and neuropsychometric evaluation. For PBR28 PET, distribution volumes (V_T) were calculated for each brain region, while amyloid load was estimated using 90–120 min target region:cerebellar uptake ratios. Region of interest analysis was performed for both tracers. Volumetric analysis of MRI was performed using Freesurfer. Voxel-wise correlations between PBR28 uptake and hippocampal volume were interrogated using statistical parametric mapping software.

Results. We detected microglial activation in one third of mild cognitive impairment subjects, mainly evident in the frontal, parietal and occipital cortices. 40% of mild cognitive impairment subjects showed widespread amyloid deposition compared with healthy controls. PBR28 uptake in different cortical areas was positively correlated with hippocampal volume.

Conclusions. We report increased PBR28 binding in a cohort of subjects with mild cognitive impairment, which is in accordance with early onset of neuroinflammatory changes in the brain. This was associated with higher hippocampal volume, suggesting that microglial activation can play a significant protective role in early stages of neurodegenerative diseases.

Keywords: mild cognitive impairment, inflammation, PBR28, flutemetamol

β-Amyloid PET imaging of neurodegenerative disorders in a Chinese specialty hospital

HW Qiao¹, <u>John Seibyl</u>², Y Han¹, W Mao¹, EH Xu¹, J Lu¹, Kenneth Marek², Gilles Tamagnan², Piu Chan¹

¹Xuanwu Hospital, Beijing Capitol University, Beijing, CN ²Molecular Neuroimaging, LLC, New Haven, CT, USA

Objective: The objective of this study was to assess brain β-amyloid with florbetapir PET in healthy controls (HC) and subjects with Subjective Cognitive Deficit (SCD), Alzheimer's Disease (AD), Parkinson disease (PD) and other neurodegenerative disorders patients at a large Chinese specialty hospital.

Methods: PET brain imaging was completed in 32 subjects: eight HC (age 53-79, MMSE 28-30), seven SCD subjects (age 50-67, MMSE 27-30), six mild to moderate AD subjects (age 58-79, MMSE 8-22), seven PD subjects (age 61-75, MMSE 11-30), and four other neurodegenerative disease subjects (DLB, MSA, FTD) (age 51-71, MMSE 15-25). Image quantitation was performed using a standardized florbetapir image analysis algorithm and compared with visual interpretation by an experienced reader. Composite SUVrs were compared across cohorts against abnormality thresholds (between 1.1-1.2).

Results: Cortical composite SUVrs were greater than 1.2 in 3/4 moderate AD subjects compared to 0/8 HC, 0/7 SCD, 0/2 subjects with mild AD. Quantitation in the PD subjects showed 2/7 greater than 1.2. Of the four other subjects 1/2 of the DLB subjects and the single FTD subject were greater than 1.2. Visual assessment showed complete concordance with quantitation at a 1.2 SUVr cut-off. At the lower threshold of 1.1, 2 /32 cases were discordant between assessment approaches.

Conclusions: These data represent the largest PET amyloid experience to date in a Chinese neurodegenerative disorder clinical cohort. In this ongoing study, the numbers of amyloid positive PET scans in clinically diagnosed AD and PD is roughly similar to reports from the literature. The lack of amyloid in healthy subjects and subjective cognitive deficit may reflect the modest sample size. Both quantitative and visual approaches give consistent assessments of brain amyloid status. The range of values for composite SUVr in this Chinese cohort is similar to published data in other cohorts using identical image analysis strategies.



Keywords: PET, amyloid, subjective cognitive deficit, SUVr quantitation

Potential for Braak staging based on quantitative analysis of THK 5351 PET images

Christopher Buckley¹, Elisabeth Lysvic², Grethe Dalsgaard¹, Nobuyuki Okamura³

¹GE Healthcare, Amersham, United Kingdom ²Oslo University Hospital, Oslo, NO ³Tohoku University, Tohoku, Japan

Introduction & Methods: Braak staging through analysis of PET tau agents has the potential to identify subjects who may respond optimally to Alzheimer's disease modifying therapies. For this reason, a quantitative analysis scheme has been created for THK3531 PET images.

Images from 11 healthy volunteers (4 young healthy (YHV) and 7 elderly healthy (EHV)), 4 amnestic Mild Cognitive Impairment (aMCI) and 12 Alzheimer's Disease (AD) subjects were imaged at Tohoku University. Subjects were administered 185Mbq of THK5351 and underwent Dynamic PET imaging. 40-60minute post-injection images were derived from these. T1-weighted 3D MRI were also performed.

The PET images were co-registered to the MR images, followed by spatial normalisation of the MRIs to MNI-152 space. The inverse of the normalisation transforms were applied to an atlas developed to represent the Braak regions. This atlas was applied to PET images to obtain SUVR_{CER} for the regions implicated in stages II-VI.

Results: The results of the analysis were combined in a box-plot denoting the SUVR_{CER} values for the YHVs, EHVs, aMCI & AD subject images (see figure 1).



Braak stage II Braak stage III Braak stage IV Braak stage V Braak stage VI Figure 1. SUVR (cerebellum reference) by Braak stage region determined for 27 subjects. Box plot colours: Young healthy volunteers (brown/dark green), Elderly Healthy (purple/yellow), aMCI(orange/light-blue) & AD (green/red). The inset is a 3D representation of the staging atlas. Stages: II-light blue, III-green, IVpurple, V-gold, VI-red and blue is the cerebellum.

Discussion: While the subject numbers in this study are relatively small, the atlas does show differentiation

between the groups in the regions implicated in Braak stages II to V. Future work will consist of accumulating more images from clinically well-characterised subjects to create statistically valid SUVR thresholds for these regions and use these on individual scans to non-evasively estimate Braak staging in living subjects.

References

- 1. Braak et al. Acta Neuropathol (1991) 82:239 259
- 2. Mandal et. al. J Alzheimers Dis. (2012) 31 (0 3) 169-188

Keywords: Tau, Braak, VOI, Atlas

Both odor identification and amyloid status predict memory decline in older adults

<u>William Kreisl</u>¹, Peng Jin¹, Seonjoo Lee¹, Ezra Dayan¹, Shankar Vallabhajosula², Gregory Pelton¹, Leslie Shaw³, D. P. Devanand¹

¹Columbia University Medical Center, New York, NY, USA ²Weill Cornell Medicine, New York, NY, USA ³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

Background: Odor identification can be inexpensively tested using the 40-item University of Pennsylvania Smell Identification Test (UPSIT), and odor identification deficits have been shown to predict cognitive decline in older adults. We sought to compare the predictive utility of odor identification to that of central nervous system amyloid status for future memory decline.

Methods: Eighty-four adults (age 68.4 ± 7.4 years; 58 with amnestic mild cognitive impairment and 26 controls) had UPSIT, cognitive testing, and PET imaging with ¹¹C-Pittsburgh Compound B (PIB) and/or lumbar puncture at baseline, plus at least 6 months' follow-up. Amyloid-positivity was defined as either PIB uptake in composite gray matter \geq 1.4 times that in cerebellum or CSF A β_{42} < 250 pg/mL. Logistic regression and Receiver Operating Characteristic Curve analysis were conducted to test predictability of amyloid-positivity and UPSIT on memory decline.

Results: At follow-up, 67% of participants showed memory decline. After correcting for age, gender, and education, both amyloid-positivity (OR = 3.11; 95% CI = 1.01, 9.55; p = 0.0473) and UPSIT score <35 (OR = 3.95; 95% CI = 1.25, 12.49; p = 0.0192) predicted memory decline. Combining amyloid status and UPSIT score did not improve prediction of decline. UPSIT score correlated with PIB binding (r = -0.4582, p < 0.0001), and concordance between low UPSIT score and positive amyloid status was 62%.

Conclusion: Both UPSIT score and amyloid status predict memory decline. The moderate concordance between UPSIT and amyloid status suggests that plaque burden alone does not drive the relationship between odor identification and memory decline, and is consistent with neuropathological findings that neurofibrillary tangle pathology is prominent in the olfactory bulb in the early stages of AD. UPSIT may have utility as a low-cost, non-invasive alternative to amyloid PET or lumbar puncture in predicting memory decline. *Keywords: PIB, amyloid, olfaction, memory decline*

Relationship between neuroticism and biomarkers of AD pathology in familial Alzheimer's disease

<u>Yakeel Quiroz</u>^{1,2}, Ana Baena², Daniel Norton¹, Danielle Cosio¹, Aaron Schultz¹, Jennifer Gatchel¹, Reisa Sperling¹, Keith Johnson¹, Francisco Lopera²

¹Massachusetts General Hospital, Boston, MA, USA

²Grupo de Neurociencias, Universidad de Antioquia, Medellin, MA, Colombia

Objective: Neuroticism, a personality trait characterized by the tendency to experience negative emotions, is associated with increased risk for dementia and cognitive impairment. However, it is unclear whether this is because neuroticism worsens cognitive performance independently of dementia, or because dementia-related processes contribute to neuroticism. We investigated whether neuroticism is associated with genetic predisposition to Alzheimer's disease (AD), and with biomarkers of AD pathology. We hypothesized that cognitively unimpaired individuals with autosomal-dominant AD would have elevated levels of neuroticism, and that these would be related to increased tau and amyloid accumulation, as measured by PET imaging.

Methods: Eighteen cognitively unimpaired individuals of the Colombian kindred with early-onset autosomaldominant AD (aged 25 to 44) traveled to Boston for PET imaging. Eight were carriers of the Presenilin-1 (*PSEN-1*) E280A mutation and ten were non-carrier family members. All participants were blind to genetic status, and all carried a 50% risk of developing early onset AD. All participants completed the NEO Five-Factor Inventory, and underwent PiB and AV1451 PET imaging. PiB PET cerebral-to-cerebellar DVRs and AV1451-PET cerebral-to-cerebellar SUVRs were compared based on mutation status. Both PiB and AV1451 utilized structural ROIs as defined by Freesurfer. Groups were matched for age, sex, education level, and neuropsychological test performance.

Results: Mutation carriers had higher levels of neuroticism compared to non-carriers (p=0.05), and neuroticism in carriers only was associated with increased levels of tau in entorhinal (r=0.77, p=0.04) and inferior temporal cortices (r=0.87, p<0.001). Other personality traits did not relate to AD pathology or differ between groups.

Conclusions: Initial findings from this ongoing study revealed that neuroticism is elevated in cognitively unimpaired individuals with autosomal-dominant AD, years before clinical onset, and it is related to tau accumulation. Further research with a larger sample size is needed to understand the underlying mechanisms explaining these associations.

Keywords: Personality, neuroticism, autosomal-dominant Alzheimer's disease, preclinical

Functional network integrity predicts cognitive decline in preclinical Alzheimer's disease

<u>Rachel Buckley</u>^{1,2,3,4}, Aaron Schultz^{3,5,6}, Trey Hedden^{4,5}, Kathryn Papp^{3,4,9}, Bernard Hanseeuw^{3,4,5}, Gad Marshall^{3,4,9}, Jorge Sepulcre^{5,7}, Emily Smith⁸, Dorene Rentz^{3,4,9}, Keith Johnson^{3,4,5,9,10}, Reisa Sperling^{3,4,9}, Jasmeer Chhatwal^{3,4,9}

¹Florey Institutes of Neuroscience and Mental Health, Melbourne, MA, USA
²Melbourne School of Psychological Science, University of Melbourne, Melbourne, Australia
³Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
⁴Harvard Medical School, Boston, MA, USA
⁵Department of Radiology, Bost, MA, USA
⁶Department of Psychiatry, Bo, MA, USA
⁷Gordon Center for Medical Imaging, Division of Nuclear Medical School, Bost, MA, USA
⁸Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA
⁹Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA
¹⁰Division of Nuclear Medicine and Molecular Imaging, B, MA, USA

Objective: To examine the utility of resting-state functional connectivity MRI based (rs-fcMRI) measurements of network integrity as a predictor of future cognitive decline in preclinical Alzheimer's disease (AD).

Methods: 237 clinically-normal older adults (aged 63–90 years, Clinical Dementia Rating = 0) underwent baseline β -amyloid (A β) imaging with Pittsburgh compound-B (PiB)-PET, and structural and rs-fcMRI. Seven networks were chosen for analysis, including four cognitive networks (default, salience, dorsal attention, and frontoparietal control), and three non-cognitive networks (primary visual, extrastriate visual, motor). Using linear and curvilinear mixed models, baseline connectivity in these networks was used to predict longitudinal changes in a preclinical Alzheimer cognitive composite (PACC), both alone and in interaction with A β burden. Median neuropsychological follow-up was three years.

Results: Baseline connectivity in the default (p=0.0005), salience (p=0.0009) and control networks (p=0.004) predicted longitudinal PACC decline, in contrast to connectivity in the dorsal attention (p=0.51) and all non-cognitive networks (ps=0.41-0.59; see Fig 1). Default, salience, and control network connectivity was also synergistic with A β burden in predicting curvilinear decline (ps<0.0001) with combined higher A β and lower connectivity predicting the steepest decline in PACC performance (see Fig 2).

Conclusions: In clinically-normal older adults, lower functional connectivity predicted a more rapid decline in PACC scores over time, particularly when coupled with increased A β burden. Among examined networks, default, salience and control networks were the strongest predictors of rate of change in PACC scores, with the inflection point of greatest decline beyond the fourth year of follow-up. These results suggest rs-fcMRI may be a useful predictor of early, AD-related cognitive decline in clinical research settings.



1. Model estimates of PACC decline according to rs-fcMRI networks



Fig 2. Non-linear model estimates of PACC slopes according to default, salience or control networks by amyloid interaction

Fig



Subjective cognitive concerns exhibit region-specific relationships with tauopathy in the Harvard Aging Brain Study

<u>Rachel Buckley</u>^{1,2,3,4}, Bernard Hanseeuw^{2,4,5}, Patrizia Vannini^{3,4,5}, Elizabeth Mormino^{3,4}, Dorene Rentz^{3,4,7}, Reisa Sperling^{3,4,7}, Keith Johnson^{3,4,5,7,8}, Rebecca Amariglio^{3,4,7}

¹Florey Institutes of Neuroscience and Mental Health, Melbourne, Australia
 ²Melbourne School of Psychological Science, University of Melbourne, Melbourne, Australia
 ³Department of Neurology, Massachusetts General Hospital, Boston, MA, Australia
 ⁴Harvard Medical School, Boston, MA, USA
 ⁵Department of Radiology, Massachusetts General Hospital, Boston, MA, USA
 ⁶Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
 ⁷Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA
 ⁸Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Boston, MA, USA

Introduction: Subjective cognitive concerns (SCC) are associated with early signs of abnormal biomarkers in Alzheimer's disease (AD), but until now, SCC has not been investigated in relation to region-specific tau deposition. We examined relationships between SCC, β -amyloid, entorhinal cortical (EC) tau, an area that exhibits very early signs of tauopathy, and inferior temporal (IT) tau, a region posited as more likely to manifest AD-related tauopathy.

Methods: 135 clinically-normal older participants (76yrs, *SD*=6.9) participating in the Harvard Aging Brain Study underwent AV1451-PET and PiB-PET. An SCC composite was created using z-transformed subscales from the Memory Functioning Questionnaire, the Everyday Cognition battery and a seven-item questionnaire. β -amyloid burden was used continuously according to a summary distribution volume ratio of frontal, lateral and retrosplenial tracer uptake. AV1451 measures were computed as standardized uptake value ratios, and partial volume corrected (PVC). Three separate models were run, focusing on main and interactive effects of β -amyloid, EC and IT tau on SCC, controlling for age, sex, education, and Geriatric Depression Scale score.

Results: SCC was associated with β -amyloid after accounting for demographics (β =0.22,p=.008). SCC also positively associated with EC PVC tau (β =0.36,p<.0001; see Fig 1). IT tau did not significantly predict SCC (β =0.10,p=.26; see Fig 2). An interactive effect of β -amyloid and EC tau on SCC was not significant (p=.22). A full *post-hoc* model suggested that EC tau was the only significant biomarker predictor, accounting for the largest variance in the model (38%).

Discussion: Greater EC tau and β -amyloid were singularly associated with greater SCC, however, synergistic relationships were not apparent. We argue that while SCC is clearly related to neuroimaging markers of tau and β -amyloid, it is possible that SCC, considered here as an aggregate composite, is a behavioral manifestation of a range of aetiologies. Future studies will examine which SCC symptoms are more indicative of AD-related pathology.



Keywords: subjective cognitive concerns, amyloid, tau, PET imaging

Longitudinal Measures of Cognition and Clinical Status are Associated with Tau Deposition in Early Symptomatic Stages of AD

Shannon Risacher^{1,2}, Kacie Deters^{1,2}, Adam Schwarz^{3,4}, Andrew Saykin^{1,2}

 ¹Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA
 ²Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA
 ³Eli Lilly and Company, Indianapolis, IN, USA
 ⁴Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA

Introduction: flortaucipir (AV-1451) is a novel PET tracer to visualize tau deposition *in vivo*. One group of interest is early stage individuals who are more mildly symptomatic than traditional amnestic mild cognitive impairment. We sought to investigate the relationship between clinical and biomarker measurements and tau deposition in these individuals.

Methods: 32 individuals from ADNI were included (9 significant memory concerns (SMC), 23 early mild cognitive impairment (EMCI)). flortaucipir scans and longitudinal CDR-Sum of Boxes (CDRsb), MMSE scores, florbetapir scans, and structural MRIs were downloaded from each visit from the initial ADNI-2 visit to the time of the flortaucipir scan. Florbetapir scans were processed with intensity normalization to the cerebellum and a composite ROI of eroded cerebral white matter, cerebellum, and brainstem for cross-sectional and longitudinal measures, respectively; SUVR was extracted from the whole cortex and precuneus. MRI scans were processed using Freesurfer v5.1 and mean hippocampal, hippocampal subfield, and total cortical grey matter volumes were extracted. Measures from the baseline visit, visit closest to the flortaucipir scan, and the slope of change between these visits (Δ), along with demographics, *APOE* genotype, and time between visits were entered into a step-wise linear regression model to determine the strongest associated measures with medial temporal lobe (MTL), lateral temporal lobe (LTL), and parietal lobe flortaucipir SUVR, normalized to the cerebellum crus.

Results: Δ MMSE was associated with tau in all regions (Table 1; p<0.01), while *APOE* and concurrent cortical amyloid were also associated with MTL and parietal tau, respectively (p<0.05). In amyloid-positive participants (n=15), Δ MMSE and Δ hippocampal volume were associated with MTL and LTL tau (p<0.05), while Δ MMSE and Δ CDRsb were associated with parietal tau (p<0.05).

Discussion: These findings support the association between the emergence and progression of cognitive symptoms and tau deposition in early stages of AD.

Table 1. Step-wise Linear Regression Results

All SMC,	EMCI						
	R ²	Variable 1	В	р	Variable 2	в	р
MTL.	0.619	AMMSE	-0.214	0.002	APOE	0.118	0.031
LTL	0.692	AMMSE	-0.324	<0.001	í	va.	
		Company and the second	The second second	Concerned A	Same and a second	a second and	10.14100
Parietal	0.864	AMMSE	-0.324	<0.001	Cortical AV45	0.383	0.02
Parietal Amyloid	0.864 -positive R ²	SMC, EMCI Variable 1	-0.324 B	<0.001	Cortical AV45	0.383 B	0.025
Amyloid MTL	0.864 -positive R ² 0.923	SMC, EMCI Variable 1	-0.324 B -0.270	<0.001 p 0.002	Variable 2	0.383 B -0.003	p 0.010
Amyloid MTL LTL	0.864 -positive R ² 0.923 0.981	AMMSE SMC, EMCI Variable 1 AMMSE AMMSE	-0.324 B -0.270 -0.461	\$0.001 p 0.002 <0.001	Variable 2 AHippVol	0.383 B -0.003 -0.001	p 0.010 0.042

Keywords: flortaucipir (AV-1451), early stage disease, amyloid PET, magnetic resonance imaging, Alzheimer's Disease Neuroimaging Initiative (ADNI)

Determining smallest detectable difference from longitudinal data – Application to hippocampal volume data from ADNI

Aniket Joshi¹, Dai Feng², Richard Baumgartner²

¹Novartis Institute for Biomedical Research, Cambridge, MA, USA ²Merck Research Laboratory, Rahway, NJ, USA

Introduction: Hippocampal loss measured with MRI has been postulated to be a sensitive marker of Alzheimer's disease (AD) progression and is typically evaluated as a group mean difference between baseline and follow-up scans. At a subject level, the longitudinal change is a combination of two components; physiological change due to aging/progression and within-subject variability (related to test-retest). We apply random effects ANOVA model to estimate these two components from longitudinal ADNI hippocampal volume data. Furthermore, using the within-subject variability, we propose a threshold for true physiological change at a subject level and assess if this threshold can determine transitions from normal (NL) to mild cognitive impairment (MCI), and MCI to AD.

Methods: We model the hippocampal volume data using one-way random analysis of variance with 3 components; mean longitudinal change, subject-specific random effect, and within-subject variability (see equations below). From this model, we can calculate the smallest detectable difference (SDD). The method was applied to baseline and 12-month ADNI hippocampal data (Schuff et al, 2009). The model parameters were estimated using NL and MCI non-converters.

Results and Conclusion: The mean one year hippocampal change for NL and MCI non-converters was 43 mm³ and 64 mm³, respectively. The Bland-Altman plots show a large variability over one year. Though group mean hippocampal volumes reduction is significantly higher for converters compared to non-converters, at subject level this trend is not consistent. Thus, from this dataset, the hippocampal volume change does not appear to be a predictive marker of the disease at subject level.

The SDDs obtained for NL and MCI non-converters were 189 mm³ and 175 mm³, respectively. Change greater than SDD for a subject can be attributed to true physiological change at 95% confidence level. This approach can be applied to other ADNI longitudinal biomarkers to determine a conservative threshold for physiological change at subject level.



Bland-Altman plots for hippocampal volume longitudinal change from baseline (T₀) to 12-month follow-up (T₁₂). The dotted lines represent smallest detectable difference (SDD) and the dashed line denotes the mean difference. The solid symbols represent the converters from NL to MCI (left) and MCI to AD (right)

Modeling Longitudinal Change with Random Effects ANOVA:

The hippocampal volume is modeled as follows :

 $Y_{ij} = \mu + s_i + r_j + e_{ij},$

where,

 Y_{ij} is the hippocampal volume of the *i*' th subject at *j*' th timepoint.

 μ is the population mean of the hippocampal volume

 $s_i \sim N(0, \sigma_s^2)$ is random subject - specific effect

 r_j represents the longitudinal change at timepoint j as fixed effect. It is assumed that at

baseline $(j = 1), r_1 = 0$.

 $e_{ii} \sim N(0, \sigma_e^2)$ is measurement error associated with within subject variability.

For a subject *i*, the longitudinal change between 12 - month scan (j = 2) and baseline (j = 1) is

$$Y_{i2} - Y_{i1} = r_2 + (e_{i2} - e_{i1}) = r_2 + \Delta e_i$$

$$\Delta e_i \sim N(0, 2\sigma_e^2)$$

SDD is estimated as follows :

 $SDD = \sqrt{2} z_{1-\alpha/2} \hat{\sigma}_e$ (Barnhart et al., 2009)

where $z_{1-\alpha/2}$ is the 1- $\alpha/2$ quantile of standard normal distribution

(with $\alpha = 0.05$, $z_{1-\alpha/2} = 1.96$)

Keywords: smallest detectable difference, progression biomarker, hippocampal volume change, ADNI

Additive effects of subjective cognitive decline and amyloid- β burden predict cognitive decline in healthy elderly individuals

<u>Jacob Vogel</u>¹, Monika Varga Dolezalova¹, Renaud La Joie², Shawn Marks¹, Henry Schwimmer¹, Susan Landau¹, William Jagust¹

¹*Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA* ²*Memory and Aging Center, University of California, San Francisco, CA, USA*

Background Brain amyloid- β (A β) and subjective cognitive decline (SCD) are both predictors of longitudinal cognitive decline in cognitively intact elderly individuals. However, the relationship between these variables and cognitive decline remains unexplored.

Methods A data-driven SCD measure was extracted from the Geriatric Depression Scale(GDS) using principle axis factor analysis on data from 347 healthy, non-depressed (GDS < 11) elderly individuals from the Berkeley Aging Cohort Study. This sample was also used to generate cognitive factor scores. PiB-PET scans were acquired from participants with at least three cognitive testing sessions (n=136) to determine the presence (PiB+) or absence (PiB-) of A β pathology. Cognitive decline was measured using mixed effects modeling. Models included age, gender, education, a composite score summarizing subsyndromal depression, and the interaction between each of these covariate and time, as covariates of no interest.

Findings A significant three-way time x A β status x SCD interaction was found for episodic memory (p<0.005) and global cognition (p<0.01). SCD and presence of A β at baseline demonstrated additive effects on change in cognition over time, where PiB+ individuals exhibiting SCD demonstrated the steepest cognitive decline.



Figure 1 Model results visualizing the three-way interaction between time (years since baseline, x-axis), SCD and β -amyloid (PiB) status on longitudinal cognitive measurements (left, episodic memory; right, global cognition). For the purpose of visualization, participants were binarized into SCD+ or SCD- groups based on a median split. Participants were then further split based on their SCD and PiB status as follows: PiB-/SCD- (blue), PiB-/SCD+ (red), PiB+/SCD- (green), PiB+/SCD+ (purple). PiB+/SCD+ demonstrated the steepest cognitive decline in both episodic memory (left) and global cognition (right). A main effect of SCD is also observable in both plots.

Additionally, significant conditional effects of SCD (p<0.05) and time (p<0.001) on episodic memory were observed, as well as significant conditional effects of SCD (p<0.01), time (p<0.001) and SCD x time (p<0.05;) on global cognition.



Predicted Global Cognition vs. Years since Baseline

Figure 2: Model results visualizing the conditional two-way interaction between time (years since baseline, x-axis), and SCD (y-axis) on measurements of longitudinal global cognitive. For the purpose of visualization, participants were binarized into SCD+ or SCD- groups based on a median split. Participants exhibiting more pronounced SCD (red) at baseline showed reductions in global cognition over time compared to participants with less intense SCD at baseline, adjusting for covariates.

Interpretation Our results suggest that the presence of SCD in combination with brain A β is predictive of cognitive decline over time. These findings have implications for clinical trials, suggesting individuals with evidence for both A β and SCD are at higher risk for cognitive decline than those that exhibit one or the other. The conditional effects observed suggest SCD alone to predict change in global cognition over time, but that neither SCD or amyloid can fully explain changes in cognition observed in this cohort. *Keywords: amyloid, SCD, cognition, longitudinal, aging*
Amyloid-β associated cortical thinning of the lateral temporoparietal cortex predicts symptom severity over time in amnestic MCI patients

Federico d'Oleire Uquillas¹, Heidi I.L. Jacobs², Michael Properzi¹, Aaron P. Schultz^{1,3}, Molly R. LaPoint¹, Bernard Hanseeuw^{2,4}, Keith A. Johnson^{2,3,4}, Reisa A. Sperling^{1,3,4}, Patrizia Vannini^{2,3,4}

¹Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ²Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ³Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ⁴Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Introduction: While previous studies in Alzheimer's disease (AD) dementia have shown β -amyloid (A β)-associated cortical thinning in medial and lateral temporal cortices, it remains unknown whether similar patterns can be detected in mild cognitive impairment (MCI). Here we explored the neuroanatomical correlates of amyloid pathology in MCI patients, and investigated whether these structural correlates predict changes in symptom severity.

Methods: Forty-one patients with amnestic MCI underwent MRI and PiB-PET scans. Baseline PIB-DVR (from AD-vulnerable regions) was regressed vertex-wise on baseline cortical thickness, covarying for age. Results were cluster-wise corrected (p<0.05). Cortical thickness values were then extracted from each region and used in linear mixed effects models (LMEs) to investigate associations with clinical progression over time using the Clinical Dementia Rating Sum-of-Boxes (CDR-SB). All LMEs included age, gender and their interaction with time. PiB-DVR>1.2 indicated A β + status (N=21). The fit of complex models was compared with simpler models using ANOVA. Results were Bonferroni-corrected (6 models, p<0.0083).

Results: A β burden was negatively associated with thickness of the right lateral temporo-parietal cortex (LTP) and right entorhinal cortex (EC). Interaction of A β -status × LTP-thickness × time, but not A β -status × EC-thickness × time, on CDR-SB was significant (*p*=0.0017)–an effect driven by A β + patients (*p*<0.0001). Model fit comparisons showed that this three-way interaction predicted CDR-SB change better than assessing the independent effects of the two-way interactions (*p*=0.0039).

Conclusion: Cortical thinning of the LTP predicted CDR-SB change, and this was particularly evident in $A\beta$ + patients. These $A\beta$ -associated cortical regions are similar to those found in previous studies looking at the association of CSF-A β and cortical thickness in MCI. These spatial patterns also overlap with the distribution of Tau pathology in the brain. Our findings support the hypothesis that neocortical A β is associated with distal cortical thinning of memory-related regions, and that these processes occur even before diagnosis of

rostral lateral medial posterior 0.001 clinical AD.

Figure 1. Association map of amyloid- β on cortical thickness across the entire cortical mantle after correcting for multiple comparisons. Right hemisphere shown.

Figure 2.

Two-way interaction of CDR-SB over time by right lateral temporo-parietal cortical thickness in $A\beta$ + patients shows that the lower the cortical thickness in this region the greater the increase in CDR-SB over time. This interaction was not significant in $A\beta$ - patients.

CDR-SB, Clinical Dementia Rating Sum of Boxes.



Table 1

Dependent variable:	CDR-SB (N=134)	
	Estimate	p-value
I. LME model with only Aβ Status × Time	0.06 (0.01)	<0.0001**
II. LME model with only r.EC Thickness × Time	-0.05 (0.02)	0.0119*
III. LME model with only r.LTP Thickness × Time	-0.25 (0.04)	<0.0001**
IV. LME model with both A β Status and r.EC Thickness × Time		
Aβ Status × Time	0.06 (0.01)	<0.0001**
r.Entorhinal Cortical Thickness × Time	-0.004 (0.02)	0.8229
V. LME model with both Aβ Status and r.LTP Thickness × Time		
Aβ Status × Time	0.03 (0.01)	0.0515
r.Lateral Temporo-Parietal Cortical Thickness × Time	-0.17 (0.05)	0.0019**
VI. LME model with interaction of A β Status, r.LTP Thickness, and Time		
Aβ Status × Time	0.79 (0.24)	0.0011**
r.Lateral Temporo-Parietal Cortical Thickness × Time	-0.04 (0.07)	0.5448
Aβ Status × r.Lateral Temporo-Parietal Cortical Thickness	3.07 (2.72)	0.2663
Aβ Status × r.Lateral Temporo-Parietal Cortical Thickness × Time	-0.30 (0.09)	0.0017**

All LME models included age, gender and their effect by time as covariates. A β -PiB and gender are a dichotomous variable, and age and cortical thickness measures are continuous. Females are used as the reference group for gender. Age, as a control variable, was centered at the group mean (72.43). LME, linear mixed-effects model; CDR-SB, Clinical Dementia Rating Sum of Boxes; r.EC, right entorhinal cortex; r.LTP, right lateral temporo-parietal; A β , amyloid- β ; PiB, Pittsburgh compound B; r, right. *p<0.05, **p-value significant at Bonferroni-level p<0.0083.

Keywords: cortical thickness, amyloid, mild cognitive impairment (MCI), symptom severity, CDR Sum-of-Boxes

Does high baseline amyloid predict declines in activity participation and need for cognition over four years? Results from the Dallas Lifespan Brain Study

<u>Allison Parker¹</u>, Sara Festini¹, Michelle Farrell¹, Denise Park¹

¹Center for Vital Longevity, University of Texas at Dallas, Dallas, TX, USA

Introduction: Lower amyloid deposition has been associated with high lifetime cognitive engagement (Landau et al., 2012), and other studies suggest high activity levels defer an Alzheimer's disease diagnosis (Wilson et al., 2007). These relationships may occur because individuals withdraw from activities as neuropathology spreads. We examined whether baseline amyloid positivity in cognitively normal adults predicted a decline in activity level and need for cognition over a four-year interval.

Method: Participants (*N*=184) from the Dallas Lifespan Brain Study (ages 30-89) with F-18 Florbetapir PET imaging completed engagement surveys both at baseline and four years later. Baseline amyloid status (positive or negative) was used to predict changes in self-reported need for cognition and activity participation, measured by six subscales of the Victoria Longitudinal Study Activity Lifestyle Questionnaire. Linear mixed models included amyloid status, APOE e4 status, gender, and time as factors, age and education as covariates, and participant as a random effect.

Results: Analysis of need for cognition revealed a significant Amyloid x Time interaction. Amyloid positive individuals exhibited a decline in need for cognition over 4 years, whereas amyloid negative individuals did not. Importantly, this relationship remained even after controlling for baseline episodic memory performance and change in episodic memory. The Amyloid x Time interaction was not significant for any of the activity subscales. There were, however, marginal main effects of amyloid status on hobbies (p=.053) and self-maintenance activities (p=.098). Amyloid positive individuals reported lower levels of hobbies and self-maintenance activities across time points.

Conclusion: Amyloid positive, but not Amyloid negative, individuals exhibited decline over four years in need for cognition and reported less engagement in self-maintenance and hobbies across time points. These results indicate that amyloid pathology may contribute to withdrawal from engagement in cognitively stimulating activities in healthy adults.

Keywords: Amyloid, Need for Cognition, Engagement Activities

Amyloid-β related memory decline is modified by years of school education in cognitively normal subjects: A study of PiB PET and cognitive reserve

<u>Takashi Kato</u>^{1,2}, Iwata Kaori², Izumi Kuratsubo², Yoshitaka Inui¹, Naohiko Fukaya¹, Kengo Ito¹, Akinori Nakamura², Study Group MULNIAD²

¹Department of Radiology, National Center for Geriatrics and Gerontology, Obu, Japan ²Department of Clinical and Experimental Neuroimaging, National Center for Geriatrics and Gerontology, Obu, Japan

A number of studies have demonstrated evidence of cognitive deficits (especially decline of episodic memory) in association with amyloid-beta deposition in cognitively normal elderly people. The purpose of this study was to investigate effects of cognitive reserve on the amyloid-related memory decline.

Subjects selected from in-house studies were 61 cognitively normal (CN) subjects (age: 69.8±5.7 (60-82) y.o., years of school education (YSE): 12.2±2.4 (9-18) years). They underwent a test of logical memory-II (LM-II) of Wechsler memory scale revised. Distribution volume ratio (DVR) image was calculated from dynamic PiB PET using simplified reference tissue mode 2. The DVR images spatially normalized using DARTEL method. Statistical analyses of the DVR images were performed with SPM8 for multiple regressions to assess the relationship with memory, age, and YSE. Correlation and regression analyses among regional DVR value, age, LM-II score and YSE were performed using SPSS.

Eleven out of 61 cases were visually evaluated as positive scans. LM-II score was 16.8 ± 6 . A significant correlation was observed between LM-II and YSE (r>0.5, p<0.001). The correlation between LM-II and age was not statistically significant (r=-0.16, p=0.21). A SPM analysis showed that the bilateral medial temporal DVR was inversely associated with LM-II score (p<0.005, ext>50). Multiple regression analyses with LM-II as a dependent variable represented that statistically significant terms were YSE (p<0.001) and an interaction term of YSE and regional DVR in the medial temporal lobe in all the cases (n=61). When two outlier cases showing higher DVR value in the medial temporal lobe were excluded (n=59), statistically significant terms were YSE (p<0.001) and medial temporal DVR value (p=0.041).

The results suggest that, in cognitively normal subjects, recent memory declines in associated with amyloid deposition in the medial temporal lobe, and the negative association is modified by cognitive reserve. *Keywords: preclinical AD, amyloid PET, memory, cognitively normal, cognitively reserve*

Memory encoding and recalling assessed by functional Near-Infrared Spectroscopy

Sahar Jahani¹, David Harper², Jim Ellison², <u>Antoniu Fantana¹</u>, David Boas¹, Meryem Yucel¹

¹MGH, Charlestown, MA, USA ²Mclean, Belmont, MA, USA

Background: Alzheimer's disease (AD) is a chronic neurodegenerative disorder which is the sixth leading cause of death in the United States (NIA-NIH). Early detection of AD is the key to preventing, slowing and stopping the disease. The earliest cognitive impairments in patients with Alzheimer's disease are seen in learning and memory skills as in normal aging, however, with different underlying neurological changes (Sperling2003). This preliminary study is performed to assess the NIRS's utility to measure brain activation during memory encoding on young healthy adults.

Paired-associate learning: Paired-associate learning (PAL) the pairing of two items e.g. for face-name pairs, when the learner is prompted with the face, he responds with the appropriate name. The face-name encoding task activates the striate, fusiform, prefrontal cortices and the anterior hippocampus in young healthy adults (Sperling2001).

Data and Analysis: NIRS acquisition was performed for 19 healthy adult subjects. fNIRS data were processed by using HOMER2 and MATLAB, Mathworks, Natick, MA.Paired t-test threshold was set to 0.05 for significance.

Results and Discussion: Robust activation was obtained during both encoding and recalling by fNIRS. Encoding and retrieval of information requires use of the short term memory buffer.Broader activation during recalling novel faces compared to encoding may be due to the inherent difficulty in recalling task that requires involvement of more regions.Default mode network may be responsible for the activation during encoding of same faces in medial frontal cortex.

References

- Sperling RA et al., (2003). "fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease." J Neurol Neurosurg Psychiatry. 74(1):44-50.
- Sperling RA, et al., (2001). "Encoding novel face-name associations: a functional MRI study." Hum Brain Map, 14:129–39.

Keywords: near infrared spectroscopy, memory, Alzheimer's

Associations between regional amyloid load, cortical thickness, APOE genotype and cognition in ADNIGO/ADNI2 participants

<u>Chunfei Li</u>¹, Ranjan Duara^{2,4}, David A. Loewenstein^{3,4,5}, Mercedes Cabrerizo¹, Warren Barker^{2,4}, Malek Adjouadi^{1,4}

¹Center for Advanced Technology and Education, School of Engineering, Florida International University, Miami, FL, USA

²Wien Center for Alzheimer's Disease & Memory Disorders, Mount Sinai Medical Center, Miami, FL, USA ³Psychological Services and Neuropsychology Laboratory, Mount Sinai Medical Center, Miami, FL, USA ⁴Florida ADRC (Florida Alzheimer's Disease Research Center at Gainesville, Miami Beach, Miami and Boca Raton, FL), Gainesville, Miami and Boca Raton, FL, USA

⁵Center on Aging and Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, FL, USA

Background/Objective: We examined the independent effects of A β load and (APOEe4 (e4) genotype on cortical thickness (CTh) and cognition in AD vulnerable regions¹ among participants in the ADNI/GO/ADNI2 study.

Methods: Subjects were classified as (a) CN (n=251) early MCI (EMCI) (n=297), late (LMCI) (n= 196) and AD (n=162); (b) e4+ or e4-; (c) amyloid positive (AMY+) or negative (AMY-), based on a mean Standard Uptake Value Ratios (SUVRs) (cut point of 1.10 for mean SUVR in 34 bilateral brain regions). ANCOVA was used to determine the independent association of A β load and e4 status on measures of CTh and cognition for each of 12 selectively vulnerable left regions, as well as on cognitive scores across all four diagnostic groups.

Results: (1) Across all diagnostic groups, greater A β load was associated with reduced CTh in most AD vulnerable regions; (2) e4+ status was associated with higher A β load in all regions and across all diagnostic groups; (3) Higher A β load was associated with impaired RAVLT, MMSE and ADAS13 cognitive scores, independent of diagnosis or e4 status (Table 1 and 2); (4) Among CN and EMCI subjects, e4+ status (controlling for amyloid load), was associated with *increased* cortical thickness in the Entorhinal Cortex, Parahippocampal Gyrus, Inferior Temporal Gyrus and Temporal Pole, but no independent association with cognition across diagnostic groups (Table 3).

Conclusions: The current findings suggest that $A\beta$ load has an independent effect on reducing CTh and on impairing cognitive performance in all diagnostic groups. The effect of e4+ status on CTh and cognition is almost exclusively mediated via its effect on increasing SUVR in all brain regions. However, CTh in limbic regions is increased among CN and EMCI subjects who are e4+, independent of the effect of $A\beta$ load, perhaps representing brain/cognitive reserve or genetic mechanisms².

TABLE 1: Regional Cortical Thickness and Cognition as a Function of ADNI Diagnosis and Amyloid Load Status Adjusting for ApoE4 Status

	CN	EMCI	LMCI	AD	Fa	F	Fa	Fa	
	AMY- 165	AMY- 149	AMY- 66	AMY- 19	Amyloid	E4 Status	Diagnosis	DX by Amyloid	
	AMY+ 86	AMY+ 148	AMY+ 130	AMY+ 143	/ y loi u	Liotatus	Diagnosis	en ay ningiona	
Age	74.51(6.84) ^b	69.19(7.4)	73.68(9.42)	77.49(8.15)	10 64** ^c	29 92***	15 79***	4 78**	
	76.75(5.74)	73.46(6.83)	73.61(7.29)	74.38(7.71)	10.04	25.52	15.75	4.70	
Regional Cortical Th	nickness (left	hemisphere	e)						
Entorhinal	3.34(0.38)	3.32(0.46)	3.17(0.52)	2.77(0.74)	1/ 50***	2 51	12 18***	1 56	
Lincomman	3.27(0.37)	3.26(0.43)	2.96(0.52)	2.58(0.49)	14.55	2.51	42.10	1.50	
Parahinnocampal	2.67(0.34)	2.66(0.36)	2.52(0.39)	2.44(0.39)	6 7/**	1 00*	15 6***	1 22	
Faramppocampar	2.58(0.41)	2.67(0.31)	2.5(0.4)	2.31(0.35)	0.74	4.00	15.0	1.25	
Inforior tomporal	2.66(0.16)	2.66(0.18)	2.61(0.18)	2.57(0.26)	21 10***	12 07***	12 06***	2 12*	
interior temporal	2.61(0.16)	2.61(0.19)	2.57(0.23)	2.39(0.24)	51.10	15.07	15.00	5.15	
Tomporal pala	3.56(0.33)	3.48(0.37)	3.5(0.35)	3.08(0.63)	2.46	2 5 1	22 10***	1.00	
remporal pole	3.53(0.36)	3.5(0.34)	3.35(0.45)	3.11(0.51)	2.40	5.51.	23.19	1.99	
Medial	2.28(0.15)	2.27(0.14)	2.23(0.17)	2.25(0.2)	0 1/**	2.05*	4 57**	1 0	
orbitofrontal	2.27(0.18)	2.23(0.16)	2.22(0.17)	2.19(0.16)	0.14	5.95	4.57	1.5	
Superior frontal	2.48(0.17)	2.52(0.15)	2.45(0.17)	2.37(0.17)	2 70	1.02	45 47444	0.14	
Superior frontai	2.46(0.17)	2.49(0.15)	2.42(0.16)	2.36(0.18)	5.79.	1.82	15.17		
Rostral Middle	2.15(0.14)	2.18(0.13)	2.14(0.14)	2.09(0.16)	1.07	0.02	8.2***	0.64	
Frontal	2.15(0.15)	2.15(0.12)	2.11(0.13)	2.07(0.15)	1.07				
Superior Deviated	1.96(0.17)	2.01(0.14)	1.97(0.16)	1.95(0.12)	c 00*	* 0.8	10 03***	1.60	
Superior Parietai	1.96(0.17)	2.01(0.14)	1.94(0.16)	1.86(0.18)	0.08		10.02	1.69	
Inferies Deviated	2.19(0.16)	2.23(0.14)	2.2(0.14)	2.18(0.18)	20.02*** 0.75	10 07***	4 70**		
Interior Parletai	2.18(0.17)	2.21(0.15)	2.13(0.16)	2.02(0.2)	20.82***	20.82*** 0.75	10.67***	4.78**	
Commence	2.31(0.18)	2.37(0.15)	2.3(0.17)	2.26(0.19)	10 00*** 2 44	10 51***	4 74		
Supramarginal	2.31(0.18)	2.34(0.16)	2.26(0.17)	2.16(0.18)	10.98***	10.98*** 3.44.	16.51***	1./1	
Deserve	2.14(0.17)	2.19(0.14)	2.14(0.16)	2.11(0.14)	46 55 *** 0.07	10 22***	1.00		
Precuneus	2.12(0.17)	2.15(0.15)	2.1(0.15)	1.99(0.18)	16.55***	.6.55*** 0.97	10.33***	1.92	
Destarian Cinculate	2.38(0.18)	2.41(0.17)	2.4(0.17)	2.39(0.22)	4.25*	4.25* 0.4	1.7	1.00	
Posterior Cingulate	2.4(0.18)	2.39(0.17)	2.37(0.17)	2.31(0.18)	4.25*			1.66	
Cognition Test									
MMSE	29.13(1.24)	28.62(1.39)	28.35(1.5)	22.74(2.9)	6.19* 1.	1.64	218.36***	2.47	
	28.88(1.22)	28.03(1.69)	27.24(1.9)	22.77(2.7)				2.47.	
RAVLT immediate	45.96(10.3)	41.7(11.15)	36.59(12.1)	23.58(7.0)	10 5 5 4 0	10.56** 0.53	07 02***	4.95	
	44.2(10.97)	37.24(9.98)	31.49(9.7)	22.15(7.0)	10.56**		97.83***	1.35	
RAVLT percent	35.83(28.4)	42.56(29.5)	55.34(32.1)	87.63(20.0)) = ====			77 40***	2*
forgetting	36.97(26.7)	51.44(29.3)	73.47(29.2)	90.43(19.9)	5.9/*	3.2.	//.19***	5*	
1046 60612	8.73(4.44)	11.26(5.05)	14.71(6.4)	29.53(7.31)	21 20***	0.07	214.73***	* 2.81*	
ADAS-COG13	9.78(4.69)	14.18(5.58)	19.53(7.5)	31.82(8.98)	21.28***	0.37			

^a F value is adjusted for E4 Status ^b Values are represented as mean(SD), upper is for AMY- group and lower is for AMY+ group

^c p<.1; *p<.05; **p< .01; ***p< .001

TABLE 2: Regional Cortical Thickness, Cognition and ApoE4 Status Across Diagnostic Groups Controlling for Global Amyloid Load

	CN	EMCI	LMCI	AD	-	F a	- a	Fa	
	E4- 184	E4- 169	E4- 92	E4- 54	r Amulaid	F EA Statue	F Diagnosis	DX by	
	E4+ 67	E4+ 128	E4+ 104	E4+ 108	Amyloid	E4 Status	Diagnosis	E4	
Age	75.77(6.35) ^b	72.07(7.31)	74.96(8.55)	76.43(8.57)	10*** ^C	20 12***	12 00***	0.44	
	73.93(6.98)	70.33(7.49)	72.46(7.42)	73.9(7.28)	19.	29.12	12.89***		
Regional Cortical Thic	kness (left he	misphere)							
Enterhinal	3.3(0.38)	3.22(0.46)	3.11(0.54)	2.69(0.6)	F C 4*	0.02	68.18***	4.84**	
Entorninai	3.35(0.37)	3.37(0.41)	2.96(0.51)	2.55(0.48)	5.64*	0.02			
Devakionecomnal	2.62(0.38)	2.64(0.32)	2.5(0.39)	2.37(0.38)		1 71		4 00	
Paranippocampai	2.68(0.34)	2.7(0.34)	2.52(0.39)	2.31(0.34)	2.29	1./1	25.50	1.08	
Inforier to manage	2.63(0.15)	2.62(0.19)	2.57(0.21)	2.42(0.27)	25 75***	0.00**	22 41***	0 F	
Interior temporal	2.68(0.17)	2.65(0.19)	2.59(0.22)	2.41(0.24)	25.75	9.99	32.41	0.5	
Terrandorala	3.53(0.35)	3.45(0.37)	3.42(0.4)	3.11(0.53)	1 5 7		32.87***	1.1	
Temporal pole	3.6(0.32)	3.53(0.34)	3.38(0.44)	3.1(0.52)	1.57	1.55			
Madial arbitafrontal	2.27(0.15)	2.25(0.15)	2.22(0.16)	2.17(0.18)	11 02***	4.024	4 70**	0.53	
iviedial orbitofrontal	2.28(0.18)	2.25(0.15)	2.22(0.18)	2.21(0.15)	11.92	4.85	4.78		
Currentes frontel	2.46(0.18)	2.51(0.14)	2.44(0.17)	2.33(0.15)	2.00	2.01	22.2***	1.49	
Superior frontal	2.5(0.16)	2.5(0.16)	2.42(0.16)	2.37(0.19)	2.98.	2.01			
Destrol Middle Frantal	2.14(0.15)	2.18(0.12)	2.13(0.14)	2.05(0.16)	0.59	0	14 70***	1.0	
Rostral Middle Frontal	2.15(0.14)	2.15(0.13)	2.11(0.12)	2.08(0.15)		0	14.73	1.8	
Conservation Deviated	1.95(0.16)	2.02(0.14)	1.96(0.16)	1.88(0.18)	3.03.	0.57	18.66***	1.7	
Superior Parietai	2(0.17)	2(0.14)	1.94(0.16)	1.87(0.18)					
Inferior Deviatel	2.18(0.16)	2.22(0.15)	2.18(0.16)	2.06(0.2)	14 10***	0.1	25.75***	2.11.	
Interior Parietai	2.21(0.18)	2.22(0.15)	2.13(0.15)	2.03(0.21)	14.18	0.1			
Cummanaanainal	2.3(0.18)	2.35(0.15)	2.29(0.17)	2.17(0.19)	c	2.00	20 71***	0.00	
Supramarginal	2.34(0.17)	2.36(0.16)	2.26(0.17)	2.17(0.18)	6.26*	2.08	30.71***	0.99	
Dessurgers	2.12(0.16)	2.17(0.14)	2.12(0.16)	2.03(0.17)	0.64**	0.20	22.49***	1.39	
Precuneus	2.16(0.17)	2.16(0.15)	2.1(0.16)	2(0.18)	9.64	0.36			
Posterior Cingulate	2.37(0.18)	2.41(0.17)	2.38(0.16)	2.33(0.2)	4.50 0.40	0.16	5.47***	2.03	
	2.42(0.18)	2.38(0.17)	2.38(0.18)	2.31(0.18)	1.50	0.16			
Cognition Test						5d			
MMSE	29.1(1.24)	28.49(1.4)	27.92(1.66)	22.85(2.54)	7.68** 2.07	2.07			
	28.88(1.21)	28.1(1.7)	27.34(1.98)	22.72(2.7)		2.07	329.04***	0.42	
RAVLT immediate	45.84(10.6)	40.41(10.9)	34.59(11.7)	22.02(7.3)					
	44.01(10.5)	38.24(10.5)	31.99(9.9)	22.46(6.9)	23.43***	0.09	114.99***	0.79	
RAVLT percent	36.2(29.04)	44.84(29.3)	57.73(33.6)	88.56(24.3)	4 - 4 + 4		02 02 ***		
forgetting	36.26(24.2)	49.82(30.2)	75.89(26.5)	90.87(17.4)	15***	15*** 2.77	2.77.	92.83***	3.29*
	8.99(4.46)	12.05(5.33)	16.4(7.46)	31.45(8.3)					
ADAS-COG13	9.36(4.8)	13.61(5.64)	19.21(7.3)	31.59(9.1)	38.61***	0.1	301.44***	1.18	

^a F value is adjusted for Global Amyloid Load

^b Values are represented as mean(SD), upper is for E4- group and lower is for E4+ group

^c p<.1; *p<.05; **p< .01; ***p< .001

	controlling for clobal / inflora coad						
	E4- (353)	E4+ (195)	F_SUVR	F_E4 ^a			
Regional Cortical Thickness (left hemisphere)							
Entorhinal	3.27(0.42) ^b	3.36(0.4)	7.02** ^c	10.89***			
Parahippocampal	2.63(0.35)	2.7(0.34)	3.26.	7.07**			
Inferior temporal	2.62(0.17)	2.66(0.18)	15.36***	11.98***			
Temporal pole	3.49(0.36)	3.56(0.33)	3.2.	6.56*			
Medial orbitofrontal	2.26(0.15)	2.26(0.16)	11.87***	1.41			
Superior frontal	2.48(0.16)	2.5(0.16)	1.4	1.32			
Rostral Middle							
Frontal	2.16(0.14)	2.15(0.13)	0.01	0.56			
Superior Parietal	1.98(0.16)	2(0.15)	0.06	1.84			
Inferior Parietal	2.2(0.15)	2.22(0.16)	1.69	3.05.			
Supramarginal	2.32(0.17)	2.35(0.17)	0.87	4.65*			
Precuneus	2.15(0.15)	2.16(0.16)	3.09.	1.68			
Posterior Cingulate	2.39(0.17)	2.4(0.18)	0.08	0.21			
Cognition Test							
MMSE	28.81(1.37)	28.37(1.6)	15.35***	4.11*			
RAVLT immediate	43.24(11.09)	40.23(10.83)	16.3***	2.83.			
RAVLT percent							
forgetting	5.57(2.38)	5.36(2.57)	5.95*	0.02			
ADAS-COG13	3.99(2.81)	4.17(2.41)	2.42	0.06			

TABLE 3: Regional Cortical Thickness, Cognition and ApoE4 Status among combined CN and EMCI Groups Controlling for Global Amyloid Load

^a F value is adjusted for Global Amyloid Load

^b Values are represented as mean(SD)

^c p<.1; *p<.05; **p< .01; ***p< .001

Keywords: Alzheimer's Disease, Regional Amyloid Load, Cortical Thickness, APOE genotype, Cognition

Regional uptake of FDDNP and exposure to professional fighting

Sarah Banks¹, Vladimir Kepe², Frank DiFilippo², Bern Lee¹, Jorge Barrio², Charles Bernick¹

¹Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA ²Cleveland Clinic, Cleveland, OH, USA ³University of California Los Angeles, Los Angeles, CA, USA

Background: Exposure to repeated traumatic head injury has been associated at autopsy with increased tau. In football players, there is some evidence to suggest that PET tracers including FDDNP can demonstrate pathology during life. We used FDDNP to assess active and retired professional boxers and mixed martial arts fighters.

Methods: Fighters were recruited from a large, ongoing longitudinal study, the Professional Fighters Brain Health Study. This analysis represents the first 34 fighters, who ranged in age from 19 to 66 years, with a mean of 40 years. We used the MIAKAT kinetic analysis software to analyze FDDNP PET data. Fighters also underwent cognitive tests, and structured interview.

Results: While there were several relationships between exposure to fighting and FDDNP uptake in cortical and subcortical regions, these did not survive correcting for age. There was also an interesting relationship between nonverbal memory and FDDNP uptake in the amygdala.

Discussion: This preliminary evidence shows some limited support for increased regional uptake of FDDNP in fighters with more exposure. With ongoing data collection from normal controls and more fighters, we will be able to elucidate the relationship with age.

Keywords: FDDNP; brain injury; tau; amyloid; sports

Tau imaging in professional fighters

Sarah Banks, Karthik Sreenivisan, Charles Bernick

Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

Background: Repeated traumatic brain injury sustained in sports has been associated with neurodegenerative disease, and specifically with tauopathy. ¹⁸F-AV1451, a PET tracer that binds to certain forms of tau, has been shown to follow the expected trajectory of spreading tauopathy in Alzheimer's patients. In a symptomatic retired football player, PET tracers that bind to tau have been shown to have increased uptake in regions that show increased tau at autopsy.

The Professional Fighters' Brain Health Study is a longitudinal study of professional boxers and mixed martial arts fighters. For the current study, we added ¹⁸F-AV1451 scans to the usual battery which includes cognitive testing, demographic and clinical data collection, and MRI scanning. We expected fighters who showed extensive fight history, or those with poor scores on cognitive tests, to show more extensive uptake in regions known to be vulnerable to tau deposition in autopsy proven cases of CTE.

Methods: 12 professional fighters were scanned as part of a larger study with further recruitment planned. Mean SUVR values were extracted for FreeSurfer-defined regions. Given the small n we concentrated on the hippocampus, amygdala and thalamus bilaterally, and assessed correlations with age and number of fights. For regions that were significant, we performed a secondary analysis looking at correlations with cognitive test scores.

Results: Number of fights correlated with uptake in the amygdala bilaterally (left r=.622, right r=.746) and this effect was independent of age. Uptake in both amygdalae correlated negatively with processing speed score (left r=-.653, right r=-.585).

Discussion: These data suggest increased tau deposition in professional fighters with extensive fight experience, and that this is not an effect only of age. Furthermore, those fighters with the most tau deposition in the amygdala performed worse on a processing speed test. Further analysis with larger datasets will be important to clarify the meaning of this finding. *Keywords: tau, sports, head trauma, cognition*

Clinical utility of amyloid PET in amnestic mild cognitive impairment.

Ko Woon Kim¹, Jin San Lee¹, Young Kyoung Jang¹, Sang Won Seo^{1,2}

¹Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Seoul, Korea ²Neuroscience Center, Samsung Medical Center, Seoul, Korea, Seoul, Korea

Background & Objective: Mild cognitive impairment (MCI) refers to a transitional zone between normal ageing and dementia. Despite clinical trials, a standard treatment strategy for MCI patients has not been established. Previous amyloid PET studies also showed that just 50-60% MCI patients had amyloid positivity, which predicted their worse clinical outcomes. The purpose of this study is to examine how an amyloid PET scan helps guide doctors in treating mild cognitive impairment (MCI) patients.

Methods: Data on all amyloid PET scan from May 2009 through May 2016 were retrieved from Samsung medical center. We compared pre-PET intended management to post-PET actual management recorded 90 days after the scan. Examples of changes in management include: use of Alzheimer's drug therapy, other drug therapy such as ginkgo biloba.

Among 168 MCI patients, the overall treatment change rate was 61%. In contrast, treatment non-change rate was 39%. Of the 39% patients with treatment non-change, amyloid positive group occupied as high as 52% compared amyloid negative group occupied only 29%. Of the 61% patients with treatment change, amyloid positive group was 44% and amyloid negative group was 41%.

Results of this study showed amyloid PET data could influence physicians' decision for MCI. Especially, physicians confidently started choline esterase inhibitors when amyloid PET result was positive. However, when amyloid PET showed a negative result, physicians hesitated stop choline esterase inhibitors. Future multi-center studies will be required to ascertain the clinical roll of brain amyloid PET that is an important factor to change treatment plan for MCI patients. *Keywords: MCI, amyloid PET, treatment*

227

Relationships between [11C]PIB, [18F]AV1451 PET, and gray matter volumes within functional networks in Alzheimer's disease

Jungho Cha¹, Alexandre Bejanin¹, Renaud La Joie¹, Nagehan Ayakta¹, Suzanne L. Baker³, Mustafa Janabi³, James P. O'Neil³, Bruce L. Miller¹, William J. Jagust^{2,3}, Gil D. Rabinovici^{1,2}

¹Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA ²Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, USA ³Life Science Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA

The objective of this study was to assess the relationships between amyloid and tau accumulation and gray matter volumes across the cortex and within functional networks in patients with Alzheimer's Disease (AD). We included forty-seven patients (mean age 62.9±8.2 yrs, mean MMSE 22.7±5.5) with a clinical diagnosis of probable AD and positive amyloid (PIB) PET. T1-weighted MRI was used to measure modulated gray matter volumes (mGM). PIB 90-minute DVR and AV1451 80-100 minutes SUVR were created using a cerebellar gray matter reference region. We assessed bivariate Spearman correlations between modulated gray matter volumes (mGM, SPM12), PIB DVR, and AV1451 SUVR across all cortical regions (210 regions-of-interest from the Human Brainnetome Atlas), and within 13 functional network templates from the Stanford FIND Lab (dorsal/ventral default mode networks (DMN), left/right executive controls networks (ECN), precuneus, auditory, language, anterior/posterior salience, higher visual, primary visual, visuospatial, and sensorimotor networks).

We found a positive correlation between PIB and AV1451 (ρ =0.40, p<0.001) across all cortical regions (**Figure 1**). Both AV1451 (ρ =-0.33) and PIB (ρ =-0.12) were negatively correlated with mGM (p<0.001), though correlation with AV1451 was greater than with PIB (Z=15.95, p<0.001).

Figure 1. Relationships between [18F]AV1451 SUVR, [11C]PIB DVR, and modulated gray matter volumes across the cortex using Human Brainnetome atlas (Fan et al., 2016). Histograms of each variable across the cortex appear along the diagonal. ρ values are colored red if $\rho < 0.05$.



Human Brainnetome atlas (210 cortical regions)

In all 13 functional networks, there were positive correlations between AV1451 and PIB (average $\rho = 0.45$, p<0.05). AV1451 was negatively correlated with mGM in dDMN, left ECN, right ECN, anterior salience, language, higher visual, and primary visual network, while PIB only showed associations with mGM in right ECN (**Figure 2**). No significant correlations between mGM and PIB or AV1451 were found in other networks.



In conclusion, we found significant correlations between tau and amyloid accumulation across the cortex, but tau was more strongly linked to gray matter loss within cognitive networks. These results are consistent with AD being an amyloid-facilitated tauopathy, in which network-based spread of tau drives neurodegeneration and ultimately cognitive decline.

Keywords: [18F]AV1451, [11C]PIB, Neurodegeneration, Functional network, Alzheimer's disease

Prevalence of amyloid PET positivity according to APOE genotype in subcortical vascular cognitive impairment

<u>Jin San Lee</u>¹, Seonwoo Kim², Heejin Yoo², Seongbeom Park¹, Yeongsim Choe¹, Young Kyoung Jang¹, Rik Ossenkoppele³, Ko Woon Kim¹, Yeshin Kim¹, Hyemin Jang¹, Hee Jin Kim¹, Key-Chung Park⁴, Duk L. Na¹, Sang Won Seo¹

¹Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

²Biostatistics Team, Samsung Biomedical Research Institute, Seoul, Korea
³Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, Netherlands
⁴Department of Neurology, Kyung Hee University School of Medicine, Seoul, Korea

Objectives: We compared the prevalence of amyloid positivity on PET between patients with subcortical vascular cognitive impairment (SVCI) and cognitively normal (CN) subjects. We also investigated the effects of APOE genotyping on the prevalence of amyloid positivity in CN subjects and SVCI patients. **Methods:** A total 373 subjects (224 SVCI patients from the Samsung Medical Center and 149 CN subjects from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing dataset) who underwent ¹¹C-Pittsburgh compound B or ¹⁸F-florbetaben PET scans were included in this study. All study participants were genotyped for the APOE $\epsilon 2/\epsilon 3/\epsilon 4$ alleles. Statistical analyses to compare between the groups were performed by chi-square test (Fisher's exact test) or Student's *t*-test. Multivariate logistic regression model was used to determine the prevalence of amyloid positivity according to age.

Results: The prevalence of amyloid positivity was significantly higher in SVCI patients than in CN subjects (34.4% vs. 24.2%, p=0.036). In comparison with non-carriers, the APOE ε 4 carriers had significantly higher amyloid positivity in the SVCI and CN groups. Interestingly, the APOE ε 2 carriers seemed to have higher amyloid positivity than the APOE ε 3/ ε 3 groups in SVCI patients although their relationships were not significant. Furthermore, there were interaction of APOE ε 2 and groups (SVCI and CN) for amyloid positivity (p=0.031).





angiopathy (CAA) in the cerebral vasculature, as shown in the previous studies that higher level of $A\beta$ was associated with the increased risk of hemorrhages in CAA with APOE ϵ 2 patients.

Figure 1. Comparision of amyloid positivity according to cognitive status (A) and APOE genotype (B, C)



Figure 2. Interaction of APOE ɛ2 and groups (CN and SVCI) for amyloid positivity



Figure 3. Association of age with prevalence estimates of amyloid positivity according to cognitive status and APOE genotype

Keywords: Subcortical vascular cognitive impairment, Amyloid positivity, APOE genotype, Cerebral amyloid angiopathy, Alzheimer's disease

Genetic drivers of resilience in asymptomatic Alzheimer's disease

Timothy Hohman, Logan Dumitrescu

¹Vanderbilt University Medical Center, Nashville, TN, USA

Background: Asymptomatic Alzheimer's disease (AD) is characterized by the presence of autopsyconfirmed pathological AD (plaques and tangles) without the clinical manifestation of cognitive impairment. My lab has leveraged biomarker, neuroimaging, and cognitive data to build a robust metric of resilience that predicts protection from future cognitive decline, brain atrophy, and clinical progression (Hohman et al, *Neurology*, in press). The current project applied this measure of resilience as an endophenotype in a predicted gene expression analysis to identify novel genetic effects that promote resilience from cognitive decline, particularly in the presence of enhanced biomarkers of AD neuropathology.

Methods: Participants were drawn from the AD Neuroimaging Initiative (ADNI; n=686), the National Alzheimer's Coordinating Center (NACC; n=479), and the Rush Memory and Aging Project/Religious Orders Study (ROS/MAP, n=713). A partial-least squares latent variable model was used to calculate a continuous metric of resilience representing better or worse cognitive performance given an individual's level of cerebrospinal fluid biomarkers (ADNI) or an individual's burden of plaques and tangles (NACC/ROS/MAP). PrediXcan, a technique to "impute" gene expression, was leveraged to assess the association between tissue-specific gene expression and resilience. Analyses adjusted for age and sex while correcting for multiple comparisons (α =1x10⁻⁶).

Results: Lower predicted expression of GTP Binding Protein 2 (*GTPBP2*) in the cerebellar cortex was associated with higher levels of resilience in all three datasets (Fixed effects β =-0.27, p=8.8x10⁻⁷). The effect was particularly strong among individuals who were biomarker positive, and among those individuals who met neuropathological criteria for AD.

Conclusions: Model system work has highlighted the role of *GTPBP2* in neurodegenerative cascade, particularly when ribosomal protein production has been stalled. Our results further highlight the potential role of *GTPBP2* in neurodegeneration and suggest that brain expression of *GTPBP2* may be particular relevant to the clinical manifestation of disease in the presence of AD neuropathology. *Keywords: Asymptomatic AD, Resilience, Biomarkers, Neuropathology, Genetics*

Heterogeneity of amyloid-related cognitive decline in clinically normal older adults

<u>Kate Papp</u>¹, Dorene Rentz^{1,2}, Rebecca Amariglio², Aaron Schultz², Keith Johnson^{1,2}, Reisa Sperling^{1,2}, Elizabeth Mormino²

¹Brigham and Women's Hospital, Boston, MA, USA ²Massachusetts General Hospital, Boston, MA, USA

Background: Previous work indicates that a subset of clinically normal older adults with elevated amyloid (Ab) on PET imaging are at risk of cognitive decline. However, how cognition declines by cognitive domain remains unclear. We therefore sought to examine A β -related decline across different cognitive domains in participants from the Harvard Aging Brain Study.

Methods: Clinically normal older adults (mean age=73.67, 63-90) underwent baseline imaging (PiB-PET; dichotomized into $A\beta$ -/ $A\beta$ + groups) and annual neuropsychological testing for up to 5 years (mean follow up=3.6±1.1 years). We constructed cognitive composites for Memory, Semantic Processing, and Executive Functions. Linear mixed models controlling for age, sex and education were used to examine cognitive decline in Memory (*6-trial SRT DR, Logical Memory DR*), Semantic Processing (*BNT, category fluency*), and Executive Functions (*TMTB-A, Digit Symbol Coding*).

Results: The A β + group declined across all cognitive domains in comparison with the A β - group. Estimated mean annual z-score change for the A β + group was as follows: Memory (beta= -0.08, p=0.001), Semantic Processing (beta= -0.09, p

Conclusions: Elevated amyloid was associated with longitudinal decline across multiple cognitive domains. Furthermore, our findings that Memory, Semantic Processing, and Executive Functions independently capture Aβ-related early decline provides evidence for the heterogeneity of the preclinical AD cognitive phenotype. *Keywords: cognition, amyloid*

Predicting the rate of amyloid accumulation using multimodal data

Yan Jin¹, Shuai Huang¹, the ADNI²

¹University of Washington, Seattle, WA, USA ²Washington University in St. Louis, St. Louis, MI, USA

Background: Alzheimer disease (AD) is the most common form of dementia and its incidence increases exponentially with age. Amyloid PET enables the early detection of brain amyloidosis, and the rate of amyloid accumulation is an important biomarkers especially in anti-amyloid clinical trials. In this project, we investigate the feasibility of predicting the longitudinal rate of amyloid accumulation based on multimodal data including APOE genotypes, FDG-PET, MRI volumetrics, and demographics. Specifically we adopt a widely used machine learning technique, RuleFit, to perform the predictive modeling and compare with traditional regression approaches.

Methods: Multimodal biomarker data was obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. 1737 subjects in total are included in this study. Rate of amyloid accumulation was estimated based on longitudinal Florbetapir scans from ADNI-GO/2 cohort. RuleFit, an ensemble method that uses LASSO penalization to combine predictions from individual trees, was applied to establish the model for prediction of amyloid accumulation rate. The mean squared errors (MSE) of the RuleFit model was estimated and compared to three other popular regression models.

Results: The five most important rules found by the RuleFit algorithm is reported in Tab. 1. The importance score (Impo.) describes the relative importance of the respective input variables, while the support (Supp.) represents the percentage of the samples that satisfy the corresponding rules. Fig. 1 demonstrates the relative importance of selected biomarkers. Tab. 2 reports the MSE and R squared of the RuleFit model in comparison with other models. The performance of RuleFit model is better, where particularly it explains 75% of total variance.

Conclusion: RuleFit is a promising machine learning technique that can characterize the relationship of multiple biomarkers to the longitudinal accumulation of amyloid plaques. The predictive model may be used to improve participant selection in future longitudinal studies of AD progression and AD therapy/prevention trials targeting amyloid.

rende 71.5 million antihousanir rende im bendera				
IMPO.	SUPP.	RULE		
100	0.17	AGE>64.55; ADA\$13>16.50		
52.64	0.42	MidTemp>1.25		
47.41	0.38	APOE4#0; MMSE>19.50		
44.30	0.50	APOE4=0; Ventricles<3.95		
34.35	0.20	WholeBrain<70.20; MidTemp<1.28		
33.07	0.35	ADAS13>12.50; Enterhinal>0.23		

Table 4: C move increases when entry in Redsfill movied

	Table 2: prediction accuracy companison			
	$\overline{MSE}(10^{-3})$	$\sigma^2(MSE)(10^{-4})$	R ²	
RULEFIT	6.74	0.81	0.75	
LINEAR REGRESSION	26.25	18.09	0.36	
LASSO REGRESSION	6.79	5.33	0.68	
RANDOM FOREST	6.81	3.98	0.71	



Keywords: RuleFit, AV45, Prediction, ADNI

PET based network analysis reveals temporal lobe as a hub for tau propagation in MCI

<u>Sulantha Mathotaarachchi</u>^{1,2}, Tharick Pascoal^{1,2}, Monica Shin^{1,2}, Min Su Kang^{1,2}, Vladimir Fonov^{1,2}, Andrea Benedet^{1,2}, Serge Gauthier¹, Pedro Rosa-Neto^{1,2}

¹McGill University, Montreal, QC, Canada

²Translational Neuroimaging Laboratory, McGill University Research Center for Studies in Aging, Verdun, QC, Canada

Introduction: The Braak and Braak neurofibrillary tangle(NFT) staging of Alzheimer's suggests a symmetric pathway for tau propagation. However, it remains to be established whether patterns of NFT deposition follows specific brain networks. We propose a data-driven minimum spanning tree (MST) based approach for determining the underlying structure of the NFT network. MST networks are constructed to incorporate the minimum number of connections required to reach all nodes of a network and believed to represent the backbone structure of a network. We hypothesize that the abnormal NFT occurs in the set of anatomical brain regions interconnected with the temporal lobe.

Methods: AV1451 images were acquired for 41 cognitively normal (CN) and 38 mild cognitive impairment (MCI) individuals from the ADNI cohort and the SUVr maps were generated using cerebellum gray matter as the reference region. CN and MCI, TAU networks were then constructed using 745 nodes distributed across the brain cortex. Subsequently, the minimum spanning tree networks were generated and the average degree distribution was calculated for 55 cortical regions.

Results: In MCI individuals, the right inferior temporal gyrus and the left medial frontal orbital gyrus showed a considerably high average degree distribution compared to the other brain regions. They also showed an increase when comparing the same regions in CN individuals (Figure 1, 2, <u>https://www.youtube.com/watch?v=AA9SbnGmCKw</u>)

Discussion: Our results indicate that in MCI, the main hubs of the brain tau networks are asymmetric, predominantly temporal in the right and orbitofrontal on the left hemisphere. These asymmetric hubs, suggests independent propagation in both hemispheres. As a caveat, the current study includes a cross-sectional analysis and a longitudinal study is required to validate the findings.



Keywords: tau, network, brain, minimum spanning tree

Regional tau correlates of instrumental activities of daily living and apathy in mild cognitive impairment and Alzheimer's disease dementia

<u>Gad Marshall</u>^{1,2}, Jennifer Gatchel⁴, Nancy Donovan^{4,5}, Aaron Schultz³, J. Alex Becker³, Jasmeer Chhatwal², Bernard Hanseeuw², Kathryn Papp^{1,2}, Rebecca Amariglio^{1,2}, Dorene Rentz^{1,2}, Reisa Sperling^{1,2}, Keith Johnson^{1,3}

¹Department of Neurology, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

²Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ³Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ⁴Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ⁵Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Background: Instrumental activities of daily living (IADL) impairment and apathy co-occur in mild cognitive impairment (MCI), worsen in mild Alzheimer's disease (AD) dementia, and are associated with regional atrophy, hypoperfusion, and hypometabolism in vivo, as well as greater tau burden in post-mortem studies.

Objective: To explore the association between IADL, apathy, and in vivo regional tau, visualized by T807 PET, in MCI and AD dementia.

Methods: Twenty-four subjects (13 MCI, 11 AD dementia) underwent assessments of IADL using the informant-based Functional Activities Questionnaire (FAQ) and apathy using the Apathy Evaluation Scale Clinician report (AES-C). Tau burden was assessed using T807 PET in 9 cortical and subcortical regions and cortical amyloid burden was assessed using Pittsburgh Compound B PET. Unadjusted correlations were performed to assess the relationship between FAQ, AES-C, and tau burden. Regions with associations of $p \le 0.01$ were entered into regression models assessing the relationship between tau burden and FAQ or AES-C (dependent variables) in separate models, adjusting for age and sex (and depression in apathy models). Models were repeated with an interaction between tau and amyloid.

Results: Greater tau burden in dorsolateral prefrontal (partial r (pr)=0.56, p=0.005), supramarginal (pr=0.55, p=0.005), inferior temporal (pr=0.54, p=0.006), lateral temporal (pr=0.50, p=0.01), and entorhinal cortex (pr=0.50, p=0.01) was associated with greater IADL impairment. Greater dorsolateral prefrontal tau burden (pr=-0.52, p=0.02) was associated with greater apathy. The interaction between tau and amyloid was not significant, while independent associations with both tau and amyloid were retained (amyloid: IADL p=0.006; apathy p=0.08).

Conclusions: Our results suggest that IADL impairment in AD is associated with widespread tau burden, while apathy is associated with frontal tau. That said, both IADL impairment and apathy may be serving as a proxy of global cognition. Therefore, these findings need to be replicated in a larger sample adjusting for cognition to better inform specific treatments.

Keywords: Alzheimer's disease, apathy, instrumental activities of daily living, mild cognitive impairment, tau

SESSION 8: Preclinical AD

SESSION 8 Preclinical AD	CHAIRS: Reisa Sperling <i>Harvard Medical School</i> Elizabeth Mormino <i>Harvard Medical School</i>
Implementing and testing the new A/T/N classification in AIBL participants combining fluid (CSF) and different A β and tau imaging radiotracers	Victor Villemagne University of Melbourne
The Relationship of Elevated Medial Temporal Lobe and Diffuse Brain Tau-PET Signal in Clinically Normal Participants	Val Lowe <i>Mayo Clinic</i>
Prevalence and incidence of amyloid positivity in cognitively normal elderly individuals	Neelesh Nadkarni University of Pittsburgh
Longitudinal tau accumulation is associated with cognitive decline in normal elderly	Bernard Hanseeuw Harvard Medical School
Baseline amyloid burden predicts cognitive decline four years later in healthy adults: The value of a dose-response analysis	Michelle Farrell University of Texas at Dallas
Discussion	

Implementing and testing the new A/T/N classification in AIBL participants combining fluid (CSF) and different $A\beta\Box$ and tau imaging radiotracers

Samantha C Burnham^{1,2}, Christopher C Rowe³, Pierrick Bourgeat⁴, Vincent Doré^{3,4}, Greg Savage⁵, Simon Laws², Qiao-Xin Li⁶, Steven Collins⁶, Ralph Martins², Olivier Salvado⁴, Colin L Masters⁶, <u>Victor L Villemagne^{3,6}</u>

¹eHealth, CSIRO Health and Biosecurity, Perth, WA, Australia
²Edith Cowan University, Perth, WA, Australia
³Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC, Australia
⁴eHealth, CSIRO Health and Biosecurity, Brisbane, QLD, Australia
⁵Department of Psychology, Macquarie University, Sydney, NSW, Australia
⁶The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia

Background: Extending their previous two-biomarker approach, Jack and colleagues (*Neurology*, 2016) have proposed a new classification scheme based on a triad of biomarkers: "A" (A β -amyloid), "T" (tau), and "N" (neuronal injury). We implemented and tested the A/T/N classification in AIBL participants.

Methods: Two-hundred and ninety AIBL participants (218 HC, 45 MCI, and 27 AD) underwent A β imaging (either ¹¹C-PiB, ¹⁸F-florbetapir, ¹⁸F-flutemetamol, or ¹⁸F-NAV4694) and 3D MRI, where 146 of them had "T" status determined by CSF p-tau and 144 by tau imaging (either ¹⁸F-AV1451, ¹⁸F-THK5351 or ¹⁸F-THK5317). A binary high(+)/low(-) classification was adopted for each marker. The A/T/N distribution in each clinical group and the relationship with cognition were explored.

Results: Application of the A/T/N classification showed that 51% of HC, 20% of MCI and 15% of AD had no marker abnormality, while 1% of HC, 22% of MC and 56% of AD presented with all three abnormal markers.

In HC, 12% were A+ and 12% N+ (*T*- *SNAP*), with 8% being T+. In MCI, 11% were A+T-N-, while 4% and 2% were A-T+N- and A-T-N+, respectively. When considering two-biomarker abnormality, only 1% of HC were A-T+N+ (T+ *SNAP*), while 20% of MCI were A+T-N+, 15% A+T+N-, and 4% A-T+N+. In AD, 19% were A+T-N+ and 7% A+T+N-.

Increasing biomarker abnormality was associated with increasing cognitive impairment. When only one biomarker was abnormal, A+T-N- HC and MCI had worse performance than A-T+N- and A-T-N+. Interestingly, when two biomarkers were abnormal, A+T-N+ had worse cognitive performance than A+T+N- and A-T+N+, as well as significantly faster cognitive decline than A-T-N-.

Conclusions: The new proposed A/T/N categories allows a more comprehensive classification of the aging population. That said, translation of the new A/T/N classification into research and clinical practice will require larger series and longer follow-up, to fully assess its clinical and prognostic performance. *Keywords: tau imaging, Aβ-imaging, CSF, cognitive performance*

The relationship of elevated medial temporal lobe and diffuse brain Tau-PET signal in clinically normal participants

<u>Val Lowe</u>¹, Emily Lundt¹, Heather Wiste¹, Ping Fang¹, Matthew Senjem¹, Bradley Boeve¹, Keith Josephs¹, Mukesh Pandey¹, Melissa Murray², Kejal Kantarci¹, David Jones¹, Christopher Schwarz¹, David Knopman¹, Ronald Petersen¹, Clifford Jack¹

¹Mayo Clinic, Rochester, MN, USA ²Mayo Clinic, Jacksonville, FL, USA

Background: Medial temporal lobe (MTL) uptake on tau-PET is seen in AD dementia but also in the aging population. Some AD dementia patients have much less MTL tau-PET signal compared to other isocortical signal. The relationship of these findings to the development of AD dementia needs to be better understood.

Methods: Tau-PET with AV-1451 was performed on 439 CN participants ages 50-94. For each cortical region, we defined abnormal tau-PET as cortical-to-cerebellar crus gray matter ratio (SUVr) greater than the 95th percentile among 71 CN participants ages 30-49. We included enthorinal cortex, parahippocampal gyrus, and hippocampus as MTL regions. All other cortical regions were considered extra-MTL regions. Off-target regions, such as pallidum, were excluded. The number of CNs with and without abnormal MTL regions and those with or without extra-MTL abnormities were determined. We characterized the age, PiB and APOE status of the groups.

Results: Of CN participants, 37% (163/439) had MTL abnormalities. Of those with MTL findings, 95% (155/163) had extra-MTL abnormality with most having more than one (Figure 1). Of the 276 without an MTL abnormality, 29% (81/276) had extra-MTL abnormalities (Figure 2). Participants having MTL abnormalities tended to be older (p<0.001) and have elevated amyloid (p<0.001). Among those having MTL abnormalities, no age or PiB differences were seen between the groups with or without extra-MTL abnormalities. There were no significant differences in the percentage of APOE e4 carriers.

Conclusions: MTL tau-PET signal is often associated with abnormal extra-MTL tau-PET signal in CN participants and likely represents neurofibrillary tangle development in participants likely to develop AD dementia. Tau-PET signal exclusively outside of the MTL is seen in 29% of CN participants and could be the initial finding in a unique subset of participants in the AD dementia pathway. These findings need to be evaluated with longitudinal data.



Figure 1. Numeric distribution of regional abnormalities outside medial temporal lobe (MTL) among those having any MTL abnormality



Figure 2. Numeric distribution of regional abnormalities outside medial temporal lobe (MTL) among those having no MTL abnormality

Keywords: tau-PET, medial temporal lobe (MTL), AD

Prevalence and incidence of amyloid positivity in cognitively normal elderly individuals

<u>Neelesh Nadkarni</u>^{1,5}, Dana Tudorascu^{2,4}, Beth Snitz^{3,5}, Edythe Halligan³, Annie Cohen^{4,5}, Howard Aizenstein^{3,4}, Oscar Lopez^{3,4,5}, William Klunk^{4,5}

¹Division of Geriatric Medicine, Department of Medicine, University of Pittsburgh, Pittburgh, PA, USA ²Division of Internal Medicine, University of Pittsburgh, Pittsburgh, PA, USA ³Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA ⁴Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA ⁵Alzheimer's Disease Research Center,, Pittsburgh, PA, USA

Aims: We estimated the prevalence of amyloid positivity at baseline, and incidence of amyloid positivity in participants without an amyloid positive baseline scan in the Amyloid Pathology and Cognition in Normal Elderly study cohort.

Methods: Community-dwelling elderly individuals (n=98), screened for psychiatric and neurologic conditions, were deemed CN based on their performance on standardized tests of cognition. Participants underwent Pittsburgh-B (PiB)-PET scan at baseline and a subset had repeat scans over subsequent 1-10 years (average: 6). Amyloid positivity was defined as regional PiB(+) (any one ROI) and global PiB(+) (average of 6 ROI) using established PiB-SUVR cutoffs. Person-years were calculated for each PiB(-) individual as years to conversion to a PiB(+) scan (amyloid positive converters) or total number of years of follow-up of persistently PiB(-) scans (non-converters). Incidence rates were derived by dividing the observed incidence by sum of person years.

Results: In this sample of CN elderly individuals, mean (SD) age was 73.6 years (5.7 years), 64% were female, 21.25% were APOE-ɛ4 carriers and 83% white. There were no significant differences between the global PiB(+) and PiB(-) group on demographic measures and MMSE scores. Regional PiB(+) participants were older (p=0.019), but were otherwise similar to PiB(-) participants. Regional amyloid positivity was observed in 25 (25.51%) and global amyloid positivity was observed in 19 (19.4%). Of the 75 PiB(-) participants at baseline, 19 (25.33%) progressed to regional PiB(+), and 14 (18.67%) progressed to global PiB(+). Incidence rate of regional and global amyloid positivity was 19/239 (8 cases per 100 person- years) and 14/258 (5.4 cases per 100 person-years) respectively.

Conclusion: Estimates of prevalence and incidence of amyloid positivity in CN elderly individuals can inform the design of future secondary prevention trials targeting MCI and AD. *Keywords: amyloid positivity, prevalence, incidence rate*

Longitudinal tau accumulation is associated with cognitive decline in normal elderly

<u>Bernard Hanseeuw</u>, Alex Becker, Aaron Schultz, Jorge Sepulcre, Beth Mormino, Kate Papp, Heidi Jacobs, Danielle Cosio, Jasmeer Chhatwal, Trey Hedden, Reisa Sperling, Keith Johnson

Massachusetts General Hospital, Boston, MA, USA

Background: Early PET data have shown associations between PHF tau and cognitive performance, including in clinically normal (CN) older adults. Recently acquired serial tau-PET data allowed us to assess the association between longitudinal tau imaging and change in cognition.

Methods: Forty-three CN (age=65-90; MMSE \geq 26) had Flortaucipir-PET (FTP, cortical white matter reference), cognitive assessment (Preclinical Alzheimer Cognitive Composite (PACC) within a 3-months delay, and were subsequently followed during 24 months. Linear regressions investigated the association between tau and cognitive performance at baseline. Linear mixed models with random intercepts and slopes investigated the association between cognitive decline, baseline tau, and annual change in tau. Analyses were conducted in bilateral inferior temporal gyri, restricted to the voxels with the highest signal (SUVr>1.06=97.5th percentile of all cortical voxels). Analyses were adjusted for age, sex, and education.

Results: Elevated baseline tau signal was associated with low baseline cognition (Fig.1; Estimate=- 5.8 ± 2.90 , p=0.050). High baseline tau predicted cognitive decline in the following two years (Fig.2; Estimate=- 6.2 ± 1.74 , p=0.001). Change in tau also predicted cognitive decline (Fig.3; Estimate=- 24.3 ± 6.23 , p=0.00015). A tau increase of 0.01 SUVr was thus associated with a cognitive decline of 0.243 z-scores on the PACC. Cognitive decline was more strongly related to change in tau (p=0.022) than to baseline tau (p=0.100) when both predictors were simultaneously modeled. Change in tau was significantly associated with change in each individual PACC component (Logical Memory: Estimate=- 17.7 ± 9.1 , p=0.037; Free and Cued Selective Reminding Test (/96): Estimate=- 27.2 ± 9.1 , p=0.003; MMSE: Estimate=- 46.6 ± 12.5 , p=0.0003; Digit-Symbol: Estimate=- 11.6 ± 4.2 , p=0.006).

Conclusion: Cognitive decline in CN is associated with temporal tau accumulation, beyond the association with baseline tau. Serial tau-PET imaging is a promising marker to predict cognitive deterioration and track disease progression. Larger samples are required to further explore the longitudinal associations between tauopathy and cognition.

Fig.1 Baseline tau predicts baseline cognition





Fig.2: Baseline tau predicts change in cognition

Keywords: Tau accumulation; Longitudinal PET imaging, Preclinical Alzheimer Cognitive Composite; Clinically Normal;

Baseline amyloid burden predicts cognitive decline four years later in healthy adults: the value of a dose-response analysis

<u>Michelle E. Farrell</u>¹, Kristen M. Kennedy¹, Karen M. Rodrigue¹, Gagan S. Wig¹, Gérard N. Bischof², Xi Chen¹, Sara B. Festini¹, Denise C. Park¹

¹University of Texas at Dallas, Dallas, TX, USA ²University Hospital Cologne, Cologne, Germany

Background: Longitudinal studies in cognitively-normal adults have largely treated amyloid as a categorical variable, reporting greater cognitive decline for amyloid-positive adults compared to amyloid-negative adults. We examined whether a continuous, dose-response relationship between amyloid burden and cognitive decline was present in middle-aged and older adults, with increasing baseline amyloid burden predicting increasing rates of cognitive decline.

Methods: Participants (n=174, age=40-89) completed amyloid imaging (f-18-Florbetapir) at baseline and cognitive assessments at baseline and a 4-year follow-up. Linear mixed models assessed SUVR, Time and SUVR x Time effects on episodic memory, reasoning, processing speed, vocabulary and MMSE performance. Age, sex, education, APOE, and the random effect of intercept were included as covariates.

Results: The primary analysis yielded significant SUVR x Time interactions in episodic memory (p=.001), processing speed (p=.04), vocabulary (p=.004), and MMSE (p=.028), but not reasoning. Figures 1A-1D show that increasing SUVR projects a steeper trajectory of decline. A sub-group analysis of older adults (ages 60-89) yielded similar effects. In middle-aged adults (ages 40-59), increasing SUVR predicted vocabulary decline (p=.021). When amyloid was treated as a categorical variable (positive/negative), significantly greater decline was observed for amyloid positive than negative adults in episodic memory (p=.010) and vocabulary (p=.011), but processing speed was mitigated to a trend (p=.082) and MMSE was non-significant (p=0.364).

Conclusions: The results indicate that there is a significant dose-response relationship between baseline amyloid burden and cognitive decline over 4 years in episodic memory, processing speed, vocabulary and MMSE performance. Furthermore, continuous SUVR provided a more sensitive predictor of the trajectories of cognitive decline than amyloid positivity. The magnitude of SUVR potentially provides useful information about expected preclinical disease trajectory.



Figure 1. Model Projections of the Impact of Increasing Baseline Amyloid Burden on Cognitive Change Trajectories over Four Years. To evaluate the significant SUVR x Time interactions, estimated means were computed using simple slope analysis for each time point based on increasing values of SUVR. Across (a) episodic memory, (b) processing speed, (c) vocabulary, and (d) MMSE, the model projected that high levels of SUVR predicted cognitive decline, while negative or low levels of SUVR predicted modest or no cognitive decline (or in the case of MMSE, a practice effect).

Keywords: cognition, longitudinal, aging, memory, preclinical

Keynote Lecture

Alzheimer's disease clinical trials: 2017 update—Staying the course? Correcting the course? Shifting the paradigms used in trials?

Howard Feldman

University of California, San Diego, La Jolla, CA

The National Alzheimer Project Act (2011-present) set out an ambitious roadmap of therapeutic development that would be needed to reach a cure by 2025, with an estimated 30 new therapeutic drugs in early testing and with a projection of the number of trials with known targets, novel targets and repurposed medicines. However, there have not been any successful late phase clinical AD trials resulting in regulatory approval since 2003. There have been over 200 trials reach phase 2 or beyond, however, all those advancing to phase 3 have had a null or inconclusive result. There is voiced concern that that the opportunity for new therapies by 2025 is getting smaller, however, there are course corrections that can be made to change the outcome.

This presentation will provide some directions that could improve the likelihood of more successful development. The conceptual considerations include the need and approach to more rigorously pursuing proof of concept, diversifying target selection and combinatorial approaches, redefining the disease as a syndrome with multiple etiologies, proteinopathies and contributing factors, and deploying innovative trial designs which allow for more rapid screening seeking larger effect sizes. Central to each of these considerations, is the need for accelerated pace of discovery and research into amyloid and tau PET, novel MRI measures, dynamic CSF biomarkers to address synaptic and cellular function, and blood measures to more rapidly screen populations at risk.

Friday, January 13, 2017 - 02:15 pm - 03:15 pm

SESSION 9: Amyloid, Tau, and Neurodegeneration

SESSION 9 Amyloid, Tau, and Neurodegeneration	CHAIRS: Clifford Jack <i>Mayo Clinic</i> Tammie Benzinger Washington University at St Louis
Neocortical Tau and hippocampus volume reflect distinct processes in preclinical Alzheimer's disease	Elizabeth Mormino Massachusetts General Hospital
Do neurodegeneration or amyloid pathology contribute to the relationship between AV-1451 and cognitive symptoms in Alzheimer's disease?	Alexandre Bejanin University of California, San Francisco
Comparing the contributions of tau and neurodegenerative biomarkers to cognitive decline	Susan Landau University of California, Berkeley
Differential genotypic variance in PET and CSF measures of amyloid burden: Findings from the DIAN Study	Jasmeer Chhatwal Massachusetts General Hospital
Relationships between AV1451-PET and CSF biomarkers in a heterogeneous clinical sample	Renaud La Joie, University of California, San Francisco
Discussion	

Neocortical Tau and hippocampus volume reflect distinct processes in preclinical Alzheimer's disease

<u>Elizabeth Mormino</u>¹, Aaron Schultz¹, Kathryn Papp¹, Molly LaPoint¹, Bernard Hanseeuw¹, Trey Hedden¹, Dorene Rentz¹, Reisa Sperling¹, Keith Johnson¹

¹Massachusetts General Hospital, Boston, CA, USA

Objective: To explore neocortical Tau and hippocampus volume as a function of age and $A\beta$ status, as well as the contributions of these biomarkers to memory among older clinically normal (CN) participants.

Methods: We examined 143 CN participants from the Harvard Aging Brain Study that underwent Amyloid PET with PIB, Tau PET with AV1451, structural MRI and memory performance within 1 year (mean age=75.5 \pm 6.9, age range=55-90). Effects related to age and A β status were compared for inferior temporal Tau and hippocampus volume. Hierarchical regression was used to assess the unique contributions of inferior temporal Tau, hippocampus volume, and age to memory performance for A β - and A β + groups separately.

Results: Age was related to hippocampus volume, regardless of A β status (within A β -: r= -0.63; within A β +: r= -0.52) (**Figure 1A**). A β + showed significantly higher inferior temporal Tau than A β - (r= 0.42); age was related to inferior temporal Tau in A β - (r= 0.35) but not within A β + (r= 0.04)(**Figure 1B**). Although inferior temporal Tau was related to hippocampus volume among A β + (r= -0.29), the strength of this relationship was smaller than the association between age and hippocampus volume in A β + (r= -0.52). Among A β -, 5.0% of the total variance in memory was explained by age, inferior temporal Tau, and hippocampus volume, with age accounting for the most unique variance (ΔR^2 =1.84%). Among A β +, 31% of the total variance in memory was explained by age, inferior temporal Tau, and hippocampus volume, with inferior temporal Tau accounting for the most unique variance (ΔR^2 =20%)(**Figure 2**).

Conclusions: These results suggest that hippocampus volume largely reflects non-AD age-related etiologies whereas neocortical Tau is a more specific marker of early AD processes among older CN. Further simultaneous evaluation of Tau and hippocampus volume among CN is essential to clarify the interpretation of these markers in preclinical staging criteria.





Keywords: AV1451, PIB, hippocampus volume, memory, preclinical AD
Do neurodegeneration or amyloid pathology contribute to the relationship between AV-1451 and cognitive symptoms in Alzheimer's disease?

<u>Alexandre Bejanin¹</u>, Daniel R. Schonhaut¹, Renaud La Joie¹, Joel H. Kramer¹, Suzanne L. Baker², James P. O'Neil², Bruce L. Miller¹, William J. Jagust^{2,3}, Gil D. Rabinovici^{1,3}

¹Memory and Aging Center, University of California San Francisco, San Francisco, CA, USA ²Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA ³Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA

Objective: To test the relationship between cognition and tau pathology in Alzheimer's disease (AD) and to assess whether neurodegeneration or amyloid pathology mediate this relationship.

Methods: Forty patients with heterogeneous AD phenotypes (5 with Aβ-PET+ mild cognitive impairment and 35 with $A\beta$ -PET+ probable AD dementia, including 12 posterior cortical atrophy and 8 logopenic-variant primary progressive aphasia) underwent 3T MRI, ¹¹C-PiB-PET and ¹⁸F-AV1451-PET, and episodic and semantic memory, language, executive and visuo-spatial functions assessment. Raw cognitive scores were converted to Wscores (age-adjusted Z-scores) and averaged to compute composite scores for each cognitive domain. Independent regressions were performed between ¹⁸F-AV-1451 SUVR and each domain and **Biological Parametric Mapping (BPM) was** used to further control for local grey matter volumes, PIB-DVR, or both. Partial correlations and mediation analyses were performed in the regions showing an association between cognition and both ¹⁸F-AV-1451 SUVR and grey matter volume/PIB-DVR. The average direct effect (ADE) and average causal mediation effect (ACME), reflecting direct and indirect effects ¹⁸F-AV-1451 on cognition, were computed using the mediation R package (non-parametric bootstrapping, 5000 simulations).

Results: Decreased cognitive performance in each domain was related to increased ¹⁸F-AV-1451 SUVR in specific brain regions conforming to established brainbehavior relationships (Figure 1).



with imaging covariates (<i>BPM, p<0.001 - k>500 mm3</i>)						
	Relationship with ¹⁸ F-AV-1451 SUVR					
	Controlling for local grey matter atrophy	Controlling for local ¹¹ C-PiB DVR uptake	Controlling for local grey matter atrophy and ¹¹ C-PiB DVR uptake			
Episodic memory						
Semantic memory						
Language						
Executive functions						
Visuo-spatial functions						

AEA OLIVE

This pattern of regional associations remained essentially unchanged when grey matter volume or ¹¹C-PiB-DVR maps were added as covariates (Figure 2).

Mediation analyses revealed both direct effects (ADE) of ¹⁸F-AV-1451 on cognitive performances and mediating effects (ACME) of grey matter atrophy on these relationships (Figure 3).



Discussion: Tau shows distinct regional correlations with performance in specific cognitive domains. The relationships between tau and cognition in AD are not related to amyloid burden, but are in part mediated by grey matter volumes. These results suggest that tau pathology may lead to cognitive deficits through a variety of mechanisms, including, but not limited, to neuronal loss.

Keywords: tau, cognition, atrophy, amyloid, mediation analyses

Comparing the contributions of tau and neurodegenerative biomarkers to cognitive decline

Susan Landau, Andy Horng, William Jagust

¹Helen Wills Neuroscience Department, University of California, Berkeley, CA, USA

Objectives: Tau deposition and neurodegeneration are hypothesized downstream effects of amyloid deposition in Alzheimer's disease but their relative contributions to cognitive decline are poorly understood. Here, we compared the relationship of these measurements to retrospective longitudinal cognitive decline across individuals at different levels of disease severity, and stratified by amyloid status.

Methods: Participants included 74 ADNI subjects (38 normal, 15 EMCI, 16 MCI, 5 AD) with AV1451-PET who had concurrent florbetpair-PET scans, as well as MRIs and FDG-PET obtained prior to AV1451. We used a Braak staging method to assess partial volume corrected AV1451 retention relative to cerebellar cortex at different levels of progression: medial temporal (Braak 1/2), lateral temporal (Braak 3/4), neocortical (Braak 5/6) regions. We also measured hippocampal volume (HV) adjusted for total intracranial volume, hypometabolism (FDG) within a set of AD-specific regions, and retrospective cognitive decline using 3.3 +/-1.1 yrs of longitudinal ADAS-cog measurements. Regression models were adjusted for age, sex, education, and ApoE4 status.

Results: In florbetapir- subjects (n=42), no biomarker (AV1451, FDG, HV) was predictive of ADAS-cog decline. In florbetapir+ subjects (n=32; 13 normal, 4 EMCI, 10 LMCI, 5 AD), however, AV1451, FDG, and HV were all predictive of ADAS-cog decline in univariate models. Furthermore, AV1451 retention in all Braak stages was associated with ADAS-cog decline, but medial temporal AV1451 was most closely linked to decline. In a multivariate model with FDG, HV, and medial temporal AV1451, only AV1451 remained significantly associated with ADAS-cog decline (p=0.001; florbetapir status X AV1451 interaction, p = 0.01; see Figure).

Conclusion: In amyloid+ individuals at different stages of disease, neurodegeneration and medial temporal

tau deposition in particular are related to ongoing cognitive decline. These findings support a model in which amyloid and tau have a synergistic influence on cognitive decline.

In florbetapir+ but not florbetapir- individuals, greater medial temporal AV1451 is associated with greater ADAS-cog decline.





Differential genotypic variance in PET and CSF measures of amyloid burden: findings from the DIAN Study

<u>Jasmeer Chhatwal</u>¹, Eric McDade², Peter Wang², Tammie Benzinger², Anne Fagan², Aaron Schultz¹, Bernard Hanseeuw¹, Colin Masters³, Adrian Danek⁵, Peter Schofield⁴, Martin Farlow⁷, John Morris², Randall Bateman¹, Keith Johnson¹, Reisa Sperling

¹Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

²Washington University School of Medicine, St. Louis, MA, USA
³The Florey Institute, The University of Melbourne, Parkville, Australia
⁴Neuroscience Research Australia, Sydney, Australia
⁵German Center for Neurodegenerative Disease, Tuebingen, Germany
⁶Mount Sinai School of Medicine, New York, NY, USA
⁷Indiana University School of Medicine, Indianapolis, IN, USA

Rationale: Pathogenic mutations in Presenilin (PSEN) 1, 2 or amyloid precursor protein (APP) lead to autosomal dominant Alzheimer's disease (ADAD) by altering beta-amyloid production and deposition. Though these mutations are all highly penetrant, *in vitro* studies suggest that there is substantial molecular diversity in the amyloid species produced by each mutation. Using data from the Dominantly Inherited Alzheimer Network (DIAN), we examine inter-genotypic variance in the temporal pattern of amyloid burden assessed using both Pittsburgh Compound B (PiB) PET and cerebrospinal fluid (CSF) Aβ42.

Methods: CSF Aβ42 and PiB PET were assessed in 174 individuals (117 mutation carriers, 67 non-carriers). Thirty-seven unique PSEN1 genotypes were categorized into 7 groups based on affected topologic domain. In addition to these PSEN1 groupings, three well-represented non-PSEN1 genotypes were included in the analysis (2 APP, 1 PSEN2). We used linear mixed-effect regression models to examine interactions between estimated years to symptom onset (EYO) and genotype.

Results: Significant genotype-by-EYO interactions were observed in mean cortical PiB binding, and in a composite posterior cingulate and precuneus ROI. Intriguingly, significant inter-genotypic variance was not observed in CSF A β 42 in the same sample. CDR sum of boxes also did not show significant genotype-by-EYO interactions, suggesting grossly similar clinical progression across genotypes.

Conclusion: These results suggest that the nature of particular ADAD mutations can lead to differential temporal patterns of amyloid burden as measured by PiB PET. The same effect was not observed in CSF A β 42, suggesting greater inter-genotypic variance in insoluble fibrillar amyloid as compared to amyloid species measured in CSF. These results are relevant for the use of PiB PET and CSF A β 42 in ongoing ADAD prevention trials, and, more broadly, in understanding how CSF- vs. PET-based amyloid measurements may relate to AD-related cognitive decline.



Figure 1: Inter-genotype Variance in Measures of Amyloid Burden in ADAD. (A) Amyloid burden in the posterior cingulate and precuneus as measured by PiB PET varies significantly across genotype category (genotype by EYO interaction, p = 0.009). (B and C) Beta-amyloid as assessed by immunoassays for CSF A β 42 on the XMAP (B) and INNOTEST ELISA platforms (C) do not show significant variation by genotype category (genotype by EYO interaction, p > 0.8 for both comparisons). (D) Clinical Dementia Rating Scale Sum of Boxes scores across the spectrum of EYO also do not vary by genotype category (genotype by EYO interaction, p = 0.34). Trajectories illustrated using locally weighted scatter plot smoothing (LOWESS).

Keywords: Pittsburgh Compound B, Alzheimer's Disease, CSF, genetics, Presenilin

Relationships between AV1451-PET and CSF biomarkers in a heterogeneous clinical sample

<u>Renaud La Joie</u>¹, Alexandre Bejanin^{2,3,4}, Anne Fagan¹, Nagehan Ayakta⁵, Suzanne Baker¹, Viktoriya Bourakova¹, Anna Karydas⁵, James O'Neil¹, Julie Pham¹, Adrienne Visani¹, Howard Rosen¹, Adam Boxer¹, Bruce Miller¹, William Jagust^{5,6}, Gil Rabinovici^{1,6}

¹1 Memory and Aging Center, University of California San Francisco, san francisco, CA, USA
²2 Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MI, USA
³Department of Neurology, Washington University in St. Louis, St. Louis, MI, USA
⁴The Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, St. Louis, MI, USA
⁵Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
⁶Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA

Objective: To determine the relationships between AV1451-PET and cerebrospinal fluid (CSF) biomarkers in a heterogeneous sample of memory clinic patients.

Methods: We studied patients seen at UCSF Memory and Aging Center with available AV1451-PET, PIB-PET and CSF biomarkers (median between PET and lumbar puncture: 114 days). This included 19 A β -PET positive patients with AD and 13 patients with suspected non-AD etiologies (see Table 1). CSF samples were analyzed for total tau (T-tau), phosphorylated tau (P-tau181), and A β_{42} at Washington University using Alzbio3 xMAP immunoassay (Fujirebio). AV1451 data were processed using Freesurfer 5.3 and SPM12. We examined associations between CSF markers and 1) global gray matter AV1451 SUVR, ii) spatial extent of elevated AV1451-uptake (i.e. the percentage of voxels with Z value > 2 compared to 41 A β -PET-negative healthy older adults), and iii) the topography of AV1451 using voxelwise analyses.

Results: In the full sample, both P-tau and T-tau were strongly related to AV1451-PET measures but also to PIB-PET uptake (Figure 1, black lines), these associations being mostly driven by differences between the AD and non-AD groups. When restricting the analyses to A β -PET-positive AD patients, significant associations were found between measures of cortical AV1451 and P-tau (Figure 1, yellow lines), but not between AV1451 and total tau or A β_{42} . On voxel-wise analysis in A β + AD, P-tau was associated with AV1451 retention in cingulate, precuneus and lateral parietal areas, whereas T-tau was related to increased medial prefrontal and left temporal uptake (Figure 2).

Conclusion: In a heteregenenous clinical sample, AV1451 imaging was strongly associated with CSF measures of tau but not A β_{42} . In AD, although P-tau was the only correlate of global AV1451 metrics, P-tau and T-tau showed distinct regional correlations with AV1451 uptake, suggesting they may be capturing different elements of disease pathophysiology or stage.

	Αβ+ ΑΟ	Other patients	statistics
n	19	13	
Age	61 [57, 65]	68 [60, 74]	U = 84, p = .13
Gender: n _F / n _M	11 / 8	4 / 9	p = .17
Years of education	17 [16, 18]	16 [14.25, 18]	U = 122, p = .38
MMSE	22 [19.5, 26.3]	27 [19.5, 28]	U = 88, p=.25
CDR n ₀ / n _{0.5} / n ₁ / n ₂	1/8/9/2	3/8/1/1	U = 173.5, p=.03

Table 1. Continuous variables are presented as median [1st quartile, 3rd quartile] while exact numbers are provided for categorical and ordinal variables. Groups were compared using Mann Whitney test for continuous and ordinal variables and Fisher's exact text for categorical variables.



Figure 1. Correlation between CSF biomarkers and metrics of AV1451-PET (global burden and spatial extent) as well as PIB-PET. Associations were assessed using spearman correlations in the whole group (black line when p<0.05) and in the A β -PET-positive AD group (yellow line when p<0.05). Statistical indices are indicated for each pair of variables (top line: full sample, bottom line: A β -PET-positive AD group).



Figure 2. Areas of significant association between AV1451-uptake and P-tau or T-tau in the group of 19 A β -PET-positive AD patients. A combination of thresholds (P_{uncorrected}<0.005 at the voxel level and P_{FWE}<0.05 at the cluster level) was used.

Keywords: Alzheimer's disease, AV1451, Cerebrospinal fluid

Friday, January 13, 2017 - 04:00 pm - 04:45 pm

Poster Session 3B - see 3A

Friday, January 13, 2017 - 04:50 pm - 05:35 pm

SESSION 10: Amyloid and Tau PET in Distinct Populations

SESSION 10 Amyloid and Tau PET in Distinct Populations	CHAIRS: Trey Hedden <i>Massachusetts General Hospital</i> Charles de Carli <i>University of California, Davis</i>
Association of regional FDG hypometabolism with age, amyloid, tau, and cardiac and metabolic conditions along the AD continuum	Prashanthi Vemuri Mayo Clinic
18F-AV1451 PET in patients with subcortical vascular cognitive impairment	Sang Won Seo Sungkyunkwan University School of Medicine
White matter hyperintensities and brain amyloid deposition: The ARIC-PET Study	Rebecca Gottesman Johns Hopkins University
Association of amyloid-beta plaque accumulation and glucose hypometabolism in Down syndrome demonstrates pattern associated with Alzheimer's disease	Patrick Lao University of Wisconsin
Discussion	

Association of regional FDG hypometabolism with age, amyloid, tau, and cardiac and metabolic conditions along the AD continuum

<u>Prashanthi Vemuri</u>, Val Lowe, David Knopman, Jonathan Graff-Radford, David Jones, Matthew Senjem, Heather Wiste, Mary Machulda, Ronald Petersen, Clifford Jack Jr.

¹Mayo Clinic, Rochester, MN, USA

Introduction: Our goal was to understand the association of age, amyloid via PIB-PET, tau via AV1451-PET, and cardiac and metabolic conditions (CMC variable – composite of presence/absence of hypertension, hyperlipidemia, cardiac-arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, stroke) with hypometabolism via FDG-PET in individuals along the AD continuum. We hypothesized that regional tau deposition, age, and CMC but not amyloid would be strongly coupled with regional hypometabolism.

Methods: We identified 474 individuals (52 between 30-49 years as reference group, 360 clinically normal (CN) elderly \geq 50 years of whom 120 were amyloid positive, and 62 amyloid positive MCI and dementia) with Tau-PET, FDG-PET, and amyloid-PET scans from the Mayo Clinic Study of Aging and Mayo Alzheimer's disease research center. We estimated correlations between each of the variables with regional FDG-PET. We computed regional z-scores for tau and FDG based on the reference group such that higher z-scores corresponded to worse biomarkers. We used a cut-off of 2 and applied it to individuals in the 50+ group to classify regions as normal and abnormal.

Results: In CN, age and CMC were more correlated with FDG hypometabolism compared to regional amyloid and tau deposition correlations with regional FDG adjusted for age. In clinically impaired individuals, regional tau had stronger associations with regional FDG compared to regional or global amyloid or age and the associations between FDG and tau were high in the parietal, temporal, and frontal lobes (p<0.001). Using regional z-score cutoff of 2 for FDG and tau in 50+ CN, we found that regional tau was more often abnormal due to amyloid positivity than regional FDG.

Discussion: These results provide evidence that tau deposition may be an earlier event compared to FDG hypometabolism and FDG is more likely to be abnormal when individuals start showing clinical symptoms along the AD continuum.

Keywords: Amyloid PET, Tau PET, FDG hypometabolism, cardiac and metabolic conditions

18F-AV1451 PET in patients with subcortical vascular cognitive impairment

Hee Jin Kim¹, Hanna Cho², Seongbeom Park¹, Young Kyoung Jang¹, Jin San Lee¹, Hyemin Jang¹, Yeshin Kim¹, Ko Woon Kim¹, Young Hoon Ryu³, Jae Yong Choi³, Duk L. Na¹, Chul Hyoung Lyoo², <u>Sang Won Seo¹</u>

¹Departments of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

²Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

³Department of Nuclear Medicine, Gangnam Severance Hospital, Younsei University College of Medicine, Seoul, Korea

Background: We aimed to evaluate the distribution and clinical significance of tau in patients with subcortical vascular cognitive impairment (SVCI).

Methods: We recruited 51 SVCI patients and 20 normal controls (NCs). We assessed imaging markers for small vessel disease such as the volume of white matter hyperintensities, number of lacunes, deep micorbleeds and lobar microbleeds. The presence of amyloid was assessed by ¹⁸F-florbetaben PET. All participants underwent ¹⁸F-AV1451 PET to measure paired helical filament (PHF)-tau at Gangnam Severance Hospital. Using cerebellar gray matter as a reference region, we measured regional AV1451 SUVR. We used freeSurfer-derived region of interests that approximates the anatomical definitions of the Braak stages: Braak I/II ROI corresponded to the entorhinal stage, Braak III/IV ROI to the limbic stage, and Braak V/VI ROI to the isocortical stage.

Results: NCs showed localized AV1451 uptake in the bilateral medial temporal subregions while, SVCI patients showed increased uptake in more extended areas which included the medial, inferior and lateral temporal areas; precuneus; and medial and orbitofrontal regions. When we compared AV1451 SUVR in each Braak stage ROI, SVCI patients showed higher AV1451SUVR across all the Braak stage ROIs, compared to NCs. Among the SVCI patients, those who were amyloid positive showed higher AV1451 uptake in the medial and inferior temporal regions. The higher number of lobar microbleeds was associated with higher AV1451 uptake in the inferior and lateral temporal, precuneus, and lateral parietal regions. In SVCI patients, higher AV1451 uptake correlated with worse cognitive function in language, visuospatial function, and general cognition. Path analysis showed that amyloid and lobar microbleed each contributed to increased AV1451 uptake which in turn led to cognitive impairment.

Conclusions: SVCI patients had increased tau compared to NCs. Amyloid and lobar microbleeds each contributed to increased tau, which in turn led to cognitive impairments.

Keywords: Subcortical vascular cognitive impairment, AV1451, paired helical filament tau, amyloid, small vessel disease

White matter hyperintensities and brain amyloid deposition: The ARIC-PET Study

<u>Rebecca Gottesman</u>¹, Zeyi Wang¹, Yun Zhou¹, Brian Caffo¹, Edward Green², Naresh Gupta³, Timothy Hughes⁴, Cliff Jack⁵, David Knopman⁵, Akiva Mintz⁴, Arman Rahmim¹, A. Richey Sharrett¹, Lynne Wagenknecht⁴, Dean Wong¹, Thomas Mosley²

¹Johns Hopkins University, Baltimore, MD, USA ²University of Mississippi Medical Center, Jackson, MS, USA ³Hagerstown Imaging, Hagerstown, MD, USA ⁴Wake Forest University, Winston-Salem, NC, USA ⁵Mayo Clinic, Rochester, MN, USA

Objective: Microvascular changes in the brain have been associated with cognitive impairment and clinical dementia, but data are conflicting as to the role of brain microvascular disease in Alzheimer's Disease (AD) specifically. In this study, we evaluated the cross-sectional association between brain small vessel disease and brain amyloid, among participants in the community-based Atherosclerosis Risk in Communities (ARIC)-PET Amyloid Imaging Study.

Methods: Dementia-free participants from three U.S. communities, (n=326) aged 67-89, underwent brain MRI scans, with standardized measurement of brain infarcts and white matter hyperintensities (WMH), and florbetapir PET, with standardized uptake value ratio (SUVR) measurement in regions of interest. A global cortex SUVR measure was calculated; values above the sample median (SUVR>1.2) were considered abnormal. Logistic multivariable regressions were considered, with sequential adjustment for demographics and vascular risk factors, as well as APOE genotype. Effect modification by race and APOE status was also evaluated.

Results: The cohort was 43% black, 57% female, with mean age 75.8 years. Presence of any infarct, or any lacunar infarct, was not significantly associated with increased odds of amyloid positivity (Table 1). In the overall sample, WMH volume (per standard deviation) was associated with higher odds of elevated brain amyloid only in unadjusted models (unadjusted OR 1.41, 95% CI 1.10, 1.88), with loss of significance with further adjustment (Table 1). However, in demographic-adjusted models, WMH was associated with elevated amyloid among APOE e4 noncarriers (OR 1.39, 95% CI 1.01-1.99), but not in carriers (OR 1.09, NS; Table 2). No formal interactions by APOE or by race were identified, although associations tended to be stronger in blacks than in whites (p-interaction NS; Table 3).

Conclusions: We did not find evidence of an association between brain small vessel disease and elevated amyloid, although this may be due to lack of adequate power, in this community-based cohort.

Table 1. Associations between markers of cerebrovascular disease by brain MRI and elevated brain amyloid (defined as SUVR>1.2).

	Model 1	95% CI	Model 2	95% CI	Model 3	95% CI
	OR		OR		OR	
Any infarct	1.34	0.81-2.23	1.33	0.80-2.22	1.33	0.79-2.25
Any lacunar	1.06	0.60-1.86	1.04	0.59-1.84	0.96	0.53-1.74
infarct						
White matter	1.28	0.98-1.74	1.26	0.96-1.71	1.29	0.97-1.76
hyperintensity						
volume (per SD)*						

Model 1 : adjusted for age, sex, race, educational attainment

Model 2: Model 1 + hypertension, diabetes, current smoking, BMI

Model 3: Model 2 + APOE

*Total intracranial volume added as covariate in all models for white matter hyperintensity volume

Table 2. Association between white matter hyperintensity volume and elevated brain amyloid, stratified by APOE status.

	OR: APOE	95% CI	OR: APOE	95% CI
	ε4 carriers		ε4	
	(N=102)		noncarriers	
			(N=224)	
Model 1	1.09	0.64-2.16	1.39	1.01-1.99
Model 2	0.97	0.56-2.00	1.34	0.98-1.92
Model 3	NA	NA	NA	NA

Model 1 : adjusted for age, sex, race, educational attainment, total intracranial volume

Model 2: Model 1 + hypertension, diabetes, current smoking, BMI Model 3: Model 2 + APOE

Table 3. Association between white matter hyperintensity volume and elevated brain amyloid, stratified by race.

	OR: Blacks	95% CI	OR: Whites	95% CI
	(N=141)		(N=185)	
Model 1	1.54	0.95-2.83	1.15	0.83-1.60
Model 2	1.58	0.95-2.99	1.15	0.83-1.61
Model 3	1.59	0.95-3.02	1.20	0.86-1.70

Model 1 : adjusted for age, sex, race, educational attainment, total intracranial volume Model 2: Model 1 + hypertension, diabetes, current smoking, BMI Model 3: Model 2 + APOE

Keywords: cerebrovascular disease, epidemiology, amyloid, white matter hyperintensities

Association of amyloid-β plaque accumulation and glucose hypometabolism in Down syndrome demonstrates pattern associated with Alzheimer's disease

Patrick Lao¹, Tobey Betthauser¹, Julie Price², William Klunk², Peter Bulova², Sigan Hartley¹, Regina Hardison², Rameshwari Tumuluru², Dhanbalan Murali¹, Chester Mathis², Annie Cohen², Todd Barnhart¹, Dana Tudorascu², Darlynne Devenny³, Charles Laymon², Sterling Johnson¹, Ben Handen², Bradley Christian¹

¹University of Wisconsin-Madison, Madison, WI, USA ²University of Pittsburgh, Pittsburgh, PA, USA ³New York State Institute for Basic Research in Developmental Disabilities, New York City, NY, USA

Background: Amyloid- β plaques and cerebral hypometabolism are two common biomarkers for Alzheimer's disease (AD). The aim of this work was to use amyloid PET and FDG PET to provide insight into the association between these two AD biomarkers in the Down syndrome (DS) population, which is genetically predisposed to both the overproduction of amyloid- β and AD.

Methods: Twenty-three non-demented adults (38.6 \pm 7.0yrs;12M,11F) with DS underwent PiB PET scan and a subsequent FDG PET scan (124.7 \pm 102.6 days apart). Standard uptake value ratios (SUVRs) were calculated for PiB (50-70 min) and FDG (40-60 min) using cerebellar gray matter as reference region. Parametric SUVR images were spatially normalized using tracer-specific templates and analyzed in MNI space. Biological parametric mapping (BPM; MATLAB2011a,SPM5) was used to investigate associations between PiB and FDG SUVR images, adjusted and unadjusted for chronological age and sex using a linear regression model on the voxel level (8mm smoothing, cluster size >1000 voxels, α =0.001 uncorrected).

Results: PiB SUVR and FDG SUVR were negatively associated in the precuneus and temporal cortex (|r|=0.62-0.84), which survived separate correction for sex and age. There were no clusters of significant positive association between PiB and FDG SUVRs. Representative SUVR images demonstrate that subjects with low PiB retention also had uniform FDG uptake (with the exception of elevation occipital lobe uptake), and subjects with high PiB retention in the striatum and cortex had low FDG uptake in the precuneus and temporal cortex (Figure 1).

Conclusions: Non-demented adults with DS demonstrated early and elevated PiB retention followed by reductions in FDG uptake. Glucose hypometabolism occurred in the precuneus and temporal cortex in a pattern typical of that seen in late-onset AD. Also similar to late-onset AD, PiB retention and metabolism were negatively associated only in these posterior regions, and not in frontal cortex.

Research Support: R01 AG031110, U54 HD090256, U01 AG051406



Representative [¹¹C]PiB and [¹⁸F]FDG SUVR images from two non-demented adults with Down syndrome demonstrating the expected progression of Alzheimer's disease. The bottom row shows the statistically significant clusters of negative association between PiB and FDG SUVRs (p<0.001) from a voxel-wise analysis.

Keywords: Down syndrome, Alzheimer's disease, PiB, FDG, BPM

NOTES

Funding for this conference was made possible in part by grant R13 AG042201 from the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering.

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

The 11^h Human Amyloid Imaging Conference is supported through educational grants from:

PLATINUM



For further information concerning Lilly grant funding visit www.lillygrantoffice.com

GOLD





Silver



Bronze









www.worldeventsforum.com/hai or mobile app: http://my.yapp.us/HAICONF